




|                                                                                                                  |                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (86) Date de dépôt PCT/PCT Filing Date: 2000/09/25                                                               | (51) Cl.Int. <sup>7</sup> /Int.Cl. <sup>7</sup> A61K 31/7088, A61K 39/395,<br>A61K 39/39, A23L 1/30, A61K 35/12, A61P 37/04,<br>A61K 48/00, A61K 38/00, A61K 31/00 |
| (87) Date publication PCT/PCT Publication Date: 2001/04/05                                                       |                                                                                                                                                                    |
| (85) Entrée phase nationale/National Entry: 2002/03/20                                                           |                                                                                                                                                                    |
| (86) N° demande PCT/PCT Application No.: US 2000/026383                                                          | (71) Demandeurs/Applicants:<br>UNIVERSITY OF IOWA RESEARCH FOUNDATION,<br>US;<br>COLEY PHARMACEUTICAL GMBH, DE                                                     |
| (87) N° publication PCT/PCT Publication No.: 2001/022972                                                         |                                                                                                                                                                    |
| (30) Priorités/Priorities: 1999/09/25 (60/156,113) US;<br>1999/09/27 (60/156,135) US; 2000/08/23 (60/227,436) US | (72) Inventeurs/Inventors:<br>KRIEG, ARTHUR M., US;<br>SCHETTER, CHRISTIAN, DE;<br>VOLLMER, JORG, DE                                                               |
|                                                                                                                  | (74) Agent: SMART & BIGGAR                                                                                                                                         |

(54) Titre : ACIDES NUCLEIQUES IMMUNOSTIMULATEURS  
(54) Title: IMMUNOSTIMULATORY NUCLEIC ACIDS

(57) **Abrégé/Abstract:**

The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25 % T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/or greater than 50 % c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.





## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
**WO 01/22972 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/7088**,  
39/39, 48/00, 35/12, A23L 1/30, A61P 37/04 // (A61K  
31/7088, 31:00) (A61K 31/7088, 38:00) (A61K 31/7088,  
39:395)

4, D-40724 Hilden (DE). **VOLLMER, Jörg**; Coley Pharmaceutical Group GmbH, Qiagen GmbH, Max-Volmer Strabe 4, D-40724 Hilden (DE).

(21) International Application Number: PCT/US00/26383

(74) Agent: **LOCKHART, Helen, C.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(22) International Filing Date:  
25 September 2000 (25.09.2000)

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/156,113 25 September 1999 (25.09.1999) US  
60/156,135 27 September 1999 (27.09.1999) US  
60/227,436 23 August 2000 (23.08.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants: **UNIVERSITY OF IOWA RESEARCH FOUNDATION** [US/US]; 214 Technology Innovation Center, Oakdale Research Campus, Iowa City, IA 52242 (US). **COLEY PHARMACEUTICAL GMBH** [DE/DE]; Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld (DE).

**Published:**

— with international search report


(72) Inventors: **KRIEG, Arthur, M.**; University of Iowa, Dept. of Internal Medicine, 540 EM RB, Iowa City, IA 52242 (US). **SCHETTER, Christian**; Coley Pharmaceutical Group GmbH, Qiagen GmbH, Max-Volmer Strabe

(88) Date of publication of the international search report:  
17 January 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMMUNOSTIMULATORY NUCLEIC ACIDS

(57) Abstract: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25 % T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/or greater than 50 % c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.



**WO 01/22972 A3**



- 1 -

**IMMUNOSTIMULATORY NUCLEIC ACIDS****BACKGROUND OF THE INVENTION**

5

Bacterial DNA, but not vertebrate DNA, has direct immunostimulatory effects on peripheral blood mononuclear cells (PBMC) *in vitro* (Krieg *et al.*, 1995). Bacterial DNA has immune stimulatory effects to activate B cells and natural killer cells, but vertebrate DNA does not (Tokunaga, T., et al., 1988. *Jpn. J. Cancer Res.* 79:682-686; Tokunaga, T., et al., 1984, *JNCI* 72:955-962; Messina, J.P., et al., 1991, *J. Immunol.* 147:1759-1764; and reviewed in Krieg, 1998, In: Applied Oligonucleotide Technology, C.A. Stein and A.M. Krieg, (Eds.), John Wiley and Sons, Inc., New York, NY, pp. 431-448). It is now understood that these immune stimulatory effects of bacterial DNA are a result of the presence of unmethylated CpG dinucleotides in particular base contexts (CpG motifs), which are common in bacterial DNA, but methylated and underrepresented (CpG suppression, 1/50 to 1/60) in vertebrate DNA (Krieg et al, 1995 *Nature* 374:546-549; Krieg, 1999 *Biochim. Biophys. Acta* 93321:1-10). The immune stimulatory effects of bacterial DNA can be mimicked with synthetic oligodeoxynucleotides (ODN) containing these CpG motifs. It appears likely that the rapid immune activation in response to CpG DNA may have evolved as one component of the innate immune defense mechanisms that recognize structural patterns specific to microbial molecules.

CpG ODN have highly stimulatory effects on human and murine leukocytes, inducing proliferation of almost all (>95%) B cells and increases immunoglobulin (Ig) secretion; cytokine secretion; natural killer (NK) cell lytic activity and IFN- $\gamma$  secretion; and activation of dendritic cells (DCs) and other antigen presenting cells to express costimulatory molecules and secrete cytokines, especially the Th1-like cytokines that are important in promoting the development of Th1-like T cell responses. B cell activation by CpG DNA is T cell independent and antigen non-specific. However, B cell activation by low concentrations of CpG DNA has strong synergy with signals delivered through the B cell antigen receptor for both B cell proliferation and Ig secretion (Krieg *et al.*, 1995). This strong synergy between the B cell signaling pathways triggered through the B cell antigen receptor and by CpG DNA promotes antigen specific immune responses. In addition to its direct effects on B cells, CpG



<sup>a</sup>  
- 1A -

DNA also directly activates monocytes, macrophages, and dendritic cells to secrete a variety of cytokines, including high levels of IL-12 (Klinman *et al.*, 1996; Halpern *et al.*, 1996; Cowdery *et al.*, 1996). These cytokines stimulate natural killer (NK) cells to secrete g-interferon (IFN- $\gamma$ ) and have increased lytic activity (Klinman *et al.*, 1996, *supra*; Cowdery *et al.*, 1996, *supra*; Yamamoto *et al.*, 1992; Ballas *et al.*, 1996). Overall, CpG DNA induces a Th1 like pattern of cytokine production dominated by IL-12 and IFN- $\gamma$  with little secretion of Th2 cytokines (Klinman *et al.*, 1996). The strong direct effects (T cell independent) of CpG DNA on B cells, as well as the induction of cytokines which could have indirect effects on B-cells via T-help pathways, suggests utility of CpG DNA in the form of ODN as a vaccine adjuvant. (See PCT Patent Application Publication No.: WO98/40100.)

These immune stimulatory effects of native phosphodiester backbone CpG ODN are highly CpG specific in that the effects are essentially abolished if the CpG motif is methylated, changed to a GpC, or otherwise eliminated or altered (Krieg *et al.*, 1995 Nature 374:546-549; Hartmann *et al.*, 1999 Proc. Natl. Acad. Sci USA 96:9305-10). Phosphodiester CpG ODN can be formulated in lipids, alum, or other types of vehicles with depot properties or improved cell uptake in order to enhance the immune stimulatory effects (Yamamoto *et al.*, 1994 Microbiol. Immunol. 38:831-836; Gramzinski *et al.*, 1998 Mol. Med. 4:109-118).

In early studies, it was thought that the immune stimulatory CpG motif followed the formula purine-purine-CpG-pyrimidine-pyrimidine (Krieg *et al.*, 1995 Nature 374:546-549; Pisetsky, 1996 J. Immunol. 156:421-423; Hacker *et al.*, 1998 EMBO J. 17:6230-6240; Lipford *et al.*, 1998 Trends in Microbiol. 6:496-500). However, it is now clear that mouse lymphocytes respond quite well to phosphodiester CpG motifs that do not follow this "formula" (Yi *et al.*, 1998 J. Immunol. 160:5898-5906) and the same is true of human B cells and dendritic cells (Hartmann *et al.*, 1999 Proc. Natl. Acad. Sci USA 96:9305-10; Liang, 1996 J. Clin. Invest. 98:1119-1129).

Several past investigators have looked at whether the nucleotide content of ODN may have effects independently of the sequence of the ODN. Interestingly, antisense ODN have been found to be generally enriched in the content of GG, CCC, CC, CAC, and CG sequences, while having reduced frequency of TT or TCC nucleotide sequences compared to what would be expected if base usage were random (Smetsers *et al.*, 1996 Antisense Nucleic



- 2 -

Acid Drug Develop. 6:63-67). This raised the possibility that the over-represented sequences may comprise preferred targeting elements for antisense oligonucleotides or visa versa. One reason to avoid the use of thymidine-rich ODN for antisense experiments is that degradation of the ODN by nucleases present in cells releases free thymidine which competes with <sup>3</sup>H-thymidine which is frequently used in experiments to assess cell proliferation (Matson et al., 1992 Antisense Research and Development 2:325-330).

10

### SUMMARY OF THE INVENTION

The present invention relates in part to pyrimidine rich (Py-rich) and in some embodiments thymidine (T) rich immunostimulatory nucleic acids which do not require the presence of a CpG motif. The present invention also relates in part to the discovery that nucleic acids which contain a TG dinucleotide motif are also immunostimulatory. The invention is based in part on the unexpected finding that nucleic acid sequences which do not contain CpG motifs are immunostimulatory. It was discovered upon analysis of the immune stimulation properties of many nucleic acid sequences that these sequences may be Py-rich e.g., T-rich or that they may contain TG motifs. It was also discovered that these sequences preferentially activate non-rodent immune cells. The Py-rich and TG sequences are only minimally immunostimulatory with respect to rodent immune cells, compared to non-rodent immune cells. Thus, it is possible according to the methods of the invention to induce an immune response in a non-rodent subject by administering Py-rich or TG immunostimulatory nucleic acids. The Py-rich and TG immunostimulatory nucleic acids of the invention may optionally include CpG motifs. These findings have important implications for the clinical development of immunostimulatory CpG containing and non-CpG containing nucleic acids.



- 3 -

In one aspect the invention is a pharmaceutical composition comprising an effective amount for stimulating an immune response of isolated Py-rich or TG immunostimulatory nucleic acids, and a pharmaceutically acceptable carrier. In other aspects the invention is a composition of matter, comprising an isolated Py-rich or TG immunostimulatory nucleic acid. In other embodiments, the immunostimulatory nucleic acid may be T-rich. In still other embodiments, the immunostimulatory nucleic acid may be T-rich and also have at least one TG motif.

Preferably the Py-rich nucleic acid is a T-rich nucleic acid. In some embodiments the T-rich immunostimulatory nucleic acid is a poly T nucleic acid comprising 5' TTTT 3'. In yet other embodiments the poly T nucleic acid comprises 5' X<sub>1</sub> X<sub>2</sub>TTTXX<sub>3</sub> X<sub>4</sub> 3' wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are nucleotides. In some embodiments X<sub>1</sub>X<sub>2</sub> is TT and/or X<sub>3</sub>X<sub>4</sub> is TT. In other embodiments X<sub>1</sub>X<sub>2</sub> is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and/or X<sub>3</sub>X<sub>4</sub> is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

The T-rich immunostimulatory nucleic acid may have only a single poly T motif or it may have a plurality of poly T nucleic acid motifs. In some embodiments the T-rich immunostimulatory nucleic acid comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 T motifs. In other embodiments it comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 CpG motifs. In preferred embodiments the plurality of CpG motifs and poly T motifs are interspersed.

In yet other embodiments at least one of the plurality of poly T motifs comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 contiguous T nucleotide residues. In other embodiments the plurality of poly T motifs is at least 3 motifs and wherein at least 3 motifs each comprises at least 3 contiguous T nucleotide residues or the plurality of poly T motifs is at least 4 motifs and wherein the at least 4 motifs each comprises at least 3 contiguous T nucleotide residues.

In some cases the T-rich immunostimulatory nucleic acid may be free of poly T motifs but may rather comprise a nucleotide composition of greater than 25% T. In other embodiments the T-rich immunostimulatory nucleic acids have poly T motifs and also comprise a nucleotide composition of greater than 25% T. In preferred embodiments the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater



- 4 -

than 35% T, greater than 40% T, greater than 50% T, greater than 60% T, greater than 80% T, or greater than 90% T nucleotide residues. In important embodiments, the nucleic acid is at least 50% T.

The T-rich and TG immunostimulatory nucleic acids can have any length greater than 7 nucleotides, but in some embodiments can be between 8 and 100 nucleotide residues in length. In preferred embodiments the T-rich immunostimulatory nucleic acid comprises at least 20 nucleotides, at least 24 nucleotides, at least 27, nucleotides, or at least 30 nucleotides. In preferred embodiments, the TG immunostimulatory nucleic acid is between 15 and 25 nucleotides in length. The T-rich and TG immunostimulatory nucleic acids may be single stranded or double stranded.

In one preferred embodiment, the immunostimulatory nucleic acid has a T-rich region located in the middle of its length (i.e., an approximately equal number of nucleotides flank the T-rich region on the 5' and 3' ends).

The T rich nucleic acid in some embodiments is selected from the group consisting of SEQ ID NO: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. In other embodiments the T rich nucleic acids are sequence selected from the group consisting of SEQ ID NO: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

In other embodiments the Py-rich immunostimulatory nucleic acid is a C-rich nucleic acid. An immunostimulatory C-rich nucleic acid is a nucleic acid including at least one and preferably at least 2 poly-C regions or which includes 50% or greater C nucleotides.

The Py-rich and TG immunostimulatory nucleic acids may include one or more CpG motifs. The motifs may be methylated or unmethylated. In other embodiments the Py-rich and TG immunostimulatory nucleic acids are free of one or more CpG dinucleotides.

In other embodiments the Py-rich and TG immunostimulatory nucleic acids also include poly-A, poly G, and/or poly C motifs. In yet other embodiments the Py-rich or



- 5 -

TG immunostimulatory nucleic acid is free of two poly C sequences of at least 3 contiguous C nucleotide residues or is free of two poly A sequences of at least 3 contiguous A nucleotide residues. In other embodiments the Py-rich or TG immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25% C or greater than 25% A. In yet other embodiments the Py-rich or TG immunostimulatory nucleic acid is free of poly-C sequences, poly-G sequences or poly-A sequences.

A poly G nucleic acid in some embodiments is selected from the group consisting of SEQ ID NO: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes a sequence selected from the group consisting of SEQ ID NO: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

According to another aspect of the invention, the immunostimulatory nucleic acids may be defined as those which possess a TG motif, herein referred to as TG immunostimulatory nucleic acids. The TG nucleic acid in one embodiment contains at least one TG dinucleotide having a sequence including at least the following formula:  $5'N_1X_1TGX_2N_23'$ . In related embodiments,  $N_1$  is a nucleic acid sequence composed of a number of nucleotides ranging from  $(11-N_2)$  to  $(21-N_2)$  and  $N_2$  is a nucleic acid sequence composed of a number of nucleotides ranging from  $(11-N_1)$  to  $(21-N_1)$ . In a preferred embodiment,  $X_2$  is thymidine.

In other embodiments, the TG nucleic acid has at least the following formula:  $5'X_1X_2TGX_3X_43'$ . In yet another embodiment, the TG nucleic acid comprises the following sequence:  $5'N_1X_1X_2TGX_3X_4N_23'$ . In a related embodiment,  $N_1$  is a nucleic acid sequence composed of a number of nucleotides ranging from  $(9-N_2)$  to  $(19-N_2)$  and  $N_2$  is a nucleic acid sequence composed of a number of nucleotides ranging from  $(9-N_1)$  to  $(19-N_1)$ . In one preferred embodiment,  $X_3$  is thymidine.  $X_1X_2$  are nucleotides which may be selected from the group consisting of GT, GG, GA, AA, AT, AG, CT, CA, CG, TA and TT, and  $X_3X_4$  are nucleotides which may be selected from the group consisting of TT, CT, AT, AG, CG, TC, AC, CC, TA, AA, and CA. In some preferred embodiments,  $X_3$  is a thymidine. In important embodiments,  $X_3X_4$  are nucleotides



- 6 -

selected from the group consisting of TT, TC, TA and TG. In other embodiments  $X_1X_2$  are GA or GT and  $X_3X_4$  are TT. In yet other embodiments  $X_1$  or  $X_2$  or both are purines and  $X_3$  or  $X_4$  or both are pyrimidines or  $X_1X_2$  are GpA and  $X_3$  or  $X_4$  or both are pyrimidines. In one embodiment  $X_2$  is a T and  $X_3$  is a pyrimidine.

5 In one embodiment the 5'  $X_1X_2TGX_3X_4$  3' sequence of the TG nucleic acid or the entire length or some fragment thereof of the TG nucleic acid is a non-palindromic sequence, and in other embodiments it is a palindromic sequence.

In some preferred embodiments, the TG nucleic acid is also T-rich.

10 The Py-rich and TG immunostimulatory nucleic acids in some embodiments have a nucleotide backbone which includes at least one backbone modification, such as a phosphorothioate modification. The nucleotide backbone may be chimeric, or preferably the nucleotide backbone is entirely modified. In one preferred embodiment, the immunostimulatory nucleic acid has a poly T motif and a phosphorothioate backbone.

15 In another aspect the invention is a composition of an immunostimulatory nucleic acid, in the form of a Py-rich or a TG nucleic acid, and an antigen, wherein the nucleic acid is free of unmethylated CpG motifs.

20 Another composition of the invention is a Py-rich or TG immunostimulatory nucleic acid and an anti-microbial agent, wherein the Py-rich or TG nucleic acid is free of unmethylated CpG motifs. Preferably the anti-microbial agent is selected from the group consisting of an anti-viral agent, an anti-parasitic agent, an anti-bacterial agent and an anti-fungal agent.

25 A composition of a sustained release device including a Py-rich and/or TG immunostimulatory nucleic acid, wherein the Py-rich and/or TG nucleic acid is free of unmethylated CpG motifs, is provided according to another aspect of the invention.

The invention also includes nutritional supplements of a Py-rich or TG immunostimulatory nucleic acid in a delivery device selected from the group consisting of a capsule, a pill, and a sublingual tablet, wherein the Py-rich or TG nucleic acid is free of unmethylated CpG motifs.

30 It should be understood that when it is useful to administer a Py-rich e.g., poly T, T-rich, C-rich, or TG oligonucleotide and a CpG oligonucleotide, it may also be desirable to co-administer a Py-rich or a TG oligonucleotide together with a physically separate CpG, Py-rich or TG oligonucleotide. Alternatively, the CpG, Py-rich or TG



- 7 -

motif may be present on the same contiguous nucleic acid as the Py-rich or TG oligonucleotide. In yet a further embodiment, all or some combination of Py-rich, TG and CpG nucleic acids may be co-administered either on separate nucleic acids or in the same nucleic acid molecule. By co-administer it is intended that the nucleic acids be administered close enough in time to one another to achieve a combined benefit of both oligonucleotides, preferably more than the benefit achieved by administering each of the oligonucleotides alone at the same dose.

CpG oligonucleotides have, in general, the formula 5'X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>4</sub>3', wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are nucleotides and wherein at least the C of CpG is unmethylated. Preferred CpG oligonucleotides are 8-100 nucleotides in length and have modified back bones. Particular structures are detailed in the published PCT applications, U.S. applications and references cited herein, the disclosures of which are incorporated herein in their entirety. In one embodiment, the CpG oligonucleotide is free of poly T and TG motifs and is not T-rich.

In other embodiments, the CpG oligonucleotide has a sequence selected from the group consisting of SEQ ID NO: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 790-792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904, and 909-913.

In another embodiment, the Py-rich or TG oligonucleotide is free of a CpG motifs. This embodiment of the invention also involves pharmaceutical compositions and kits which contain both a CpG oligonucleotide (which can be free of poly T and TG motifs and not be T-rich) and a Py-rich and/or TG oligonucleotide physically separate



- 8 -

from the CpG oligonucleotide. The pharmaceutical preparations are in effective amounts and typically include pharmaceutically acceptable carriers, all as set forth in detail herein with respect to Py-rich and TG oligonucleotides. The kits include at least one container containing an oligonucleotide which is a Py-rich or TG oligonucleotide (or some  
5 combination thereof). The same container, or in other embodiments, a second container, may contain an oligonucleotide with a CpG motif, which may be free of Py-rich and/or TG motifs. The kit also contains instructions for administering the oligonucleotides to a subject. The kits also may include a container containing a solvent or a diluent.

In summary, as if fully recited herein, a CpG oligonucleotide physically separate  
10 from the Py-rich or TG oligonucleotide can be used together with the Py-rich or TG oligonucleotides in the methods, compositions and products described above.

The invention relates in other aspects to immunostimulatory oligonucleotides which have chimeric backbones and which do not require the presence of a CpG motif. The invention is based in part on the discovery that nucleic acid sequences which did not  
15 contain CpG motifs were immunostimulatory, and that those which have chimeric backbones have unexpectedly enhanced immune stimulating properties. Thus the invention in one aspect relates to a composition of an oligonucleotide having a formula:  $5' Y_1 N_1 Z N_2 Y_2 3'$ , wherein  $Y_1$  and  $Y_2$  are, independent of one another, nucleic acid molecules having between 1 and 10 nucleotides, wherein  $Y_1$  includes at least one  
20 modified internucleotide linkage and  $Y_2$  includes at least one modified internucleotide linkage and wherein  $N_1$  and  $N_2$  are nucleic acid molecules, each independent of one another, having between 0 and 5 nucleotides, but wherein  $N_1 Z N_2$  has at least 6 nucleotides in total and wherein the nucleotides of  $N_1 Z N_2$  have a phosphodiester backbone, and wherein  $Z$  is an immunostimulatory nucleic acid motif but does not  
25 include a CG. In one embodiment  $Z$  is a nucleic acid sequence selected from the group consisting of TTTT, TG, and a sequence wherein at least 50% of the bases of the sequence are Ts.

In some embodiments  $Y_1$  and/or  $Y_2$  have between 3 and 8 nucleotides. In other embodiments  $Y_1$  and/or  $Y_2$  are comprised of at least three Gs, at least four Gs, least  
30 seven Gs, or all Gs. In other embodiments  $Y_1$  and/or  $Y_2$  are selected from the group consisting of TCGTCG, TCGTCGT, and TCGTCGTT (SEQ ID NO:1145). In yet other



- 9 -

embodiments  $Y_1$  and/or  $Y_2$  include at least one, two, three, four, or five poly-A, poly-T, or poly-C sequences.

The center nucleotides ( $N_1ZN_2$ ) of the formula  $Y_1N_1ZN_2Y_2$  have phosphodiester internucleotide linkages and  $Y_1$  and  $Y_2$  have at least one modified internucleotide linkage. In some embodiments  $Y_1$  and/or  $Y_2$  have at least two modified internucleotide linkages. In other embodiments  $Y_1$  and/or  $Y_2$  have between two and five modified internucleotide linkages. In yet other embodiments  $Y_1$  has two modified internucleotide linkages and  $Y_2$  has five modified internucleotide linkages or  $Y_1$  has five modified internucleotide linkages and  $Y_2$  has two modified internucleotide linkages. The modified internucleotide linkage, in some embodiments is a phosphorothioate modified linkage, a phosphorodithioate modified linkage or a p-ethoxy modified linkage.

Portions of the formula  $Y_1N_1ZN_2Y_2$  may optionally form a palindrome. Thus, in some embodiments the nucleotides of  $N_1ZN_2$  form a palindrome. In some embodiments the palindrome is not a direct repeat. In yet other embodiments the nucleotides of  $N_1ZN_2$  do not form a palindrome.

According to other embodiments  $N_1ZN_2$  has a sequence of nucleotides selected from the group consisting of GATTTTATCGTC (SEQ ID NO:1098), TCGATTTTTCGA (SEQ ID NO: 1099); TCATTTTATGA (SEQ ID NO: 1100); GTTTTTTACGAC (SEQ ID NO: 1101); TCAATTTTGA (SEQ ID NO: 1102); ACGTTTTTACGT (SEQ ID NO: 1103); TCGTTTTTACGA (SEQ ID NO: 1104); TCGATTTTACGTCGA (SEQ ID NO: 1105); AATTTTAAACGTT (SEQ ID NO: 1106); TCGTTTTTAAACGA (SEQ ID NO: 1107); ACGTTTTTAAACGT (SEQ ID NO: 1108); GATTTTATCGTC (SEQ ID NO: 1109); GACGATTTTTCGTC (SEQ ID NO: 1110); GATTTTAGCTCGTC (SEQ ID NO: 1111); GATTTTACGTC (SEQ ID NO: 1112); ATTTTATCGT (SEQ ID NO: 1113); AACGATTTTTCGTT (SEQ ID NO: 1114); TCACTTTTGTGA (SEQ ID NO: 1115); TCGTATTTTA (SEQ ID NO: 1116); ACTTTTGTACCGGT (SEQ ID NO: 1117); TCGATTTTTCGACGTCGA (SEQ ID NO: 1118); ACGATTTTTCGT (SEQ ID NO: 1119); GATGATCGTC (SEQ ID NO: 1120); TCGATGTCGA (SEQ ID NO: 1121); TCATGTATGA (SEQ ID NO: 1122); GTGTTACGAC (SEQ ID NO: 1123); TCAATGTTGA (SEQ ID NO: 1124); ACGTGTACGT (SEQ ID NO: 1125); TCGTGTACGA (SEQ ID NO: 1126); TCGATGTACGTCGA (SEQ ID NO: 1127); AATGTAAACGTT (SEQ ID NO: 1128);



- 10 -

TCGTGTTAACGA (SEQ ID NO: 1129); ACGTGTTAACGT (SEQ ID NO: 1130);  
 GATGTATCGTC (SEQ ID NO: 1131); GACGATGTCGTC (SEQ ID NO: 1132);  
 GATGAGCTCGTC (SEQ ID NO: 1133); GATGTACGTC (SEQ ID NO: 1134);  
 ATGATCGT (SEQ ID NO: 1135); AACGATGTCGTT (SEQ ID NO: 1136);  
 5 TCACTGGTGA (SEQ ID NO: 1137); TCGTATGA (SEQ ID NO: 1138);  
 ACTGGTACCGGT (SEQ ID NO: 1139); TCGATGTCGACGTCGA (SEQ ID NO:  
 1140); and ACGATGTCGT (SEQ ID NO: 1141).

The composition may optionally include a pharmaceutical carrier and/or be  
 formulated in a delivery device. In some embodiments the delivery device is selected  
 10 from the group consisting of cationic lipids, cell permeating proteins, and sustained  
 release devices. In one preferred embodiment the sustained release device is a  
 biodegradable polymer. In another embodiment the sustained release device is a  
 microparticle.

In another aspect the invention is a composition of an immunostimulatory  
 15 oligonucleotide having the formula  $Y_1N_1ZN_2Y_2$ , and an antigen.

Another composition of the invention is an immunostimulatory oligonucleotide  
 having the formula  $Y_1N_1ZN_2Y_2$ , and an anti-microbial therapeutic agent. Preferably the  
 anti-microbial therapeutic agent is selected from the group consisting of an anti-viral  
 agent, an anti-parasitic agent, an anti-bacterial agent, or an anti-fungal agent.

20 A composition of a sustained release device including an immunostimulatory  
 oligonucleotide having the formula  $Y_1N_1ZN_2Y_2$ , is provided according to another aspect  
 of the invention.

The invention also includes nutritional supplements of an immunostimulatory  
 oligonucleotide having the formula  $Y_1N_1ZN_2Y_2$ , in a delivery device selected from the  
 25 group consisting of a capsule, a sublingual tablet, and a pill.

In another aspect the compositions described above also include an  
 immunostimulatory nucleic acid having an unmethylated CG dinucleotide, a TG  
 dinucleotide or a Py-rich sequence wherein the immunostimulatory nucleic acid having  
 an unmethylated CG dinucleotide, a TG dinucleotide or a Py-rich sequence has a  
 30 different sequence than the oligonucleotide comprising  $5' Y_1N_1ZN_2Y_2 3'$ .

In some embodiments the immunostimulatory nucleic acid having an  
 unmethylated CG dinucleotide, a TG dinucleotide or a Py-rich sequence has a



- 11 -

completely phosphodiester backbone and in other embodiments the immunostimulatory nucleic acid having an unmethylated CG dinucleotide, a TG dinucleotide or a Py-rich sequence has a modified backbone, which optionally may have internucleotide linkages selected from the group consisting of phosphorothioate, phosphorodithioate, and p-ethoxy.

In one embodiment immunostimulatory nucleic acid having an unmethylated CG dinucleotide has a formula comprising: 5'  $X_1X_2CGX_3X_4$  3' wherein  $X_1$ ,  $X_2$ ,  $X_3$  and  $X_4$  are nucleotides. In other embodiments the immunostimulatory nucleic acid sequence includes at least the following formula: 5' TCNT $X_1X_2CGX_3X_4$  3' wherein N is a nucleic acid sequence composed of from about 0-25 nucleotides, wherein at least one nucleotide has a modified internucleotide linkage, and wherein the nucleic acid has less than or equal to 100 nucleotides. According to some embodiments  $X_1X_2$  are nucleotides selected from the group consisting of: GT, GG, GA and AA and  $X_3X_4$  are nucleotides selected from the group consisting of: TT, CT or GT. In a preferred embodiment  $X_1X_2$  are GA and  $X_3X_4$  are TT.

In another embodiment the immunostimulatory nucleic acid sequence having an unmethylated CG dinucleotide includes at least one of the following sequences:  
 ATCGACTCTCGAGCGTTCTC (SEQ ID No.15); TCCATGTCGGTCCTGCTGAT (SEQ ID No. 32); TCCATGTCGGTZCTGATGCT (SEQ ID No. 31);  
 ATCGACTCTCGAGCGTTZTC (SEQ ID No. 18); TCCATGTCGGTCCTGATGCT (SEQ ID No. 28); GGGGGG (SEQ ID No. 12); TCCATGACGGTCCTGATGCT (SEQ ID No. 35); TCCATGGCGGTCCTGATGCT (SEQ ID No. 34);  
 TCCATGACGTTCTGATGCT (SEQ ID No. 7); TCCATGTCGTTCTGATGCT (SEQ ID No. 38); GGGGTCAGTCTTGACGGGG (SEQ ID No. 41);  
 TCCATGTCGCTCCTGATGCT (SEQ ID No. 37); TCCATGTCGATCCTGATGCT (SEQ ID No. 36); TCCATGCCGGTCCTGATGCT (SEQ ID No. 33);  
 TCCATAACGTTCTGATGCT (SEQ ID No. 3); TCCATGACGTTCTGATGCT (SEQ ID No. 7); TCCATGACGTCCCTGATGCT (SEQ ID No 39);  
 TCCATCACGTGCCTGATGCT (SEQ ID No. 48); TCCATGACGTTCTGACGTT (SEQ ID No.10); ATGACGTTCTGACGTT (SEQ ID No. 70);  
 TCTCCCAGCGCGCGCCAT (SEQ ID No. 72); TCCATGTCGTTCTGTCGTT (SEQ ID No. 73); TCCATAGCGTTCTAGCGTT (SEQ ID No. 74);



- 12 -

TCCTGACG TTCCTGACGTT (SEQ ID No. 76); TCCTGTCG TTCCTGTCGTT (SEQ ID No. 77); TCCTGTCG TTCCTTGTCGTT (SEQ ID No. 52); TCCTTGTCG TTCCTGTCGTT (SEQ ID No. 121); TCCTGTCG TTTTGTGTCGTT (SEQ ID No. 208); TCGTCGCTGTTGTCGTTTCTT (SEQ ID No. 120);

5 TCCATGCGTTGCGTTGCGTT (SEQ ID No. 81); TCCACGACGTTTTCGACGTT (SEQ ID No. 82); TCGTCGTTGTCGTTGTCGTT (SEQ ID No. 47); TCGTCGTTTGTGTCGTTTGTGTCGTT (SEQ ID No. 46); TCGTCGTTGTCGTTTGTGTCGTT (SEQ ID No. 49); GCGTGCGTTGTCGTTGTCGTT (SEQ ID No. 56); TGTCGTTTGTGTCGTTTGTGTCGTT (SEQ ID No. 48); TGTCGTTGTCGTTGTCGTTGTCGTT (SEQ ID No. 84); TGTCGTTGTCGTTGTCGTT (SEQ ID No. 50); TCGTCGTCGTCGTT (SEQ ID No. 51); and TGTCGTTGTCGTT (SEQ ID No. 85). In another embodiment the immunostimulatory nucleic acid having a Py-rich or TG sequence is a nucleic acid as described above.

15 In another aspect the invention relates to pharmaceutical compositions and kits which contain both an oligonucleotide having the formula  $Y_1N_1ZN_2Y_2$  and a CpG oligonucleotide (which optionally may be free of poly T and TG motifs and not be Py-rich), a Py-rich and/or TG oligonucleotide physically separate from the oligonucleotide having the formula  $Y_1N_1ZN_2Y_2$ . The pharmaceutical preparations are in effective

20 amounts and typically include pharmaceutically acceptable carriers, all as set forth in detail herein. The kits include at least one container containing an oligonucleotide having the formula  $Y_1N_1ZN_2Y_2$ . The same container, or in other embodiments, a second container, may contain an oligonucleotide with a CpG motif, which optionally may be free of Py-rich and/or TG motifs and/or a Py-rich or TG oligonucleotide (or some

25 combination thereof). The kit also contains instructions for administering the oligonucleotides to a subject. The kits also may include a container containing a solvent or a diluent.

In summary, as if fully recited herein, an oligonucleotide having the formula  $Y_1N_1ZN_2Y_2$  which is physically separate from the CpG, Py-rich or TG oligonucleotide

30 can be used together with the CpG, Py-rich, TG oligonucleotides, in the methods, compositions and products described herein.



- 13 -

In another aspect the invention relates to a pharmaceutical composition including at least two oligonucleotides of the invention, wherein the at least two oligonucleotides have different sequences from one another and a pharmaceutically acceptable carrier.

A vaccine formulation is provided according to another aspect of the invention.

- 5 The vaccine includes any of the compositions of the invention in combination with an antigen.

According to another aspect of the invention a method of stimulating an immune response is provided. The method involves administering a Py-rich or a TG immunostimulatory nucleic acid to a non-rodent subject in an amount effective to induce  
10 an immune response in the non-rodent subject. Preferably the Py-rich or TG immunostimulatory nucleic acid is administered orally, locally, in a sustained release device, mucosally to a mucosal surface, systemically, parenterally, or intramuscularly. When the Py-rich or TG immunostimulatory nucleic acid is administered to the mucosal surface it may be delivered in an amount effective for inducing a mucosal immune  
15 response or a systemic immune response. In preferred embodiments the mucosal surface is selected from the group consisting of an oral, nasal, rectal, vaginal, and ocular surface.

In some embodiments the method includes exposing the subject to an antigen wherein the immune response is an antigen-specific immune response. The antigen may be encoded by a nucleic acid vector which can be delivered to the subject. In some  
20 embodiments the antigen is selected from the group consisting of a tumor antigen, a viral antigen, a bacterial antigen, a parasitic antigen and a peptide antigen.

Py-rich and TG immunostimulatory nucleic acids are capable of provoking a broad spectrum of immune response. For instance these immunostimulatory nucleic acids can be used to redirect a Th2 to a Th1 immune response. Py-rich and TG nucleic  
25 acids may also be used to activate an immune cell, such as a leukocyte, a dendritic cell, and an NK cell. The activation can be performed *in vivo*, *in vitro*, or *ex vivo*, i.e., by isolating an immune cell from the subject, contacting the immune cell with an effective amount to activate the immune cell of the Py-rich or TG immunostimulatory nucleic acid and re-administering the activated immune cell to the subject. In some embodiments the  
30 dendritic cell expresses a cancer antigen. The dendritic cell can be exposed to the cancer antigen *ex vivo*.



- 14 -

The immune response produced by Py-rich or TG nucleic acids may also result in induction of cytokine production, e.g., production of IL-6, IL-12, IL-18 TNF, IFN- $\alpha$  and IFN- $\gamma$ .

In still another embodiment, the Py-rich and TG nucleic acids are useful for treating cancer. The Py-rich and TG nucleic acids are also useful according to other aspects of the invention in preventing cancer (e.g., reducing a risk of developing cancer) in a subject at risk of developing a cancer. The cancer may be selected from the group consisting of biliary tract cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, gastric cancer, intraepithelial neoplasms, lymphomas, liver cancer, lung cancer (e.g. small cell and non-small cell), melanoma, neuroblastomas, oral cancer, ovarian cancer, pancreas cancer, prostate cancer, rectal cancer, sarcomas, thyroid cancer, and renal cancer, as well as other carcinomas and sarcomas. In some important embodiments, the cancer is selected from the group consisting of bone cancer, brain and CNS cancer, connective tissue cancer, esophageal cancer, eye cancer, Hodgkin's lymphoma, larynx cancer, oral cavity cancer, skin cancer, and testicular cancer.

Py-rich and TG nucleic acids may also be used for increasing the responsiveness of a cancer cell to a cancer therapy (e.g., an anti-cancer therapy), optionally when the Py-rich or TG immunostimulatory nucleic acid is administered in conjunction with an anti-cancer therapy. The anti-cancer therapy may be a chemotherapy, a vaccine (e.g., an in vitro primed dendritic cell vaccine or a cancer antigen vaccine) or an antibody based therapy. This latter therapy may also involve administering an antibody specific for a cell surface antigen of, for example, a cancer cell, wherein the immune response results in antigen dependent cellular cytotoxicity (ADCC). In one embodiment, the antibody may be selected from the group consisting Ributaxin, Herceptin, Quadramet, Panorex, IDEC-Y2B8, BEC2, C225, Oncolym, SMART M195, ATRAGEN, Ovarex, Bexxar, LDP-03, ior t6, MDX-210, MDX-11, MDX-22, OV103, 3622W94, anti-VEGF, Zenapax, MDX-220, MDX-447, MELIMMUNE-2, MELIMMUNE-1, CEACIDE, Pretarget, NovoMAb-G2, TNT, Gliomab-H, GNI-250, EMD-72000, LymphoCide, CMA 676, Monopharm-C, 4B5, ior egf.r3, ior c5, BABS, anti-FLK-2, MDX-260, ANA Ab, SMART 1D10 Ab, SMART ABL 364 Ab and ImmuRAIT-CEA.

Thus, according to some aspects of the invention, a subject having cancer or at risk of having a cancer is administered an immunostimulatory nucleic acid and an anti-



- 15 -

cancer therapy. In some embodiments, the anti-cancer therapy is selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent and a cancer vaccine. The chemotherapeutic agent may be selected from the group consisting of methotrexate, vincristine, adriamycin, cisplatin, non-sugar containing

5 chloroethylnitrosoureas, 5-fluorouracil, mitomycin C, bleomycin, doxorubicin, dacarbazine, taxol, fragyline, Meglamine GLA, valrubicin, carmustaine and poliferposan, MMI270, BAY 12-9566, RAS famesyl transferase inhibitor, famesyl transferase inhibitor, MMP, MTA/LY231514, LY264618/Lometexol, Glamolec, CI-994, TNP-470, Hycamtin/Topotecan, PKC412, Valspodar/PSC833,

10 Novantrone/Mitroxantrone, Metaret/Suramin, Batimastat, E7070, BCH-4556, CS-682, 9-AC, AG3340, AG3433, Incel/VX-710, VX-853, ZD0101, ISI641, ODN 698, TA 2516/Marmistat, BB2516/Marmistat, CDP 845, D2163, PD183805, DX8951f, Lemonal DP 2202, FK 317, Picibanil/OK-432, AD 32/Valrubicin, Metastron/strontium derivative, Temodal/Temozolomide, Evacet/liposomal doxorubicin, Yewtaxan/Placlitaxel,

15 Taxol/Paclitaxel, Xeload/Capecitabine, Furtulon/Doxifluridine, Cyclopax/oral paclitaxel, Oral Taxoid, SPU-077/Cisplatin, HMR 1275/Flavopiridol, CP-358 (774)/EGFR, CP-609 (754)/RAS oncogene inhibitor, BMS-182751/oral platinum, UFT(Tegafur/Uracil), Ergamisol/Levamisole, Eniluracil/776C85/5FU enhancer, Campto/Levamisole, Camptosar/Irinotecan, Tumodex/Ralitrexed, Leustatin/Cladribine, Paxex/Paclitaxel,

20 Doxil/liposomal doxorubicin, Caelyx/liposomal doxorubicin, Fludara/Fludarabine, Pharmarubicin/Epirubicin, DepoCyt, ZD1839, LU 79553/Bis-Naphtalimide, LU 103793/Dolastain, Caetyx/liposomal doxorubicin, Gemzar/Gemcitabine, ZD 0473/Anormed, YM 116, Iodine seeds, CDK4 and CDK2 inhibitors, PARP inhibitors, D4809/Dexifosamide, Ifes/Mesnex/Ifosamide, Vumon/Teniposide,

25 Paraplatin/Carboplatin, Plantinol/cisplatin, Vepeside/Etoposide, ZD 9331, Taxotere/Docetaxel, prodrug of guanine arabinoside, Taxane Analog, nitrosoureas, alkylating agents such as melphelan and cyclophosphamide, Aminoglutethimide, Asparaginase, Busulfan, Carboplatin, Chlorombucil, Cytarabine HCl, Dactinomycin, Daunorubicin HCl, Estramustine phosphate sodium, Etoposide (VP16-213), Floxuridine,

30 Fluorouracil (5-FU), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alfa-2a, Alfa-2b, Leuprolide acetate (LHRH-releasing factor analogue), Lomustine (CCNU), Mechlorethamine HCl (nitrogen mustard), Mercaptopurine, Mesna,



- 16 -

Mitotane (o.p'-DDD), Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Amsacrine (m-AMSA), Azacitidine, Erthropoietin, Hexamethylmelamine (HMM), Interleukin 2, Mitoguazone (methyl-GAG; methyl glyoxal bis-guanyldihydrazone; MGBG), Pentostatin  
5 (2'-deoxycoformycin), Semustine (methyl-CCNU), Teniposide (VM-26) and Vindesine sulfate, but it is not so limited.

The immunotherapeutic agent may be selected from the group consisting of Ributaxin, Herceptin, Quadramet, Panorex, IDEC-Y2B8, BEC2, C225, Oncolym, SMART M195, ATRAGEN, Ovarex, Bexxar, LDP-03, ior t6, MDX-210, MDX-11,  
10 MDX-22, OV103, 3622W94, anti-VEGF, Zenapax, MDX-220, MDX-447, MELIMMUNE-2, MELIMMUNE-1, CEACIDE, Pretarget, NovoMAb-G2, TNT, Gliomab-H, GNI-250, EMD-72000, LymphoCide, CMA 676, Monopharm-C, 4B5, ior egf.r3, ior c5, BABS, anti-FLK-2, MDX-260, ANA Ab, SMART 1D10 Ab, SMART ABL 364 Ab and ImmuRAIT-CEA, but it is not so limited.

15 The cancer vaccine may be selected from the group consisting of EGF, Anti-idiotypic cancer vaccines, Gp75 antigen, GMK melanoma vaccine, MGv ganglioside conjugate vaccine, Her2/neu, Ovarex, M-Vax, O-Vax, L-Vax, STn-KHL theratope, BLP25 (MUC-1), liposomal idiotype vaccine, Melacine, peptide antigen vaccines, toxin/antigen vaccines, MVA-based vaccine, PACIS, BCG vaccine, TA-HPV, TA-CIN,  
20 DISC-virus and ImmuCyst/TheraCys, but it is not so limited.

In still another embodiment of the methods directed to preventing or treating cancer, the subject may be further administered interferon- $\alpha$ .

The invention in other aspects relates to methods for preventing disease in a subject. The method involves administering to the subject a Py-rich or a TG  
25 immunostimulatory nucleic acid on a regular basis to promote immune system responsiveness to prevent disease in the subject. Examples of diseases or conditions sought to be prevented using the prophylactic methods of the invention include microbial infections (e.g., sexually transmitted diseases) and anaphylactic shock from food allergies.

30 In other aspects, the invention is a method for inducing an innate immune response by administering to the subject a Py-rich or a TG immunostimulatory nucleic acid in an amount effective for activating an innate immune response.



- 17 -

According to another aspect of the invention a method for treating or preventing a viral or retroviral infection is provided. The method involves administering to a subject having or at risk of having a viral or retroviral infection, an effective amount for treating or preventing the viral or retroviral infection of any of the compositions of the invention.

5 In some embodiments the virus is caused by a hepatitis virus, HIV, hepatitis B, hepatitis C, herpes virus, or papillomavirus.

A method for treating or preventing a bacterial infection is provided according to another aspect of the invention. The method involves administering to a subject having or at risk of having a bacterial infection, an effective amount for treating or preventing  
10 the bacterial infection of any of the compositions of the invention. In one embodiment the bacterial infection is due to an intracellular bacteria.

In another aspect the invention is a method for treating or preventing a parasite infection by administering to a subject having or at risk of having a parasite infection, an effective amount for treating or preventing the parasite infection of any of the  
15 compositions of the invention. In one embodiment the parasite infection is due to an intracellular parasite. In another embodiment the parasite infection is due to a non-helminthic parasite.

In some embodiments the subject is a human and in other embodiments the subject is a non-human vertebrate selected from the group consisting of a dog, cat, horse,  
20 cow, pig, goat, fish, monkey, chicken, and sheep.

In yet another aspect, the invention is a method for treating or preventing asthma, by administering to a subject having or at risk of having asthma, an effective amount for treating or preventing the asthma of any of the compositions of the invention. In one embodiment the asthma is allergic asthma.

25 In another aspect the invention relates to a method for treating or preventing allergy. The method involves administering to a subject having or at risk of having allergy, an effective amount for treating or preventing the allergy of any of the compositions of the invention.

A method for treating or preventing an immune deficiency is provided according  
30 to another aspect of the invention. The method involves administering to a subject having or at risk of an immune deficiency, an effective amount for treating or preventing the immune deficiency of any of the compositions of the invention.



- 18 -

In another aspect the invention relates to a method for inducing a TH1 immune response by administering to a subject any of the compositions of the invention in an effective amount to produce a TH1 immune response.

In one embodiment the methods of the invention involve administering an oligonucleotide of formula 5' Y<sub>1</sub>N<sub>1</sub>ZN<sub>2</sub>Y<sub>2</sub> 3' and an immunostimulatory nucleic acid having an unmethylated CG dinucleotide a TG dinucleotide or a T-rich sequence. In an embodiment the oligonucleotide comprising 5' Y<sub>1</sub>N<sub>1</sub>ZN<sub>2</sub>Y<sub>2</sub> 3' is administered separately from the immunostimulatory nucleic acid. In some embodiments the oligonucleotide comprising 5' Y<sub>1</sub>N<sub>1</sub>ZN<sub>2</sub>Y<sub>2</sub> 3' and the immunostimulatory nucleic acid are administered on an alternating weekly schedule and in other embodiments the oligonucleotide comprising 5' Y<sub>1</sub>N<sub>1</sub>ZN<sub>2</sub>Y<sub>2</sub> 3' and the immunostimulatory nucleic acid are administered on an alternating biweekly schedule.

The invention provides in another aspect a composition, comprising an immunostimulatory nucleic acid and an anti-cancer therapy, formulated in a pharmaceutically-acceptable carrier and in an effective amount to treat a cancer or to reduce the risk of developing a cancer. In important embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid.

The invention further provides a kit comprising a first container housing an immunostimulatory nucleic acid and at least one other container (e.g., a second container) housing a an anti-cancer therapy, and instructions for use. In one embodiment, the kit further comprises interferon- $\alpha$ , which may be separately housed in yet another container (e.g., a third container). In an important embodiment, the kit comprises a sustained-release vehicle containing an immunostimulatory nucleic acid, and at least one container housing an anti-cancer therapy, and instructions for timing of administration of the anti-cancer therapy. The immunostimulatory nucleic acid may be selected from the group consisting of a Py-rich nucleic acid, a TG nucleic acid and a CpG nucleic acid, wherein the CpG nucleic acid has a nucleotide sequence comprising SEQ ID NO: 246.

The invention further provides a method for preventing or treating asthma or allergy, comprising administering an immunostimulatory nucleic acid and an asthma/allergy medicament in an effective amount to treat or prevent the asthma or



- 19 -

allergy. In important embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid.

In one embodiment the immunostimulatory nucleic acid is a T-rich nucleic acid. In a related embodiment, the T-rich nucleic acid has a nucleotide sequence selected from the group consisting of SEQ ID NO: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. In other embodiments the T-rich nucleic acids are sequence selected from the group consisting of SEQ ID NO: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

In yet a further related embodiment, the T-rich nucleic acid is not a TG nucleic acid. In yet still another embodiment, the T-rich nucleic acid is not a CpG nucleic acid.

In one embodiment, the immunostimulatory nucleic acid is a TG nucleic acid. In a further related embodiment, the TG nucleic acid is not a T-rich nucleic acid. In another related embodiment, the TG nucleic acid is not a CpG nucleic acid.

In one embodiment, the immunostimulatory nucleic acid is a CpG nucleic acid, wherein the CpG nucleic acid has a nucleotide sequence comprising SEQ ID NO: 246.

In another embodiment, the asthma/allergy medicament is a medicament selected from the group consisting of PDE-4 inhibitor, Bronchodilator/beta-2 agonist, K<sup>+</sup> channel opener, VLA-4 antagonist, Neurokin antagonist, TXA<sub>2</sub> synthesis inhibitor, Xanthanine, Arachidonic acid antagonist, 5 lipoxygenase inhibitor, Thromboxin A<sub>2</sub> receptor antagonist, Thromboxane A<sub>2</sub> antagonist, Inhibitor of 5-lipoxygenase activation protein, and Protease inhibitor, but is not so limited. In some important embodiments, the asthma/allergy medicament is a Bronchodilator/beta-2 agonist selected from the group consisting of salmeterol, salbutamol, terbutaline, D2522/formoterol, fenoterol, and orciprenaline.

In another embodiment, the asthma/allergy medicament is a medicament selected from the group consisting of Anti-histamines and Prostaglandin inducers. In one embodiment, the anti-histamine is selected from the group consisting of loratidine, cetirizine, buclizine, ceterizine analogues, fexofenadine, terfenadine, desloratadine,



- 20 -

norastemizole, epinastine, ebastine, ebastine, astemizole, levocabastine, azelastine, tranilast, terfenadine, mizolastine, betatastine, CS 560, and HSR 609. In another embodiment, the Prostaglandin inducer is S-5751.

5 In yet another embodiment, the asthma/allergy medicament is selected from the group consisting of Steroids and Immunomodulators. The immunomodulators may be selected from the group consisting of anti-inflammatory agents, leukotriene antagonists, IL4 muteins, Soluble IL-4 receptors, Immunosuppressants, anti-IL-4 antibodies, IL-4 antagonists, anti-IL-5 antibodies, soluble IL-13 receptor-Fc fusion proteins, anti-IL-9 antibodies, CCR3 antagonists, CCR5 antagonists, VLA-4 inhibitors, and Downregulators  
10 of IgE, but are not so limited. In one embodiment, the downregulator of IgE is an anti-IgE.

In another embodiment, the Steroid is selected from the group consisting of beclomethasone, fluticasone, tramcinolone, budesonide, and budesonide. In still a further embodiment, the Immunosuppressant is a Tolerizing peptide vaccine.

15 In one embodiment, the immunostimulatory nucleic acid is administered concurrently with the asthma/allergy medicament. In another embodiment, the subject is an immunocompromised subject

The immunostimulatory nucleic acids to be administered to a subject in the methods disclosed herein relating to the prevention and treatment of asthma/allergy are  
20 as described for other method aspects of the invention.

In another aspect, the invention provides a kit comprising a first container housing an immunostimulatory nucleic acid, and at least another container (e.g., a second container) housing an asthma/allergy medicament, and instructions for use. The immunostimulatory nucleic acid useful in the kit is as described herein. In important  
25 embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid. In another important embodiment, the kit comprises a sustained-release vehicle containing an immunostimulatory nucleic acid, and at least one container housing an asthma/allergy medicament, and instructions for timing of administration of the asthma/allergy  
30 medicament. The asthma/allergy medicament may be selected from the group of asthma/allergy medicaments described in the foregoing methods directed towards the prevention or treatment of asthma/allergy.



- 21 -

In yet another aspect, the invention provides a composition, comprising an immunostimulatory nucleic acid and an asthma/allergy medicament, formulated in a pharmaceutically-acceptable carrier and in an effective amount for preventing or treating an immune response associated with exposure to a mediator of asthma or allergy. The immunostimulatory nucleic acid may be selected from the group of immunostimulatory nucleic acids described for the foregoing methods and compositions. In important  
5       embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid. The asthma/allergy medicament may be selected from the group consisting of asthma medicaments and  
10       allergy medicaments as described in the foregoing methods and compositions.

In still a further aspect, the invention provides a composition comprising an immunostimulatory nucleic acid selected from the group consisting of SEQ ID NO: 95-136, SEQ ID NO: 138-152, SEQ ID NO: 154-222, SEQ ID NO: 224-245, SEQ ID NO: 247-261, SEQ ID NO: 263-299, SEQ ID NO: 301, SEQ ID NO: 303-4109, SEQ ID NO:  
15       414-420, SEQ ID NO: 424, SEQ ID NO: 426-947, SEQ ID NO: 959-1022, SEQ ID NO: 1024-1093, and a pharmaceutically acceptable carrier. Preferably the immunostimulatory nucleic acid is present in the composition in an effective amount. In one embodiment, the immunostimulatory nucleic acid is present in an effective amount to induce an immune response. In another embodiment, the immunostimulatory nucleic  
20       acid is present in an effective amount to prevent or treat cancer. In yet a further embodiment, the immunostimulatory nucleic acid is present in an effective amount to prevent or treat asthma/allergy. The invention also provides kits comprising any of the foregoing immunostimulatory nucleic acid compositions, and instructions for use.

In another aspect the invention includes a composition of an immunostimulatory  
25       nucleic acid consisting essentially of: 5' M<sub>1</sub>TCGTCGTTM<sub>2</sub> 3' wherein at least one of the Cs is unmethylated, wherein M<sub>1</sub> is a nucleic acid having at least one nucleotide, wherein M<sub>2</sub> is a nucleic acid having between 0 and 50 nucleotides, and wherein the immunostimulatory nucleic acid has less than 100 nucleotides.

In yet other aspects the invention relates to a pharmaceutical composition of an  
30       immunostimulatory nucleic acid comprising: 5' TCGTCGTT 3' wherein at least one of the Cs is unmethylated, wherein the immunostimulatory nucleic acid has less than 100 nucleotides and a phosphodiester backbone, and a sustained release device. In some



- 22 -

embodiments the sustained release device is a microparticle. In other embodiments the composition includes an antigen.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a histogram of the expression of CD86 (Y-axis) by CD19+ cells following exposure of these cells to the oligonucleotides shown on the X-axis at a concentration of 0.15  $\mu\text{g/ml}$ .

Figure 1B is a histogram of the expression of CD86 (Y-axis) by CD19+ cells following exposure of these cells to the oligonucleotides shown on the X-axis at a concentration of 0.30  $\mu\text{g/ml}$ .

Figure 2 is a graph comparing the abilities of ODN 2137, ODN 2177, ODN 2200 and ODN 2202 to stimulate B cell proliferation at concentrations ranging from 0.2  $\mu\text{g/ml}$  to 20  $\mu\text{g/ml}$ .

Figure 3 is a graph comparing the abilities of ODN 2188, ODN 2189, ODN 2190 and ODN 2182 to stimulate B cell proliferation at concentrations ranging from 0.2  $\mu\text{g/ml}$  to 20  $\mu\text{g/ml}$ .

Fig. 4 is a bar graph depicting dose-dependent B cell activation induced by non-CpG ODN. PBMC of a blood donor were incubated with the indicated concentrations of ODNs 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 5126 (SEQ ID NO.: 1058) and 5162 (SEQ ID NO.: 1094) and stained with mAb for CD19 (B cell marker) and CD86 (B cell activation marker, B7-2). Expression was measured by flow cytometry.

Fig. 5 is a bar graph depicting stimulation of B cells by a diverse set of non-CpG ODNs. PBMC of one representative donor were stimulated by 0.4 $\mu\text{g/ml}$ , 1.0 $\mu\text{g/ml}$  or 10.0 $\mu\text{g/ml}$  of the following ODNs: 2006 (SEQ ID NO.: 246), 2196 (SEQ ID NO.: 913), 2194 (SEQ ID NO.: 911), 5162 (SEQ ID NO.: 1094), 5163 (SEQ ID NO.: 1095), 5168 (SEQ ID NO.: 1096) and 5169 (SEQ ID NO.: 1097) and expression of the activation marker CD86 (B7-2) on CD19-positive B cells was measured by flow cytometry.



- 23 -

Fig 6 is a bar graph depicting B cell activation by non-CpG ODNs 1982 and 2041. PBMC were incubated with the indicated concentrations of ODN 2006 (SEQ ID NO.: 246), 1982 (SEQ ID NO.: 225) and 2041 (SEQ ID NO.: 282) and B cell activation (expression of the activation marker CD86) was measured by flow cytometry.

5 Fig. 7 is a bar graph depicting NK cells are activated by non-CpG ODNs. PBMC were incubated with 6µg/ml of the following ODNs: 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058) and stained with mAb for CD3 (T cell marker), CD56 (NK cell marker) and CD69 (early activation marker). Expression of  
10 CD69 on CD56-positive NK cells was measured by flow cytometry.

Fig. 8 is a bar graph depicting NK-mediated cytotoxicity is enhanced by non-CpG ODN. NK-mediated lysis of K-562 target cells was measured after over night incubation of PBMC with 6µg/ml of the ODN 2006 (SEQ ID NO.: 246), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058).

15 Fig. 9 is a bar graph depicting NKT cells can be activated by non-CpG ODN. PBMC of one representative donor were incubated with 6µg/ml ODN 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058) for 24h and activation of NKT cells was measured by flow cytometry after staining of cells with mAb for CD3 (T  
20 cell marker), CD56 (NK cell marker) and CD69 (early activation marker).

Fig. 10 is a bar graph depicting stimulation of monocytes by different CpG and non-CpG ODN. PBMC were incubated with 6µg/ml 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2178 (SEQ ID NO.: 428), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911), 5126 (SEQ ID NO.: 1058) and 5163 (SEQ ID NO.:  
25 1095) and stained for CD14 (monocyte marker) and CD80 (B7-1, activation marker). Expression was measured by flow cytometry.

Fig. 11 is a bar graph depicting release of TNFα upon culture of human cells with non-CpG ODN. PBMC were cultured for 24h with or without 6µg/ml of the indicated ODNs or 1µg/ml LPS as positive control and TNFα measured by ELISA.

30 Fig. 12 is a bar graph depicting release of IL-6 after culture with non-CpG ODNs shows the same pattern as for TNFα. PBMC were cultured with the indicated ODNs (1.0µg/ml) and IL-6 was measured in the supernatants by ELISA.



- 24 -

DETAILED DESCRIPTION

The invention in one aspect involves the finding that pyrimidine (Py) rich and preferably thymidine (T) rich nucleic acids as well as nucleic acids that contain TG dinucleotide motifs are effective in mediating immune stimulatory effects. It was known in the prior art that CpG containing nucleic acids are therapeutic and prophylactic compositions that stimulate the immune system to treat cancer, infectious diseases, allergy, asthma and other disorders and to help protect against opportunistic infections following cancer chemotherapies. The strong yet balanced, cellular and humoral immune responses that result from CpG stimulation reflect the body's own natural defense system against invading pathogens and cancerous cells. CpG sequences, while relatively rare in human DNA are commonly found in the DNA of infectious organisms such as bacteria. The human immune system has apparently evolved to recognize CpG sequences as an early warning sign of infection, and to initiate an immediate and powerful immune response against invading pathogens without causing adverse reactions frequently seen with other immune stimulatory agents. Thus CpG containing nucleic acids, relying on this innate immune defense mechanism, can utilize a unique and natural pathway for immune therapy. The effects of CpG nucleic acids on immune modulation were discovered by the inventor of the instant patent application and have been described extensively in co-pending patent applications, such as U.S. Patent Application Serial Nos: 08/386,063 filed on 02/07/95 (and related PCT US95/01570); 08/738,652 filed on 10/30/96; 08/960,774 filed on 10/30/97 (and related PCT/US97/19791, WO 98/18810); 09/191,170 filed on 11/13/98; 09/030,701 filed on 02/25/98 (and related PCT/US98/03678; 09/082,649 filed on 05/20/98 (and related PCT/US98/10408); 09/325,193 filed on 06/03/99 (and related PCT/US98/04703); 09/286,098 filed on 04/02/99 (and related PCT/US99/07335); 09/306,281 filed on 05/06/99 (and related PCT/US99/09863). The entire contents of each of these patents and patent applications is hereby incorporated by reference.

The findings of the instant invention are applicable to all of the above described uses of CpG containing nucleic acids as well as any other known use for CpG nucleic acids. The invention involves, in one aspect, the discovery that Py-rich and preferably T-rich and TG nucleic acids have similar immune stimulatory properties to CpG oligonucleotides regardless of whether a CpG motif is present. Thus the invention is



- 25 -

useful for any method for stimulating the immune system using Py-rich or TG nucleic acids. It was also discovered surprisingly according to the invention that chimeric oligonucleotides which lack a CpG motif are immune stimulatory and have many of the same prophylactic and therapeutic activities as a CpG oligonucleotide.

5 A Py-rich nucleic acid is a T-rich or C-rich immunostimulatory nucleic acid. In some embodiments T-rich nucleic acids are preferred. A T-rich nucleic acid is a nucleic acid which includes at least one poly T sequence and/or which has a nucleotide composition of greater than 25% T nucleotide residues. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'TTTT3'. Preferably the T-rich  
10 nucleic acid includes more than one poly T sequence. In preferred embodiments the T-rich nucleic acid may have 2, 3, 4, etc poly T sequences, such as oligonucleotide #2006 (SEQ ID NO:246). One of the most highly immunostimulatory T-rich oligonucleotides discovered according to the invention is a nucleic acid composed entirely of T nucleotide residues, e.g., oligonucleotide #2183 (SEQ ID NO:433). Other T-rich nucleic acids  
15 according to the invention have a nucleotide composition of greater than 25% T nucleotide residues, but do not necessarily include a poly T sequence. In these T-rich nucleic acids the T nucleotide residues may be separated from one another by other types of nucleotide residues, i.e., G, C, and A. In some embodiments the T-rich nucleic acids have a nucleotide composition of greater than 35%, 40%, 50%, 60%, 70%, 80%, 90%,  
20 and 99%, T nucleotide residues and every integer % in between. Preferably the T-rich nucleic acids have at least one poly T sequence and a nucleotide composition of greater than 25% T nucleotide residues.

It was discovered according to the invention that the T content of an ODN has a dramatic effect on the immune stimulatory effect of the ODN and that T-rich ODN can  
25 activate multiple human immune cell types in the absence of any CpG motifs. An oligonucleotide having a 3' poly-T region and 2 5'CGs e.g., ODN 2181 (SEQ ID NO:431) is highly immune stimulatory. An oligonucleotide of similar length, ODN 2116 (SEQ ID NO:357) which contains two CG dinucleotides at the 5' end and a poly-C region at the 3' end was also immune stimulatory but to a lesser extent than the T-rich  
30 oligonucleotide using standard experimental conditions. Thus, although C and T have almost identical structures, their effects on the immune properties of an ODN are varied. They both are capable of inducing an immune response but to different extents. Thus



- 26 -

both T-rich and C-rich oligonucleotides are useful according to the invention, but T-rich oligonucleotides are preferred. Furthermore, if the T content of the ODN is reduced by incorporating other bases such as G, A, or C, then the immune stimulatory effects are reduced (ODN #2188 (SEQ ID NO:905), 2190 (SEQ ID NO:907), 2191 (SEQ ID  
5 NO:908), and 2193 (SEQ ID NO:910)).

A C-rich nucleic acid is a nucleic acid molecule having at least one or preferably at least two poly-C regions or which is composed of at least 50% C nucleotides. A poly-C region is at least four C residues in a row. Thus a poly-C region is encompassed by the formula 5'CCCC 3'. In some embodiments it is preferred that the poly-C region  
10 have the formula 5'CCCCC 3'. Other C-rich nucleic acids according to the invention have a nucleotide composition of greater than 50% C nucleotide residues, but do not necessarily include a poly C sequence. In these C-rich nucleic acids the C nucleotide residues may be separated from one another by other types of nucleotide residues, i.e., G, T, and A. In some embodiments the C-rich nucleic acids have a nucleotide composition  
15 of greater than 60%, 70%, 80%, 90%, and 99%, C nucleotide residues and every integer % in between. Preferably the C-rich nucleic acids have at least one poly C sequence and a nucleotide composition of greater than 50% C nucleotide residues, and in some embodiments are also T-rich.

As shown in the Examples, several ODN previously believed to be non-  
20 immunostimulatory, including two ODNs SEQ ID NO.: 225 and SEQ ID NO.: 282 previously described to be non-stimulatory and mainly used as control ODNs (Takahashi, T et al 2000. *J. Immunol.* 164:4458) were found to be immunostimulatory. Our experiments, demonstrated that these ODNs can stimulate B cells, although at higher concentrations compared to CpG ODNs (Fig. 6). A long Poly T ODN (30mer) induced,  
25 at least in some experiments, comparable strong activation of B cells to one of the strongest CpG ODN activators of B cells. These experiments also revealed the surprising finding that even Poly C ODNs can lead to stimulation of B cells.

Immunostimulation by these ODNs, however, was not limited to human B cells. Different experimental assays clearly demonstrated in addition that monocytes, NK cells  
30 and even NKT cells can be activated by such non-CpG ODNs (Fig. 7 – 10). In contrast to Poly T and Poly C sequences, immunostimulation by Poly A sequences (at least for monocytes, B and NK cells) was not achieved. Interestingly it was found that the



- 27 -

introduction of a CpG motif into SEQ ID NO.: 225 enhanced the immunostimulatory activity whereas the elongation with a Poly T stretch did not enhance immunostimulation. This suggests that CpG and T-rich ODN may operate through different mechanisms or pathways. It is also possible that insertion of a poly-T motif  
 5 into a different position of SEQ ID NO.: 225 may result in a change in immunostimulatory properties.

A "TG nucleic acid" or a "TG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one TpG dinucleotide (thymidine-guanine dinucleotide sequence, i.e. "TG DNA" or DNA containing a 5' thymidine followed by 3' guanosine  
 10 and linked by a phosphate bond) and activates a component of the immune system.

In one embodiment the invention provides a TG nucleic acid represented by at least the formula:



wherein  $X_1$  and  $X_2$  are nucleotides and N is any nucleotide and  $N_1$  and  $N_2$  are  
 15 nucleic acid sequences composed of any number of N provided that the sum total of  $N_1$  and  $N_2$  is in the range of 11 to 21. As an example, if  $N_1$  is 5, then  $N_2$  may be 6 (leading to a total length for the oligonucleotide of 15 nucleotides). The TG may be located anywhere within the oligonucleotide stretch, including the 5' end, the center and the 3' end. Thus,  $N_1$  may be zero through to 21, inclusive, provided that  $N_2$  is appropriately  
 20 chosen to give a sum of  $N_2$  and  $N_1$  equal to 11 through to 21, inclusive. Similarly,  $N_2$  may be zero through to 21, inclusive, provided that the sum total of  $N_1$  and  $N_2$  equals 11 to 21, inclusive. In some embodiments  $X_1$  is adenine, guanine, or thymidine and  $X_2$  is cytosine, adenine, or thymidine. In one preferred embodiment,  $X_2$  is thymidine. In other  
 25 embodiments  $X_1$  is cytosine and/or  $X_2$  is guanine. In other embodiments, as discussed herein, the nucleic acid may encompass other motifs, provided it is long enough to do so.

In other embodiments the TG nucleic acid is represented by at least the formula:



wherein  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  are nucleotides. In some embodiments,  $X_1X_2$  are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, TpA and TpT; and  $X_3X_4$  are nucleotides selected from the group consisting  
 30 of: TpT, CpT, ApT, ApG, TpC, ApC, CpC, TpA, ApA, and CpA; N is any nucleotide and  $N_1$  and  $N_2$  are nucleic acid sequences composed of any number of nucleotides



- 28 -

provide that the sum total of  $N_1$  and  $N_2$  is in the range of 9 to 19. In some embodiments,  $X_1X_2$  are GpA or GpT and  $X_3X_4$  are TpT. In other embodiments  $X_1$  or  $X_2$  or both are purines and  $X_3$  or  $X_4$  or both are pyrimidines or  $X_1X_2$  are GpA and  $X_3$  or  $X_4$  or both are pyrimidines. In one preferred embodiment,  $X_3X_4$  are nucleotides selected from the group consisting of: TpT, TpC and TpA.

The immunostimulatory nucleic acid may be any size (i.e., length) provided it is at least 4 nucleotides. In important embodiments, the immunostimulatory nucleic acids have a length in the range of between 6 and 100. In still other embodiments, the length is in the range of between 8 and 35 nucleotides. Preferably, the TG oligonucleotides range in size from 15 to 25 nucleotides.

The size (i.e., the number of nucleotide residues along the length of the nucleic acid) of the immunostimulatory nucleic acid may also contribute to the stimulatory activity of the nucleic acid. It has been discovered, surprisingly that even for highly immune stimulating immunostimulatory nucleic acids, the length of the nucleic acid influences the extent of immunostimulation that can be achieved. It has been demonstrated that increasing the length of a T-rich nucleic acid up to 24 nucleotides causes increased immune stimulation. The experiments presented in the examples demonstrate that when the length of the T-rich nucleic acid is increased from 18 to 27 nucleotides the ability of the nucleic acid to stimulate an immune response is increased significantly (compare ODN #2194, 2183, 2195, and 2196 decreasing in size from 27-18 nucleotides). Increasing the length of the nucleic acid up to 30 nucleotides had a dramatic impact on the biological properties of the nucleic acid but increasing the length beyond 30 nucleotides did not appear to further influence the immune stimulatory effect (e.g., compare ODN 2179 to 2006).

It has been shown that TG nucleic acids ranging in length from 15 to 25 nucleotides in length may exhibit an increased immune stimulation. Thus, in one aspect, the invention provides an oligonucleotide that is 15-27 nucleotides in length (i.e., an oligonucleotide that is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27 nucleotides in length) that may be a T-rich nucleic acid or may be a TG nucleic acid, or may be both a T-rich and a TG nucleic acid. In one embodiment, the oligonucleotide is not a T-rich nucleic acid nor is it a TG nucleic acid. In other embodiments, the oligonucleotide does not have a CG motif. The invention similarly provides oligonucleotides that are 15-27



- 29 -

nucleotides in length, oligonucleotides that are 18-25 nucleotides in length, oligonucleotides that are 20-23 nucleotides in length, and oligonucleotides that are 23-25 nucleotides in length. Any of the foregoing embodiments relating to oligonucleotides 15-27 in length also relate to the oligonucleotides of these differing lengths. The invention further embraces the use of any of these foregoing oligonucleotides in the methods recited herein.

Although a maximal level of immune stimulation is achieved with some T-rich nucleic acids when the nucleic acid is 24-30 nucleotide residues in length, as well as with some TG nucleic acids that range from 15 to 25 nucleotides in length, shorter or longer immunostimulatory nucleic acids can also be used according to the methods of the invention. For facilitating uptake into cells immunostimulatory nucleic acids preferably have a minimum length of 6 nucleotide residues. Nucleic acids of any size greater than 6 nucleotides (even many kb long) are capable of inducing an immune response according to the invention if sufficient immunostimulatory motifs are present, since larger nucleic acids are degraded inside of cells. Preferably the immunostimulatory nucleic acids are in the range of between 8 and 100 and in some embodiments T-rich containing immunostimulatory nucleic acids are between 24 and 40 nucleotides in length and TG containing immunostimulatory nucleic acids are between 15 and 25 nucleotides in length.

In one embodiment the T-rich nucleic acid is represented by at least the formula:



wherein  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  are nucleotides. In one embodiment  $X_1X_2$  is TT and/or  $X_3X_4$  is TT. In another embodiment  $X_1X_2$  are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC; and  $X_3X_4$  are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC.

In some embodiments it is preferred that the immunostimulatory nucleic acids do not contain poly-C (CCCC), or poly-A (AAAA). In other embodiments it is preferred that the immunostimulatory nucleic acid include poly-C, poly-A, poly-G (GGGG) or multiple GGs. In particular poly-G or multiple GG motifs have dramatic effects on some immunostimulatory nucleic acids. The effect of these non-T sequences depends in part on the status of the nucleic acid backbone. For instance, if the nucleic acid has a



- 30 -

phosphodiester backbone or a chimeric backbone the inclusion of these sequences in the nucleic acid will only have minimal if any effect on the biological activity of the nucleic acid. If the backbone is completely phosphorothioate (or other phosphate modification) or significantly phosphorothioate then the inclusion of these sequences may have more influence on the biological activity or the kinetics of the biological activity, causing a decrease in potency of the T-rich and TG immunostimulatory nucleic acids.

Although C-rich nucleic acids have been demonstrated to have immune stimulating properties, insertion of Poly-C sequences into a T-rich nucleic acid in a manner that would reduce the relative proportion of T nucleotides in the nucleic acid can have a negative impact on the nucleic acid. Although applicants are not bound by a proposed mechanism, it is believed that the immune system has developed a mechanism for distinguishing nucleic acids having different nucleotide properties, possibly resulting from different sets of binding proteins which recognize different sequences or specific binding proteins which recognize all the immunostimulatory sequences but with different affinities. In general nucleic acids including unmethylated CpG motifs are the most immunostimulatory, followed by T-rich nucleic acids, TG nucleic acids and C-rich nucleic acids. This generalization, however, has many exceptions. For instance a strong T-rich nucleic acid like SEQ ID NO.: 886 is more immune stimulatory in some assays than some CpG containing nucleic acids (e.g., a phosphorothioate CpG nucleic acid containing a single CpG motif).

It has also been discovered that the addition of a poly-A tail to an immunostimulatory nucleic acid can enhance the activity of the nucleic acid. It was discovered that when a highly immune stimulatory CpG nucleic acid (SEQ ID NO.: 246) was modified with the addition of a poly-A tail (AAAAAA) or a poly-T tail (TTTTTT), the resultant oligonucleotides increased in immune stimulatory activity. The ability of the poly-A tail and the poly-T tail to increase the immunostimulating properties of the oligonucleotide was very similar. SEQ ID NO.: 246 is a T-rich oligonucleotide. It is likely that if poly-A and poly-T tails are added to a nucleic acid which is not T-rich, it would have a bigger impact on the immune stimulating capability of the nucleic acid. Since the poly-T tail was added to a nucleic acid that was already highly T-rich the immune stimulating properties of the poly-T addition was diluted somewhat, although not completely. This finding has important implications for the use of poly-A regions.



- 31 -

Thus in some embodiments the immunostimulatory nucleic acids include a poly-A region and in other embodiments they do not.

Some of the immunostimulatory nucleic acids of the invention include one or more CG motifs. The presence of CG motifs in the immunostimulatory nucleic acids also has an influence on the biological activity of the nucleic acids. If the total length of an immunostimulatory nucleic acid is 20 nucleotide residues or less, then CpG motifs are important in determining the immune effect of the nucleic acid, and methylation of these motifs reduces the potency of the immune stimulatory effects of the nucleic acid. If the length of the immunostimulatory nucleic acid is increased to 24, then the immune stimulatory effects of the nucleic acid become less dependent on the CpG motifs, and are no longer abolished by methylation of the CpG motifs or by their inversion to GC dinucleotides, provided the other immune-stimulatory properties described herein are present.

For example, ODN 2006 (SEQ ID NO:246) is a highly immune stimulatory T-rich nucleic acid of 24 nucleotide residues in length with four CpG dinucleotides. However, ODN 2117 (SEQ ID NO:358), in which the CpG motifs are methylated is also highly immune stimulatory. ODN 2137 (SEQ ID NO:886), in which the CpG motifs of ODN 2006 are inverted to GpC, and which as a result possesses six TG dinucleotides is also immune stimulatory. The immune stimulatory effects of nucleic acids such as ODN 2117 and 2137 are regulated by their T and TG content. Each of these three nucleic acids is T-rich and ODN 2137 is additionally TG rich. If their T content is reduced by inserting other bases such as A (ODN 2117 (SEQ ID NO:358)) or if their TG content is reduced by substituting TG with AG, then the immune stimulatory effects are somewhat reduced. In another example, a nucleic acid 24 nucleotides in length in which all of the positions are randomized has only a modest immune stimulatory effect (ODN 2182 (SEQ ID NO:432)). Likewise, a nucleic acid 24 nucleotides in length with other nucleotide compositions have variable immune stimulatory effects, depending on their T content (ODN 2188 (SEQ ID NO:905), 2189 (SEQ ID NO:906), 2190 (SEQ ID NO:907), 2191 (SEQ ID NO:908), 2193 (SEQ ID NO:910), 2183 (SEQ ID NO:433), and 2178 (SEQ ID NO:428)). ODN 2190 which contains TGT motifs is more immune stimulatory than ODN 2202 which possesses TGG motifs. Thus, in some embodiments, TGT motifs are preferred. In still other embodiments, the number of TG motifs is



- 32 -

important in that an increase in the number of TG motifs leads to an increase in immune stimulation. Some preferred TG nucleic acids contain at least three TG motifs.

Examples of CpG nucleic acids include but are not limited to those listed in Table A, such as SEQ ID NO: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69,  
 5 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-150,  
 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-  
 240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302,  
 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365,  
 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-  
 10 437, 439, 441-443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478,  
 480, 483-485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541,  
 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622,  
 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737,  
 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 7900792,  
 15 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865,  
 872, 874-877, 879-881, 883-885, 888-904, and 909-913.

In some embodiments of the invention the immunostimulatory nucleic acids include CpG dinucleotides and in other embodiments the immunostimulatory nucleic acids are free of CpG dinucleotides. The CpG dinucleotides may be methylated or  
 20 unmethylated. A nucleic acid containing at least one unmethylated CpG dinucleotide is a nucleic acid molecule which contains an unmethylated cytosine-guanine dinucleotide sequence (i.e. "CpG DNA" or DNA containing an unmethylated 5' cytosine followed by 3' guanosine and linked by a phosphate bond) and activates the immune system. A nucleic acid containing at least one methylated CpG dinucleotide is a nucleic acid which  
 25 contains a methylated cytosine-guanine dinucleotide sequence (i.e., a methylated 5' cytosine followed by a 3' guanosine and linked by a phosphate bond).

Examples of T rich nucleic acids that are free of CpG nucleic acids include but are not limited to those listed in Table A, such as SEQ ID NO: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491,  
 30 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. Examples of T rich nucleic acids that include CpG nucleic acids include but are not limited to those listed in Table A, such as SEQ ID NO: 64, 98, 112,



- 33 -

146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

The immunostimulatory nucleic acids can be double-stranded or single-stranded. Generally, double-stranded molecules are more stable *in vivo*, while single-stranded molecules have increased immune activity. Thus in some aspects of the invention it is preferred that the nucleic acid be single stranded and in other aspects it is preferred that the nucleic acid be double stranded.

The term T-rich nucleic acid and TG nucleic acid, as used herein, refers to an immunostimulatory T-rich nucleic acid and an immunostimulatory TG nucleic acid, respectively, unless otherwise indicated. The T-rich nucleic acid sequences of the invention are those broadly described above as well as the nucleic acids shown in Table A that have at least one poly T motif and/or have a composition of greater than 25% T or preferably 35% nucleotide residues. The C-rich nucleic acids are those having at least one and preferably at least two poly-C regions. The TG nucleic acids of the invention are those broadly described above as well as the specific nucleic acids shown in Table A that have at least one TG motif.

The nucleic acids of the invention may, but need not, also include a poly G motif. Poly G containing nucleic acids are also immunostimulatory. A variety of references, including Pisetsky and Reich, 1993 *Mol. Biol. Reports*, 18:217-221; Krieger and Herz, 1994, *Ann. Rev. Biochem.*, 63:601-637; Macaya et al., 1993, *PNAS*, 90:3745-3749; Wyatt et al., 1994, *PNAS*, 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, ed. Krieg and Stein, p. 335-352; and Kimura et al., 1994, *J. Biochem.* 116, 991-994 also describe the immunostimulatory properties of poly G nucleic acids.

Poly G nucleic acids preferably are nucleic acids having the following formulas:



wherein  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  are nucleotides. In preferred embodiments at least one of  $X_3$  and  $X_4$  are a G. In other embodiments both of  $X_3$  and  $X_4$  are a G. In yet other embodiments the preferred formula is 5' GGGNGGG 3', or 5' GGGNGGGNGGG 3' wherein N represents between 0 and 20 nucleotides. In other embodiments the poly G nucleic acid is free of unmethylated CG dinucleotides, such as, for example, the nucleic



- 34 -

acids listed below as SEQ ID NO: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes at least one unmethylated CG dinucleotide, such as, for example, the nucleic acids listed above as

5 SEQ ID NO: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

The terms “nucleic acid” and “oligonucleotide” are used interchangeably to mean multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose)

10 linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymidine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)). As used herein, the terms refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e. a polynucleotide minus the phosphate) and any other organic base

15 containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g. produced by nucleic acid synthesis).

The terms nucleic acid and oligonucleotide also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars.

20 For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be

25 heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide- nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments, the nucleic acids are homogeneous in backbone composition. Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne modified bases (Wagner et al., *Nature*

30 *Biotechnology* 14:840- 844, 1996). Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymidine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and



- 35 -

non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties. Other such modifications are well known to those of skill in the art.

For use in the instant invention, the nucleic acids of the invention can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the b-cyanoethyl phosphoramidite method (Beaucage, S.L., and Caruthers, M.H., *Tet. Let.* 22:1859, 1981); nucleoside H-phosphonate method (Garegg *et al.*, *Tet. Let.* 27:4051-4054, 1986; Froehler *et al.*, *Nucl. Acid. Res.* 14:5399-5407, 1986, ; Garegg *et al.*, *Tet. Let.* 27:4055-4058, 1986, Gaffney *et al.*, *Tet. Let.* 29:2619-2622, 1988). These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These nucleic acids are referred to as synthetic nucleic acids. Alternatively, T-rich and/or TG dinucleotides can be produced on a large scale in plasmids, (see Sambrook, T., *et al.*, "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor laboratory Press, New York, 1989) and separated into smaller pieces or administered whole. Nucleic acids can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases. Nucleic acids prepared in this manner are referred to as isolated nucleic acid. An isolated nucleic acid generally refers to a nucleic acid which is separated from components which it is normally associated with in nature. As an example, an isolated nucleic acid may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin. The terms Py-rich nucleic acids and TG nucleic acids encompasses both synthetic and isolated Py-rich nucleic acids and TG nucleic acids.

For use *in vivo*, the Py-rich and TG nucleic acids may optionally be relatively resistant to degradation (e.g., are stabilized). A "stabilized nucleic acid molecule" shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an nucleic acid has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the nucleic acid becomes stabilized and therefore exhibits more activity.



- 36 -

Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. Preferred stabilized nucleic acids of the instant invention have a modified backbone. It has been demonstrated that modification of the nucleic acid backbone provides enhanced activity of the Py-rich and TG nucleic acids when administered *in vivo*. These stabilized structures are preferred because the Py-rich and TG molecules of the invention have at least a partial modified backbone. Py-rich and TG constructs having phosphorothioate linkages provide maximal activity and protect the nucleic acid from degradation by intracellular exo- and endo-nucleases. Other modified nucleic acids include phosphodiester modified nucleic acids, combinations of phosphodiester and phosphorothioate nucleic acid, methylphosphonate, methylphosphorothioate, phosphorodithioate, p-ethoxy, and combinations thereof. Each of these combinations and their particular effects on immune cells is discussed in more detail with respect to CpG nucleic acids in PCT Published Patent Applications PCT/US95/01570 (WO 96/02555) and PCT/US97/19791 (WO 98/18810) claiming priority to U.S. Serial Nos. 08/386,063 and 08/960,774, filed on February 7, 1995 and October 30, 1997 respectively, the entire contents of which are hereby incorporated by reference. It is believed that these modified nucleic acids may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization.

The compositions of the invention may optionally be chimeric oligonucleotides. The chimeric oligonucleotides are oligonucleotides having a formula: 5' Y<sub>1</sub>N<sub>1</sub>ZN<sub>2</sub>Y<sub>2</sub> 3'. Y<sub>1</sub> and Y<sub>2</sub> are nucleic acid molecules having between 1 and 10 nucleotides. Y<sub>1</sub> and Y<sub>2</sub> each include at least one modified internucleotide linkage. Since at least 2 nucleotides of the chimeric oligonucleotides include backbone modifications these nucleic acids are an example of one type of "stabilized immunostimulatory nucleic acids."

With respect to the chimeric oligonucleotides, Y<sub>1</sub> and Y<sub>2</sub> are considered independent of one another. This means that each of Y<sub>1</sub> and Y<sub>2</sub> may or may not have different sequences and different backbone linkages from one another in the same molecule. The sequences vary, but in some cases Y<sub>1</sub> and Y<sub>2</sub> have a poly-G sequence. A poly-G sequence refers to at least 3 Gs in a row. In other embodiments the poly-G sequence refers to at least 4, 5, 6, 7, or 8 Gs in a row. In other embodiments Y<sub>1</sub> and Y<sub>2</sub> may be TCGTCG, TCGTCGT, or TCGTCGTT (SEQ ID NO:1145). Y<sub>1</sub> and Y<sub>2</sub> may also



- 37 -

have a poly-C, poly-T, or poly-A sequence. In some embodiments  $Y_1$  and/or  $Y_2$  have between 3 and 8 nucleotides.

$N_1$  and  $N_2$  are nucleic acid molecules having between 0 and 5 nucleotides as long as  $N_1ZN_2$  has at least 6 nucleotides in total. The nucleotides of  $N_1ZN_2$  have a  
5 phosphodiester backbone and do not include nucleic acids having a modified backbone.

$Z$  is an immunostimulatory nucleic acid motif but does not include a CG. For instance,  $Z$  may be a nucleic acid a T-rich sequence, e.g. including a TTTT motif or a sequence wherein at least 50% of the bases of the sequence are Ts or  $Z$  may be a TG sequence.

10 The center nucleotides ( $N_1ZN_2$ ) of the formula  $Y_1N_1ZN_2Y_2$  have phosphodiester internucleotide linkages and  $Y_1$  and  $Y_2$  have at least one, but may have more than one or even may have all modified internucleotide linkages. In preferred embodiments  $Y_1$  and/or  $Y_2$  have at least two or between two and five modified internucleotide linkages or  
15  $Y_1$  has two modified internucleotide linkages and  $Y_2$  has five modified internucleotide linkages or  $Y_1$  has five modified internucleotide linkages and  $Y_2$  has two modified internucleotide linkages. The modified internucleotide linkage, in some embodiments is a phosphorothioate modified linkage, a phosphorodithioate modified linkage or a p-ethoxy modified linkage.

Modified backbones such as phosphorothioates may be synthesized using  
20 automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents.  
25 Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A., *Chem. Rev.* 90:544, 1990; Goodchild, J., *Bioconjugate Chem.* 1:165, 1990).

Other stabilized nucleic acids include: nonionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or  
30 aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Nucleic acids which contain diol, such as tetraethyleneglycol or



- 38 -

hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

In the case when the Py-rich or TG nucleic acid is administered in conjunction with an antigen which is encoded in a nucleic acid vector, it is preferred that the backbone of the Py-rich or TG nucleic acid be a chimeric combination of phosphodiester and phosphorothioate (or other phosphate modification). The cell may have a problem taking up a plasmid vector in the presence of completely phosphorothioate nucleic acid. Thus when both a vector and a nucleic acid are delivered to a subject, it is preferred that the nucleic acid have a chimeric backbone or have a phosphorothioate backbone but that the plasmid be associated with a vehicle that delivers it directly into the cell, thus avoiding the need for cellular uptake. Such vehicles are known in the art and include, for example, liposomes and gene guns.

The nucleic acids described herein as well as various control nucleic acids are presented below in Table A.

**Table A**

| SEQ ID NO: | ODN SEQUENCE              | BACKBONE |
|------------|---------------------------|----------|
| 1          | tctcccagcgtgcgccat        | S        |
| 2          | ataatccagcttgaaccaag      | S        |
| 3          | ataatcgacgttcaagcaag      | S        |
| 4          | taccgcgtgcgaccctct        | S        |
| 5          | ggggaggggt                | S        |
| 6          | ggggagggg                 | S        |
| 7          | ggtgaggtg                 | S        |
| 8          | tccatgtzgttcctgatgct      | O        |
| 9          | gctaccttagzgtga           | O        |
| 10         | tccatgazgttcctgatgct      | O        |
| 11         | tccatgacgttcztgatgct      | O        |
| 12         | gctagazgttagtgt           | O        |
| 13         | agctccatggtgctcactg       | S        |
| 14         | ccacgtcgaccctcaggcga      | S        |
| 15         | gcacatcgtcccgcagccga      | S        |
| 16         | gtcactcgtggtacctcga       | S        |
| 17         | gttggatacaggccagactttgttg | O        |
| 18         | gattcaacttgcgctcatcttaggc | O        |
| 19         | accatggacgaactgtttcccctc  | S        |
| 20         | accatggacgagctgtttcccctc  | S        |
| 21         | accatggacgacctgtttcccctc  | S        |
| 22         | accatggacgtactgtttcccctc  | S        |
| 23         | accatggacggtctgtttcccctc  | S        |
| 24         | accatggacgttctgtttcccctc  | S        |
| 25         | ccactcacatctgctgctccacaag | O        |
| 26         | acttctcatagtccttttggtccag | O        |



- 39 -

|    |                                         |     |
|----|-----------------------------------------|-----|
| 27 | tccatgagcttcctgagtct                    | o   |
| 28 | gaggaaggigiggaigacgt                    | o   |
| 29 | gtgaaticgttcicgggict                    | o   |
| 30 | aaaaaa                                  | s   |
| 31 | cccccc                                  | s   |
| 32 | ctgtca                                  | s   |
| 33 | tcgtag                                  | s   |
| 34 | tcgtgg                                  | s   |
| 35 | cgtcgt                                  | s   |
| 36 | tccatgtcggtcctgagtct                    | sos |
| 37 | tccatgccggtcctgagtct                    | sos |
| 38 | tccatgacggtcctgagtct                    | sos |
| 39 | tccatgacggtcctgagtct                    | sos |
| 40 | tccatgtcgatcctgagtct                    | sos |
| 41 | tccatgtcgctcctgagtct                    | sos |
| 42 | tccatgtcgttcctgagtct                    | sos |
| 43 | tccatgacgttcctgagtct                    | sos |
| 44 | tccataacgttcctgagtct                    | sos |
| 45 | tccatgacgtccctgagtct                    | sos |
| 46 | tccatcacgtgcctgagtct                    | sos |
| 47 | tccatgctggtcctgagtct                    | sos |
| 48 | tccatgtzggtcctgagtct                    | sos |
| 49 | ccgcttcctccagatgagctcatgggtttctccaccaag | o   |
| 50 | cttggtggagaaacccatgagctcatctggaggaagcgg | o   |
| 51 | cccaaagggatgagaagtt                     | o   |
| 52 | agatagcaaatacggctgacg                   | o   |
| 53 | ggttcacgtgctcatggctg                    | o   |
| 54 | tctcccagcgtgcgccat                      | s   |
| 55 | tctcccagcgtgcgccat                      | s   |
| 56 | taccgcgtgcgaccctct                      | s   |
| 57 | ataatccagcttgaaccaag                    | s   |
| 58 | ataatcgacgttcaagcaag                    | s   |
| 59 | tccatgattttcctgatttt                    | o   |
| 60 | ttgtttttttgtttttttgttttt                | s   |
| 61 | ttttttttgtttttttgttttt                  | o   |
| 62 | tgtgtcttttgtgtttttgtgtct                | s   |
| 63 | tgtgtcttgtgtttttgtgtct                  | o   |
| 64 | gcattcatcaggcgggcaagaat                 | o   |
| 65 | taccgagcttcgacgagatttca                 | o   |
| 66 | gcatgacgttgagct                         | s   |
| 67 | cacgttgaggggcat                         | s   |
| 68 | ctgctgagactggag                         | s   |
| 69 | tccatgacgttcctgacgtt                    | s   |
| 70 | gcatgagcttgagctga                       | o   |
| 71 | tcagcgtgcgcc                            | s   |
| 72 | atgacgttcctgacgtt                       | s   |
| 73 | ttttggggttttggggtttt                    | s   |
| 74 | tctaggctttttaggcttcc                    | s   |
| 75 | tgcattttttaggccaccat                    | s   |
| 76 | tctcccagcgtgcgtgcgccat                  | s   |
| 77 | tctcccagcgggcgcacat                     | s   |



- 40 -

|     |                              |     |
|-----|------------------------------|-----|
| 78  | tctcccagcgcgagcgccat         | s   |
| 79  | tctcccagcgcgcgagccat         | s   |
| 80  | ggggtgacgttcagggggg          | sos |
| 81  | ggggtccagcgtgcgccatggggg     | sos |
| 82  | ggggtgtcggttcagggggg         | sos |
| 83  | tccatgtcggttcctgtcggt        | s   |
| 84  | tccatagcgttcctagcggt         | s   |
| 85  | tcgtcgctgtctccgcttctt        | s   |
| 86  | gcatgacgttgagct              | sos |
| 87  | tctcccagcgtgcgccatat         | sos |
| 88  | tccatgazgttcctgazgtt         | s   |
| 89  | gcatgazgttgagct              | o   |
| 90  | tccagcgtgcgccata             | sos |
| 91  | tctcccagcgtgcgccat           | o   |
| 92  | tccatgagcttcctgagttct        | o   |
| 93  | gcatgtcggttgagct             | sos |
| 94  | tcctgacgttcctgacgtt          | s   |
| 95  | gcatgatgttgagct              | o   |
| 96  | gcatttcgaggagct              | o   |
| 97  | gcatgtagctgagct              | o   |
| 98  | tccaggacgttcctagttct         | o   |
| 99  | tccaggagcttcctagttct         | o   |
| 100 | tccaggatgttcctagttct         | o   |
| 101 | tccagtctaggcctagttct         | o   |
| 102 | tccagttcgagcctagttct         | o   |
| 103 | gcatggcggttgagct             | sos |
| 104 | gcatagcgttgagct              | sos |
| 105 | gcattgcgttgagct              | sos |
| 106 | gcttgcggttgcgttt             | sos |
| 107 | tctcccagcgttgcgccatat        | sos |
| 108 | tctcccagcgtgcggttatat        | sos |
| 109 | tctccctgcgtgcgccatat         | sos |
| 110 | tctgcgtgcgtgcgccatat         | sos |
| 111 | tctcctagcgtgcgccatat         | sos |
| 112 | tctcccagcgtgcgcctttt         | sos |
| 113 | gctandcghhagc                | o   |
| 114 | tcctgacgttccc                | o   |
| 115 | ggaagacgttaga                | o   |
| 116 | tcctgacgttaga                | o   |
| 117 | tcagaccagctgggtcggtgttcctga  | o   |
| 118 | tcaggaacacccgaccagctgggtctga | o   |
| 119 | gctagtcgatagc                | o   |
| 120 | gctagtcgctagc                | o   |
| 121 | gcttgacgtctagc               | o   |
| 122 | gcttgacgttttagc              | o   |
| 123 | gcttgacgtcaagc               | o   |
| 124 | gctagacgttttagc              | o   |
| 125 | tccatgacattcctgatgct         | o   |
| 126 | gctagacgtctagc               | o   |
| 127 | ggctatgtcggttcctagcc         | o   |
| 128 | ggctatgtcgatcctagcc          | o   |



- 41 -

|     |                                               |     |
|-----|-----------------------------------------------|-----|
| 129 | ctcatggggtttctccaccaag                        | o   |
| 130 | cttggtggagaaacccatgag                         | o   |
| 131 | tccatgacgttcctagttct                          | o   |
| 132 | ccgcttcctccagatgagctcatg                      | o   |
| 133 | catgagctcatctggaggaagcgg                      | o   |
| 134 | ccagatgagctcatggggtttctcc                     | o   |
| 135 | ggagaaacccatgagctcatctgg                      | o   |
| 136 | agcatcaggaacgacatgga                          | o   |
| 137 | tccatgacgttcctgacgtt                          | rna |
| 138 | gcgcgcgcgcgcgcgcgcgcg                         | o   |
| 139 | ccggccggccggccggccgg                          | o   |
| 140 | ttccaatcagccccaccgctctggccccaccctcaccctcca    | o   |
| 141 | tggaggggtgaggggtggggccagagcgggtggggctgattggaa | o   |
| 142 | tcaaatgtgggattttcccatgagtct                   | o   |
| 143 | agactcatgggaaaatcccacatttga                   | o   |
| 144 | tgccaagtgctgagtcactaataaaga                   | o   |
| 145 | tctttattagtgactcagcacttggca                   | o   |
| 146 | tgcaggaagtcggggttttccccaaccccc                | o   |
| 147 | ggggggttggggaaaacccggacttcctgca               | o   |
| 148 | ggggactttccgctggggactttccagggggactttcc        | sos |
| 149 | tccatgacgttcctctccatgacgttcctctccatgacgttcctc | o   |
| 150 | gaggaacgtcatggagaggaacgtcatggagaggaacgtcatgga | o   |
| 151 | ataatagagcttcaagcaag                          | s   |
| 152 | tccatgacgttcctgacgtt                          | s   |
| 153 | tccatgacgttcctgacgtt                          | sos |
| 154 | tccaggactttcctcagggtt                         | s   |
| 155 | tcttgcatgctaaaggacgtcacattgcacaatcttaataaggt  | o   |
| 156 | accttattaagattgtgcaatgtgacgtcctttagcatcgcaaga | o   |
| 157 | tcctgacgttcctggcggctcctgtcgt                  | o   |
| 158 | tcctgtcgtcctgtcgt                             | o   |
| 159 | tcctgacgttgaagt                               | o   |
| 160 | tcctgtcgttgaagt                               | o   |
| 161 | tcctggcgttgaagt                               | o   |
| 162 | tcctgccgttgaagt                               | o   |
| 163 | tccttacgttgaagt                               | o   |
| 164 | tcctaacgttgaagt                               | o   |
| 165 | tcctcacgttgaagt                               | o   |
| 166 | tcctgacgatgaagt                               | o   |
| 167 | tcctgacgctgaagt                               | o   |
| 168 | tcctgacggtgaagt                               | o   |
| 169 | tcctgacgtagaagt                               | o   |
| 170 | tcctgacgtcgaagt                               | o   |
| 171 | tcctgacgtggaagt                               | o   |
| 172 | tcctgagcttgaagt                               | o   |
| 173 | gggggacgttggggg                               | o   |
| 174 | tcctgacgttccttc                               | o   |
| 175 | tctcccagcgcgcgcgcgcgc                         | s   |
| 176 | tcctgacgttcccctggcggctcccctgtcgt              | o   |
| 177 | tcctgtcgtcctgtcgtcctgtcgt                     | o   |
| 178 | tcctggcggggaagt                               | o   |
| 179 | tcctgazgttgaagt                               | o   |



- 42 -

|     |                                           |          |
|-----|-------------------------------------------|----------|
| 180 | tcztgacggttgaagt                          | o        |
| 181 | tcctagcggttgaagt                          | o        |
| 182 | tccagacggttgaagt                          | o        |
| 183 | tcctgacggggaagt                           | o        |
| 184 | tcctggcggtgaagt                           | o        |
| 185 | ggctccggggagggaatttttgtctat               | o        |
| 186 | atagacaaaaattccctccccggagcc               | o        |
| 187 | tccatgagcttccttgagtct                     | rna      |
| 188 | tcgtcgctgtctccgcttctt                     | so       |
| 189 | tcgtcgctgtctccgcttctt                     | s20      |
| 190 | tcgagacattgcacaatcatctg                   | o        |
| 191 | cagattgtgcaatgtctcga                      | o        |
| 192 | tccatgtcggttcctgatgcg                     | o        |
| 193 | gcgatgtcggttcctgatgct                     | o        |
| 194 | gcgatgtcggttcctgatgcg                     | o        |
| 195 | tccatgtcggttcgcgcgcgcg                    | o        |
| 196 | tccatgtcggttcctgccgct                     | o        |
| 197 | tccatgtcggttcctgtagct                     | o        |
| 198 | gcggcgggcggcgcgcgccc                      | o        |
| 199 | atcaggaacgtcatgggaagc                     | o        |
| 200 | tccatgagcttcctgagtct                      | p-ethoxy |
| 201 | tcaacggt                                  | p-ethoxy |
| 202 | tcaagctt                                  | p-ethoxy |
| 203 | tcctgtcggttcctgtcggt                      | s        |
| 204 | tccatgtcggtttttgtcggt                     | s        |
| 205 | tcctgtcggttcctgtcggt                      | s        |
| 206 | tcctgtcggttcctgtcggt                      | s        |
| 207 | btccattccatgacgttcctgatgcttcca            | os       |
| 208 | tcctgtcggtttttgtcggt                      | s        |
| 209 | tcgtcgctgtctccgcttctt                     | s        |
| 210 | tcgtcgctgtctgcccttctt                     | s        |
| 211 | tcgtcgctgttgctgcttctt                     | s        |
| 212 | tcctgtcggttcctgtcggttggaacgacagg          | o        |
| 213 | tcctgtcggttcctgtcggttcaacgtcaggaacgacagga | o        |
| 214 | ggggtctgtcggttttgggggg                    | sos      |
| 215 | ggggtctgtcggttttgggggg                    | sos      |
| 216 | tccggccggttgaagt                          | o        |
| 217 | tccggacggtgaagt                           | o        |
| 218 | tcccggccggttgaagt                         | o        |
| 219 | tccagacggtgaagt                           | o        |
| 220 | tcccagcgggtgaagt                          | o        |
| 221 | tccagagcttgaagt                           | o        |
| 222 | tccatgtzgttcctgtzgtt                      | s        |
| 223 | tccatgacgttcctgacgtt                      | sos      |
| 224 | ggggttgacgttttgggggg                      | sos      |
| 225 | tccaggacttctctcaggtt                      | s        |
| 226 | tttttttttttttttttttt                      | s        |
| 227 | tccatgccgttcctgccgtt                      | s        |
| 228 | tccatggcgggcctggcggg                      | s        |
| 229 | tccatgacgttcctgccgtt                      | s        |
| 230 | tccatgacgttcctggcggg                      | s        |



- 43 -

|     |                                          |     |
|-----|------------------------------------------|-----|
| 231 | tccatgacggttcctgcggtt                    | s   |
| 232 | tccatgacggtcctgacggt                     | s   |
| 233 | tccatgcgtgcgtgcgtttt                     | s   |
| 234 | tccatgcgttgcgttgcgtt                     | s   |
| 235 | btccattccattctaggcctgagtcttccat          | os  |
| 236 | tccatagcggtcctagcggt                     | o   |
| 237 | tccatgtcgttcctgtcggt                     | o   |
| 238 | tccatagcgatcctagcgat                     | o   |
| 239 | tccattgcgttccttgcgtt                     | o   |
| 240 | tccatagcggtcctagcggt                     | o   |
| 241 | tccatgattttcctgcagttcctgatttt            |     |
| 242 | tccatgacggtcctgcagttcctgacggt            | s   |
| 243 | ggcggcggcggcggcggcgg                     | o   |
| 244 | tccacgacgttttcgacggt                     | s   |
| 245 | tcgtcggttgctggttgctggt                   | s   |
| 246 | tcgtcggttttgctggttttgctggt               | s   |
| 247 | tcgtcggttgctggttttgctggt                 | s   |
| 248 | gcgtgcgttgctggttgctggt                   | s   |
| 249 | czggczggczggczccgg                       | o   |
| 250 | gcggcgggcggcgcgcgcgc                     | s   |
| 251 | agicccgigaacgiattcac                     | o   |
| 252 | tgctggttgctggttgctggt                    | s   |
| 253 | tgctggttgctggttgctggttgctggt             | s   |
| 254 | tgctggttgctggttgctggttgctggt             | s   |
| 255 | tcgtcgtcgtcggt                           | s   |
| 256 | tgctggttgctggt                           | s   |
| 257 | cccccccccccccccccccc                     | s   |
| 258 | tctagcggtttttagcggtcc                    | sos |
| 259 | tgcattccccagggccaccat                    | s   |
| 260 | tcgtcgtcgtcgtcgtcgtcggt                  | sos |
| 261 | tcgtcggttgctggttgctggt                   | sos |
| 262 | tcgtcggttttgctggttttgctggt               | sos |
| 263 | tcgtcggttgctggttttgctggt                 | sos |
| 264 | ggggaggagggaacttcttaaaattcccccagaatgttt  | o   |
| 265 | aaacattctgggggaatttttaagaagttcctccctcccc | o   |
| 266 | atgtttacttcttaaaattcccccagaatgttt        | o   |
| 267 | aaacattctgggggaatttttaagaagtaaacat       | o   |
| 268 | atgtttactagacaaaattcccccagaatgttt        | o   |
| 269 | aaacattctgggggaattttgtctagtaaacat        | o   |
| 270 | aaaattgacgtttttaaaaaa                    | sos |
| 271 | ccccttgacgttttcccccc                     | sos |
| 272 | ttttcggttggttttgctggt                    |     |
| 273 | tcgtcggttttgctggttttgctggt               | sos |
| 274 | ctgcagcctgggac                           | o   |
| 275 | acccgtcgtaattatagtaaaaccc                | o   |
| 276 | ggtacctgtggggacattgtg                    | o   |
| 277 | agcaccgaacgtgagagg                       | o   |
| 278 | tccatgccgttcctgccgtt                     | o   |
| 279 | tccatgacggtcctgacggt                     | o   |
| 280 | tccatgccggtcctgccggt                     | o   |
| 281 | tccatgcgcgtcctgcgcgt                     | o   |



- 44 -

|     |                                    |     |
|-----|------------------------------------|-----|
| 282 | ctggtctttctgggtttttttctgg          | s   |
| 283 | tcaggggtggggggaacctt               | sos |
| 284 | tccatgazgttcctagttct               | o   |
| 285 | tccatgatgttcctagttct               | o   |
| 286 | cccgaagtcatttcctcttaacctgg         | o   |
| 287 | ccaggttaagaggaaatgacttcggg         | o   |
| 288 | tcctggzggggaagt                    | o   |
| 289 | gzggzgggzggzgzgzgccc               | x   |
| 290 | tccatgtgcttcctgatgct               | o   |
| 291 | tccatgtccttcctgatgct               |     |
| 292 | tccatgtcgttcctagttct               |     |
| 293 | tccaagtagttcctagttct               | o   |
| 294 | tccatgtagttcctagttct               | o   |
| 295 | tcccgcgcgttcgcgcgtt                | s   |
| 296 | tcctggcggctcctggcgggtt             | s   |
| 297 | tcctggaggggaagt                    | o   |
| 298 | tcctgggggggaagt                    | o   |
| 299 | tcctgggtggggaagt                   | o   |
| 300 | tcgtcgttttgtcgttttgtcggtt          | o   |
| 301 | ctggtctttctgggtttttttctgg          | o   |
| 302 | tccatgacgttcctgacgtt               | o   |
| 303 | tccaggacttctctcagggtt              | sos |
| 304 | tzgtzgttttgtzgttttgtzgtt           | o   |
| 305 | btcgtcgttttgtcgttttgtcgttttttt     | os  |
| 306 | gctatgacgttccaagg                  | s   |
| 307 | tcaacgtt                           | s   |
| 308 | tccaggactttcctcagggtt              | o   |
| 309 | ctctctgtaggcccgttgg                | s   |
| 310 | ctttccgttggacccctggg               | s   |
| 311 | gtccgggccaggccaaagtc               | s   |
| 312 | gtgcgcgcgagcccgaatc                | s   |
| 313 | tccatgaigttcctgaigtt               | s   |
| 314 | aatagtcgccataacaaaac               | o   |
| 315 | aatagtcgcatggcggggc                | o   |
| 316 | btttttccatgtcgttcctgatgcttttt      | os  |
| 317 | tcctgtcgttgaagtttttt               | o   |
| 318 | gctagcttttagagcttttagagctt         | o   |
| 319 | tgtgtcttcccccccccccc               | o   |
| 320 | tcgacgttcccccccccccc               | o   |
| 321 | tcgtcgttcccccccccccc               | o   |
| 322 | tcgtcgttcccccccccccc               | o   |
| 323 | tcgccgttcccccccccccc               | o   |
| 324 | tcgtcgatcccccccccccc               | o   |
| 325 | tcctgacgttgaagt                    | s   |
| 326 | tcctgccgttgaagt                    | s   |
| 327 | tcctgacggtgaagt                    | s   |
| 328 | tcctgagcttgaagt                    | s   |
| 329 | tcctggcggggaagt                    | s   |
| 330 | aaaatctgtgcttttaaaaaa              | sos |
| 331 | gatccagtcacagtgacctggcagaatctggat  | o   |
| 332 | gatccagattctgccaggctcactgtgactggat | o   |



- 45 -

|     |                                       |     |
|-----|---------------------------------------|-----|
| 333 | gatccagtcacagtgactcagcagaatctggat     | o   |
| 334 | gatccagattctgctgagtcactgtgactggat     | o   |
| 335 | tcgtcggtccccccczzccc                  | o   |
| 336 | tzgtggtcccccccccccc                   | o   |
| 337 | tzgtcggtcccccccccccc                  | o   |
| 338 | tcgtzgttcccccccccccc                  | o   |
| 339 | tcgtcggtcccccccccccc                  | o   |
| 340 | tcgtcggtcccccccccccc                  | o   |
| 341 | tcggcggtcccccccccccc                  | o   |
| 342 | ggccttttcccccccccccc                  | o   |
| 343 | tcgtcggttttgacgttttggtcggt            | s   |
| 344 | tcgtcggttttgacgttttgacgtt             | s   |
| 345 | ccgtcggtcccccccccccc                  | o   |
| 346 | gcgtcggtcccccccccccc                  | o   |
| 347 | tcgtcattcccccccccccc                  | o   |
| 348 | acgtcggtcccccccccccc                  | o   |
| 349 | ctgtcggtcccccccccccc                  | o   |
| 350 | bttttctgctggtcccccccccccc             | os  |
| 351 | tcgtcggtccccccccccccb                 | o   |
| 352 | tcgtcggttttggtcggttttggtcggtb         | o   |
| 353 | tccagttccttcctcagttct                 | o   |
| 354 | tzgtcggttttggtcggttttggtcggt          | o   |
| 355 | tcctggaggggaagt                       | s   |
| 356 | tcctgaaaaggaagt                       | s   |
| 357 | tcgtcggtcccccccccc                    | s   |
| 358 | tzgtzgttttggtzgttttggtzgtt            | s   |
| 359 | ggggtcaagcttgagggggg                  | sos |
| 360 | tgctgcttcccccccccccc                  | s   |
| 361 | tcgtcggtcggtcggt                      | s2  |
| 362 | tcgtcggtcggtcggt                      | s20 |
| 363 | tcgtcggtcggtcggt                      | os2 |
| 364 | tcaacggtga                            | s   |
| 365 | tcaacggt                              | s   |
| 366 | atagttttccatttttttac                  |     |
| 367 | aatagtcgcatcgcgcgac                   | o   |
| 368 | aatagtcgcatcccgggac                   | o   |
| 369 | aatagtcgcatcccccccc                   | o   |
| 370 | tgctgcttttggtgcttttggtgctt            | o   |
| 371 | ctgtgctttctgtgtttttctgtg              | s   |
| 372 | ctaacttttctaatttttttctaa              | s   |
| 373 | tcgtcggtggtggtcggtggtggtcggt          | s   |
| 374 | tcgtcggtggtggtcggttttggtt             | s   |
| 375 | accatggacgagctgtttccctc               |     |
| 376 | tcgtcggttttggtggtggtt                 | s   |
| 377 | ctgtaagtgagcttgagag                   |     |
| 378 | gagaacgctggaccttc                     |     |
| 379 | cgggcgactcagtttatcgg                  |     |
| 380 | gttctcagataaagcggaaccagcaacagacacagaa |     |
| 381 | ttctgtgtctgttggtggttccgctttatctgagaac |     |
| 382 | cagacacagaagcccgatagacg               |     |
| 383 | agacagacacgaaacgaccg                  |     |



- 46 -

|     |                                      |     |
|-----|--------------------------------------|-----|
| 384 | gtctgtcccatgatctcgaa                 |     |
| 385 | gctggccagcttacctcccg                 |     |
| 386 | ggggcctctatacaacctggg                |     |
| 387 | ggggtccctgagactgcc                   |     |
| 388 | gagaacgctggaccttccat                 |     |
| 389 | tccatgtcggtcctgatgct                 |     |
| 390 | ctcttgcgacctggaaggta                 |     |
| 391 | aggtacagccaggactacga                 |     |
| 392 | accatggacgacctgtttccctc              |     |
| 393 | accatggattacctttttccctt              |     |
| 394 | atggaagggtccagcgttctc                | o   |
| 395 | agcatcaggaccgacatgga                 | o   |
| 396 | ctctccaagctcacttacag                 |     |
| 397 | tccctgagactgccccacctt                |     |
| 398 | gccacccaaaacttgtccatg                |     |
| 399 | gtccatggcgtgcgggatga                 |     |
| 400 | cctctatacaacctgggac                  |     |
| 401 | cgggcgactcagtctatcgg                 |     |
| 402 | gcgctaccggtagcctgagt                 |     |
| 403 | cgactgccgaacaggatatcggtgatcagcactgg  |     |
| 404 | ccagtgctgatcaccgatatacctgttcggcagtcg |     |
| 405 | ccaggttgtatagaggc                    |     |
| 406 | tctcccagcgtacgccat                   | s   |
| 407 | tctcccagcgtgcgtttt                   | s   |
| 408 | tctcccagcgtgcgccat                   | s   |
| 409 | tctcccgtcgtgcgccat                   | s   |
| 410 | ataatcgctcgttcaagcaag                | s   |
| 411 | tcgtcgttttgcgttttgcgt                | s2  |
| 412 | tcgtcgttttgcgttttgcgtt               | s2  |
| 413 | tcgtcgttttgcgttttgcgtt               | s2  |
| 414 | tntcgtntntcgtntntcgtnt               | s   |
| 415 | tctcccagcgtcgccat                    | s   |
| 416 | tctcccatcgtcgccat                    | s   |
| 417 | ataatcgctgcgttcaagaaag               | s   |
| 418 | ataatcgacgttcccccccc                 | s   |
| 419 | tctatcgacgttcaagcaag                 | s   |
| 420 | tcc tga cgg gg agt                   | s   |
| 421 | tccatgacgttcctgatcc                  |     |
| 422 | tccatgacgttcctgatcc                  |     |
| 423 | tccatgacgttcctgatcc                  |     |
| 424 | tcc tgg cgt gga agt                  | s   |
| 425 | tccatgacgttcctgatcc                  |     |
| 426 | tcgtcgtgttgctcgtttctt                | s   |
| 427 | agcagcttttagagcttttagagctt           | s   |
| 428 | cccccccccccccccccccc                 | s   |
| 429 | tcgtcgttttgcgttttgcgttttgcgtt        | s   |
| 430 | tcgtcgttttttgcgttttttgcgtt           | s   |
| 431 | tcgtcgtttttttttttttt                 | s   |
| 432 | tttttcaacgttgatttttt                 | sos |
| 433 | tttttttttttttttttttt                 | s   |
| 434 | ggggtcgtcgttttgggggg                 |     |



- 47 -

|     |                             |   |
|-----|-----------------------------|---|
| 435 | tcgtcgttttgtcgttttggggg     |   |
| 436 | tcgtcgctgtctccgcttcttcttgcc | s |
| 437 | tcgtcgctgtctccg             | s |
| 438 | ctgtaagtgagcttggagag        |   |
| 439 | gagaacgctggaccttccat        |   |
| 440 | ccaggttgtatagaggc           |   |
| 441 | gctagacgtttagcgtga          |   |
| 442 | ggagctcttcgaacgccata        |   |
| 443 | tctccatgatggttttatcg        |   |
| 444 | aaggtggggcagtctcagga        |   |
| 445 | atcggaggactggcgcgccc        |   |
| 446 | ttaggacaaggtctagggtg        |   |
| 447 | accacaacgagaggaacgca        |   |
| 448 | ggcagtgcaggctcaccggg        |   |
| 449 | gaaccttccatgctgtt           |   |
| 450 | gctagacgtttagcgtga          |   |
| 451 | gcttggagggcctgtaagtg        |   |
| 452 | gtagccttccta                |   |
| 453 | cggtagccttccta              |   |
| 454 | cacggtagccttccta            |   |
| 455 | agcacggtagccttccta          |   |
| 456 | gaacgctggaccttccat          |   |
| 457 | gaccttccat                  |   |
| 458 | tggaccttccat                |   |
| 459 | gctggaccttccat              |   |
| 460 | acgctggaccttccat            |   |
| 461 | taagctctgtcaacgccagg        |   |
| 462 | gagaacgctggaccttccatgt      |   |
| 463 | tccatgtcggtcctgatgct        |   |
| 464 | ttcatgccttgcaaaatggcg       |   |
| 465 | tgctagctgtgctgtacct         |   |
| 466 | agcatcaggaccgacatgga        |   |
| 467 | gaccttccatgtcggtcctgat      |   |
| 468 | acaaccacgagaacgggaac        |   |
| 469 | gaaccttccatgctgttccg        |   |
| 470 | caatcaatctgaggagacc         |   |
| 471 | tcagctctggtactttttca        |   |
| 472 | tggttacggctctgtcccatg       |   |
| 473 | gtctatcggaggactggcgc        |   |
| 474 | cattttacgggcgggcgggc        |   |
| 475 | gaggggaccattttacgggc        |   |
| 476 | tgtccagccgaggggacat         |   |
| 477 | cgggcttacggcggatgctg        |   |
| 478 | tggaccttctatgtcggtcc        |   |
| 479 | tgtcccatgtttttagaagc        |   |
| 480 | gtggttacggctcgtgccat        |   |
| 481 | cctccaaatgaaagaccccc        |   |
| 482 | ttgtactctccatgatggtt        |   |
| 483 | ttccatgctgttccggctgg        |   |
| 484 | gaccttctatgtcggtcctg        |   |
| 485 | gagaccgctcgaccttcgat        |   |



- 48 -

|     |                                      |     |
|-----|--------------------------------------|-----|
| 486 | ttgccccatatatttagaaac                |     |
| 487 | ttgaaactgaggtgggac                   |     |
| 488 | ctatcggaggactggcgcgcc                |     |
| 489 | cttggagggcctcccggcgg                 |     |
| 490 | gctgaaccttccatgctgtt                 |     |
| 491 | tagaaacagcattcttcttttagggcagcaca     |     |
| 492 | agatggttctcagataaagcggaa             |     |
| 493 | ttccgctttatctgagaaccatct             |     |
| 494 | gtcccaggttgtatagaggctgc              |     |
| 495 | gcgccagtcctccgatagac                 |     |
| 496 | atcggaggactggcgcgccg                 |     |
| 497 | ggtctgtcccatatttttag                 |     |
| 498 | tttttcaacgttgagggggg                 | sos |
| 499 | tttttcaagcgttgatttttt                | sos |
| 500 | ggggtcaacgttgatttttt                 | sos |
| 501 | ggggttttcaacgtttgagggggg             | sos |
| 502 | ggttacggtctgtcccatat                 |     |
| 503 | ctgtcccatatttttagaca                 |     |
| 504 | accatcctgaggccattcgg                 |     |
| 505 | cgtctatcgggcttctgtgtctg              |     |
| 506 | ggccatcccacattgaaagt                 |     |
| 507 | ccaaatatcgggtggtcaagcac              |     |
| 508 | gtgcttgaccaccgatatttgg               |     |
| 509 | gtgctgatcaccgatatcctgttcgg           |     |
| 510 | ggccaactttcaatgtgggatggcctc          |     |
| 511 | ttccgccgaatggcctcaggatggtac          |     |
| 512 | tatagtccctgagactgccccaccttctcaacaacc |     |
| 513 | gcagcctctatacaacctgggacggga          |     |
| 514 | ctatcggaggactggcgcgccg               |     |
| 515 | tatcggaggactggcgcgccg                |     |
| 516 | gatcggaggactggcgcgccg                |     |
| 517 | ccgaacaggatatcgggtgatcagcac          |     |
| 518 | ttttggggtcaacgttgagggggg             |     |
| 519 | ggggtcaacgttgagggggg                 | sos |
| 520 | cgcgcgcgcgcgcgcgcgcg                 | s   |
| 521 | ggggcatgacgttcggggggg                | ss  |
| 522 | ggggcatgacgttcaaaaaa                 | s   |
| 523 | ggggcatgagcttcggggggg                | s   |
| 524 | ggggcatgacgttcggggggg                | sos |
| 525 | aaaacatgacgttcaaaaaa                 | sos |
| 526 | aaaacatgacgttcggggggg                | sos |
| 527 | ggggcatgacgttcaaaaaa                 | sos |
| 528 | accatggacgatctgtttccctc              | s   |
| 529 | gccatggacgaactgttccctc               | s   |
| 530 | cccccccccccccccccc                   | sos |
| 531 | gggggggggggggggggggg                 | sos |
| 532 | gctgtaaaatgaatcggccg                 | sos |
| 533 | ttcgggaggactcctccatt                 | sos |
| 534 | tatgccgcgcccggacttat                 | sos |
| 535 | ggggtaatcgatcagggggg                 | sos |
| 536 | tttgagaacgctggaccttc                 | sos |



- 49 -

|     |                                                |     |
|-----|------------------------------------------------|-----|
| 537 | gatcgctgatctaataatgctcg                        | sos |
| 538 | gtcggtcctgatgctgttcc                           | sos |
| 539 | tcgtcgtcagttcgtgctcg                           | sos |
| 540 | ctggaccttccatgtcgg                             | sos |
| 541 | gctcgttcagcgcgtct                              | sos |
| 542 | ctggaccttccatgtc                               | sos |
| 543 | cactgtccttcgtcga                               | sos |
| 544 | cgctggaccttccatgtcgg                           | sos |
| 545 | gctgagctcatgccgtctgc                           | sos |
| 546 | aacgctggaccttccatgtc                           | sos |
| 547 | tgcataccgtacacagctct                           | sos |
| 548 | ccttccatgtcggtcctgat                           | sos |
| 549 | tactcttcggatcccttgcg                           | sos |
| 550 | ttccatgtcggtcctgat                             | sos |
| 551 | ctgattgctctctcgtga                             | sos |
| 552 | ggcgttattcctgactcgcc                           | o   |
| 553 | cctacgttgatgcgccagct                           | o   |
| 554 | ggggtaatcgatgagggggg                           | o   |
| 555 | ttcgggaggactcctccatt                           | o   |
| 556 | tttttttttttttttttttt                           | o   |
| 557 | gggggtttttttttttggggg                          | o   |
| 558 | tttttgggggggggggttttt                          | o   |
| 559 | gggggggggggggggggggt                           | o   |
| 560 | aaaaaaaaaaaaaaaaaaaaa                          | o   |
| 561 | cccccaaaaaaaaaaaccccc                          | o   |
| 562 | aaaaaccccccccccaaaaa                           | o   |
| 563 | tttgaattcaggactggtgaggttgag                    | o   |
| 564 | tttgaatcctcagcggctcctcagtggc                   | o   |
| 565 | aattctctatcggggcttctgtgtctgttgctgggttccgctttat | o   |
| 566 | ctagataaagcggaaccagcaacagacacagaagccccgatagag  | o   |
| 567 | ttttctagagaggtgcacaatgctctgg                   | o   |
| 568 | tttgaattccgtgtacagaagcgagaagc                  | o   |
| 569 | tttgccggcgttagacttaacctgagagata                | o   |
| 570 | tttgggcccacgagagacagagacacttc                  | o   |
| 571 | tttgggcccgccttctcgcttctgtacacg                 | o   |
| 572 | gagaacgctggaccttccat                           | s   |
| 573 | tccatgtcggtcctgatgct                           | s   |
| 574 | ctgtcg                                         | s   |
| 575 | tcgtga                                         | s   |
| 576 | cgtcga                                         | s   |
| 577 | agtgct                                         | s   |
| 578 | ctgtcg                                         | o   |
| 579 | agtgct                                         | o   |
| 580 | cgtcga                                         | o   |
| 581 | tcgtga                                         | o   |
| 582 | gagaacgctccagcttcgat                           | o   |
| 583 | gctagacgtaagcgtga                              | o   |
| 584 | gagaacgctcgaccttccat                           | o   |
| 585 | gagaacgctggacctatccat                          | o   |
| 586 | gctagaggttagcgtga                              | o   |
| 587 | gagaacgctggacttccat                            | o   |



- 50 -

|     |                         |   |
|-----|-------------------------|---|
| 588 | tcacgctaacgtctagc       | o |
| 589 | bgctagacgcttagcgtga     | o |
| 590 | atggaagggtcgagcgttctc   | o |
| 591 | gagaacgctggaccttcgat    | o |
| 592 | gagaacgatggaccttccat    | o |
| 593 | gagaacgctggatccat       | o |
| 594 | gagaacgctccagcactgat    | o |
| 595 | tccatgtcgggtcctgctgat   | o |
| 596 | atgtcctcgggtcctgatgct   | o |
| 597 | gagaacgctccaccttccat    | o |
| 598 | gagaacgctggaccttcgta    | o |
| 599 | batggaagggtccagcgttctc  | o |
| 600 | tcctga                  | o |
| 601 | tcaacgtt                | o |
| 602 | aacgtt                  | o |
| 603 | aacgttga                | o |
| 604 | tcacgctaacctctagc       | o |
| 605 | gagaacgctggaccttgcat    | o |
| 606 | gctggaccttccat          | o |
| 607 | gagaacgctggacctcatccat  | o |
| 608 | gagaacgctggacgctcatccat | o |
| 609 | aacgttgaggggcat         | o |
| 610 | atgccctcaacgtt          | o |
| 611 | tcaacgttga              | o |
| 612 | gctggaccttccat          | o |
| 613 | caacgtt                 | o |
| 614 | acaacgttga              | o |
| 615 | tcacgt                  | o |
| 616 | tcaagctt                | o |
| 617 | tcgtca                  | o |
| 618 | aggatatc                | o |
| 619 | tagacgtc                | o |
| 620 | gacgtcat                | o |
| 621 | ccatcgat                | o |
| 622 | atcgatgt                | o |
| 623 | atgcatgt                | o |
| 624 | ccatgcat                | o |
| 625 | agcgctga                | o |
| 626 | tcagcgct                | o |
| 627 | ccttcgat                | o |
| 628 | gtgccgggggtctccgggc     | s |
| 629 | gctgtggggcggtcctg       | s |
| 630 | btcaacgtt               | o |
| 631 | ftcaacgtt               | o |
| 632 | faacgttga               | o |
| 633 | tcaacgt                 | s |
| 634 | aacgttg                 | s |
| 635 | cgacga                  | o |
| 636 | tcaacgtt                | o |
| 637 | tcgga                   | o |
| 638 | agaacgtt                | o |



- 51 -

|     |                           |   |
|-----|---------------------------|---|
| 639 | tcatcgat                  | O |
| 640 | taaacgtt                  | S |
| 641 | ccaacgtt                  | S |
| 642 | gctcga                    | S |
| 643 | cgacgt                    | S |
| 644 | cgtcgt                    | S |
| 645 | acgtgt                    | S |
| 646 | cgttcg                    | S |
| 647 | gagcaagctggaccttccat      | S |
| 648 | cgcgta                    | S |
| 649 | cgtacg                    | S |
| 650 | tcaccggt                  | S |
| 651 | caagagatgctaacaatgca      | S |
| 652 | acccatcaatagctctgtgc      | S |
| 653 | ccatcgat                  | O |
| 654 | tcgacgtc                  | O |
| 655 | ctagcgct                  | O |
| 656 | taagcgct                  | O |
| 657 | tcgcgaattcgcg             | O |
| 658 | atggaaggtccagcggtct       | O |
| 659 | actggacgcttagcgtga        | O |
| 660 | cgcctggggctggtctgg        | O |
| 661 | gtgtcggggctctccgggc       | O |
| 662 | gtgccggggctctccgggc       | O |
| 663 | cgccgtcgcggcggttgg        | O |
| 664 | gaagttcacgcttgaggggcat    | O |
| 665 | atctggtgagggcaagctatg     | S |
| 666 | gttgaaacccgagaacatcat     | S |
| 667 | gcaacgtt                  | O |
| 668 | gtaacgtt                  | O |
| 669 | cgaacgtt                  | O |
| 670 | gaaacgtt                  | O |
| 671 | caaacgtt                  | O |
| 672 | ctaacgtt                  | O |
| 673 | ggaacgtt                  | O |
| 674 | tgaacgtt                  | O |
| 675 | acaacgtt                  | O |
| 676 | ttaacgtt                  | O |
| 677 | aaaacgtt                  | O |
| 678 | ataacgtt                  | O |
| 679 | aacgttct                  | O |
| 680 | tccgatcg                  | O |
| 681 | tccgtacg                  | O |
| 682 | gctagacgctagcgtga         | O |
| 683 | gagaacgctggacctcatcatccat | O |
| 684 | gagaacgctagaccttctat      | O |
| 685 | actagacgcttagtgtga        | O |
| 686 | cacaccttggtcaatgtcacgt    | O |
| 687 | tctccatcctatggttttatcg    | O |
| 688 | cgtggaccttccat            | O |
| 689 | caccaccttggtcaatgtcacgt   | O |



- 52 -

|     |                          |     |
|-----|--------------------------|-----|
| 690 | gctagacgtttagctgga       | o   |
| 691 | agtgcgattgcagatcg        | o   |
| 692 | ttttcgttttgtggttttgtggtt |     |
| 693 | ttttcgtttgtcgttttgtcggt  |     |
| 694 | tttttgttttgtggttttgtggtt |     |
| 695 | accgcatggattctaggcca     | s   |
| 696 | gctagacgtttagcgt         | o   |
| 697 | aacgctggaccttccat        | o   |
| 698 | tcaazggt                 | o   |
| 699 | ccttcgat                 | o   |
| 700 | actagacgtttagtgtga       | s   |
| 701 | gctagaggtttagcgtga       | s   |
| 702 | atggactctccagcgttctc     | o   |
| 703 | atcgactctcgagcgttctc     | o   |
| 704 | gctagacgtttagc           | o   |
| 705 | gctagacgt                | o   |
| 706 | agtgcgattcgagatcg        | o   |
| 707 | tcagzgct                 | o   |
| 708 | ctgattgctctctcgtga       | o   |
| 709 | tzaacggt                 | o   |
| 710 | gagaazgctggaccttccat     | o   |
| 711 | gctagacgttaggctga        | o   |
| 712 | gctacttagcgtga           | o   |
| 713 | gctaccttagcgtga          | o   |
| 714 | atcgactctcgagcgttctc     | o   |
| 715 | atgcactctgcagcgttctc     | o   |
| 716 | agtgactctccagcgttctc     | o   |
| 717 | gccagatgtttagctgga       | o   |
| 718 | atcgactcgagcgttctc       | o   |
| 719 | atcgatcgagcgttctc        | o   |
| 720 | bgagaacgctcgaccttcgat    | o   |
| 721 | gctagacgtttagctgga       | sos |
| 722 | atcgactctcgagcgttctc     | sos |
| 723 | tagacgtttagcgtga         | o   |
| 724 | cgactctcgagcgttctc       | o   |
| 725 | ggggtcgaccttggagggggg    | sos |
| 726 | gctaacgtttagcgtga        | o   |
| 727 | cgtcgtcgt                | o   |
| 728 | gagaacgctggaczttccat     | o   |
| 729 | atcgacctacgtgcgttztc     | o   |
| 730 | atzgacctacgtgcgttctc     | o   |
| 731 | gctagazgtttagcgt         | o   |
| 732 | atcgactctcgagzggttctc    | o   |
| 733 | ggggtaatgcatcagggggg     | sos |
| 734 | ggctgtattcctgactgcc      | s   |
| 735 | ccatgctaacctctagc        | o   |
| 736 | gctagatgtttagcgtga       | o   |
| 737 | cgtaccttacggtga          | o   |
| 738 | tccatgctggctcctgatgct    | o   |
| 739 | atcgactctctcgagcgttctc   | o   |
| 740 | gctagagcttagcgtga        | o   |



- 53 -

|     |                              |     |
|-----|------------------------------|-----|
| 741 | atcgactctcgagtgttctc         | o   |
| 742 | aacgctcgaccttcgat            | o   |
| 743 | ctcaacgctggaccttccat         | o   |
| 744 | atcgacctacgtgcgttctc         | o   |
| 745 | gagaatgctggaccttccat         | o   |
| 746 | tcacgctaacctctgac            | o   |
| 747 | bgagaacgctccagcactgat        | o   |
| 748 | bgagcaagctggaccttccat        | o   |
| 749 | cgctagagggttagcgtga          | o   |
| 750 | gctagatgttaacgt              | o   |
| 751 | atggaagggtccacgttctc         | o   |
| 752 | gctagatgttagcgt              | o   |
| 753 | gctagacgttagtgt              | o   |
| 754 | tccatgacgggtcctgatgct        | o   |
| 755 | tccatggcggtcctgatgct         | o   |
| 756 | gctagacgatagcgt              | o   |
| 757 | gctagtcgatagcgt              | o   |
| 758 | tccatgacgttcctgatgct         | o   |
| 759 | tccatgtcggtcctgatgct         | o   |
| 760 | gctagacgttagzgt              | o   |
| 761 | gctaggcggttagcgt             | o   |
| 762 | tccatgtzgggtcctgatgct        | o   |
| 763 | tccatgtcggtzctgatgct         | o   |
| 764 | atzgactctzgagzgttctc         | o   |
| 765 | atggaagggtccagtgttctc        | o   |
| 766 | gcatgacgttgagct              | o   |
| 767 | ggggtcaacgttgagggggg         | s   |
| 768 | ggggtcaagtctgagggggg         | sos |
| 769 | cgcgcgcgcgcgcgcgcgcg         | o   |
| 770 | cccccccccccccccccccccccccccc | s   |
| 771 | cccccccccccccccccccccccccccc | s   |
| 772 | tccatgtcgctcctgatcct         | o   |
| 773 | gctaaacgttagcgt              | o   |
| 774 | tccatgtcgatcctgatgct         | o   |
| 775 | tccatgccgggtcctgatgct        | o   |
| 776 | aaaatcaacgttgaaaaaaa         | sos |
| 777 | tccataacgttcctgatgct         | o   |
| 778 | tggaggtcccaccgagatcggag      | o   |
| 779 | cgtcgtcgtcgtcgtcgtcg         | s   |
| 780 | ctgctgctgctgctgctgctg        | s   |
| 781 | gagaacgctccgaccttcgat        | s   |
| 782 | gctagatgttagcgt              | s   |
| 783 | gcatgacgttgagct              | s   |
| 784 | tcaatgctgaf                  | o   |
| 785 | tcaacgttgaf                  | o   |
| 786 | tcaacgttgab                  | o   |
| 787 | gcaatattgcb                  | o   |
| 788 | gcaatattgcf                  | o   |
| 789 | agttgcaact                   | o   |
| 790 | tcttcgaa                     | o   |
| 791 | tcaacgtc                     | o   |



- 54 -

|     |                                      |     |
|-----|--------------------------------------|-----|
| 792 | ccatgtcggtcctgatgct                  | o   |
| 793 | gtttttatataatttggg                   | o   |
| 794 | tttttgtttgctgttttgctgctt             | o   |
| 795 | ttgggggggggtt                        | s   |
| 796 | gggggttgggggtt                       | s   |
| 797 | ggtggtgtaggttttgg                    | o   |
| 798 | bgagaazgctcgaccttcgat                | o   |
| 799 | tcaacgtttaacgtttaacgtt               | o   |
| 800 | bgagcaagztggaccttccat                | o   |
| 801 | bgagaazgctccagcactgat                | o   |
| 802 | tcaazggtgax                          | o   |
| 803 | gzaatattgcx                          | o   |
| 804 | tgctgctttttgctgcttttgtgctt           | o   |
| 805 | ctgcttagcaatttaactgtg                | o   |
| 806 | tccatgacgttcctgatgct                 | s   |
| 807 | tgcattgccgtgcatccgtacacagctct        | s   |
| 808 | tgcattgccgtacacagctct                | s   |
| 809 | tgcattcagctct                        | s   |
| 810 | tgcctctct                            | s   |
| 811 | cccccccccccccccccccc                 | s   |
| 812 | cccccccccccc                         | s   |
| 813 | cccccccc                             | s   |
| 814 | tgcattcagctct                        | sos |
| 815 | tgcattgccgtacacagctct                | o   |
| 816 | gagcaagctggaccttccat                 | s   |
| 817 | tcaacgtttaacgtttaacgtttaacgtttaacgtt | s   |
| 818 | gagaacgctcgaccttcgat                 | s   |
| 819 | gtccccattttcccagaggaggaaat           | o   |
| 820 | ctagcggctgacgtcatcaagctag            | o   |
| 821 | ctagcttgatgacgtcagccgctag            | o   |
| 822 | cggctgacgtcatcaa                     | s   |
| 823 | ctgacgtg                             | o   |
| 824 | ctgacgtcat                           | o   |
| 825 | attcgatcggggcggggag                  | o   |
| 826 | ctcgccccgccccgatcgaat                | o   |
| 827 | gactgacgtcagcgt                      | o   |
| 828 | ctagcggctgacgtcataaagctagc           | s   |
| 829 | ctagctttatgacgtcagccgctagc           | s   |
| 830 | ctagcggctgagctcataaagctagc           | s   |
| 831 | ctagtggctgacgtcatcaagctag            | s   |
| 832 | tccaccacgtggtctatgct                 | s   |
| 833 | gggaatgaaagattttattataag             | o   |
| 834 | tctaaaaaccatctattcttaaccct           | o   |
| 835 | agctcaacgtcatgc                      | o   |
| 836 | ttaacggtggtagcgggtattggtc            | o   |
| 837 | ttaagaccaataccgctaccaccg             | o   |
| 838 | gatctagtgatgagtcagccggatc            | o   |
| 839 | gatccggctgactcatcactagatc            | o   |
| 840 | tccaagacgttcctgatgct                 | o   |
| 841 | tccatgacgtccctgatgct                 | o   |
| 842 | tccaccacgtggctgatgct                 | o   |



- 55 -

|     |                                 |     |
|-----|---------------------------------|-----|
| 843 | ccacgtggacctctagc               | o   |
| 844 | tcagaccacgtggtcgggtgttcctga     | o   |
| 845 | tcaggaacacccgaccacgtgggtctga    | o   |
| 846 | catttccacgatttccca              | o   |
| 847 | ttcctctctgcaagagact             | o   |
| 848 | tgtatctctctgaaggact             | o   |
| 849 | ataaagcgaaactagcagcagtttc       | o   |
| 850 | gaaactgctgctagtttcgctttat       | o   |
| 851 | tgcccaaagaggaaaatttgtttcatacag  | o   |
| 852 | ctgtatgaaacaaattttcctctttgggca  | o   |
| 853 | ttagggtttagggtttagggtt          | ss  |
| 854 | tccatgagcttcctgatgct            | ss  |
| 855 | aaaacatgacgttcaaaaaa            | ss  |
| 856 | aaaacatgacgttcggggggg           | ss  |
| 857 | ggggcatgagcttcggggggg           | sos |
| 858 | ctaggctgacgtcatcaagctagt        | o   |
| 859 | tctgacgtcatctgacgttggtgacgtct   | o   |
| 860 | ggaattagtaatagatatagaagtt       | o   |
| 861 | tttaccttttataaacataactaaaacaaa  | o   |
| 862 | gcgttttttttttgcg                | s   |
| 863 | atatctaatacaaacattaacaaa        | o   |
| 864 | tctatcccagggtggttcctgtag        | o   |
| 865 | btccatgacgttcctgatgct           | o   |
| 866 | btccatgagcttcctgatgct           | o   |
| 867 | ttttttttttttttf                 | o   |
| 868 | ttttttttttttttf                 | so  |
| 869 | ctagcttgatgagctcagccgctag       | o   |
| 870 | ttcagttgtcttgctgcttagctaa       | o   |
| 871 | tccatgagcttcctgagtct            | s   |
| 872 | ctagcggctgacgtcatcaatctag       | o   |
| 873 | tgctagctgtgcctgtacct            | s   |
| 874 | atgctaaaggacgtcacattgca         | o   |
| 875 | tgcaatgtgacgtccttttagcat        | o   |
| 876 | gtaggggactttccgagctcgagatcctatg | o   |
| 877 | cataggatctcgagctcggaaagtcacctac | o   |
| 878 | ctgtcaggaactgcaggtaagg          | o   |
| 879 | cataacataggaatatctactcctcgc     | o   |
| 880 | ctccagctccaagaaaggacg           | o   |
| 881 | gaagtttctggtaagtcttcg           | o   |
| 882 | tgctgcttttgtgcttttgtgctt        | s   |
| 883 | tcgtcgttttgtggttttgtggtt        | s   |
| 884 | tcgtcgtttgtcgttttgtcgtt         | s   |
| 885 | tcctgacgttcggcgcgcgccc          | s   |
| 886 | tgctgcttttgtgcttttgtgctt        |     |
| 887 | tccatgagcttcctgagctt            | s   |
| 888 | tcgtcgtttcgtcgttttgacgtt        | s   |
| 889 | tcgtcgtttgctgctgtttcgtcggtt     | s   |
| 890 | tcgctgctgttttgtcgttttgacgtt     | s   |
| 891 | ttcgtcgttttgtcgttttgtcgtt       | s   |
| 892 | tcctgacggggaagt                 | s   |
| 893 | tcctggcgtggaagt                 | s   |



- 56 -

|     |                          |          |
|-----|--------------------------|----------|
| 894 | tcttggcgggtgaagt         | S        |
| 895 | tcttggcgttgaagt          | S        |
| 896 | tcttgacgtggaagt          | S        |
| 897 | gcgacgttcggcgcgcgccc     | S        |
| 898 | gcgacggggcgcgcgcgccc     | S        |
| 899 | gcggcgtgcggcgcgcgccc     | S        |
| 900 | gcggcggtcggcgcgcgccc     | S        |
| 901 | gcgacggtcggcgcgcgccc     | S        |
| 902 | gcggcgttcggcgcgcgccc     | S        |
| 903 | gcgacgtgcggcgcgcgccc     | S        |
| 904 | tcgtcgctgtctccg          | S        |
| 905 | tgtgggggttttggttttgg     | S        |
| 906 | aggggaggggaggggagggg     | S        |
| 907 | tgtgtgtgtgtgtgtgtgtgt    | S        |
| 908 | ctctctctctctctctctctct   | chimeric |
| 909 | ggggtcgacgtcgagggggg     | S        |
| 910 | atatatatatatatatatat     | S        |
| 911 | tttttttttttttttttttttt   | S        |
| 912 | tttttttttttttttttttttt   | S        |
| 913 | tttttttttttttttttttttt   | S        |
| 914 | gctagaggggaggggt         |          |
| 915 | gctagatgttagggg          |          |
| 916 | gcatgagggggagct          |          |
| 917 | atggaagggtccagggggctc    |          |
| 918 | atggactctggagggggctc     |          |
| 919 | atggaagggtccaaggggctc    |          |
| 920 | gagaaggggggaccttgat      |          |
| 921 | gagaaggggggaccttccat     |          |
| 922 | gagaagggggccagcactgat    |          |
| 923 | tccatgtggggcctgatgct     |          |
| 924 | tccatgaggggcctgatgct     |          |
| 925 | tccatgtggggcctgctgat     |          |
| 926 | atggactctccgggggttctc    |          |
| 927 | atggaagggtccgggggttctc   |          |
| 928 | atggactctggaggggttctc    |          |
| 929 | atggaggctccatggggctc     |          |
| 930 | atggactctgggggggttctc    |          |
| 931 | tccatgtgggtggggatgct     |          |
| 932 | tccatgcgggtggggatgct     |          |
| 933 | tccatgggggtcctgatgct     |          |
| 934 | tccatgggggtccctgatgct    |          |
| 935 | tccatgggggtgctgatgct     |          |
| 936 | tccatgggggttctgatgct     |          |
| 937 | tccatcgggggcctgatgct     |          |
| 938 | gctagagggagtggt          |          |
| 939 | tttttttttttttttttttttt   | S        |
| 940 | gmgggtcaacgttgagggmggg   | S        |
| 941 | ggggaggttcgttgaggggggg   | S        |
| 942 | tcgtcgtttccccccccccc     | S        |
| 943 | ttgggggggttttttttttttttt | S        |
| 944 | tttaaatttttaaattttaaaata | S        |



- 57 -

|     |                              |     |
|-----|------------------------------|-----|
| 945 | ttgggttttttttgggttttttttttgg | s   |
| 946 | tttccctttttccctttttccctc     | s   |
| 947 | ggggtcatcgatgagggggg s       | sos |
| 948 | tccatgacgttcctgacgtt         |     |
| 949 | tccatgacgttcctgacgtt         |     |
| 950 | tccatgacgttcctgacgtt         |     |
| 951 | tccatgacgttcctgacgtt         |     |
| 952 | tccatgacgttcctgacgtt         |     |
| 953 | tccatgacgttcctgacgtt         |     |
| 954 | tccatgacgttcctgacgtt         |     |
| 955 | tccatgacgttcctgacgtt         |     |
| 956 | tccatgacgttcctgacgtt         |     |
| 957 | tccatgacgttcctgacgtt         |     |
| 958 | tccatgacgttcctgacgtt         |     |
| 959 | gggggacgatcgtcggggg          | sos |
| 960 | gggggtcgtagacggggg           | sos |
| 961 | tttttttttttttttttttttttt     | po  |
| 962 | aaaaaaaaaaaaaaaaaaaaaaaa     | po  |
| 963 | cccccccccccccccccccccccc     | po  |
| 964 | tcgtcgttttgtcgttttgtcgtt     |     |
| 965 | tcgtcgttttgtcgttttgtcgtt     |     |
| 966 | tcgtcgttttgtcgttttgtcgtt     |     |
| 967 | tcgtcgttttgtcgttttgtcgtt     |     |
| 968 | ggggtcaacgttgagggggg         |     |
| 969 | ggggtcaacgttgagggggg         |     |
| 970 | ggggtcaagcttgagggggg         |     |
| 971 | tgtgttcccccccccccc           |     |
| 972 | ggggacgtcgacgtgggggg         | sos |
| 973 | ggggtcgtagacgagggggg         | sos |
| 974 | ggggtcgacgtacgtcgagggggg     | sos |
| 975 | ggggaccggtaccggtgggggg       | sos |
| 976 | gggtcgacgtcgagggggg          | sos |
| 977 | ggggtcgacgtcgagggggg         | sos |
| 978 | ggggaacgttaacgttgggggg       | sos |
| 979 | ggggtcaccggtgagggggg         | sos |
| 980 | ggggtcggttcgaacgagggggg      | sos |
| 981 | ggggacgttcgaacgtgggggg       | sos |
| 982 | tcaactttga                   | s   |
| 983 | tcaagcttga                   | s   |
| 984 | tcacgatcgta                  | s   |
| 985 | tcagcatgctga                 | s   |
| 986 | gggggagcatgctggggggg         | sos |
| 987 | ggggggggggggggggggggg        | sos |
| 988 | gggggacgatatcgtcgggggg       | sos |
| 989 | gggggacgacgtcgtcgggggg       | sos |
| 990 | gggggacgagctcgtcgggggg       | sos |
| 991 | gggggacgtacgtcgggggg         | sos |
| 992 | tcaacgtt                     |     |
| 993 | tccataccggtcctgatgct         |     |
| 994 | tccataccggtcctaccggt         | s   |



- 58 -

|      |                             |     |
|------|-----------------------------|-----|
| 995  | gggggacgatcggtgggggg        | sos |
| 996  | ggggaacgatcgtcgggggg        | sos |
| 997  | ggg ggg acg atc gtc ggg ggg | sos |
| 998  | ggg gga cga tcg tcg ggg ggg | sos |
| 999  | aaa gac gtt aaa             | po  |
| 1000 | aaagagcttaaa                | po  |
| 1001 | aaagazgttaaa                | po  |
| 1002 | aaattcggaaaa                | po  |
| 1003 | gggggtcatcgatgagggggg       | sos |
| 1004 | gggggtcaacgttgagggggg       | sos |
| 1005 | atgtagcttaataacaaagc        | po  |
| 1006 | ggatcccttgagttacttct        | po  |
| 1007 | ccattccacttctgattacc        | po  |
| 1008 | tatgtattatcatgtagata        | po  |
| 1009 | agcctacgtattcaccctcc        | po  |
| 1010 | ttcctgcaactactattgta        | po  |
| 1011 | atagaaggccctacaccagt        | po  |
| 1012 | ttacaccggtctatggaggt        | po  |
| 1013 | ctaaccagatcaagtctagg        | po  |
| 1014 | cctagacttgatctggtag         | po  |
| 1015 | tataagcctcgtccgacatg        | po  |
| 1016 | catgtcggacgaggttata         | po  |
| 1017 | tggtggtggggagtaagctc        | po  |
| 1018 | gagctactccccaccacca         | po  |
| 1019 | gccttcgatcttcggttgga        | po  |
| 1020 | tggacttctctttgccgtct        | po  |
| 1021 | atgctgtagcccagcgataa        | po  |
| 1022 | accgaatcagcggaaagtga        | po  |
| 1023 | tccatgacgttcctgacgtt        |     |
| 1024 | ggagaaacccatgagctcatctgg    |     |
| 1025 | accacagaccagcaggcaga        |     |
| 1026 | gagcgtgaactgcgcgaaga        |     |
| 1027 | tcggtacccttgacgcggtt        |     |
| 1028 | ctggagccctagccaaggat        |     |
| 1029 | gcgactccatcaccagcgat        |     |
| 1030 | cctgaagtaagaaccagatgt       |     |
| 1031 | ctgtgttatctgacatacacc       |     |
| 1032 | aattagccttaggtgattggg       |     |
| 1033 | acatctggttcttacttcagg       |     |
| 1034 | ataagtcataatgttggaactac     |     |
| 1035 | cccaatcacctaaggctaatt       |     |
| 1036 | ggggtcgtcgacgagggggg        | sos |
| 1037 | ggggtcgttcgaacgagggggg      | sos |
| 1038 | ggggacgttcgaacgtgggggg      | sos |
| 1039 | tcctggcgqggaagt             | s   |
| 1040 | ggggaacgacgtcggtgggggg      | sos |
| 1041 | ggggaacgtacgtcgggggg        | sos |
| 1042 | ggggaacgtacgtacgttggggg     | sos |
| 1043 | ggggtcaccggtgagggggg        | sos |



- 59 -

|      |                                     |     |
|------|-------------------------------------|-----|
| 1044 | ggggtcgacgtacgtcgagggggg            | sos |
| 1045 | ggggaccggtaccggtggggggg             | sos |
| 1046 | gggtcgacgtcgagggggg                 | sos |
| 1047 | ggggtcgacgtcgagggg                  | sos |
| 1048 | ggggaacgttaacgttggggggg             | sos |
| 1049 | ggggacgtcgacgtggggg                 | sos |
| 1050 | gcactcttcgaagctacagccggcagcctctgat  |     |
| 1051 | cggctcttccatgaggtctttgctaattcttg    |     |
| 1052 | cggctcttccatgaaagtctttggacgatgtgagc |     |
| 1053 | tcctgcaggttaagt                     | s   |
| 1054 | gggggtcgttcgttggggggg               | sos |
| 1055 | gggggatgattggtggggggg               | sos |
| 1056 | gggggazgatzggtggggggg               | sos |
| 1057 | gggggagctagcttggggggg               | sos |
| 1058 | ggttcttttggtccttgtct                | s   |
| 1059 | ggttcttttggtcctcgtct                | s   |
| 1060 | ggttcttttggtccttatct                | s   |
| 1061 | ggttcttggtttccttgtct                | s   |
| 1062 | tggtcttttggtccttgtct                | s   |
| 1063 | ggttcaaattggtccttgtct               | s   |
| 1064 | gggtcttttgggccttgtct                | s   |
| 1065 | tccaggacttctctcaggtttttt            | s   |
| 1066 | tccaaaacttctctcaaatt                | s   |
| 1067 | tactacttttatacttttatactt            | s   |
| 1068 | tgtgtgtgtgtgtgtgtgtgtgtg            | s   |
| 1069 | ttgttggtgtgtgtgtgtgtgtgtg           | s   |
| 1070 | ggctccggggaggggaatttttgtctat        | s   |
| 1071 | gggacgatcgtcggggggg                 | sos |
| 1072 | gggtcgtcgacgaggggggg                | sos |
| 1073 | ggtcgtcgacgaggggggg                 | sos |
| 1074 | gggtcgtcgtcgtaggggggg               | sos |
| 1075 | ggggacgatcgtcggggggg                | sos |
| 1076 | ggggacgtcgtcgtagggggg               | sos |
| 1077 | ggggtcgacgtcgacgtcgagggggg          | sos |
| 1078 | ggggaaccgcggttggggggg               | sos |
| 1079 | ggggacgacgtcgtagggggg               | sos |
| 1080 | tcgtcgtcgtcgtaggggggg               | sos |
| 1081 | tcctgccgggggaagt                    | s   |
| 1082 | tcctgcagggggaagt                    | s   |
| 1083 | tcctgaaggggaagt                     | s   |
| 1084 | tcctggcgggcaagt                     | s   |
| 1085 | tcctggcgggtaagt                     | s   |
| 1086 | tcctggcgggaaagt                     | s   |
| 1087 | tccgggcggggaagt                     | s   |
| 1088 | tcggggcggggaagt                     | s   |
| 1089 | tccgggcggggaagt                     | s   |
| 1090 | gggggacgttggggg                     | s   |
| 1091 | ggggtttttttttttgggggg               | sos |
| 1092 | ggggccccccccccgggggg                | sos |



|      |                                |     |
|------|--------------------------------|-----|
| 1093 | gggggttggttggttggtgggggg       | Sos |
| 1094 | tttttttttttttttttttttttttttttt |     |
| 1095 | aaaaaaaaaaaaaaaaaaaaaaaaaaaaa  |     |
| 1096 | cccccccccccccccccccccccccccccc |     |
| 1097 | cgcgcgcgcgcgcgcgcgcgcgcgcgcg   |     |

While CpG effects in mice are well characterized, information regarding the human system is limited. CpG phosphorothioate oligonucleotides with strong stimulatory activity in the mouse system show lower activity on human and other non-rodent immune cells. In the examples the development of a potent human CpG motif and the characterization of its effects and mechanisms of action on human primary B-cells is described. DNA containing this CpG motif strongly stimulated primary human B-cells to proliferate, to produce IL-6 and to express increased levels of CD86, CD40, CD54 and MHC II. It increased DNA binding activity of the transcription factors NF $\kappa$ B and AP-1, as well as phosphorylation of the stress activated protein kinases JNK and p38, and the transcription factor ATF-2. B-cell signaling pathways activated by CpG DNA were different from those activated by the B-cell receptor which activated ERK and a different isoform of JNK, but did not activate p38 and ATF-2. In general the data on CpG DNA-initiated signal transduction are consistent with those obtained in mice (Hacker H., et al. 1998. *Embo J* 17:6230, Yi A. K., and Krieg A. M. 1998. *J Immunol* 161:4493).

The preferred non-rodent motif is 5' TCGTCGTT 3'. Base exchanges within the most potent 8mer CpG motif (5' TCGTCGTT 3') diminished the activity of the oligonucleotide. The thymidines at the 5' and the 3' position of this motif were more important than the thymidine at the middle position. An adenine or guanosine at the middle position produced a decrease in the activity.

Of note, our studies demonstrate that one human CpG motif within a phosphodiester oligonucleotide (2080) is sufficient to produce the maximal effect, and that additional CpG motifs (2059) did not further enhance the activity. The oligonucleotide with the 8mer motif 5' TCG TCG TT 3' (2080) containing two CpG dinucleotides showed the highest activity in the studies. Replacement of the bases flanking the two CpG dinucleotides (5' position, middle position, 3' position) reduced the activity of this sequence. Both CpG dinucleotides within the 8mer CpG motif were required for the optimal activity (2108, 2106). Cytidine methylation of the CpG dinucleotides (2095) abolished the activity of 2080, while methylation of an unrelated



- 61 -

cytidine (2094) did not. The addition of two CpG motifs into the sequence of 2080 resulting in 2059 did not further increase the activity of the phosphodiester oligonucleotide. The sequence of 2080 with a phosphorothioate backbone (2116) demonstrated less activity, suggesting that additional CpG motifs are preferred for a  
5 potent phosphorothioate oligonucleotide.

It has been discovered according to the invention that the immunostimulatory nucleic acids have dramatic immune stimulatory effects on human cells such as NK cells, B cells, and DCs *in vitro*. It has been demonstrated that that the *in vitro* assays used herein predict *in vivo* effectiveness as a vaccine adjuvant in non-rodent vertebrates  
10 (Example 12), suggesting that immunostimulatory nucleic acids are effective therapeutic agents for human vaccination, cancer immunotherapy, asthma immunotherapy, general enhancement of immune function, enhancement of hematopoietic recovery following radiation or chemotherapy, and other immune modulatory applications.

Thus the immunostimulatory nucleic acids are useful in some aspects of the  
15 invention as a prophylactic vaccine for the treatment of a subject at risk of developing an infection with an infectious organism or a cancer in which a specific cancer antigen has been identified or an allergy or asthma where the allergen or predisposition to asthma is known. The immunostimulatory nucleic acids can also be given without the antigen or allergen for shorter term protection against infection, allergy or cancer, and in this case  
20 repeated doses will allow longer term protection. A subject at risk as used herein is a subject who has any risk of exposure to an infection causing pathogen or a cancer or an allergen or a risk of developing cancer. For instance, a subject at risk may be a subject who is planning to travel to an area where a particular type of infectious agent is found or it may be a subject who through lifestyle or medical procedures is exposed to bodily  
25 fluids which may contain infectious organisms or directly to the organism or even any subject living in an area where an infectious organism or an allergen has been identified. Subjects at risk of developing infection also include general populations to which a medical agency recommends vaccination with a particular infectious organism antigen. If the antigen is an allergen and the subject develops allergic responses to that particular  
30 antigen and the subject may be exposed to the antigen, i.e., during pollen season, then that subject is at risk of exposure to the antigen. A subject at risk of developing an allergy to asthma includes those subjects that have been identified as having an allergy or



- 62 -

asthma but that don't have the active disease during the immunostimulatory nucleic acid treatment as well as subjects that are considered to be at risk of developing these diseases because of genetic or environmental factors.

5 A subject at risk of developing a cancer is one who is who has a high probability of developing cancer. These subjects include, for instance, subjects having a genetic abnormality, the presence of which has been demonstrated to have a correlative relation to a higher likelihood of developing a cancer and subjects exposed to cancer causing agents such as tobacco, asbestos, or other chemical toxins, or a subject who has previously been treated for cancer and is in apparent remission. When a subject at risk of  
10 developing a cancer is treated with an antigen specific for the type of cancer to which the subject is at risk of developing and a immunostimulatory nucleic acid, the subject may be able to kill the cancer cells as they develop. If a tumor begins to form in the subject, the subject will develop a specific immune response against the tumor antigen.

In addition to the use of the immunostimulatory nucleic acids for prophylactic  
15 treatment, the invention also encompasses the use of the immunostimulatory nucleic acids for the treatment of a subject having an infection, an allergy, asthma, or a cancer.

A subject having an infection is a subject that has been exposed to an infectious pathogen and has acute or chronic detectable levels of the pathogen in the body. The immunostimulatory nucleic acids can be used with an antigen to mount an antigen  
20 specific systemic or mucosal immune response that is capable of reducing the level of or eradicating the infectious pathogen. An infectious disease, as used herein, is a disease arising from the presence of a foreign microorganism in the body. It is particularly important to develop effective vaccine strategies and treatments to protect the body's mucosal surfaces, which are the primary site of pathogenic entry.

25 A subject having an allergy is a subject that has or is at risk of developing an allergic reaction in response to an allergen. An allergy refers to acquired hypersensitivity to a substance (allergen). Allergic conditions include but are not limited to eczema, allergic rhinitis or coryza, hay fever, conjunctivitis, bronchial asthma, urticaria (hives) and food allergies, and other atopic conditions.

30 Currently, allergic diseases are generally treated by the injection of small doses of antigen followed by subsequent increasing dosage of antigen. It is believed that this procedure induces tolerization to the allergen to prevent further allergic reactions. These



- 63 -

methods, however, can take several years to be effective and are associated with the risk of side effects such as anaphylactic shock. The methods of the invention avoid these problems.

Allergies are generally caused by IgE antibody generation against harmless  
5 allergens. The cytokines that are induced by systemic or mucosal administration of immunostimulatory nucleic acids are predominantly of a class called Th1 (examples are IL-12 and IFN- $\gamma$ ) and these induce both humoral and cellular immune responses. The types of antibodies associated with a Th1 response are generally more protective because they have high neutralization and opsonization capabilities. The other major type of  
10 immune response, which is associated with the production of IL-4, IL-5 and IL-10 cytokines, is termed a Th2 immune response. Th2 responses involve predominately antibodies and these have less protective effect against infection and some Th2 isotypes (e.g., IgE) are associated with allergy. In general, it appears that allergic diseases are mediated by Th2 type immune responses while Th1 responses provide the best  
15 protection against infection, although excessive Th1 responses are associated with autoimmune disease. Based on the ability of the immunostimulatory nucleic acids to shift the immune response in a subject from a Th2 (which is associated with production of IgE antibodies and allergy) to a Th1 response (which is protective against allergic reactions), an effective dose for inducing an immune response of a immunostimulatory  
20 nucleic acid can be administered to a subject to treat or prevent an allergy.

Thus, the immunostimulatory nucleic acids have significant therapeutic utility in the treatment of allergic and non-allergic conditions such as asthma. Th2 cytokines, especially IL-4 and IL-5 are elevated in the airways of asthmatic subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including  
25 IgE isotope switching, eosinophil chemotaxis and activation and mast cell growth. Th1 cytokines, especially IFN- $\gamma$  and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines. Asthma refers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated  
30 with atopic or allergic symptoms.

A subject having a cancer is a subject that has detectable cancerous cells. The cancer may be a malignant or non-malignant cancer. Cancers or tumors include but are



- 64 -

not limited to biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; intraepithelial neoplasms; lymphomas; liver cancer; lung cancer (e.g. small cell and non-small cell); melanoma; neuroblastomas; oral cancer; ovarian cancer; pancreas  
5 cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; and renal cancer, as well as other carcinomas and sarcomas. In one embodiment the cancer is hairy cell leukemia, chronic myelogenous leukemia, cutaneous T-cell leukemia, multiple myeloma, follicular lymphoma, malignant melanoma, squamous cell carcinoma, renal cell carcinoma, prostate carcinoma, bladder cell carcinoma, or colon  
10 carcinoma.

A subject according to the invention is a non-rodent subject. A non-rodent subject shall mean a human or vertebrate animal including but not limited to a dog, cat, horse, cow, pig, sheep, goat, chicken, primate, e.g., monkey, and fish (aquaculture species), e.g. salmon, but specifically excluding rodents such as rats and mice.

15 Thus, the invention can also be used to treat cancer and tumors in non human subjects. Cancer is one of the leading causes of death in companion animals (i.e., cats and dogs). Cancer usually strikes older animals which, in the case of house pets, have become integrated into the family. Forty-five % of dogs older than 10 years of age, are likely to succumb to the disease. The most common treatment options include surgery,  
20 chemotherapy and radiation therapy. Others treatment modalities which have been used with some success are laser therapy, cryotherapy, hyperthermia and immunotherapy. The choice of treatment depends on type of cancer and degree of dissemination. Unless the malignant growth is confined to a discrete area in the body, it is difficult to remove only malignant tissue without also affecting normal cells.

25 Malignant disorders commonly diagnosed in dogs and cats include but are not limited to lymphosarcoma, osteosarcoma, mammary tumors, mastocytoma, brain tumor, melanoma, adenosquamous carcinoma, carcinoid lung tumor, bronchial gland tumor, bronchiolar adenocarcinoma, fibroma, myxochondroma, pulmonary sarcoma, neurosarcoma, osteoma, papilloma, retinoblastoma, Ewing's sarcoma, Wilm's tumor,  
30 Burkitt's lymphoma, microglioma, neuroblastoma, osteoclastoma, oral neoplasia, fibrosarcoma, osteosarcoma and rhabdomyosarcoma. Other neoplasias in dogs include genital squamous cell carcinoma, transmissible venereal tumor, testicular tumor,



- 65 -

seminoma, Sertoli cell tumor, hemangiopericytoma, histiocytoma, chloroma (granulocytic sarcoma), corneal papilloma, corneal squamous cell carcinoma, hemangiosarcoma, pleural mesothelioma, basal cell tumor, thymoma, stomach tumor, adrenal gland carcinoma, oral papillomatosis, hemangioendothelioma and cystadenoma.

5 Additional malignancies diagnosed in cats include follicular lymphoma, intestinal lymphosarcoma, fibrosarcoma and pulmonary squamous cell carcinoma. The ferret, an ever-more popular house pet is known to develop insulinoma, lymphoma, sarcoma, neuroma, pancreatic islet cell tumor, gastric MALT lymphoma and gastric adenocarcinoma.

10 Neoplasias affecting agricultural livestock include leukemia, hemangiopericytoma and bovine ocular neoplasia (in cattle); preputial fibrosarcoma, ulcerative squamous cell carcinoma, preputial carcinoma, connective tissue neoplasia and mastocytoma (in horses); hepatocellular carcinoma (in swine); lymphoma and pulmonary adenomatosis (in sheep); pulmonary sarcoma, lymphoma, Rous sarcoma, 15 reticulendotheliosis, fibrosarcoma, nephroblastoma, B-cell lymphoma and lymphoid leukosis (in avian species); retinoblastoma, hepatic neoplasia, lymphosarcoma (lymphoblastic lymphoma), plasmacytoid leukemia and swimbladder sarcoma (in fish), caseous lymphadenitis (CLA): chronic, infectious, contagious disease of sheep and goats caused by the bacterium *Corynebacterium pseudotuberculosis*, and contagious lung 20 tumor of sheep caused by jaagsiekte.

The subject is exposed to the antigen. As used herein, the term exposed to refers to either the active step of contacting the subject with an antigen or the passive exposure of the subject to the antigen *in vivo*. Methods for the active exposure of a subject to an antigen are well-known in the art. In general, an antigen is administered directly to the 25 subject by any means such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. The antigen can be administered systemically or locally. Methods for administering the antigen and the immunostimulatory nucleic acid are described in more detail below. A subject is passively exposed to an antigen if an antigen becomes available for exposure to the 30 immune cells in the body. A subject may be passively exposed to an antigen, for instance, by entry of a foreign pathogen into the body or by the development of a tumor cell expressing a foreign antigen on its surface.



- 66 -

The methods in which a subject is passively exposed to an antigen can be particularly dependent on timing of administration of the immunostimulatory nucleic acid. For instance, in a subject at risk of developing a cancer or an infectious disease or an allergic or asthmatic response, the subject may be administered the immunostimulatory nucleic acid on a regular basis when that risk is greatest, i.e., during allergy season or after exposure to a cancer causing agent. Additionally the immunostimulatory nucleic acid may be administered to travelers before they travel to foreign lands where they are at risk of exposure to infectious agents. Likewise the immunostimulatory nucleic acid may be administered to soldiers or civilians at risk of exposure to biowarfare to induce a systemic or mucosal immune response to the antigen when and if the subject is exposed to it.

An antigen as used herein is a molecule capable of provoking an immune response. Antigens include but are not limited to cells, cell extracts, proteins, polypeptides, peptides, polysaccharides, polysaccharide conjugates, peptide and non-peptide mimics of polysaccharides and other molecules, small molecules, lipids, glycolipids, carbohydrates, viruses and viral extracts and multicellular organisms such as parasites and allergens. The term antigen broadly includes any type of molecule which is recognized by a host immune system as being foreign. Antigens include but are not limited to cancer antigens, microbial antigens, and allergens.

A cancer antigen as used herein is a compound, such as a peptide or protein, associated with a tumor or cancer cell surface and which is capable of provoking an immune response when expressed on the surface of an antigen presenting cell in the context of an MHC molecule. Cancer antigens can be prepared from cancer cells either by preparing crude extracts of cancer cells, for example, as described in Cohen, et al., 1994, *Cancer Research*, 54:1055, by partially purifying the antigens, by recombinant technology, or by de novo synthesis of known antigens. Cancer antigens include but are not limited to antigens that are recombinantly expressed, an immunogenic portion of, or a whole tumor or cancer. Such antigens can be isolated or prepared recombinantly or by any other means known in the art.

A microbial antigen as used herein is an antigen of a microorganism and includes but is not limited to virus, bacteria, parasites, and fungi. Such antigens include the intact microorganism as well as natural isolates and fragments or derivatives thereof and also



- 67 -

synthetic compounds which are identical to or similar to natural microorganism antigens and induce an immune response specific for that microorganism. A compound is similar to a natural microorganism antigen if it induces an immune response (humoral and/or cellular) to a natural microorganism antigen. Such antigens are used routinely in the art and are well known to those of ordinary skill in the art.

Examples of viruses that have been found in humans include but are not limited to: *Retroviridae* (e.g. human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such as HIV-LP; *Picornaviridae* (e.g. polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses); *Calciviridae* (e.g. strains that cause gastroenteritis); *Togaviridae* (e.g. equine encephalitis viruses, rubella viruses); *Flaviridae* (e.g. dengue viruses, encephalitis viruses, yellow fever viruses); *Coronaviridae* (e.g. coronaviruses); *Rhabdoviridae* (e.g. vesicular stomatitis viruses, rabies viruses); *Coronaviridae* (e.g. coronaviruses); *Rhabdoviridae* (e.g. vesicular stomatitis viruses, rabies viruses); *Filoviridae* (e.g. ebola viruses); *Paramyxoviridae* (e.g. parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); *Orthomyxoviridae* (e.g. influenza viruses); *Bunyaviridae* (e.g. Hantaan viruses, bunya viruses, phleboviruses and Nairo viruses); *Arenaviridae* (hemorrhagic fever viruses); *Reoviridae* (e.g. reoviruses, orbiviruses and rotaviruses); *Birnaviridae*; *Hepadnaviridae* (Hepatitis B virus); *Parvoviridae* (parvoviruses); *Papovaviridae* (papilloma viruses, polyoma viruses); *Adenoviridae* (most adenoviruses); *Herpesviridae* (herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes virus; *Poxviridae* (variola viruses, vaccinia viruses, pox viruses); and *Iridoviridae* (e.g. African swine fever virus); and unclassified viruses (e.g. the etiological agents of Spongiform encephalopathies, the agent of delta hepatitis (thought to be a defective satellite of hepatitis B virus), the agents of non-A, non-B hepatitis (class 1 = internally transmitted; class 2 = parenterally transmitted (i.e. Hepatitis C); Norwalk and related viruses, and astroviruses).

Both gram negative and gram positive bacteria serve as antigens in vertebrate animals. Such gram positive bacteria include, but are not limited to, *Pasteurella* species, *Staphylococci* species, and *Streptococcus* species. Gram negative bacteria include, but are not limited to, *Escherichia coli*, *Pseudomonas* species, and *Salmonella* species. Specific examples of infectious bacteria include but are not limited to, *Helicobacter*



- 68 -

*pyloris*, *Borelia burgdorferi*, *Legionella pneumophila*, *Mycobacteria* sps (e.g. *M. tuberculosis*, *M. avium*, *M. intracellulare*, *M. kansaii*, *M. gordonae*), *Staphylococcus aureus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes* (Group A Streptococcus), *Streptococcus agalactiae* (Group B Streptococcus), *Streptococcus* (viridans group), *Streptococcus faecalis*, *Streptococcus bovis*, *Streptococcus* (anaerobic sps.), *Streptococcus pneumoniae*, pathogenic *Campylobacter* sp., *Enterococcus* sp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium diphtheriae*, *Corynebacterium* sp., *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Pasteurella multocida*, *Bacteroides* sp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenue*, *Leptospira*, *Rickettsia*, and *Actinomyces israeli*.

Examples of fungi include *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Coccidioides immitis*, *Blastomyces dermatitidis*, *Chlamydia trachomatis*, *Candida albicans*.

Other infectious organisms (i.e., protists) include *Plasmodium* spp. such as *Plasmodium falciparum*, *Plasmodium malariae*, *Plasmodium ovale*, and *Plasmodium vivax* and *Toxoplasma gondii*. Blood-borne and/or tissues parasites include *Plasmodium* spp., *Babesia microti*, *Babesia divergens*, *Leishmania tropica*, *Leishmania* spp., *Leishmania braziliensis*, *Leishmania donovani*, *Trypanosoma gambiense* and *Trypanosoma rhodesiense* (African sleeping sickness), *Trypanosoma cruzi* (Chagas' disease), and *Toxoplasma gondii*.

Other medically relevant microorganisms have been described extensively in the literature, e.g., see C.G.A Thomas, *Medical Microbiology*, Bailliere Tindall, Great Britain 1983, the entire contents of which is hereby incorporated by reference.

Although many of the microbial antigens described above relate to human disorders, the invention is also useful for treating other nonhuman vertebrates. Nonhuman vertebrates are also capable of developing infections which can be prevented or treated with the Immunostimulatory nucleic acids disclosed herein. For instance, in addition to the treatment of infectious human diseases, the methods of the invention are useful for treating infections of animals.



- 69 -

As used herein, the term treat, treated, or treating when used with respect to an infectious disease refers to a prophylactic treatment which increases the resistance of a subject (a subject at risk of infection) to infection with a pathogen or, in other words, decreases the likelihood that the subject will become infected with the pathogen as well  
5 as a treatment after the subject (a subject who has been infected) has become infected in order to fight the infection, e.g., reduce or eliminate the infection or prevent it from becoming worse.

Many vaccines for the treatment of non-human vertebrates are disclosed in Bennett, K. *Compendium of Veterinary Products*, 3rd ed. North American  
10 Compendiums, Inc., 1995. As discussed above, antigens include infectious microbes such as virus, parasite, bacteria and fungi and fragments thereof, derived from natural sources or synthetically. Infectious viruses of both human and non-human vertebrates, include retroviruses, RNA viruses and DNA viruses. This group of retroviruses includes both simple retroviruses and complex retroviruses. The simple retroviruses include the  
15 subgroups of B-type retroviruses, C-type retroviruses and D-type retroviruses. An example of a B-type retrovirus is mouse mammary tumor virus (MMTV). The C-type retroviruses include subgroups C-type group A (including Rous sarcoma virus (RSV), avian leukemia virus (ALV), and avian myeloblastosis virus (AMV)) and C-type group B (including feline leukemia virus (FeLV), gibbon ape leukemia virus (GALV), spleen  
20 necrosis virus (SNV), reticuloendotheliosis virus (RV) and simian sarcoma virus (SSV)). The D-type retroviruses include Mason-Pfizer monkey virus (MPMV) and simian retrovirus type 1 (SRV-1). The complex retroviruses include the subgroups of lentiviruses, T-cell leukemia viruses and the foamy viruses. Lentiviruses include HIV-1, but also include HIV-2, SIV, Visna virus, feline immunodeficiency virus (FIV), and  
25 equine infectious anemia virus (EIAV). The T-cell leukemia viruses include HTLV-1, HTLV-II, simian T-cell leukemia virus (STLV), and bovine leukemia virus (BLV). The foamy viruses include human foamy virus (HFV), simian foamy virus (SFV) and bovine foamy virus (BFV).

Examples of other RNA viruses that are antigens in vertebrate animals include,  
30 but are not limited to, members of the family Reoviridae, including the genus Orthoreovirus (multiple serotypes of both mammalian and avian retroviruses), the genus Orbivirus (Bluetongue virus, Eugenangee virus, Kemerovo virus, African horse sickness



- 70 -

virus, and Colorado Tick Fever virus), the genus Rotavirus (human rotavirus, Nebraska calf diarrhea virus, simian rotavirus, bovine or ovine rotavirus, avian rotavirus); the family Picornaviridae, including the genus Enterovirus (poliovirus, Cocksackie virus A and B, enteric cytopathic human orphan (ECHO) viruses, hepatitis A virus, Simian

5 enteroviruses, Murine encephalomyelitis (ME) viruses, Poliovirus muris, Bovine enteroviruses, Porcine enteroviruses, the genus Cardiovirus (Encephalomyocarditis virus (EMC), Mengovirus), the genus Rhinovirus (Human rhinoviruses including at least 113 subtypes; other rhinoviruses), the genus Aphthovirus (Foot and Mouth disease (FMDV); the family Calciviridae, including Vesicular exanthema of swine virus, San Miguel sea

10 lion virus, Feline picornavirus and Norwalk virus; the family Togaviridae, including the genus Alphavirus (Eastern equine encephalitis virus, Semliki forest virus, Sindbis virus, Chikungunya virus, O'Nyong-Nyong virus, Ross river virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus), the genus Flavivirus (Mosquito borne yellow fever virus, Dengue virus, Japanese encephalitis virus, St. Louis

15 encephalitis virus, Murray Valley encephalitis virus, West Nile virus, Kunjin virus, Central European tick borne virus, Far Eastern tick borne virus, Kyasanur forest virus, Louping III virus, Powassan virus, Omsk hemorrhagic fever virus), the genus Rubivirus (Rubella virus), the genus Pestivirus (Mucosal disease virus, Hog cholera virus, Border disease virus); the family Bunyaviridae, including the genus Bunyavirus (Bunyamwera

20 and related viruses, California encephalitis group viruses), the genus Phlebovirus (Sandfly fever Sicilian virus, Rift Valley fever virus), the genus Nairovirus (Crimean-Congo hemorrhagic fever virus, Nairobi sheep disease virus), and the genus Uukuvirus (Uukuniemi and related viruses); the family Orthomyxoviridae, including the genus Influenza virus (Influenza virus type A, many human subtypes); Swine influenza

25 virus, and Avian and Equine Influenza viruses; influenza type B (many human subtypes), and influenza type C (possible separate genus); the family paramyxoviridae, including the genus Paramyxovirus (Parainfluenza virus type 1, Sendai virus, Hemadsorption virus, Parainfluenza viruses types 2 to 5, Newcastle Disease Virus, Mumps virus), the genus Morbillivirus (Measles virus, subacute sclerosing panencephalitis virus, distemper virus,

30 Rinderpest virus), the genus Pneumovirus (respiratory syncytial virus (RSV), Bovine respiratory syncytial virus and Pneumonia virus); the family Rhabdoviridae, including the genus Vesiculovirus (VSV), Chandipura virus, Flanders-Hart Park virus), the genus



- 71 -

Lyssavirus (Rabies virus), fish Rhabdoviruses, and two probable Rhabdoviruses (Marburg virus and Ebola virus); the family Arenaviridae, including Lymphocytic choriomeningitis virus (LCM), Tacaribe virus complex, and Lassa virus; the family Coronaviridae, including Infectious Bronchitis Virus (IBV), Hepatitis virus, Human enteric corona virus, and Feline infectious peritonitis (Feline coronavirus).

Illustrative DNA viruses that are antigens in vertebrate animals include, but are not limited to, the family Poxviridae, including the genus Orthopoxvirus (Variola major, Variola minor, Monkey pox Vaccinia, Cowpox, Buffalopox, Rabbitpox, Ectromelia), the genus Leporipoxvirus (Myxoma, Fibroma), the genus Avipoxvirus (Fowlpox, other avian poxvirus), the genus Capripoxvirus (sheeppox, goatpox), the genus Suipoxvirus (Swinepox), the genus Parapoxvirus (contagious postular dermatitis virus, pseudocowpox, bovine papular stomatitis virus); the family Iridoviridae (African swine fever virus, Frog viruses 2 and 3, Lymphocystis virus of fish); the family Herpesviridae, including the alpha-Herpesviruses (Herpes Simplex Types 1 and 2, Varicella-Zoster, Equine abortion virus, Equine herpes virus 2 and 3, pseudorabies virus, infectious bovine keratoconjunctivitis virus, infectious bovine rhinotracheitis virus, feline rhinotracheitis virus, infectious laryngotracheitis virus) the Beta-herpesviruses (Human cytomegalovirus and cytomegaloviruses of swine and monkeys); the gamma-herpesviruses (Epstein-Barr virus (EBV), Marek's disease virus, Herpes saimiri, Herpesvirus ateles, Herpesvirus sylvilagus, guinea pig herpes virus, Lucke tumor virus); the family Adenoviridae, including the genus Mastadenovirus (Human subgroups A,B,C,D,E and ungrouped; simian adenoviruses (at least 23 serotypes), infectious canine hepatitis, and adenoviruses of cattle, pigs, sheep, frogs and many other species, the genus Aviadenovirus (Avian adenoviruses); and non-cultivable adenoviruses; the family Papoviridae, including the genus Papillomavirus (Human papilloma viruses, bovine papilloma viruses, Shope rabbit papilloma virus, and various pathogenic papilloma viruses of other species), the genus Polyomavirus (polyomavirus, Simian vacuolating agent (SV-40), Rabbit vacuolating agent (RKV), K virus, BK virus, JC virus, and other primate polyoma viruses such as Lymphotropic papilloma virus); the family Parvoviridae including the genus Adeno-associated viruses, the genus Parvovirus (Feline panleukopenia virus, bovine parvovirus, canine parvovirus, Aleutian mink disease virus, etc). Finally, DNA viruses may include viruses which do not fit into the above families such as Kuru and



- 72 -

Creutzfeldt-Jacob disease viruses and chronic infectious neuropathic agents (CHINA virus).

Each of the foregoing lists is illustrative, and is not intended to be limiting.

In addition to the use of the immunostimulatory nucleic acids to induce an  
5 antigen specific immune response in humans, the methods of the preferred embodiments are particularly well suited for treatment of birds such as hens, chickens, turkeys, ducks, geese, quail, and pheasant. Birds are prime targets for many types of infections.

Hatching birds are exposed to pathogenic microorganisms shortly after birth. Although these birds are initially protected against pathogens by maternal derived  
10 antibodies, this protection is only temporary, and the bird's own immature immune system must begin to protect the bird against the pathogens. It is often desirable to prevent infection in young birds when they are most susceptible. It is also desirable to prevent against infection in older birds, especially when the birds are housed in closed quarters, leading to the rapid spread of disease. Thus, it is desirable to administer the  
15 Immunostimulatory nucleic acid and the non-nucleic acid adjuvant of the invention to birds to enhance an antigen-specific immune response when antigen is present.

An example of a common infection in chickens is chicken infectious anemia virus (CIAV). CIAV was first isolated in Japan in 1979 during an investigation of a Marek's disease vaccination break (Yuasa et al., 1979, Avian Dis. 23:366-385). Since  
20 that time, CIAV has been detected in commercial poultry in all major poultry producing countries (van Bulow et al., 1991, pp.690-699) in Diseases of Poultry, 9th edition, Iowa State University Press).

CIAV infection results in a clinical disease, characterized by anemia, hemorrhage and immunosuppression, in young susceptible chickens. Atrophy of the  
25 thymus and of the bone marrow and consistent lesions of CIAV-infected chickens are also characteristic of CIAV infection. Lymphocyte depletion in the thymus, and occasionally in the bursa of Fabricius, results in immunosuppression and increased susceptibility to secondary viral, bacterial, or fungal infections which then complicate the course of the disease. The immunosuppression may cause aggravated disease after  
30 infection with one or more of Marek's disease virus (MDV), infectious bursal disease virus, reticuloendotheliosis virus, adenovirus, or reovirus. It has been reported that pathogenesis of MDV is enhanced by CIAV (DeBoer et al., 1989, p. 28 In Proceedings



- 73 -

of the 38th Western Poultry Diseases Conference, Tempe, Ariz.). Further, it has been reported that CIAV aggravates the signs of infectious bursal disease (Rosenberger et al., 1989, Avian Dis. 33:707-713). Chickens develop an age resistance to experimentally induced disease due to CAA. This is essentially complete by the age of 2 weeks, but  
5 older birds are still susceptible to infection (Yuasa, N. et al., 1979 supra; Yuasa, N. et al., Arian Diseases 24, 202-209, 1980). However, if chickens are dually infected with CAA and an immunosuppressive agent (IBDV, MDV etc.), age resistance against the disease is delayed (Yuasa, N. et al., 1979 and 1980 supra; Bulow von V. et al., J. Veterinary Medicine 33, 93-116, 1986). Characteristics of CIAV that may potentiate disease  
10 transmission include high resistance to environmental inactivation and some common disinfectants. The economic impact of CIAV infection on the poultry industry is clear from the fact that 10% to 30% of infected birds in disease outbreaks die.

Vaccination of birds, like other vertebrate animals can be performed at any age. Normally, vaccinations are performed at up to 12 weeks of age for a live microorganism  
15 and between 14-18 weeks for an inactivated microorganism or other type of vaccine. For in ovo vaccination, vaccination can be performed in the last quarter of embryo development. The vaccine may be administered subcutaneously, by spray, orally, intraocularly, intratracheally, nasally, or by other mucosal delivery methods described herein. Thus, the immunostimulatory nucleic acids of the invention can be administered  
20 to birds and other non-human vertebrates using routine vaccination schedules and the antigen can be administered after an appropriate time period as described herein.

Cattle and livestock are also susceptible to infection. Diseases which affect these animals can produce severe economic losses, especially amongst cattle. The methods of the invention can be used to protect against infection in livestock, such as cows, horses,  
25 pigs, sheep, and goats.

Cows can be infected by bovine viruses. Bovine viral diarrhea virus (BVDV) is a small enveloped positive-stranded RNA virus and is classified, along with hog cholera virus (HOCV) and sheep border disease virus (BDV), in the pestivirus genus. Although, Pestiviruses were previously classified in the Togaviridae family, some studies have  
30 suggested their reclassification within the Flaviviridae family along with the flavivirus and hepatitis C virus (HCV) groups (Francki, et al., 1991).



- 74 -

BVDV, which is an important pathogen of cattle can be distinguished, based on cell culture analysis, into cytopathogenic (CP) and noncytopathogenic (NCP) biotypes. The NCP biotype is more widespread although both biotypes can be found in cattle. If a pregnant cow becomes infected with an NCP strain, the cow can give birth to a persistently infected and specifically immunotolerant calf that will spread virus during its lifetime. The persistently infected cattle can succumb to mucosal disease and both biotypes can then be isolated from the animal. Clinical manifestations can include abortion, teratogenesis, and respiratory problems, mucosal disease and mild diarrhea. In addition, severe thrombocytopenia, associated with herd epidemics, that may result in the death of the animal has been described and strains associated with this disease seem more virulent than the classical BVDVs.

Equine herpes viruses (EHV) comprise a group of antigenically distinct biological agents which cause a variety of infections in horses ranging from subclinical to fatal disease. These include Equine herpesvirus-1 (EHV-1), a ubiquitous pathogen in horses. EHV-1 is associated with epidemics of abortion, respiratory tract disease, and central nervous system disorders. Primary infection of upper respiratory tract of young horses results in a febrile illness which lasts for 8 to 10 days. Immunologically experienced mares may be re-infected via the respiratory tract without disease becoming apparent, so that abortion usually occurs without warning. The neurological syndrome is associated with respiratory disease or abortion and can affect animals of either sex at any age, leading to lack of co-ordination, weakness and posterior paralysis (Telford, E. A. R. et al., Virology 189, 304-316, 1992). Other EHV's include EHV-2, or equine cytomegalovirus, EHV-3, equine coital exanthema virus, and EHV-4, previously classified as EHV-1 subtype 2.

Sheep and goats can be infected by a variety of dangerous microorganisms including visna-maedi.

Primates such as monkeys, apes and macaques can be infected by simian immunodeficiency virus. Inactivated cell-virus and cell-free whole simian immunodeficiency vaccines have been reported to afford protection in macaques (Stott et al. (1990) Lancet 36:1538-1541; Desrosiers et al. PNAS USA (1989) 86:6353-6357; Murphey-Corb et al. (1989) Science 246:1293-1297; and Carlson et al. (1990) AIDS Res. Human Retroviruses 6:1239-1246). A recombinant HIV gp120 vaccine has been



- 75 -

reported to afford protection in chimpanzees (Berman et al. (1990) Nature 345:622-625).

Cats, both domestic and wild, are susceptible to infection with a variety of microorganisms. For instance, feline infectious peritonitis is a disease which occurs in both domestic and wild cats, such as lions, leopards, cheetahs, and jaguars. When it is desirable to prevent infection with this and other types of pathogenic organisms in cats, the methods of the invention can be used to vaccinate cats to protect them against infection.

Domestic cats may become infected with several retroviruses, including but not limited to feline leukemia virus (FeLV), feline sarcoma virus (FeSV), endogenous type I coronavirus (RD-114), and feline syncytia-forming virus (FeSFV). Of these, FeLV is the most significant pathogen, causing diverse symptoms, including lymphoreticular and myeloid neoplasms, anemias, immune mediated disorders, and an immunodeficiency syndrome which is similar to human acquired immune deficiency syndrome (AIDS). Recently, a particular replication-defective FeLV mutant, designated FeLV-AIDS, has been more particularly associated with immunosuppressive properties.

The discovery of feline T-lymphotropic lentivirus (also referred to as feline immunodeficiency) was first reported in Pedersen et al. (1987) Science 235:790-793. Characteristics of FIV have been reported in Yamamoto et al. (1988) Leukemia, December Supplement 2:204S-215S; Yamamoto et al. (1988) Am. J. Vet. Res. 49:1246-1258; and Ackley et al. (1990) J. Virol. 64:5652-5655. Cloning and sequence analysis of FIV have been reported in Olmsted et al. (1989) Proc. Natl. Acad. Sci. USA 86:2448-2452 and 86:4355-4360.

Feline infectious peritonitis (FIP) is a sporadic disease occurring unpredictably in domestic and wild Felidae. While FIP is primarily a disease of domestic cats, it has been diagnosed in lions, mountain lions, leopards, cheetahs, and the jaguar. Smaller wild cats that have been afflicted with FIP include the lynx and caracal, sand cat, and pallas cat. In domestic cats, the disease occurs predominantly in young animals, although cats of all ages are susceptible. A peak incidence occurs between 6 and 12 months of age. A decline in incidence is noted from 5 to 13 years of age, followed by an increased incidence in cats 14 to 15 years old.



- 76 -

Viral, bacterial, and parasitic diseases in fin-fish, shellfish or other aquatic life forms pose a serious problem for the aquaculture industry. Owing to the high density of animals in the hatchery tanks or enclosed marine farming areas, infectious diseases may eradicate a large proportion of the stock in, for example, a fin-fish, shellfish, or other aquatic life forms facility. Prevention of disease is a more desired remedy to these threats to fish than intervention once the disease is in progress. Vaccination of fish is the only preventative method which may offer long-term protection through immunity. Nucleic acid based vaccinations are described in US Patent No. 5,780,448 issued to Davis.

The fish immune system has many features similar to the mammalian immune system, such as the presence of B cells, T cells, lymphokines, complement, and immunoglobulins. Fish have lymphocyte subclasses with roles that appear similar in many respects to those of the B and T cells of mammals. Vaccines can be administered by immersion or orally.

Aquaculture species include but are not limited to fin-fish, shellfish, and other aquatic animals. Fin-fish include all vertebrate fish, which may be bony or cartilaginous fish, such as, for example, salmonids, carp, catfish, yellowtail, seabream, and seabass. Salmonids are a family of fin-fish which include trout (including rainbow trout), salmon, and Arctic char. Examples of shellfish include, but are not limited to, clams, lobster, shrimp, crab, and oysters. Other cultured aquatic animals include, but are not limited to eels, squid, and octopi.

Polypeptides of viral aquaculture pathogens include but are not limited to glycoprotein (G) or nucleoprotein (N) of viral hemorrhagic septicemia virus (VHSV); G or N proteins of infectious hematopoietic necrosis virus (IHNV); VP1, VP2, VP3 or N structural proteins of infectious pancreatic necrosis virus (IPNV); G protein of spring viremia of carp (SVC); and a membrane-associated protein, tegumin or capsid protein or glycoprotein of channel catfish virus (CCV).

Typical parasites infecting horses are *Gasterophilus* spp.; *Eimeria leuckarti*, *Giardia* spp.; *Tritrichomonas equi*; *Babesia* spp. (RBC's), *Theileria equi*; *Trypanosoma* spp.; *Klossiella equi*; *Sarcocystis* spp.



- 77 -

Typical parasites infecting swine include *Eimeria bebliecki*, *Eimeria scabra*, *Isospora suis*, *Giardia* spp.; *Balantidium coli*, *Entamoeba histolytica*; *Toxoplasma gondii* and *Sarcocystis* spp., and *Trichinella spiralis*.

The major parasites of dairy and beef cattle include *Eimeria* spp.,  
 5 *Cryptosporidium* sp., *Giardia* spp.; *Toxoplasma gondii*; *Babesia bovis* (RBC), *Babesia bigemina* (RBC), *Trypanosoma* spp. (plasma), *Theileria* spp. (RBC); *Theileria parva* (lymphocytes); *Tritrichomonas foetus*; and *Sarcocystis* spp.

The major parasites of raptors include *Trichomonas gallinae*; *Coccidia* (*Eimeria* spp.); *Plasmodium relictum*, *Leucocytozoon danilewskyi* (owls), *Haemoproteus* spp.,  
 10 *Trypanosoma* spp.; *Histomonas*; *Cryptosporidium meleagridis*, *Cryptosporidium baileyi*, *Giardia*, *Eimeria*; *Toxoplasma*.

Typical parasites infecting sheep and goats include *Eimeria* spp., *Cryptosporidium* sp., *Giardia* sp.; *Toxoplasma gondii*; *Babesia* spp. (RBC), *Trypanosoma* spp. (plasma), *Theileria* spp. (RBC); and *Sarcocystis* spp.

15 Typical parasitic infections in poultry include coccidiosis caused by *Eimeria acervulina*, *E. necatrix*, *E. tenella*, *Isospora* spp. and *Eimeria truncata*; histomoniasis, caused by *Histomonas meleagridis* and *Histomonas gallinarum*; trichomoniasis caused by *Trichomonas gallinae*; and hexamitiasis caused by *Hexamita meleagridis*. Poultry can also be infected *Emeria maxima*, *Emeria meleagridis*, *Eimeria adenoeides*, *Eimeria*  
 20 *meleagrimitis*, *Cryptosporidium*, *Eimeria brunetti*, *Emeria adenoeides*, *Leucocytozoon* spp., *Plasmodium* spp., *Hemoproteus meleagridis*, *Toxoplasma gondii* and *Sarcocystis*.

The methods of the invention can also be applied to the treatment and/or prevention of parasitic infection in dogs, cats, birds, fish and ferrets. Typical parasites of birds include *Trichomonas gallinae*; *Eimeria* spp., *Isospora* spp., *Giardia*;  
 25 *Cryptosporidium*; *Sarcocystis* spp., *Toxoplasma gondii*, *Haemoproteus/Parahaemoproteus*, *Plasmodium* spp., *Leucocytozoon/Akiba*, *Atoxoplasma*, *Trypanosoma* spp. Typical parasites infecting dogs include *Trichinella spiralis*; *Isopora* spp., *Sarcocystis* spp., *Cryptosporidium* spp., *Hammondia* spp., *Giardia duodenalis* (*canis*); *Balantidium coli*, *Entamoeba histolytica*; *Hepatozoon canis*;  
 30 *Toxoplasma gondii*, *Trypanosoma cruzi*; *Babesia canis*; *Leishmania amastigotes*; *Neospora caninum*.



- 78 -

Typical parasites infecting feline species include *Isospora* spp., *Toxoplasma gondii*, *Sarcocystis* spp., *Hammondia hammondi*, *Besnoitia* spp., *Giardia* spp.; *Entamoeba histolytica*; *Hepatozoon canis*, *Cytauxzoon* sp., *Cytauxzoon* sp., *Cytauxzoon* sp. (red cells, RE cells).

- 5 Typical parasites infecting fish include *Hexamita* spp., *Eimeria* spp.; *Cryptobia* spp., *Nosema* spp., *Myxosoma* spp., *Chilodonella* spp., *Trichodina* spp.; *Plistophora* spp., *Myxosoma Henneguya*; *Costia* spp., *Ichthyophthirius* spp., and *Oodinium* spp.

- Typical parasites of wild mammals include *Giardia* spp. (carnivores, herbivores), *Isospora* spp. (carnivores), *Eimeria* spp. (carnivores, herbivores); *Theileria* spp. (herbivores), *Babesia* spp. (carnivores, herbivores), *Trypanosoma* spp. (carnivores, herbivores); *Schistosoma* spp. (herbivores); *Fasciola hepatica* (herbivores), *Fascioloides magna* (herbivores), *Fasciola gigantica* (herbivores), *Trichinella spiralis* (carnivores, herbivores).
- 10

- Parasitic infections in zoos can also pose serious problems. Typical parasites of the bovidae family (blesbok, antelope, banteng, eland, gaur, impala, klipspringer, kudu, gazelle) include *Eimeria* spp. Typical parasites in the pinnipedae family (seal, sea lion) include *Eimeria phocae*. Typical parasites in the camelidae family (camels, llamas) include *Eimeria* spp. Typical parasites of the giraffidae family (giraffes) include *Eimeria* spp. Typical parasites in the elephantidae family (African and Asian) include *Fasciola* spp. Typical parasites of lower primates (chimpanzees, orangutans, apes, baboons, macaques, monkeys) include *Giardia* sp.; *Balantidium coli*, *Entamoeba histolytica*, *Sarcocystis* spp., *Toxoplasma gondii*; *Plasmodium* spp. (RBC), *Babesia* spp. (RBC), *Trypanosoma* spp. (plasma), *Leishmania* spp. (macrophages).
- 15
- 20

- Polypeptides of bacterial pathogens include but are not limited to an iron-regulated outer membrane protein, (IROMP), an outer membrane protein (OMP), and an A-protein of *Aeromonis salmonicida* which causes furunculosis, p57 protein of *Renibacterium salmoninarum* which causes bacterial kidney disease (BKD), major surface associated antigen (msa), a surface expressed cytotoxin (mpr), a surface expressed hemolysin (ish), and a flagellar antigen of *Yersinia*; an extracellular protein (ECP), an iron-regulated outer membrane protein (IROMP), and a structural protein of *Pasteurellosis*; an OMP and a flagellar protein of *Vibrio anguillarum* and *V. ordalii*; a flagellar protein, an OMP protein, aroA, and purA of *Edwardsiella ictaluri* and *E.*
- 25
- 30



- 79 -

tarda; and surface antigen of *Ichthyophthirius*; and a structural and regulatory protein of *Cytophaga columnari*; and a structural and regulatory protein of *Rickettsia*.

Polypeptides of a parasitic pathogen include but are not limited to the surface antigens of *Ichthyophthirius*.

5 An allergen refers to a substance (antigen) that can induce an allergic or asthmatic response in a susceptible subject. The list of allergens is enormous and can include pollens, insect venoms, animal dander dust, fungal spores and drugs (e.g. penicillin). Examples of natural, animal and plant allergens include but are not limited to proteins specific to the following genres: *Canine* (*Canis familiaris*); *Dermatophagoides*  
 10 (e.g. *Dermatophagoides farinae*); *Felis* (*Felis domesticus*); *Ambrosia* (*Ambrosia artemisiifolia*); *Lolium* (e.g. *Lolium perenne* or *Lolium multiflorum*); *Cryptomeria* (*Cryptomeria japonica*); *Alternaria* (*Alternaria alternata*); *Alder*; *Alnus* (*Alnus gultinoasa*); *Betula* (*Betula verrucosa*); *Quercus* (*Quercus alba*); *Olea* (*Olea europa*); *Artemisia* (*Artemisia vulgaris*); *Plantago* (e.g. *Plantago lanceolata*); *Parietaria* (e.g.  
 15 *Parietaria officinalis* or *Parietaria judaica*); *Blattella* (e.g. *Blattella germanica*); *Apis* (e.g. *Apis multiflorum*); *Cupressus* (e.g. *Cupressus sempervirens*, *Cupressus arizonica* and *Cupressus macrocarpa*); *Juniperus* (e.g. *Juniperus sabinoidea*, *Juniperus virginiana*, *Juniperus communis* and *Juniperus ashei*); *Thuja* (e.g. *Thuja orientalis*); *Chamaecyparis* (e.g. *Chamaecyparis obtusa*); *Periplaneta* (e.g. *Periplaneta americana*);  
 20 *Agropyron* (e.g. *Agropyron repens*); *Secale* (e.g. *Secale cereale*); *Triticum* (e.g. *Triticum aestivum*); *Dactylis* (e.g. *Dactylis glomerata*); *Festuca* (e.g. *Festuca elatior*); *Poa* (e.g. *Poa pratensis* or *Poa compressa*); *Avena* (e.g. *Avena sativa*); *Holcus* (e.g. *Holcus lanatus*); *Anthoxanthum* (e.g. *Anthoxanthum odoratum*); *Arrhenatherum* (e.g. *Arrhenatherum elatius*); *Agrostis* (e.g. *Agrostis alba*); *Phleum* (e.g. *Phleum pratense*);  
 25 *Phalaris* (e.g. *Phalaris arundinacea*); *Paspalum* (e.g. *Paspalum notatum*); *Sorghum* (e.g. *Sorghum halepensis*); and *Bromus* (e.g. *Bromus inermis*).

The antigen may be an antigen that is encoded by a nucleic acid vector or it may be not encoded in a nucleic acid vector. In the former case the nucleic acid vector is administered to the subject and the antigen is expressed *in vivo*. In the latter case the  
 30 antigen may be administered directly to the subject. An antigen not encoded in a nucleic acid vector as used herein refers to any type of antigen that is not a nucleic acid. For instance, in some aspects of the invention the antigen not encoded in a nucleic acid



- 80 -

vector is a polypeptide. Minor modifications of the primary amino acid sequences of polypeptide antigens may also result in a polypeptide which has substantially equivalent antigenic activity as compared to the unmodified counterpart polypeptide. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous.

5 All of the polypeptides produced by these modifications are included herein as long as antigenicity still exists. The polypeptide may be, for example, a viral polypeptide.

The term substantially purified as used herein refers to a polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify viral or bacterial polypeptides

10 using standard techniques for protein purification. The substantially pure polypeptide will often yield a single major band on a non-reducing polyacrylamide gel. In the case of partially glycosylated polypeptides or those that have several start codons, there may be several bands on a non-reducing polyacrylamide gel, but these will form a distinctive pattern for that polypeptide. The purity of the viral or bacterial polypeptide can also be

15 determined by amino-terminal amino acid sequence analysis. Other types of antigens not encoded by a nucleic acid vector such as polysaccharides, small molecule, mimics etc are described above, and included within the invention.

The invention also utilizes polynucleotides encoding the antigenic polypeptides. It is envisioned that the antigen may be delivered to the subject in a nucleic acid

20 molecule which encodes for the antigen such that the antigen must be expressed *in vivo*. Such antigens delivered to the subject in a nucleic acid vector are referred to as antigens encoded by a nucleic acid vector. The nucleic acid encoding the antigen is operatively linked to a gene expression sequence which directs the expression of the antigen nucleic acid within a eukaryotic cell. The gene expression sequence is any regulatory nucleotide

25 sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the antigen nucleic acid to which it is operatively linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes:

30 hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, pyruvate kinase, b-actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from



- 81 -

the cytomegalovirus (CMV), simian virus (e.g., SV40), papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

10 In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined antigen nucleic acid. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

The antigen nucleic acid is operatively linked to the gene expression sequence. As used herein, the antigen nucleic acid sequence and the gene expression sequence are said to be operably linked when they are covalently linked in such a way as to place the expression or transcription and/or translation of the antigen coding sequence under the influence or control of the gene expression sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the antigen sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the antigen sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to an antigen nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that antigen nucleic acid sequence such that the resulting transcript is translated into the desired protein or polypeptide.

30 The antigen nucleic acid of the invention may be delivered to the immune system alone or in association with a vector. In its broadest sense, a vector is any vehicle



- 82 -

capable of facilitating the transfer of the antigen nucleic acid to the cells of the immune system so that the antigen can be expressed and presented on the surface of the immune cell. The vector generally transports the nucleic acid to the immune cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. The vector optionally includes the above-described gene expression sequence to enhance expression of the antigen nucleic acid in immune cells. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murry, E.J. Methods in Molecular Biology, vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).



- 83 -

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication -deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction  
5 frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection. In addition, wild-type  
10 adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Other vectors include plasmid vectors. Plasmid vectors have been extensively  
15 described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a  
20 promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some commonly used plasmids include pBR322, pUC18, pUC19, pRC/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

25 It has recently been discovered that gene carrying plasmids can be delivered to the immune system using bacteria. Modified forms of bacteria such as *Salmonella* can be transfected with the plasmid and used as delivery vehicles. The bacterial delivery vehicles can be administered to a host subject orally or by other administration means. The bacteria deliver the plasmid to immune cells, e.g. B cells, dendritic cells, likely by  
30 passing through the gut barrier. High levels of immune protection have been established using this methodology. Such methods of delivery are useful for the aspects of the



- 84 -

invention utilizing systemic delivery of antigen, Immunostimulatory nucleic acid and/or other therapeutic agent.

Thus, the immunostimulatory nucleic acids are useful as vaccine adjuvants. It was previously established that CpG oligonucleotides are excellent vaccine adjuvants. It was also demonstrated, however, that CpG ODN which are superb vaccine adjuvants in mice are not the preferred adjuvants in non-rodent animals. In order to identify the best immunostimulatory nucleic acids for use as a vaccine adjuvant in humans and other non-rodent animals, *in vivo* screening of different nucleic acids for this purpose was conducted. Several *in vitro* assays were evaluated in mice for their predictive value of adjuvant activity *in vivo* in mice. During the course of this study, an *in vitro* test that is predictive of *in vivo* efficacy was identified. It was discovered, rather surprisingly, that both B cell and NK cell activation correlated particularly well with the ability of an immunostimulatory nucleic acid to enhance an *in vivo* immune response against an antigen.

The good predictive value of B cell activation for *in vivo* vaccine adjuvant activity is most likely linked to the central role of B cells in the establishment of a specific immune response. Polyclonal proliferation of B cells (induced by immunostimulatory nucleic acids) increases the likelihood of an antigen specific B cell/T helper cell match. Furthermore, enhanced expression of the co-stimulatory molecule CD86 on polyclonally expanded B cells activates antigen specific T helper cells. B cells also increase their CD40 expression in response to immunostimulatory nucleic acids improving the capability of CD40L expressing activated T helper cells to stimulate B cells. Increased ICAM-1 synthesis on B cells facilitates the cell to cell contact. Thus, the activation status of polyclonal B cells plays a critical role during the initiation of a specific antibody response.

The contribution of NK cell activity for the establishment of specific antibodies was, however, surprising. NK cells are part of the innate immune system and as such are involved in the first line of defense against pathogens. Most likely the cytokine pattern produced by NK cells upon activation is closely related to the initiation of a specific immune response. Thus, in one aspect the invention relates to a method of identifying an adjuvant, by detecting NK cell activation. The NK cell activation assay may be carried out as described in the Examples below or using other known NK cell activity assays. It



- 85 -

is preferred, however that a mixed cell population such as PBMC be used because of the likelihood that NK cell activation is an indirect effect. The assay is preferably useful for identifying immunostimulatory nucleic acids which are useful as adjuvants in human and other non-rodent animals.

5 Cytokine induction was also identified as an important predictor of *in vivo* adjuvant activity. As there is a 2 log higher endotoxin sensitivity of human than mouse primary monocytes, some caution, however, is required to avoid endotoxin contamination of immunostimulatory nucleic acids used for testing in the human system (Hartmann G., and Krieg A. M. 1999. *Gene Therapy* 6:893). Since TNF- $\alpha$ , IL-6 and IL-  
10 12 are produced by human monocytes in response to even low amounts of endotoxin, their value for high throughput *in vitro* screening assays is limited. On the other hand, human B cells and NK cells show only minor activation by endotoxin and thus are far more useful in testing for immunostimulatory activity.

Stimulation of cellular function in either NK or B cells (i.e., lytic activity,  
15 proliferation) requires a stronger immunostimulatory nucleic acid than the induction of activation markers at their surface (CD69, CD86). For both cell types, the use of cell surface activation markers showed a higher nonspecific background attributable to the phosphorothioate backbone compared to the functional assays. This high sensitivity of surface markers requires the use of low immunostimulatory nucleic acid concentrations  
20 for optimal discrimination between immunostimulatory nucleic acid of similar activity. Thus, the use of surface markers allows the comparison of immunostimulatory nucleic acids with weak activity, while functional assays are preferred for comparing immunostimulatory nucleic acids with high activity. It is of note that the optimal immunostimulatory nucleic acid concentrations for stimulating B cells and NK cells  
25 differ. While 0.6  $\mu\text{g/ml}$  ODN is already maximal to stimulate B cells, optimal NK cell activation may require 6  $\mu\text{g/ml}$  ODN. Both B cell activation and NK cell functional activity were measured within freshly isolated PBMC. It was previously found that highly purified human primary B cells are activated by CpG DNA. The existence of a direct effect of CpG DNA on NK cells is less clear, and a secondary mechanism  
30 mediated by another cell type within PBMC might contribute to CpG-induced functional activity of NK cells.



- 86 -

The nucleic acids of the invention may be administered to a subject with an anti-microbial agent. An anti-microbial agent, as used herein, refers to a naturally-occurring or synthetic compound which is capable of killing or inhibiting infectious microorganisms. The type of anti-microbial agent useful according to the invention will  
5 depend upon the type of microorganism with which the subject is infected or at risk of becoming infected. Anti-microbial agents include but are not limited to anti-bacterial agents, anti-viral agents, anti-fungal agents and anti-parasitic agents. Phrases such as “anti-infective agent”, “anti-bacterial agent”, “anti-viral agent”, “anti-fungal agent”, “anti-parasitic agent” and “parasiticide” have well-established meanings to those of  
10 ordinary skill in the art and are defined in standard medical texts. Briefly, anti-bacterial agents kill or inhibit bacteria, and include antibiotics as well as other synthetic or natural compounds having similar functions. Antibiotics are low molecular weight molecules which are produced as secondary metabolites by cells, such as microorganisms. In general, antibiotics interfere with one or more bacterial functions or structures which are  
15 specific for the microorganism and which are not present in host cells. Anti-viral agents can be isolated from natural sources or synthesized and are useful for killing or inhibiting viruses. Anti-fungal agents are used to treat superficial fungal infections as well as opportunistic and primary systemic fungal infections. Anti-parasite agents kill or inhibit parasites.

20 Examples of anti-parasitic agents, also referred to as parasiticides useful for human administration include but are not limited to albendazole, amphotericin B, benznidazole, bithionol, chloroquine HCl, chloroquine phosphate, clindamycin, dehydroemetine, diethylcarbamazine, diloxanide furoate, eflornithine, furazolidone, glucocorticoids, halofantrine, iodoquinol, ivermectin, mebendazole, mefloquine,  
25 meglumine antimoniate, melarsoprol, metrifonate, metronidazole, niclosamide, nifurtimox, oxamniquine, paromomycin, pentamidine isethionate, piperazine, praziquantel, primaquine phosphate, proguanil, pyrantel pamoate, pyrimethamine-sulfonamides, pyrimethamine-sulfadoxine, quinacrine HCl, quinine sulfate, quinidine gluconate, spiramycin, stibogluconate sodium (sodium antimony gluconate), suramin,  
30 tetracycline, doxycycline, thiabendazole, tinidazole, trimethoprim-sulfamethoxazole, and tryparsamide some of which are used alone or in combination with others.



- 87 -

Parasiticides used in non-human subjects include piperazine, diethylcarbamazine, thiabendazole, fenbendazole, albendazole, oxfendazole, oxibendazole, febantel, levamisole, pyrantel tartrate, pyrantel pamoate, dichlorvos, ivermectin, doramectin, milbemycin oxime, ivermectin, moxidectin, N-butyl chloride, toluene, hygromycin B thiacetarsemide sodium, melarsomine, praziquantel, epsiprantel, benzimidazoles such as fenbendazole, albendazole, oxfendazole, clorsulon, albendazole, amprolium; decoquinate, lasalocid, monensin sulfadimethoxine; sulfamethazine, sulfaquinoxaline, metronidazole.

Parasiticides used in horses include mebendazole, oxfendazole, febantel, pyrantel, dichlorvos, trichlorfon, ivermectin, piperazine; for *S. westeri*: ivermectin, benzimidazoles such as thiabendazole, cambendazole, oxibendazole and fenbendazole. Useful parasiticides in dogs include milbemycin oxime, ivermectin, pyrantel pamoate and the combination of ivermectin and pyrantel. The treatment of parasites in swine can include the use of levamisole, piperazine, pyrantel, thiabendazole, dichlorvos and fenbendazole. In sheep and goats anthelmintic agents include levamisole or ivermectin. Caparsolate has shown some efficacy in the treatment of *D. immitis* (heartworm) in cats.

Antibacterial agents kill or inhibit the growth or function of bacteria. A large class of antibacterial agents is antibiotics. Antibiotics, which are effective for killing or inhibiting a wide range of bacteria, are referred to as broad spectrum antibiotics. Other types of antibiotics are predominantly effective against the bacteria of the class gram-positive or gram-negative. These types of antibiotics are referred to as narrow spectrum antibiotics. Other antibiotics which are effective against a single organism or disease and not against other types of bacteria, are referred to as limited spectrum antibiotics. Antibacterial agents are sometimes classified based on their primary mode of action. In general, antibacterial agents are cell wall synthesis inhibitors, cell membrane inhibitors, protein synthesis inhibitors, nucleic acid synthesis or functional inhibitors, and competitive inhibitors.

Anti-bacterial agents useful in the invention include but are not limited to natural penicillins, semi-synthetic penicillins, clavulanic acid, cephalosporins, bacitracin, ampicillin, carbenicillin, oxacillin, azlocillin, mezlocillin, piperacillin, methicillin, dicloxacillin, nafcillin, cephalothin, cephapirin, cephalixin, cefamandole, cefaclor, cefazolin, cefuroxime, cefoxitin, cefotaxime, cefsulodin, cefetamet, cefixime, ceftriaxone,



- 88 -

cefoperazone, ceftazidime, moxalactam, carbapenems, imipenems, monobactams,  
 euztreonam, vancomycin, polymyxin, amphotericin B, nystatin, imidazoles,  
 clotrimazole, miconazole, ketoconazole, itraconazole, fluconazole, rifampins,  
 ethambutol, tetracyclines, chloramphenicol, macrolides, aminoglycosides, streptomycin,  
 5 kanamycin, tobramycin, amikacin, gentamicin, tetracycline, minocycline, doxycycline,  
 chlortetracycline, erythromycin, roxithromycin, clarithromycin, oleandomycin,  
 azithromycin, chloramphenicol, quinolones, co-trimoxazole, norfloxacin, ciprofloxacin,  
 enoxacin, nalidixic acid, temafloxacin, sulfonamides, gantrisin, and trimethoprim;  
 Acedapsone ; Acetosulfone Sodium; Alamecin; Alexidine; Amdinocillin; Amdinocillin  
 10 Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin Sulfate;  
 Aminosalicyclic acid; Aminosalicylate sodium; Amoxicillin; Amphomycin; Ampicillin;  
 Ampicillin Sodium; Apalcillin Sodium; Apramycin; Aspartocin; Astromicin Sulfate;  
 Avilamycin; Avoparcin; Azithromycin; Azlocillin; Azlocillin Sodium; Bacampicillin  
 Hydrochloride; Bacitracin; Bacitracin Methylene Disalicylate; Bacitracin Zinc;  
 15 Bambermycins; Benzoylpas Calcium; Berythromycin ; Betamicin Sulfate; Biapenem;  
 Biniramycin; Biphenamine Hydrochloride ; Bispyrithione Magsulfex ; Butikacin;  
 Butirosin Sulfate; Capreomycin Sulfate; Carbadox; Carbenicillin Disodium;  
 Carbenicillin Indanyl Sodium; Carbenicillin Phenyl Sodium; Carbenicillin Potassium;  
 Carumonam Sodium; Cefaclor; Cefadroxil; Cefamandole; Cefamandole Nafate;  
 20 Cefamandole Sodium; Cefaparole; Cefatrizine; Cefazaflur Sodium; Cefazolin; Cefazolin  
 Sodium; Cefbuperazone; Cefdinir; Cefepime; Cefepime Hydrochloride; Cefetecol;  
 Cefixime; Cefmenoxime Hydrochloride; Cefmetazole; Cefmetazole Sodium; Cefonicid  
 Monosodium; Cefonicid Sodium; Cefoperazone Sodium; Ceforanide; Cefotaxime  
 Sodium; Cefotetan; Cefotetan Disodium; Cefotiam Hydrochloride; Cefoxitin; Cefoxitin  
 25 Sodium; Cefpimizole; Cefpimizole Sodium; Cefpiramide; Cefpiramide Sodium;  
 Cefpirome Sulfate; Cefpodoxime Proxetil; Cefprozil; Cefroxadine; Cefsulodin Sodium;  
 Ceftazidime; Ceftibuten; Ceftizoxime Sodium; Ceftriaxone Sodium; Cefuroxime;  
 Cefuroxime Axetil; Cefuroxime Pivoxetil; Cefuroxime Sodium; Cephacetrile Sodium;  
 Cephalexin; Cephalexin Hydrochloride; Cephaloglycin; Cephaloridine; Cephalothin  
 30 Sodium; Cephapirin Sodium; Cephradine; Cetocycline Hydrochloride; Cetophenicol;  
 Chloramphenicol ; Chloramphenicol Palmitate ; Chloramphenicol Pantothenate Complex  
 ; Chloramphenicol Sodium Succinate; Chlorhexidine Phosphanilate; Chloroxylenol;



- 89 -

Chlortetracycline Bisulfate ; Chlortetracycline Hydrochloride ; Cinoxacin;  
 Ciprofloxacin; Ciprofloxacin Hydrochloride; Cirolemycin ; Clarithromycin;  
 Clinafloxacin Hydrochloride; Clindamycin; Clindamycin Hydrochloride; Clindamycin  
 Palmitate Hydrochloride; Clindamycin Phosphate; Clofazimine ; Cloxacillin Benzathine;  
 5 Cloxacillin Sodium; Cloxyquin; Colistimethate Sodium; Colistin Sulfate; Coumermycin;  
 Coumermycin Sodium; Cyclacillin; Cycloserine; Dalfopristin; Dapsone ; Daptomycin;  
 Demeclocycline; Demeclocycline Hydrochloride; Demecycline; Denofungin ;  
 Diaveridine; Dicloxacillin; Dicloxacillin Sodium; Dihydrostreptomycin Sulfate;  
 Dipyrrithione; Dirithromycin; Doxycycline; Doxycycline Calcium ; Doxycycline  
 10 Fosfatex; Doxycycline Hyclate; Droxacin Sodium; Enoxacin; Epicillin; Epite-tracycline  
 Hydrochloride; Erythromycin; Erythromycin Acistrate; Erythromycin Estolate;  
 Erythromycin Ethylsuccinate; Erythromycin Gluceptate; Erythromycin Lactobionate;  
 Erythromycin Propionate; Erythromycin Stearate; Ethambutol Hydrochloride;  
 Ethionamide; Fleroxacin; Floxacillin; Fludalanine; Flumequine; Fosfomycin;  
 15 Fosfomycin Tromethamine; Fumoxicillin; Furazolium Chloride; Furazolium Tartrate;  
 Fusidate Sodium; Fusidic Acid; Gentamicin Sulfate; Gloximonam; Gramicidin;  
 Haloprogin; Hetacillin; Hetacillin Potassium; Hexedine; Iba-floxacin; Imipenem;  
 Isoconazole; Isepamicin; Isoniazid; Josamycin; Kanamycin Sulfate; Kitasamycin;  
 Levofuraltadone; Levopropylcillin Potassium; Lexithromycin; Lincomycin; Lincomycin  
 20 Hydrochloride; Lomefloxacin; Lomefloxacin Hydrochloride; Lomefloxacin Mesylate;  
 Loracarbef; Mafenide; Meclocycline; Meclocycline Sulfosalicylate; Megalomicin  
 Potassium Phosphate; Mequidox; Meropenem; Methacycline; Methacycline  
 Hydrochloride; Methenamine; Methenamine Hippurate; Methenamine Mandelate;  
 Methicillin Sodium; Metioprime; Metronidazole Hydrochloride; Metronidazole  
 25 Phosphate; Mezlocillin; Mezlocillin Sodium; Minocycline; Minocycline Hydrochloride;  
 Mirincamycin Hydrochloride ; Monensin ; Monensin Sodium ; Nafcillin Sodium;  
 Nalidixate Sodium; Nalidixic Acid; Natamycin; Nebramycin; Neomycin Palmitate;  
 Neomycin Sulfate; Neomycin Undecylenate ; Netilmicin Sulfate; Neutramycin;  
 Nifuradene; Nifuraldezone; Nifuratel ; Nifuratrone; Nifurdazil; Nifurimide; Nifurpirinol;  
 30 Nifurquinazol; Nifurthiazole; Nitro-cycline; Nitrofurantoin; Nitromide; Norfloxacin;  
 Novobiocin Sodium; Ofloxacin; Ormetoprim; Oxacillin Sodium; Oximonam; Oximonam  
 Sodium; Oxolinic Acid; Oxytetracycline; Oxytetracycline Calcium; Oxytetracycline



- 90 -

Hydrochloride; Paldimycin; Parachlorophenol; Paulomycin; Pefloxacin; Pefloxacin Mesylate; Penamecillin; Penicillin G Benzathine; Penicillin G Potassium; Penicillin G Procaine; Penicillin G Sodium; Penicillin V; Penicillin V Benzathine; Penicillin V Hydrabamine; Penicillin V Potassium; Pentizidone Sodium; Phenyl Aminosalicylate;

5 Piperacillin Sodium; Pirbenicillin Sodium; Piridicillin Sodium; Pirlimycin Hydrochloride; Pivampicillin Hydrochloride; Pivampicillin Pamoate; Pivampicillin Probenate; Polymyxin B Sulfate; Porfiromycin ; Propikacin; Pyrazinamide; Pyrithione Zinc; Quindecamine Acetate; Quinupristin; Racephenicol; Ramoplanin; Ranimycin; Relomycin; Repromicin; Rifabutin; Rifametane; Rifamexil; Rifamide; Rifampin;

10 Rifapentine; Rifaximin; Rolitetracycline; Rolitetracycline Nitrate; Rosaramicin; Rosaramicin Butyrate; Rosaramicin Propionate; Rosaramicin Sodium Phosphate; Rosaramicin Stearate; Rosoxacin; Roxarsone; Roxithromycin; Sancycline; Sanfetrinem Sodium; Sarmoxicillin; Sarpicillin; Scopafungin ; Sisomicin; Sisomicin Sulfate; Sparfloxacin; Spectinomycin Hydrochloride; Spiramycin; Stallimycin Hydrochloride;

15 Steffimycin; Streptomycin Sulfate; Streptonicozid; Sulfabenz ; Sulfabenzamide; Sulfacetamide; Sulfacetamide Sodium; Sulfacytine; Sulfadiazine; Sulfadiazine Sodium; Sulfadoxine; Sulfalene; Sulfamerazine; Sulfameter; Sulfamethazine; Sulfamethizole; Sulfamethoxazole; Sulfamonomethoxine; Sulfamoxole; Sulfanilate Zinc; Sulfanitran ; Sulfasalazine; Sulfasomizole; Sulfathiazole; Sulfazamet; Sulfisoxazole; Sulfisoxazole

20 Acetyl; Sulfisoxazole Diolamine; Sulfomyxin; Sulopenem; Sultamicillin; Suncillin Sodium; Talampicillin Hydrochloride; Teicoplanin; Temafloxacin Hydrochloride; Temocillin; Tetracycline; Tetracycline Hydrochloride; Tetracycline Phosphate Complex; Tetroxoprim; Thiamphenicol; Thiphencillin Potassium; Ticarcillin Cresyl Sodium; Ticarcillin Disodium; Ticarcillin Monosodium; Ticlatone; Tiodonium Chloride;

25 Tobramycin; Tobramycin Sulfate; Tosufloxacin; Trimethoprim; Trimethoprim Sulfate; Trisulfapyrimidines; Troleandomycin; Trospectomycin Sulfate; Tyrothricin; Vancomycin; Vancomycin Hydrochloride; Virginiamycin; and Zorbamycin.

Antiviral agents are compounds which prevent infection of cells by viruses or replication of the virus within the cell. There are many fewer antiviral drugs than

30 antibacterial drugs because the process of viral replication is so closely related to DNA replication within the host cell, that non-specific antiviral agents would often be toxic to the host. There are several stages within the process of viral infection which can be



- 91 -

blocked or inhibited by antiviral agents. These stages include, attachment of the virus to the host cell (immunoglobulin or binding peptides), uncoating of the virus (e.g. amantadine), synthesis or translation of viral mRNA (e.g. interferon), replication of viral RNA or DNA (e.g. nucleoside analogues), maturation of new virus proteins (e.g. protease inhibitors), and budding and release of the virus.

Nucleotide analogues are synthetic compounds which are similar to nucleotides, but which have an incomplete or abnormal deoxyribose or ribose group. Once the nucleotide analogues are in the cell, they are phosphorylated, producing the triphosphate formed which competes with normal nucleotides for incorporation into the viral DNA or RNA. Once the triphosphate form of the nucleotide analogue is incorporated into the growing nucleic acid chain, it causes irreversible association with the viral polymerase and thus chain termination. Nucleotide analogues include, but are not limited to, acyclovir (used for the treatment of herpes simplex virus and varicella-zoster virus), gancyclovir (useful for the treatment of cytomegalovirus), idoxuridine, ribavirin (useful for the treatment of respiratory syncytial virus), dideoxyinosine, dideoxycytidine, and zidovudine (azidothymidine).

The interferons are cytokines which are secreted by virus-infected cells as well as immune cells. The interferons function by binding to specific receptors on cells adjacent to the infected cells, causing the change in the cell which protects it from infection by the virus.  $\alpha$  and  $\beta$ -interferon also induce the expression of Class I and Class II MHC molecules on the surface of infected cells, resulting in increased antigen presentation for host immune cell recognition.  $\alpha$  and  $\beta$ -interferons are available as recombinant forms and have been used for the treatment of chronic hepatitis B and C infection. At the dosages which are effective for anti-viral therapy, interferons have severe side effects such as fever, malaise and weight loss.

Immunoglobulin therapy is used for the prevention of viral infection. Immunoglobulin therapy for viral infections is different than bacterial infections, because rather than being antigen-specific, the immunoglobulin therapy functions by binding to extracellular virions and preventing them from attaching to and entering cells which are susceptible to the viral infection. The therapy is useful for the prevention of viral infection for the period of time that the antibodies are present in the host. In general there are two types of immunoglobulin therapies, normal immunoglobulin therapy and



- 92 -

hyper-immunoglobulin therapy. Normal immune globulin therapy utilizes a antibody product which is prepared from the serum of normal blood donors and pooled. This pooled product contains low titers of antibody to a wide range of human viruses, such as hepatitis A, parvovirus, enterovirus (especially in neonates). Hyper-immune globulin therapy utilizes antibodies which are prepared from the serum of individuals who have high titers of an antibody to a particular virus. Those antibodies are then used against a specific virus. Examples of hyper-immune globulins include zoster immune globulin (useful for the prevention of varicella in immuno-compromised children and neonates), human rabies immunoglobulin (useful in the post-exposure prophylaxis of a subject bitten by a rabid animal), hepatitis B immune globulin (useful in the prevention of hepatitis B virus, especially in a subject exposed to the virus), and RSV immune globulin (useful in the treatment of respiratory syncytial virus infections).

Another type of immunoglobulin therapy is active immunization. This involves the administration of antibodies or antibody fragments to viral surface proteins. Two types of vaccines which are available for active immunization of hepatitis B include serum-derived hepatitis B antibodies and recombinant hepatitis B antibodies. Both are prepared from HBsAg. The antibodies are administered in three doses to subjects at high risk of infection with hepatitis B virus, such as health care workers, sexual partners of chronic carriers, and infants.

Thus, anti-viral agents useful in the invention include but are not limited to immunoglobulins, amantadine, interferon, nucleoside analogues, and protease inhibitors. Specific examples of anti-virals include but are not limited to Acemannan; Acyclovir; Acyclovir Sodium; Adefovir; Alovudine; Alvircept Sudotox; Amantadine Hydrochloride; Aranotin; Arildone; Atevirdine Mesylate; Avridine; Cidofovir; Cipamfylline; Cytarabine Hydrochloride; Delavirdine Mesylate; Desciclovir; Didanosine; Disoxaril; Edoxudine; Enviroxime; Famciclovir; Famotone Hydrochloride; Fiacitabine; Fialuridine; Fosarilate; Foscarnet Sodium; Fosfonet Sodium; Ganciclovir; Ganciclovir Sodium; Idoxuridine; Kethoxal; Lamivudine; Lobucavir; Memotone Hydrochloride; Methisazone; Nevirapine; Penciclovir; Pirodavir; Ribavirin; Rimantadine Hydrochloride; Saquinavir Mesylate; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine; Tilorone Hydrochloride; Trifluridine; Valacyclovir



- 93 -

Hydrochloride; Vidarabine; Vidarabine Phosphate; Vidarabine Sodium Phosphate; Viroxime; Zalcitabine; Zidovudine; and Zinviroxime.

Anti-fungal agents are useful for the treatment and prevention of infective fungi. Anti-fungal agents are sometimes classified by their mechanism of action. Some anti-fungal agents function as cell wall inhibitors by inhibiting glucose synthase. These include, but are not limited to, basiungin/ECB. Other anti-fungal agents function by destabilizing membrane integrity. These include, but are not limited to, imidazoles, such as clotrimazole, sertaconazole, fluconazole, itraconazole, ketoconazole, miconazole, and voriconazole, as well as FK 463, amphotericin B, BAY 38-9502, MK 991, pradimicin, UK 292, butenafine, and terbinafine. Other anti-fungal agents function by breaking down chitin (e.g. chitinase) or immunosuppression (501 cream). Some examples of commercially-available agents are shown in Table B

**Table B**

| Company            | Brand Name            | Generic Name              | Indication                                | Mechanism of Action                                         |
|--------------------|-----------------------|---------------------------|-------------------------------------------|-------------------------------------------------------------|
| PHARMACIA & UPJOHN | PNU 196443            | PNU 196443                | Anti Fungal                               | n/k                                                         |
| Lilly              | LY 303366             | Basiungin/ECB             | Fungal Infections                         | Anti-fungal/cell wall inhibitor, glucose synthase inhibitor |
| Bayer              | Canesten              | Clotrimazole              | Fungal Infections                         | Membrane integrity destabilizer                             |
| Fujisawa           | FK 463                | FK 463                    | Fungal Infections                         | Membrane integrity destabilizer                             |
| Mylan              | Sertaconazole         | Sertaconazole             | Fungal Infections                         | Membrane integrity destabilizer                             |
| Genzyme            | Chitinase             | Chitinase                 | Fungal Infections, Systemic               | Chitin Breakdown                                            |
| Liposome           | Abelcet               | Amphotericin B, Liposomal | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Sequus             | Amphotec              | Amphotericin B, Liposomal | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Bayer              | BAY 38-9502           | BAY 38-9502               | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Pfizer             | Diflucan              | Fluconazole               | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Johnson & Johnson  | Sporanox              | Itraconazole              | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Sepracor           | Itraconazole (2R, 4S) | Itraconazole (2R, 4S)     | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Johnson & Johnson  | Nizoral               | Ketoconazole              | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Johnson & Johnson  | Monistat              | Miconazole                | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Merck              | MK 991                | MK 991                    | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Bristol Myers Sq'b | Pradimicin            | Pradimicin                | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Pfizer             | UK-292, 663           | UK-292, 663               | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Pfizer             | Voriconazole          | Voriconazole              | Fungal Infections, Systemic               | Membrane integrity destabilizer                             |
| Mylan              | 501 Cream             | 501 Cream                 | Inflammatory Fungal Conditions            | Immunosuppression                                           |
| Mylan              | Mentax                | Butenafine                | Nail Fungus                               | Membrane Integrity Destabiliser                             |
| Schering Plough    | Anti Fungal           | Anti Fungal               | Opportunistic Infections                  | Membrane Integrity Destabiliser                             |
| Alza               | Mycelex Troche        | Clotrimazole              | Oral Thrush                               | Membrane Integrity Stabiliser                               |
| Novartis           | Lamisil               | Terbinafine               | Systemic Fungal Infections, Onychomycosis | Membrane Integrity Destabiliser                             |

Thus, the anti-fungal agents useful in the invention include but are not limited to imidazoles, FK 463, amphotericin B, BAY 38-9502, MK 991, pradimicin, UK 292, butenafine, chitinase, 501 cream, Acrisorcin; Ambruticin; Amorolfine, Amphotericin B; Azaconazole; Azaserine; Basifungin; Bifonazole; Biphenamine Hydrochloride ; Bispyrithione Magsulfex ; Butoconazole Nitrate; Calcium Undecylenate; Candicidin;



- 94 -

Carbol-Fuchsin; Chlordantoin; Ciclopirox; Ciclopirox Olamine; Cilofungin;  
 Ciconazole; Clotrimazole; Cuprimyxin ; Denofungin ; Dipyrithione; Doconazole;  
 Econazole; Econazole Nitrate; Enilconazole; Ethonam Nitrate; Fenticonazole Nitrate;  
 Filipin; Fluconazole; Flucytosine; Fungimycin; Griseofulvin; Hamycin; Isoconazole ;  
 5 Itraconazole; Kalafungin; Ketoconazole; Lomofungin; Lydimycin; Mepartricin ;  
 Miconazole; Miconazole Nitrate; Monensin ; Monensin Sodium ; Naftifine  
 Hydrochloride; Neomycin Undecylenate ; Nifuratel ; Nifurmerone; Nitralamine  
 Hydrochloride; Nystatin; Octanoic Acid; Orconazole Nitrate; Oxiconazole Nitrate;  
 Oxifungin Hydrochloride; Parconazole Hydrochloride; Partricin ; Potassium Iodide ;  
 10 Proclonol ; Pyrrithione Zinc ; Pyrrolnitrin; Rutamycin; Sanguinarium Chloride ;  
 Saperconazole; Scopafungin ; Selenium Sulfide ; Sinefungin; Sulconazole Nitrate;  
 Terbinafine; Terconazole; Thiram; Ticlatone ; Tioconazole; Tolciclate; Tolindate;  
 Tolnaftate; Triacetin; Triafungin; Undecylenic Acid; Viridofulvin; Zinc Undecylenate;  
 and Zinoconazole Hydrochloride.

15 Immunostimulatory nucleic acids can be combined with other therapeutic agents  
 such as adjuvants to enhance immune responses. The immunostimulatory nucleic acid  
 and other therapeutic agent may be administered simultaneously or sequentially. When  
 the other therapeutic agents are administered simultaneously they can be administered in  
 the same or separate formulations, but are administered at the same time. The other  
 20 therapeutic agents are administered sequentially with one another and with  
 immunostimulatory nucleic acid, when the administration of the other therapeutic agents  
 and the immunostimulatory nucleic acid is temporally separated. The separation in time  
 between the administration of these compounds may be a matter of minutes or it may be  
 longer. Other therapeutic agents include but are not limited to adjuvants, cytokines,  
 25 antibodies, antigens, etc.

The immunostimulatory nucleic acids are useful as adjuvants for inducing a  
 systemic immune response. Thus either can be delivered to a subject exposed to an  
 antigen to produce an enhanced immune response to the antigen.

30 In addition to the immunostimulatory nucleic acids, the compositions of the  
 invention may also be administered with non-nucleic acid adjuvants. A non-nucleic acid  
 adjuvant is any molecule or compound except for the immunostimulatory nucleic acids  
 described herein which can stimulate the humoral and/or cellular immune response.



- 95 -

Non-nucleic acid adjuvants include, for instance, adjuvants that create a depo effect, immune stimulating adjuvants, and adjuvants that create a depo effect and stimulate the immune system.

5 An adjuvant that creates a depo effect as used herein is an adjuvant that causes the antigen to be slowly released in the body, thus prolonging the exposure of immune cells to the antigen. This class of adjuvants includes but is not limited to alum (e.g., aluminum hydroxide, aluminum phosphate); or emulsion-based formulations including mineral oil, non-mineral oil, water-in-oil or oil-in-water-in oil emulsion, oil-in-water emulsions such as Seppic ISA series of Montanide adjuvants (e.g., Montanide ISA 720, 10 AirLiquide, Paris, France); MF-59 (a squalene-in-water emulsion stabilized with Span 85 and Tween 80; Chiron Corporation, Emeryville, CA; and PROVAX (an oil-in-water emulsion containing a stabilizing detergent and a micelle-forming agent; IDEC, Pharmaceuticals Corporation, San Diego, CA).

15 An immune stimulating adjuvant is an adjuvant that causes activation of a cell of the immune system. It may, for instance, cause an immune cell to produce and secrete cytokines. This class of adjuvants includes but is not limited to saponins purified from the bark of the *Q. saponaria* tree, such as QS21 (a glycolipid that elutes in the 21<sup>st</sup> peak with HPLC fractionation; Aquila Biopharmaceuticals, Inc., Worcester, MA); poly[di(carboxylatophenoxy)phosphazene (PCPP polymer; Virus Research Institute, 20 USA); derivatives of lipopolysaccharides such as monophosphoryl lipid A (MPL; Ribi ImmunoChem Research, Inc., Hamilton, MT), muramyl dipeptide (MDP; Ribi) and threonyl-muramyl dipeptide (t-MDP; Ribi); OM-174 (a glucosamine disaccharide related to lipid A; OM Pharma SA, Meyrin, Switzerland); and Leishmania elongation factor (a purified *Leishmania* protein; Corixa Corporation, Seattle, WA).

25 Adjuvants that create a depo effect and stimulate the immune system are those compounds which have both of the above- identified functions. This class of adjuvants includes but is not limited to ISCOMS (Immunostimulating complexes which contain mixed saponins, lipids and form virus-sized particles with pores that can hold antigen; CSL, Melbourne, Australia); SB-AS2 (SmithKline Beecham adjuvant system #2 which 30 is an oil-in-water emulsion containing MPL and QS21: SmithKline Beecham Biologicals [SBB], Rixensart, Belgium); SB-AS4 (SmithKline Beecham adjuvant system #4 which contains alum and MPL; SBB, Belgium); non-ionic block copolymers that form micelles



- 96 -

such as CRL 1005 (these contain a linear chain of hydrophobic polyoxpropylene flanked by chains of polyoxyethylene; Vaxcel, Inc., Norcross, GA); and Syntex Adjuvant Formulation (SAF, an oil-in-water emulsion containing Tween 80 and a nonionic block copolymer; Syntex Chemicals, Inc., Boulder, CO).

5           The immunostimulatory nucleic acids are also useful as mucosal adjuvants. It has previously been discovered that both systemic and mucosal immunity are induced by mucosal delivery of CpG nucleic acids. The systemic immunity induced in response to CpG nucleic acids included both humoral and cell-mediated responses to specific antigens that were not capable of inducing systemic immunity when administered alone  
10 to the mucosa. Furthermore, both CpG nucleic acids and cholera toxin (CT, a mucosal adjuvant that induces a Th2-like response) induced CTL. This was surprising since with systemic immunization, the presence of Th2-like antibodies is normally associated with a lack of CTL (Schirmbeck *et al.*, 1995). Based on the results presented herein it is expected that the immunostimulatory nucleic acids will function in a similar manner.

15           Additionally, the immunostimulatory nucleic acids induce a mucosal response at both local (e.g., lung) and remote (e.g., lower digestive tract) mucosal sites. Significant levels of IgA antibodies are induced at distant mucosal sites by the immunostimulatory nucleic acids. CT is generally considered to be a highly effective mucosal adjuvant. As has been previously reported (Snider 1995), CT induces predominantly IgG1 isotype of  
20 antibodies, which are indicative of Th2-type response. In contrast, the immunostimulatory nucleic acids are more Th1 with predominantly IgG2a antibodies, especially after boost or when the two adjuvants are combined. Th1-type antibodies in general have better neutralizing capabilities, and furthermore, a Th2 response in the lung is highly undesirable because it is associated with asthma (Kay, 1996, Hogg, 1997).  
25 Thus the use of immunostimulatory nucleic acids as a mucosal adjuvant has benefits that other mucosal adjuvants cannot achieve. The immunostimulatory nucleic acids of the invention also are useful as mucosal adjuvants for induction of both a systemic and a mucosal immune response.

          Mucosal adjuvants referred to as non-nucleic acid mucosal adjuvants may also be  
30 administered with the Immunostimulatory nucleic acids. A non-nucleic acid mucosal adjuvant as used herein is an adjuvant other than a immunostimulatory nucleic acid that is capable of inducing a mucosal immune response in a subject when administered to a



- 97 -

mucosal surface in conjunction with an antigen. Mucosal adjuvants include but are not limited to Bacterial toxins e.g., Cholera toxin (CT), CT derivatives including but not limited to CT B subunit (CTB) (Wu et al., 1998, Tochikubo et al., 1998); CTD53 (Val to Asp) (Fontana et al., 1995); CTK97 (Val to Lys) (Fontana et al., 1995); CTK104 (Tyr to Lys) (Fontana et al., 1995); CTD53/K63 (Val to Asp, Ser to Lys) (Fontana et al., 1995); CTH54 (Arg to His) (Fontana et al., 1995); CTN107 (His to Asn) (Fontana et al., 1995); CTE114 (Ser to Glu) (Fontana et al., 1995); CTE112K (Glu to Lys) (Yamamoto et al., 1997a); CTS61F (Ser to Phe) (Yamamoto et al., 1997a, 1997b); CTS106 (Pro to Lys) (Douce et al., 1997, Fontana et al., 1995); and CTK63 (Ser to Lys) (Douce et al., 1997, Fontana et al., 1995), Zonula occludens toxin, zot, Escherichia coli heat-labile enterotoxin, Labile Toxin (LT), LT derivatives including but not limited to LT B subunit (LTB) (Verweij et al., 1998); LT7K (Arg to Lys) (Komase et al., 1998, Douce et al., 1995); LT61F (Ser to Phe) (Komase et al., 1998); LT112K (Glu to Lys) (Komase et al., 1998); LT118E (Gly to Glu) (Komase et al., 1998); LT146E (Arg to Glu) (Komase et al., 1998); LT192G (Arg to Gly) (Komase et al., 1998); LTK63 (Ser to Lys) (Marchetti et al., 1998, Douce et al., 1997, 1998, Di Tommaso et al., 1996); and LTR72 (Ala to Arg) (Giuliani et al., 1998), Pertussis toxin, PT. (Lycke et al., 1992, Spangler BD, 1992, Freytag and Clemments, 1999, Roberts et al., 1995, Wilson et al., 1995) including PT-9K/129G (Roberts et al., 1995, Cropley et al., 1995); Toxin derivatives (see below) (Holmgren et al., 1993, Verweij et al., 1998, Rappuoli et al., 1995, Freytag and Clements, 1999); Lipid A derivatives (e.g., monophosphoryl lipid A, MPL) (Sasaki et al., 1998, Vancott et al., 1998; Muramyl Dipeptide (MDP) derivatives (Fukushima et al., 1996, Ogawa et al., 1989, Michalek et al., 1983, Morisaki et al., 1983); Bacterial outer membrane proteins (e.g., outer surface protein A (OspA) lipoprotein of *Borrelia burgdorferi*, outer membrane protine of *Neisseria meningitidis*)(Marinaro et al., 1999, Van de Verg et al., 1996); Oil-in-water emulsions (e.g., MF59) (Barchfield et al., 1999, Verschoor et al., 1999, O'Hagan, 1998); Aluminum salts (Isaka et al., 1998, 1999); and Saponins (e.g., QS21) Aquila Biopharmaceuticals, Inc., Worster, MA) (Sasaki et al., 1998, MacNeal et al., 1998), ISCOMS, MF-59 (a squalene-in-water emulsion stabilized with Span 85 and Tween 80; Chiron Corporation, Emeryville, CA); the Seppic ISA series of Montanide adjuvants (e.g., Montanide ISA 720; AirLiquide, Paris, France); PROVAX (an oil-in-water emulsion containing a stabilizing detergent and a micelle-



- 98 -

forming agent; IDEC Pharmaceuticals Corporation, San Diego, CA); Syntex Adjuvant Formulation (SAF; Syntex Chemicals, Inc., Boulder, CO); poly[di(carboxylatophenoxy)phosphazene (PCPP polymer; Virus Research Institute, USA) and Leishmania elongation factor (Corixa Corporation, Seattle, WA).

5 Immune responses can also be induced or augmented by the co-administration or co-linear expression of cytokines (Bueler & Mulligan, 1996; Chow *et al.*, 1997; Geissler *et al.*, 1997; Iwasaki *et al.*, 1997; Kim *et al.*, 1997) or B-7 co-stimulatory molecules (Iwasaki *et al.*, 1997; Tsuji *et al.*, 1997) with the Immunostimulatory nucleic acids. The cytokines can be administered directly with Immunostimulatory nucleic acids or may be  
10 administered in the form of a nucleic acid vector that encodes the cytokine, such that the cytokine can be expressed *in vivo*. In one embodiment, the cytokine is administered in the form of a plasmid expression vector. The term cytokine is used as a generic name for a diverse group of soluble proteins and peptides which act as humoral regulators at nano- to picomolar concentrations and which, either under normal or pathological conditions,  
15 modulate the functional activities of individual cells and tissues. These proteins also mediate interactions between cells directly and regulate processes taking place in the extracellular environment. Examples of cytokines include, but are not limited to IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-15, IL-18, granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interferon-  
20  $\gamma$  ( $\gamma$ -IFN), IFN- $\alpha$ , tumor necrosis factor (TNF), TGF- $\beta$ , FLT-3 ligand, and CD40 ligand.

Cytokines play a role in directing the T cell response. Helper (CD4+) T cells orchestrate the immune response of mammals through production of soluble factors that act on other immune system cells, including other T cells. Most mature CD4+ T helper cells express one of two cytokine profiles: Th1 or Th2. The Th1 subset promotes  
25 delayed-type hypersensitivity, cell-mediated immunity, and immunoglobulin class switching to IgG<sub>2a</sub>. The Th2 subset induces humoral immunity by activating B cells, promoting antibody production, and inducing class switching to IgG<sub>1</sub> and IgE. In some embodiments, it is preferred that the cytokine be a Th1 cytokine.

The nucleic acids are also useful for redirecting an immune response from a Th2  
30 immune response to a Th1 immune response. Redirection of an immune response from a Th2 to a Th1 immune response can be assessed by measuring the levels of cytokines produced in response to the nucleic acid (*e.g.*, by inducing monocytic cells and other



- 99 -

cells to produce Th1 cytokines, including IL-12, IFN- $\gamma$  and GM-CSF). The redirection or rebalance of the immune response from a Th2 to a Th1 response is particularly useful for the treatment or prevention of asthma. For instance, an effective amount for treating asthma can be that amount; useful for redirecting a Th2 type of immune response that is associated with asthma to a Th1 type of response. Th2 cytokines, especially IL-4 and IL-5 are elevated in the airways of asthmatic subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including IgE isotype switching, eosinophil chemotaxis and activation and mast cell growth. Th1 cytokines, especially IFN- $\gamma$  and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines. The immunostimulatory nucleic acids of the invention cause an increase in Th1 cytokines which helps to rebalance the immune system, preventing or reducing the adverse effects associated with a predominately Th2 immune response.

The nucleic acids are also useful for improving survival, differentiation, activation and maturation of dendritic cells. The immunostimulatory nucleic acids have the unique capability to promote cell survival, differentiation, activation and maturation of dendritic cells. Dendritic precursor cells isolated from blood by immunomagnetic cell sorting develop morphologic and functional characteristics of dendritic cells during a two day incubation with GM-CSF. Without GM-CSF these cells undergo apoptosis. The immunostimulatory nucleic acids are superior to GM-CSF in promoting survival and differentiation of dendritic cells (MHC II expression, cell size, granularity). The immunostimulatory nucleic acids also induce maturation of dendritic cells. Since dendritic cells form the link between the innate and the acquired immune system, by presenting antigens as well as through their expression of pattern recognition receptors which detect microbial molecules like LPS in their local environment, the ability to activate dendritic cells with immunostimulatory nucleic acids supports the use of these immunostimulatory nucleic acid based strategies for *in vivo* and *ex-vivo* immunotherapy against disorders such as cancer and allergic or infectious diseases. The immunostimulatory nucleic acids are also useful for activating and inducing maturation of dendritic cells.

Immunostimulatory nucleic acids also increase natural killer cell lytic activity and antibody dependent cellular cytotoxicity (ADCC). ADCC can be performed using a immunostimulatory nucleic acid in combination with an antibody specific for a cellular



- 100 -

target, such as a cancer cell. When the immunostimulatory nucleic acid is administered to a subject in conjunction with the antibody the subject's immune system is induced to kill the tumor cell. The antibodies useful in the ADCC procedure include antibodies which interact with a cell in the body. Many such antibodies specific for cellular targets  
5 have been described in the art and many are commercially available. Examples of these antibodies are listed below among the list of cancer immunotherapies.

The immunostimulatory nucleic acids may also be administered in conjunction with an anti-cancer therapy. Anti-cancer therapies include cancer medicaments, radiation and surgical procedures. As used herein, a "cancer medicament" refers to a  
10 agent which is administered to a subject for the purpose of treating a cancer. As used herein, "treating cancer" includes preventing the development of a cancer, reducing the symptoms of cancer, and/or inhibiting the growth of an established cancer. In other aspects, the cancer medicament is administered to a subject at risk of developing a cancer for the purpose of reducing the risk of developing the cancer. Various types of  
15 medicaments for the treatment of cancer are described herein. For the purpose of this specification, cancer medicaments are classified as chemotherapeutic agents, immunotherapeutic agents, cancer vaccines, hormone therapy, and biological response modifiers.

As used herein, a "cancer medicament" refers to an agent which is administered  
20 to a subject for the purpose of treating a cancer. As used herein, "treating cancer" includes preventing the development of a cancer, reducing the symptoms of cancer, and/or inhibiting the growth of an established cancer. In other aspects, the cancer medicament is administered to a subject at risk of developing a cancer for the purpose of reducing the risk of developing the cancer. Various types of medicaments for the  
25 treatment of cancer are described herein. For the purpose of this specification, cancer medicaments are classified as chemotherapeutic agents, immunotherapeutic agents, cancer vaccines, hormone therapy, and biological response modifiers. Additionally, the methods of the invention are intended to embrace the use of more than one cancer medicament along with the immunostimulatory nucleic acids. As an example, where  
30 appropriate, the immunostimulatory nucleic acids may be administered with a both a chemotherapeutic agent and an immunotherapeutic agent. Alternatively, the cancer medicament may embrace an immunotherapeutic agent and a cancer vaccine, or a



- 101 -

chemotherapeutic agent and a cancer vaccine, or a chemotherapeutic agent, an immunotherapeutic agent and a cancer vaccine all administered to one subject for the purpose of treating a subject having a cancer or at risk of developing a cancer.

Cancer medicaments function in a variety of ways. Some cancer medicaments work by targeting physiological mechanisms that are specific to tumor cells. Examples include the targeting of specific genes and their gene products (i.e., proteins primarily) which are mutated in cancers. Such genes include but are not limited to oncogenes (e.g., Ras, Her2, bcl-2), tumor suppressor genes (e.g., EGF, p53, Rb), and cell cycle targets (e.g., CDK4, p21, telomerase). Cancer medicaments can alternately target signal transduction pathways and molecular mechanisms which are altered in cancer cells. Targeting of cancer cells via the epitopes expressed on their cell surface is accomplished through the use of monoclonal antibodies. This latter type of cancer medicament is generally referred to herein as immunotherapy.

Other cancer medicaments target cells other than cancer cells. For example, some medicaments prime the immune system to attack tumor cells (i.e., cancer vaccines). Still other medicaments, called angiogenesis inhibitors, function by attacking the blood supply of solid tumors. Since the most malignant cancers are able to metastasize (i.e., exist the primary tumor site and seed a distal tissue, thereby forming a secondary tumor), medicaments that impede this metastasis are also useful in the treatment of cancer. Angiogenic mediators include basic FGF, VEGF, angiopoietins, angiostatin, endostatin, TNF $\alpha$ , TNP-470, thrombospondin-1, platelet factor 4, CAI, and certain members of the integrin family of proteins. One category of this type of medicament is a metalloproteinase inhibitor, which inhibits the enzymes used by the cancer cells to exist the primary tumor site and extravasate into another tissue.

Some cancer cells are antigenic and thus can be targeted by the immune system. In one aspect, the combined administration of immunostimulatory nucleic acids and cancer medicaments, particularly those which are classified as cancer immunotherapies, is useful for stimulating a specific immune response against a cancer antigen. A "cancer antigen" as used herein is a compound, such as a peptide, associated with a tumor or cancer cell surface and which is capable of provoking an immune response when expressed on the surface of an antigen presenting cell in the context of an MHC molecule. Cancer antigens, such as those present in cancer vaccines or those used to



- 102 -

prepare cancer immunotherapies, can be prepared from crude cancer cell extracts, as described in Cohen, et al., 1994, *Cancer Research*, 54:1055, or by partially purifying the antigens, using recombinant technology, or de novo synthesis of known antigens.

Cancer antigens can be used in the form of immunogenic portions of a particular antigen  
5 or in some instances a whole cell or a tumor mass can be used as the antigen. Such antigens can be isolated or prepared recombinantly or by any other means known in the art.

The theory of immune surveillance is that a prime function of the immune system is to detect and eliminate neoplastic cells before a tumor forms. A basic principle of this  
10 theory is that cancer cells are antigenically different from normal cells and thus elicit immune reactions that are similar to those that cause rejection of immunologically incompatible allografts. Studies have confirmed that tumor cells differ, either qualitatively or quantitatively, in their expression of antigens. For example, "tumor-specific antigens" are antigens that are specifically associated with tumor cells but not  
15 normal cells. Examples of tumor specific antigens are viral antigens in tumors induced by DNA or RNA viruses. "Tumor-associated" antigens are present in both tumor cells and normal cells but are present in a different quantity or a different form in tumor cells. Examples of such antigens are oncofetal antigens (e.g., carcinoembryonic antigen), differentiation antigens (e.g., T and Tn antigens), and oncogene products (e.g.,  
20 HER/neu).

Different types of cells that can kill tumor targets *in vitro* and *in vivo* have been identified: natural killer cells (NK cells), cytolytic T lymphocytes (CTLs), lymphokine-activated killer cells (LAKs), and activated macrophages. NK cells can kill tumor cells without having been previously sensitized to specific antigens, and the activity does not  
25 require the presence of class I antigens encoded by the major histocompatibility complex (MHC) on target cells. NK cells are thought to participate in the control of nascent tumors and in the control of metastatic growth. In contrast to NK cells, CTLs can kill tumor cells only after they have been sensitized to tumor antigens and when the target antigen is expressed on the tumor cells that also express MHC class I. CTLs are thought  
30 to be effector cells in the rejection of transplanted tumors and of tumors caused by DNA viruses. LAK cells are a subset of null lymphocytes distinct from the NK and CTL populations. Activated macrophages can kill tumor cells in a manner that is not antigen



- 103 -

dependent nor MHC restricted once activated. Activated macrophages are through to decrease the growth rate of the tumors they infiltrate. *In vitro* assays have identified other immune mechanisms such as antibody-dependent, cell-mediated cytotoxic reactions and lysis by antibody plus complement. However, these immune effector  
5 mechanisms are thought to be less important *in vivo* than the function of NK, CTLs, LAK, and macrophages *in vivo* (for review see Piessens, W.F., and David, J., "Tumor Immunology", In: Scientific American Medicine, Vol. 2, Scientific American Books, N.Y., pp. 1-13, 1996.

The goal of immunotherapy is to augment a patient's immune response to an  
10 established tumor. One method of immunotherapy includes the use of adjuvants. Adjuvant substances derived from microorganisms, such as bacillus Calmette-Guerin, heighten the immune response and enhance resistance to tumors in animals.

Immunotherapeutic agents are medicaments which derive from antibodies or antibody fragments which specifically bind or recognize a cancer antigen. As used  
15 herein a cancer antigen is broadly defined as an antigen expressed by a cancer cell. Preferably, the antigen is expressed at the cell surface of the cancer cell. Even more preferably, the antigen is one which is not expressed by normal cells, or at least not expressed to the same level as in cancer cells. Antibody-based immunotherapies may function by binding to the cell surface of a cancer cell and thereby stimulate the  
20 endogenous immune system to attack the cancer cell. Another way in which antibody-based therapy functions is as a delivery system for the specific targeting of toxic substances to cancer cells. Antibodies are usually conjugated to toxins such as ricin (e.g., from castor beans), calicheamicin and maytansinoids, to radioactive isotopes such as Iodine-131 and Yttrium-90, to chemotherapeutic agents (as described herein), or to  
25 biological response modifiers. In this way, the toxic substances can be concentrated in the region of the cancer and non-specific toxicity to normal cells can be minimized. In addition to the use of antibodies which are specific for cancer antigens, antibodies which bind to vasculature, such as those which bind to endothelial cells, are also useful in the invention. This is because generally solid tumors are dependent upon newly formed  
30 blood vessels to survive, and thus most tumors are capable of recruiting and stimulating the growth of new blood vessels. As a result, one strategy of many cancer medicaments



- 104 -

is to attack the blood vessels feeding a tumor and/or the connective tissues (or stroma) supporting such blood vessels.

The use of immunostimulatory nucleic acids in conjunction with immunotherapeutic agents such as monoclonal antibodies is able to increase long-term survival through a number of mechanisms including significant enhancement of ADCC (as discussed above), activation of natural killer (NK) cells and an increase in IFN $\alpha$  levels. The nucleic acids when used in combination with monoclonal antibodies serve to reduce the dose of the antibody required to achieve a biological result.

Examples of cancer immunotherapies which are currently being used or which are in development are listed in Table C.

**Table C**

| <i>Cancer Immunotherapies in Development or on the Market</i>                                                      |                                                                                 |                                           |
|--------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------|
| <b>MARKETER</b>                                                                                                    | <b>BRAND NAME (GENERIC NAME)</b>                                                | <b>INDICATION</b>                         |
| IDEC/Genentech, Inc./Hoffmann-LaRoche (first monoclonal antibody licensed for the treatment of cancer in the U.S.) | Rituxan™ (rituximab, Mabthera) (IDEC-C2B8, chimeric murine/human anti-CD20 MAb) | non-Hodgkin's lymphoma                    |
| Genentech/Hoffmann-La Roche                                                                                        | Herceptin, anti-Her2 hMAb                                                       | Breast/ovarian                            |
| Cytogen Corp.                                                                                                      | Quadramet (CYT-424) radiotherapeutic agent                                      | Bone metastases                           |
| Centocor/Glaxo/Ajinomoto                                                                                           | Panorex® (17-1A) (murine monoclonal antibody)                                   | Adjuvant therapy for colorectal (Dukes-C) |
| Centocor/Ajinomoto                                                                                                 | Panorex® (17-1A) (chimeric murine monoclonal antibody)                          | Pancreatic, lung, breast, ovary           |
| IDEC                                                                                                               | IDEC-Y2B8 (murine, anti-CD20 MAb labeled with Yttrium-90)                       | non-Hodgkin's lymphoma                    |
| ImClone Systems                                                                                                    | BEC2 (anti-idiotypic MAb, mimics the GD <sub>3</sub> epitope) (with BCG)        | Small cell lung                           |
| ImClone Systems                                                                                                    | C225 (chimeric monoclonal antibody to epidermal growth factor receptor (EGFr))  | Renal cell                                |
| Techniclone International/Alpha Therapeutics                                                                       | Oncolym (Lym-1 monoclonal antibody linked to 131 iodine)                        | non-Hodgkin's lymphoma                    |
| Protein Design Labs                                                                                                | SMART M195 Ab, humanized                                                        | Acute myeloid leukemia                    |
| Techniclone Corporation/Cambridge Antibody Technology                                                              | <sup>131</sup> I LYM-1 (Oncolym™)                                               | non-Hodgkin's lymphoma                    |
| Aronex Pharmaceuticals, Inc.                                                                                       | ATRAGEN®                                                                        | Acute promyelocytic leukemia              |
| ImClone Systems                                                                                                    | C225 (chimeric anti-EGFr monoclonal antibody) + cisplatin or radiation          | Head & neck, non-small cell lung cancer   |



|                                                                                                                              |                                                                                        |                                                                 |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Altarex, Canada                                                                                                              | Ovarex (B43.13, anti-idiotypic CA125, mouse MAb)                                       | Ovarian                                                         |
| Coulter Pharma (Clinical results have been positive, but the drug has been associated with significant bone marrow toxicity) | Bexxar (anti-CD20 Mab labeled with <sup>131</sup> I)                                   | non-Hodgkin's lymphoma                                          |
| Aronex Pharmaceuticals, Inc.                                                                                                 | ATRAGEN®                                                                               | Kaposi's sarcoma                                                |
| IDEC Pharmaceuticals Corp./Genentech                                                                                         | Rituxan™ (MAb against CD20) pan-B Ab in combo. with chemotherapy                       | B cell lymphoma                                                 |
| LeukoSite/Ilex Oncology                                                                                                      | LDP-03, huMAb to the leukocyte antigen CAMPATH                                         | Chronic lymphocytic leukemia (CLL)                              |
| Center of Molecular Immunology                                                                                               | ior t6 (anti CD6, murine MAb) CTCL                                                     | Cancer                                                          |
| Medarex/Novartis                                                                                                             | MDX-210 (humanized anti-HER-2 bispecific antibody)                                     | Breast, ovarian                                                 |
| Medarex/Novartis                                                                                                             | MDX-210 (humanized anti-HER-2 bispecific antibody)                                     | Prostate, non-small cell lung, pancreatic, breast               |
| Medarex                                                                                                                      | MDX-11 (complement activating receptor (CAR) monoclonal antibody)                      | Acute myelogenous leukemia (AML)                                |
| Medarex/Novartis                                                                                                             | MDX-210 (humanized anti-HER-2 bispecific antibody)                                     | Renal and colon                                                 |
| Medarex                                                                                                                      | MDX-11 (complement activating receptor (CAR) monoclonal antibody)                      | Ex vivo bone marrow purging in acute myelogenous leukemia (AML) |
| Medarex                                                                                                                      | MDX-22 (humanized bispecific antibody, MAb-conjugates) (complement cascade activators) | Acute myleoid leukemia                                          |
| Cytogen                                                                                                                      | OV103 (Yttrium-90 labelled antibody)                                                   | Ovarian                                                         |
| Cytogen                                                                                                                      | OV103 (Yttrium-90 labelled antibody)                                                   | Prostate                                                        |
| Aronex Pharmaceuticals, Inc.                                                                                                 | ATRAGEN®                                                                               | non-Hodgkin's lymphoma                                          |
| Glaxo Wellcome plc                                                                                                           | 3622W94 MAb that binds to EGP40 (17-1A) pancarcinoma antigen on adenocarcinomas        | non-small cell lung, prostate (adjuvant)                        |
| Genentech                                                                                                                    | Anti-VEGF, RhuMAb (inhibits angiogenesis)                                              | Lung, breast, prostate, colorectal                              |
| Protein Design Labs                                                                                                          | Zenapax (SMART Anti-Tac (IL-2 receptor) Ab, humanized)                                 | Leukemia, lymphoma                                              |
| Protein Design Labs                                                                                                          | SMART M195 Ab, humanized                                                               | Acute promyelocytic leukemia                                    |
| ImClone Systems                                                                                                              | C225 (chimeric anti-EGFr monoclonal antibody ) + taxol                                 | Breast                                                          |
| ImClone Systems (licensed from RPR)                                                                                          | C225 (chimeric anti-EGFr monoclonal antibody ) + doxorubicin                           | prostate                                                        |
| ImClone Systems                                                                                                              | C225 (chimeric anti-EGFr monoclonal antibody ) + adriamycin                            | prostate                                                        |
| ImClone Systems                                                                                                              | BEC2 (anti-idiotypic MAb, mimics the GD <sub>3</sub> epitope)                          | Melanoma                                                        |
| Medarex                                                                                                                      | MDX-210 (humanized anti-HER-2 bispecific                                               | Cancer                                                          |



- 106 -

|                                                             |                                                               |                                                                                |
|-------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------------------------------|
|                                                             | antibody)                                                     |                                                                                |
| Medarex                                                     | MDX-220 (bispecific for tumors that express TAG-72)           | Lung, colon, prostate, ovarian, endometrial, pancreatic and gastric            |
| Medarex/Novartis                                            | MDX-210 (humanized anti-HER-2 bispecific antibody)            | Prostate                                                                       |
| Medarex/Merck KgaA                                          | MDX-447 (humanized anti-EGF receptor bispecific antibody)     | EGF receptor cancers (head & neck, prostate, lung, bladder, cervical, ovarian) |
| Medarex/Novartis                                            | MDX-210 (humanized anti-HER-2 bispecific antibody)            | Comb. Therapy with G-CSF for various cancers, esp. breast                      |
| IDEC                                                        | MELIMMUNE-2 (murine monoclonal antibody therapeutic vaccine ) | Melanoma                                                                       |
| IDEC                                                        | MELIMMUNE-1 (murine monoclonal antibody therapeutic vaccine ) | Melanoma                                                                       |
| Immunomedics, Inc.                                          | CEACIDE™ (I-131)                                              | Colorectal and other                                                           |
| NeoRx                                                       | Pretarget™ radioactive antibodies                             | non-Hodgkin's B cell lymphoma                                                  |
| Novopharm Biotech, Inc.                                     | NovoMAb-G2 (pancarcinoma specific Ab)                         | Cancer                                                                         |
| Techniclone Corporation/<br>Cambridge Antibody Technology   | TNT (chimeric MAb to histone antigens)                        | Brain                                                                          |
| Techniclone International/<br>Cambridge Antibody Technology | TNT (chimeric MAb to histone antigens)                        | Brain                                                                          |
| Novopharm                                                   | Gliomab-H (Monoclonals - Humanized Abs)                       | Brain, melanomas, neuroblastomas                                               |
| Genetics Institute/AHP                                      | GNI-250 Mab                                                   | Colorectal                                                                     |
| Merck KgaA                                                  | EMD-72000 (chimeric-EGF antagonist)                           | Cancer                                                                         |
| Immunomedics                                                | LymphoCide (humanized LL2 antibody)                           | non-Hodgkin's B-cell lymphoma                                                  |
| Immunex/AHP                                                 | CMA 676 (monoclonal antibody conjugate)                       | Acute myelogenous leukemia                                                     |
| Novopharm Biotech, Inc.                                     | Monopharm-C                                                   | Colon, lung, pancreatic                                                        |
| Novopharm Biotech, Inc.                                     | 4B5 anti-idiotypic Ab                                         | Melanoma, small-cell lung                                                      |
| Center of Molecular Immunology                              | ior egf/r3 (anti EGF-R humanized Ab)                          | Radioimmunotherapy                                                             |
| Center of Molecular Immunology                              | ior c5 (murine MAb colorectal) for radioimmunotherapy         | Colorectal                                                                     |
| Creative BioMolecules/<br>Chiron                            | BABS (biosynthetic antibody binding site) Proteins            | Breast cancer                                                                  |
| ImClone Systems/Chugai                                      | FLK-2 (monoclonal antibody to fetal liver kinase-2 (FLK-2))   | Tumor-associated angiogenesis                                                  |
| ImmunoGen, Inc.                                             | Humanized MAb/small-drug conjugate                            | Small-cell lung                                                                |
| Medarex, Inc.                                               | MDX-260 bispecific, targets GD-2                              | Melanoma, glioma,                                                              |



|                              |                  |                     |
|------------------------------|------------------|---------------------|
|                              |                  | neuroblastoma       |
| Procyon Biopharma, Inc.      | ANA Ab           | Cancer              |
| Protein Design Labs          | SMART 1D10 Ab    | B-cell lymphoma     |
| Protein Design Labs/Novartis | SMART ABL 364 Ab | Breast, lung, colon |
| Immunomedics, Inc.           | ImmuRAIT-CEA     | Colorectal          |

Yet other types of chemotherapeutic agents which can be used according to the invention include Aminoglutethimide, Asparaginase, Busulfan, Carboplatin, Chlorombucil, Cytarabine HCl, Dactinomycin, Daunorubicin HCl, Estramustine phosphate sodium, Etoposide (VP16-213), Floxuridine, Fluorouracil (5-FU), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alfa-2a, Alfa-2b, Leuprolide acetate (LHRH-releasing factor analogue), Lomustine (CCNU), Mechlorethamine HCl (nitrogen mustard), Mercaptopurine, Mesna, Mitotane (o.p'-DDD), Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Amsacrine (m-AMSA), Azacitidine, Erthropoietin, Hexamethylmelamine (HMM), Interleukin 2, Mitoguazone (methyl-GAG; methyl glyoxal bis-guanylhydrazone; MGBG), Pentostatin (2'deoxycoformycin), Semustine (methyl-CCNU), Teniposide (VM-26) and Vindesine sulfate.

Cancer vaccines are medicaments which are intended to stimulate an endogenous immune response against cancer cells. Currently produced vaccines predominantly activate the humoral immune system (i.e., the antibody dependent immune response). Other vaccines currently in development are focused on activating the cell-mediated immune system including cytotoxic T lymphocytes which are capable of killing tumor cells. Cancer vaccines generally enhance the presentation of cancer antigens to both antigen presenting cells (e.g., macrophages and dendritic cells) and/or to other immune cells such as T cells, B cells, and NK cells.

Although cancer vaccines may take one of several forms, as discussed infra, their purpose is to deliver cancer antigens and/or cancer associated antigens to antigen presenting cells (APC) in order to facilitate the endogenous processing of such antigens by APC and the ultimate presentation of antigen presentation on the cell surface in the context of MHC class I molecules. One form of cancer vaccine is a whole cell vaccine which is a preparation of cancer cells which have been removed from a subject, treated ex vivo and then reintroduced as whole cells in the subject. Lysates of tumor cells can



- 108 -

also be used as cancer vaccines to elicit an immune response. Another form cancer vaccine is a peptide vaccine which uses cancer-specific or cancer-associated small proteins to activate T cells. Cancer-associated proteins are proteins which are not exclusively expressed by cancer cells (i.e., other normal cells may still express these antigens). However, the expression of cancer-associated antigens is generally consistently upregulated with cancers of a particular type. Yet another form of cancer vaccine is a dendritic cell vaccine which includes whole dendritic cells which have been exposed to a cancer antigen or a cancer-associated antigen in vitro. Lysates or membrane fractions of dendritic cells may also be used as cancer vaccines. Dendritic cell vaccines are able to activate antigen-presenting cells directly. Other cancer vaccines include ganglioside vaccines, heat-shock protein vaccines, viral and bacterial vaccines, and nucleic acid vaccines.

The use of immunostimulatory nucleic acids in conjunction with cancer vaccines provides an improved antigen-specific humoral and cell mediated immune response, in addition to activating NK cells and endogenous dendritic cells, and increasing IFN $\alpha$  levels. This enhancement allows a vaccine with a reduced antigen dose to be used to achieve the same beneficial effect. In some instances, cancer vaccines may be used along with adjuvants, such as those described above.

As used herein, the terms "cancer antigen" and "tumor antigen" are used interchangeably to refer to antigens which are differentially expressed by cancer cells and can thereby be exploited in order to target cancer cells. Cancer antigens are antigens which can potentially stimulate apparently tumor-specific immune responses. Some of these antigens are encoded, although not necessarily expressed, by normal cells. These antigens can be characterized as those which are normally silent (i.e., not expressed) in normal cells, those that are expressed only at certain stages of differentiation and those that are temporally expressed such as embryonic and fetal antigens. Other cancer antigens are encoded by mutant cellular genes, such as oncogenes (e.g., activated ras oncogene), suppressor genes (e.g., mutant p53), fusion proteins resulting from internal deletions or chromosomal translocations. Still other cancer antigens can be encoded by viral genes such as those carried on RNA and DNA tumor viruses.

Other vaccines take the form of dendritic cells which have been exposed to cancer antigens in vitro, have processed the antigens and are able to express the cancer



- 109 -

antigens at their cell surface in the context of MHC molecules for effective antigen presentation to other immune system cells.

The immunostimulatory nucleic acids are used in one aspect of the invention in conjunction with cancer vaccines which are dendritic cell based. A dendritic cell is a professional antigen presenting cell. Dendritic cells form the link between the innate and the acquired immune system by presenting antigens and through their expression of pattern recognition receptors which detect microbial molecules like LPS in their local environment. Dendritic cells efficiently internalize, process, and present soluble specific antigen to which it is exposed. The process of internalizing and presenting antigen causes rapid upregulation of the expression of major histocompatibility complex (MHC) and costimulatory molecules, the production of cytokines, and migration toward lymphatic organs where they are believed to be involved in the activation of T cells.

Table D lists a variety of cancer vaccines which are either currently being used or are in development.

**Table D**

| <i>Cancer Vaccines in Development or on the Market</i> |                                   |                            |
|--------------------------------------------------------|-----------------------------------|----------------------------|
| <b><u>MARKETER</u></b>                                 | <b>BRAND NAME (GENERIC NAME)</b>  | <b>INDICATION</b>          |
| Center of Molecular Immunology                         | EGF                               | Cancer                     |
| Center of Molecular Immunology                         |                                   | Ganglioside cancer vaccine |
| Center of Molecular Immunology                         | Anti-idiotypic                    | Cancer vaccine             |
| ImClone Systems/Memorial Sloan-Kettering Cancer Center | Gp75 antigen                      | Melanoma                   |
| ImClone Systems/Memorial Sloan-Kettering Cancer Center | Anti-idiotypic Abs                | Cancer vaccines            |
| Progenics Pharmaceuticals, Inc.                        | GMK melanoma vaccine              | Melanoma                   |
| Progenics Pharmaceuticals, Inc.                        | MGV ganglioside conjugate vaccine | Lymphoma, colorectal, lung |
| Corixa                                                 | Her2/neu                          | Breast, ovarian            |
| AltaRex                                                | Ovarex                            | Ovarian                    |
| AVAX Technologies Inc.                                 | M-Vax, autologous whole cell      | Melanoma                   |
| AVAX Technologies Inc.                                 | O-Vax, autologous whole cell      | Ovarian                    |
| AVAX Technologies Inc.                                 | L-Vax, autologous whole cell      | Leukemia-AML               |
| Biomira Inc./Chiron                                    | Theratope, STn-KLH                | Breast, Colorectal         |



- 110 -

|                                        |                                                                                                                                            |                              |
|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| Biomira Inc.                           | BLP25, MUC-1 peptide vaccine encapsulated in liposomal delivery system                                                                     | Lung                         |
| Biomira Inc.                           | BLP25, MUC-1 peptide vaccine encapsulated in liposomal delivery system + Liposomal IL-2                                                    | Lung                         |
| Biomira Inc.                           | Liposomal idiotypic vaccine                                                                                                                | Lymphoma B-cell malignancies |
| Ribi Immunochem                        | Melacine, cell lysate                                                                                                                      | Melanoma                     |
| Corixa                                 | Peptide antigens, microsphere delivery sysem and LeIF adjuvant                                                                             | Breast                       |
| Corixa                                 | Peptide antigens, microsphere delivery sysem and LeIF adjuvant                                                                             | Prostate                     |
| Corixa                                 | Peptide antigens, microsphere delivery sysem and LeIF adjuvant                                                                             | Ovarian                      |
| Corixa                                 | Peptide antigens, microsphere delivery sysem and LeIF adjuvant                                                                             | Lymphoma                     |
| Corixa                                 | Peptide antigens, microsphere delivery sysem and LeIF adjuvant                                                                             | Lung                         |
| Virus Research Institute               | Toxin/antigen recombinant delivery system                                                                                                  | All cancers                  |
| Apollon Inc.                           | Genevax-TCR                                                                                                                                | T-cell lymphoma              |
| Bavarian Nordic Research Institute A/S | MVA-based (vaccinia virus) vaccine                                                                                                         | Melanoma                     |
| BioChem Pharma/BioChem Vaccine         | PACIS, BCG vaccine                                                                                                                         | Bladder                      |
| Cantab Pharmaceuticals                 | TA-HPV                                                                                                                                     | Cervical                     |
| Cantab Pharmaceuticals                 | TA-CIN                                                                                                                                     | Cervical                     |
| Cantab Pharmaceuticals                 | DISC-Virus, immunotherapy                                                                                                                  | Cancer                       |
| Pasteur Merieux Connaught              | ImmuCyst®/TheraCys® - BCG Immunotherapeutic (Bacillus Calmette-Guerin/Connaught), for intravesical treatment of superficial bladder cancer | Bladder                      |

As used herein, chemotherapeutic agents embrace all other forms of cancer medicaments which do not fall into the categories of immunotherapeutic agents or cancer vaccines. Chemotherapeutic agents as used herein encompass both chemical and biological agents. These agents function to inhibit a cellular activity which the cancer cell is dependent upon for continued survival. Categories of chemotherapeutic agents include alkylating/alkaloid agents, antimetabolites, hormones or hormone analogs, and miscellaneous antineoplastic drugs. Most if not all of these agents are directly toxic to cancer cells and do not require immune stimulation. Combination chemotherapy and



- 111 -

immunostimulatory nucleic acid administration increases the maximum tolerable dose of chemotherapy.

Chemotherapeutic agents which are currently in development or in use in a clinical setting are shown in Table E.

5

**Table E**

| <i>Cancer Drugs in Development or on the Market</i> |                                      |                                      |                                                              |
|-----------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------------------------------|
| <b>Marketer</b>                                     | <b>Brand Name</b>                    | <b>Generic Name</b>                  | <b>Indication</b>                                            |
| Abbott                                              | TNP 470/AGM 1470                     | Fragyline                            | Anti-Angiogenesis in Cancer                                  |
| Takeda                                              | TNP 470/AGM 1470                     | Fragyline                            | Anti-Angiogenesis in Cancer                                  |
| Scotia                                              | Meglamine GLA                        | Meglamine GLA                        | Bladder Cancer                                               |
| Medeva                                              | Valstar                              | Valrubicin                           | Bladder Cancer - Refractory<br>in situ carcinoma             |
| Medeva                                              | Valstar                              | Valrubicin                           | Bladder Cancer - Papillary<br>Cancer                         |
| Rhone Poulenc                                       | Gliadel Wafer                        | Carmustaine + Polifepr Osan          | Brain Tumor                                                  |
| Warner Lambert                                      | Undisclosed Cancer (b)               | Undisclosed Cancer (b)               | Cancer                                                       |
| Bristol Myers<br>Squib                              | RAS Famesyl Transferase<br>Inhibitor | RAS Famesyl Transferase<br>Inhibitor | Cancer                                                       |
| Novartis                                            | MMI 270                              | MMI 270                              | Cancer                                                       |
| Bayer                                               | BAY 12-9566                          | BAY 12-9566                          | Cancer                                                       |
| Merck                                               | Famesyl Transferase Inhibitor        | Famesyl Transferase<br>Inhibitor     | Cancer (Solid tumors -<br>pancrease, colon, lung,<br>breast) |
| Pfizer                                              | PFE                                  | MMP                                  | Cancer, angiogenesis                                         |
| Pfizer                                              | PFE                                  | Tyrosine Kinase                      | Cancer, angiogenesis                                         |
| Lilly                                               | MTA/LY 231514                        | MTA/LY 231514                        | Cancer Solid Tumors                                          |
| Lilly                                               | LY 264618/Lometexol                  | Lometexol                            | Cancer Solid Tumors                                          |
| Scotia                                              | Glamolec                             | LiGLA (lithium-gamma<br>linolenate)  | Cancer, pancreatic, breast,<br>colon                         |
| Warner Lambert                                      | CI-994                               | CI-994                               | Cancer, Solid Tumors /<br>Leukemia                           |
| Schering AG                                         | Angiogenesis inhibitor               | Angiogenesis Inhibitor               | Cancer / Cardio                                              |
| Takeda                                              | TNP-470                              | n/k                                  | Malignant Tumor                                              |
| Smithkline<br>Beecham                               | Hycamtin                             | Topotecan                            | Metastatic Ovarian Cancer                                    |
| Novartis                                            | PKC 412                              | PKC 412                              | Multi-Drug Resistant Cancer                                  |
| Novartis                                            | Valspodar                            | PSC 833                              | Myeloid Leukemia/Ovarian<br>Cancer                           |
| Immunex                                             | Novantrone                           | Mitoxantrone                         | Pain related to hormone<br>refractory prostate cancer.       |
| Warner Lambert                                      | Metaret                              | Suramin                              | Prostate                                                     |
| Genentech                                           | Anti-VEGF                            | Anti-VEGF                            | Prostate / Breast / Colorectal<br>/ NSCL Cancer              |
| British Biotech                                     | Batimastat                           | Batimastat (BB94)                    | Pterygium                                                    |
| Eisai                                               | E 7070                               | E 7070                               | Solid Tumors                                                 |
| Biochem<br>Pharma                                   | BCH-4556                             | BCH-4556                             | Solid Tumors                                                 |
| Sankyo                                              | CS-682                               | CS-682                               | Solid Tumors                                                 |
| Agouron                                             | AG2037                               | AG2037                               | Solid Tumors                                                 |
| IDEC Pharma                                         | 9-AC                                 | 9-AC                                 | Solid Tumors                                                 |
| Agouron                                             | VEGF/b-FGF Inhibitors                | VEGF/b-FGF Inhibitors                | Solid Tumors                                                 |
| Agouron                                             | AG3340                               | AG3340                               | Solid Tumors / Macular                                       |



- 112 -

|                      |                      |                        |                                                        |
|----------------------|----------------------|------------------------|--------------------------------------------------------|
|                      |                      |                        | Degen                                                  |
| Vertex               | Incel                | VX-710                 | Solid Tumors - IV                                      |
| Vertex               | VX-853               | VX-853                 | Solid Tumors - Oral                                    |
| Zeneca               | ZD 0101 (inj)        | ZD 0101                | Solid Tumors                                           |
| Novartis             | ISI 641              | ISI 641                | Solid Tumors                                           |
| Novartis             | ODN 698              | ODN 698                | Solid Tumors                                           |
| Tanabe Seiyaku       | TA 2516              | Marimistat             | Solid Tumors                                           |
| British Biotech      | Marimastat           | Marimastat (BB 2516)   | Solid Tumors                                           |
| Celltech             | CDP 845              | Aggrecanase Inhibitor  | Solid Tumors / Breast Cancer                           |
| Chiroscience         | D2163                | D2163                  | Solid Tumors / Metastases                              |
| Warner Lambert       | PD 183805            | PD 183805              |                                                        |
| Daiichi              | DX8951f              | DX8951f                | Anti-Cancer                                            |
| Daiichi              | Lemonal DP 2202      | Lemonal DP 2202        | Anti-Cancer                                            |
| Fujisawa             | FK 317               | FK 317                 | Anticancer Antibiotic                                  |
| Chugai               | Picibanil            | OK-432                 | Antimalignant Tumor                                    |
| Nycomed Amersham     | AD 32/valrubicin     | Valrubicin             | Bladder Cancer-Refractory Insitu Carcinoma             |
| Nycomed Amersham     | Metastron            | Strontium Derivative   | Bone Cancer (adjunct therapy, Pain)                    |
| Schering Plough      | Temodal              | Temozolomide           | Brain Tumours                                          |
| Schering Plough      | Temodal              | Temozolonide           | Brain Tumours                                          |
| Liposome             | Evacet               | Doxorubicin, Liposomal | Breast Cancer                                          |
| Nycomed Amersham     | Yewtaxan             | Paclitaxel             | Breast Cancer Advanced, Ovarian Cancer Advanced        |
| Bristol Myers Squibb | Taxol                | Paclitaxel             | Breast Cancer Advanced, Ovarian Cancer Advanced, NSCLC |
| Roche                | Xeloda               | Capecitabine           | Breast Cancer, Colorectal Cancer                       |
| Roche                | Furtulon             | Doxifluridine          | Breast Cancer, Colorectal Cancer, Gastric Cancer       |
| Pharmacia & Upjohn   | Adriamycin           | Doxorubicin            | Breast Cancer, Leukemia                                |
| Ivax                 | Cyclopax             | Paclitaxel, Oral       | Breast/Ovarian Cancer                                  |
| Rhone Poulenc        | Oral Taxoid          | Oral Taxoid            | Broad Cancer                                           |
| AHP                  | Novantrone           | Mitoxantrone           | Cancer                                                 |
| Sequus               | SPI-077              | Cisplatin, Stealth     | Cancer                                                 |
| Hoechst              | HMR 1275             | Flavopiridol           | Cancer                                                 |
| Pfizer               | CP-358, 774          | EGFR                   | Cancer                                                 |
| Pfizer               | CP-609, 754          | RAS Oncogene Inhibitor | Cancer                                                 |
| Bristol Myers Squibb | BMS-182751           | Oral Platinum          | Cancer (Lung, Ovarian)                                 |
| Bristol Myers Squibb | UFT (Tegafur/Uracil) | UFT (Tegafur/Uracil)   | Cancer Oral                                            |
| Johnson & Johnson    | Ergamisol            | Levamisole             | Cancer Therapy                                         |
| Glaxo Wellcome       | Eniluracil/776C85    | 5FU Enhancer           | Cancer, Refractory Solid & Colorectal Cancer           |
| Johnson & Johnson    | Ergamisol            | Levamisole             | Colon Cancer                                           |
| Rhone Poulenc        | Campto               | Irinotecan             | Colorectal Cancer, Cervical Cancer                     |
| Pharmacia & Upjohn   | Camptosar            | Irinotecan             | Colorectal Cancer, Cervical Cancer                     |
| Zeneca               | Tomudex              | Ralitrexed             | Colorectal Cancer, Lung                                |



- 113 -

|                          |                                  |                        |                                                                                  |
|--------------------------|----------------------------------|------------------------|----------------------------------------------------------------------------------|
|                          |                                  |                        | Cancer, Breast Cancer<br>Hairy Cell Leukaemia                                    |
| Johnson & Johnson        | Leustain                         | Cladribine             |                                                                                  |
| Ivax                     | Paxene                           | Paclitaxel             | Kaposi Sarcoma                                                                   |
| Sequus                   | Doxil                            | Doxorubicin, Liposomal | KS/Cancer                                                                        |
| Sequus                   | Caelyx                           | Doxorubicin, Liposomal | KS/Cancer                                                                        |
| Schering AG              | Fludara                          | Fludarabine            | Leukaemia                                                                        |
| Pharmacia & Upjohn       | Pharmorubicin                    | Epirubicin             | Lung/Breast Cancer                                                               |
| Chiron                   | DepoCyt                          | DepoCyt                | Neoplastic Meningitis                                                            |
| Zeneca                   | ZD1839                           | ZD 1839                | Non Small Cell Lung<br>Cancer, Pancreatic Cancer                                 |
| BASF                     | LU 79553                         | Bis-Naphtalimide       | Oncology                                                                         |
| BASF                     | LU 103793                        | Dolastain              | Oncology                                                                         |
| Shering Plough           | Caetyx                           | Doxorubicin-Liposome   | Ovarian/Breast Cancer                                                            |
| Lilly                    | Gemzar                           | Gemcitabine            | Pancreatic Cancer, Non<br>Small Cell Lung Cancer,<br>Breast, Bladder and Ovarian |
| Zeneca                   | ZD 0473/Anormed                  | ZD 0473/Anormed        | Platinum based NSCL,<br>ovarian etc.                                             |
| Yamanouchi               | YM 116                           | YM 116                 | Prostate Cancer                                                                  |
| Nycomed<br>Amersham      | Seeds/I-125 Rapid St             | Lodine Seeds           | Prostate Cancer                                                                  |
| Agouron                  | Cdk4/cdk2 inhibitors             | cdk4/cdk2 inhibitors   | Solid Tumors                                                                     |
| Agouron                  | PARP inhibitors                  | PARP Inhibitors        | Solid Tumors                                                                     |
| Chiroscience             | D4809                            | Dexifosamide           | Solid Tumors                                                                     |
| Bristol Myers<br>Squibb  | UFT (Tegafur/Uracil)             | UFT (Tegafur/Uracil)   | Solid Tumors                                                                     |
| Sankyo                   | Krestin                          | Krestin                | Solid Tumors                                                                     |
| Asta Medica              | Ifex/Mesnex                      | Ifosamide              | Solid Tumors                                                                     |
| Bristol Meyers<br>Squibb | Ifex/Mesnex                      | Ifosamide              | Solid Tumors                                                                     |
| Bristol Myers<br>Squibb  | Vumon                            | Teniposide             | Solid Tumors                                                                     |
| Bristol Myers<br>Squibb  | Paraplatin                       | Carboplatin            | Solid Tumors                                                                     |
| Bristol Myers<br>Squibb  | Plantinol                        | Cisplatin, Stealth     | Solid Tumors                                                                     |
| Bristol Myers<br>Squibb  | Plantinol                        | Cisplatin              | Solid Tumors                                                                     |
| Bristol Myers<br>Squibb  | Vepeside                         | Etoposide              | Solid Tumors Melanoma                                                            |
| Zeneca                   | ZD 9331                          | ZD 9331                | Solid Tumors, Advanced<br>Colorectal                                             |
| Chugai                   | Taxotere                         | Docetaxel              | Solid Tumors, Breast Cancer                                                      |
| Rhone Poulenc            | Taxotere                         | Docetaxel              | Solid Tumors, Breast Cancer                                                      |
| Glaxo Wellcome           | Prodrug of guanine<br>arabinside | Prodrug of arabinside  | T Cell Leukemia/Lymphoma<br>& B Cell Neoplasm                                    |
| Bristol Myers<br>Squibb  | Taxane Analog                    | Taxane Analog          | Taxol follow up                                                                  |

In one embodiment, the methods of the invention use immunostimulatory nucleic acids as a replacement to the use of IFN $\alpha$  therapy in the treatment of cancer. Currently, some treatment protocols call for the use of IFN $\alpha$ . Since IFN $\alpha$  is produced following the



- 114 -

administration of some immunostimulatory nucleic acids, these nucleic acids can be used to generate IFN $\alpha$  endogenously.

The invention also includes a method for inducing antigen non-specific innate immune activation and broad spectrum resistance to infectious challenge using the immunostimulatory nucleic acids. The term antigen non-specific innate immune activation as used herein refers to the activation of immune cells other than B cells and for instance can include the activation of NK cells, T cells or other immune cells that can respond in an antigen independent fashion or some combination of these cells. A broad spectrum resistance to infectious challenge is induced because the immune cells are in active form and are primed to respond to any invading compound or microorganism. The cells do not have to be specifically primed against a particular antigen. This is particularly useful in biowarfare, and the other circumstances described above such as travelers.

The stimulation index of a particular immunostimulatory nucleic acid can be tested in various immune cell assays. Preferably, the stimulation index of the immunostimulatory nucleic acid with regard to B cell proliferation is at least about 5, preferably at least about 10, more preferably at least about 15 and most preferably at least about 20 as determined by incorporation of  $^3\text{H}$  uridine in a murine B cell culture, which has been contacted with 20  $\mu\text{M}$  of nucleic acid for 20h at 37°C and has been pulsed with 1  $\mu\text{Ci}$  of  $^3\text{H}$  uridine; and harvested and counted 4h later as described in detail in PCT Published Patent Applications PCT/US95/01570 (WO 96/02555) and PCT/US97/19791 (WO 98/18810) claiming priority to U.S. Serial Nos. 08/386,063 and 08/960,774, filed on February 7, 1995 and October 30, 1997 respectively. For use *in vivo*, for example, it is important that the immunostimulatory nucleic acids be capable of effectively inducing an immune response, such as, for example, antibody production.

Immunostimulatory nucleic acids are effective in non-rodent vertebrate. Different immunostimulatory nucleic acid can cause optimal immune stimulation depending on the type of subject and the sequence of the immunostimulatory nucleic acid. Many vertebrates have been found according to the invention to be responsive to the same class of immunostimulatory nucleic acids, sometimes referred to as human specific immunostimulatory nucleic acids. Rodents, however, respond to different nucleic acids. As shown herein an immunostimulatory nucleic acid causing optimal



- 115 -

stimulation in humans may not generally cause optimal stimulation in a mouse and vice versa. An immunostimulatory nucleic acid causing optimal stimulation in humans often does, however, cause optimal stimulation in other animals such as cow, horses, sheep, etc. One of skill in the art can identify the optimal nucleic acid sequences useful for a particular species of interest using routine assays described herein and/or known in the art, using the guidance supplied herein.

The immunostimulatory nucleic acids may be directly administered to the subject or may be administered in conjunction with a nucleic acid delivery complex. A nucleic acid delivery complex shall mean a nucleic acid molecule associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell (e.g., B cell surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor). Preferred complexes may be sufficiently stable *in vivo* to prevent significant uncoupling prior to internalization by the target cell. However, the complex can be cleavable under appropriate conditions within the cell so that the nucleic acid is released in a functional form.

Delivery vehicles or delivery devices for delivering antigen and nucleic acids to surfaces have been described. The Immunostimulatory nucleic acid and/or the antigen and/or other therapeutics may be administered alone (e.g., in saline or buffer) or using any delivery vehicles known in the art. For instance the following delivery vehicles have been described: Cochleates (Gould-Fogerite et al., 1994, 1996); Emulsomes (Vancott et al., 1998, Lowell et al., 1997); ISCOMs (Mowat et al., 1993, Carlsson et al., 1991, Hu et al., 1998, Morein et al., 1999); Liposomes (Childers et al., 1999, Michalek et al., 1989, 1992, de Haan 1995a, 1995b); Live bacterial vectors (e.g., *Salmonella*, *Escherichia coli*, *Bacillus calmatte-guerin*, *Shigella*, *Lactobacillus*) (Hone et al., 1996, Pouwels et al., 1998, Chatfield et al., 1993, Stover et al., 1991, Nugent et al., 1998); Live viral vectors (e.g., Vaccinia, adenovirus, Herpes Simplex) (Gallichan et al., 1993, 1995, Moss et al., 1996, Nugent et al., 1998, Flexner et al., 1988, Morrow et al., 1999); Microspheres (Gupta et al., 1998, Jones et al., 1996, Maloy et al., 1994, Moore et al., 1995, O'Hagan et al., 1994, Eldridge et al., 1989); Nucleic acid vaccines (Fynan et al., 1993, Kuklin et al.,



- 116 -

1997, Sasaki et al., 1998, Okada et al., 1997, Ishii et al., 1997); Polymers (e.g. carboxymethylcellulose, chitosan) (Hamajima et al., 1998, Jabbal-Gill et al., 1998); Polymer rings (Wyatt et al., 1998); Proteosomes (Vancott et al., 1998, Lowell et al., 1988, 1996, 1997); Sodium Fluoride (Hashi et al., 1998); Transgenic plants (Tacket et al., 1998, Mason et al., 1998, Haq et al., 1995); Virosomes (Gluck et al., 1992, Mengiardi et al., 1995, Cryz et al., 1998); Virus-like particles (Jiang et al., 1999, Leibl et al., 1998). Other delivery vehicles are known in the art and some additional examples are provided below in the discussion of vectors.

The term effective amount of a immunostimulatory nucleic acid refers to the amount necessary or sufficient to realize a desired biologic effect. For example, an effective amount of a immunostimulatory nucleic acid for inducing mucosal immunity is that amount necessary to cause the development of IgA in response to an antigen upon exposure to the antigen, whereas that amount required for inducing systemic immunity is that amount necessary to cause the development of IgG in response to an antigen upon exposure to the antigen. Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular immunostimulatory nucleic acid being administered, the antigen, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular immunostimulatory nucleic acid and/or antigen and/or other therapeutic agent without necessitating undue experimentation.

Subject doses of the compounds described herein for mucosal or local delivery typically range from about 0.1  $\mu$ g to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically mucosal or local doses range from about 10  $\mu$ g to 5 mg per administration, and most typically from about 100  $\mu$ g to 1 mg, with 2 - 4 administrations being spaced days or weeks apart. More typically, immune stimulant



- 117 -

doses range from 1  $\mu$ g to 10 mg per administration, and most typically 10 $\mu$ g to 1 mg, with daily or weekly administrations. Subject doses of the compounds described herein for parenteral delivery for the purpose of inducing an antigen-specific immune response, wherein the compounds are delivered with an antigen but not another therapeutic agent are typically 5 to 10,000 times higher than the effective mucosal dose for vaccine adjuvant or immune stimulant applications, and more typically 10 to 1,000 times higher, and most typically 20 to 100 times higher. Doses of the compounds described herein for parenteral delivery for the purpose of inducing an innate immune response or for increasing ADCC or for inducing an antigen specific immune response when the immunostimulatory nucleic acids are administered in combination with other therapeutic agents or in specialized delivery vehicles typically range from about 0.1  $\mu$ g to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically parenteral doses for these purposes range from about 10  $\mu$ g to 5 mg per administration, and most typically from about 100  $\mu$ g to 1 mg, with 2 - 4 administrations being spaced days or weeks apart. In some embodiments, however, parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.

For any compound described herein the therapeutically effective amount can be initially determined from animal models. A therapeutically effective dose can also be determined from human data for CpG oligonucleotides which have been tested in humans (human clinical trials have been initiated) and for compounds which are known to exhibit similar pharmacological activities, such as other mucosal adjuvants, e.g., LT and other antigens for vaccination purposes, for the mucosal or local administration. Higher doses are required for parenteral administration. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

The formulations of the invention are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.



- 118 -

For use in therapy, an effective amount of the immunostimulatory nucleic acid can be administered to a subject by any mode that delivers the nucleic acid to the desired surface, e.g., mucosal, systemic. Administering the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan.

- 5 Preferred routes of administration include but are not limited to oral, parenteral, intramuscular, intranasal, intratracheal, inhalation, ocular, vaginal, and rectal.

For oral administration, the compounds (i.e., immunostimulatory nucleic acids, antigens and other therapeutic agents) can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.

15 Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the

20 cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer

25 solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules

30 made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as



- 119 -

talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

Microspheres formulated for oral administration may also be used. Such microspheres  
5 have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present  
10 invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of  
15 *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form,  
20 *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous  
25 solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such  
30 as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.



- 120 -

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such  
5 as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example,  
10 as a sparingly soluble salt.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

15 Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets,  
20 (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of  
25 drug delivery systems. For a brief review of methods for drug delivery, see Langer, *Science* 249:1527-1533, 1990, which is incorporated herein by reference.

The immunostimulatory nucleic acids and optionally other therapeutics and/or antigens may be administered *per se* (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable,  
30 but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric,



- 121 -

phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

5           Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

10           The pharmaceutical compositions of the invention contain an effective amount of a Immunostimulatory nucleic acid and optionally antigens and/or other therapeutic agents optionally included in a pharmaceutically-acceptable carrier. The term pharmaceutically-acceptable carrier means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or  
15 other vertebrate animal. The term carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired  
20 pharmaceutical efficiency.

The immunostimulatory nucleic acids useful in the invention may be delivered in mixtures with additional adjuvant(s), other therapeutics, or antigen(s). A mixture may consist of several adjuvants in addition to the Immunostimulatory nucleic acid or several antigens or other therapeutics.

25           A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular adjuvants or antigen selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an  
30 immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed above.



- 122 -

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the compounds into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, purpose of the immunization (i.e., prophylactic or therapeutic), nature and severity of the disorder, age and body weight of the patient, different doses may be necessary. The administration of a given dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units. Multiple administration of doses at specific intervals of weeks or months apart is usual for boosting the antigen-specific responses.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di-and tri-glycerides; hydrogel release systems; systatic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.



- 123 -

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby  
5 expressly incorporated by reference.

### Examples

#### ***Materials and Methods:***

**Oligodeoxynucleotides:** Native phosphodiester and phosphorothioate-modified ODN were purchased from Operon Technologies (Alameda, CA) and Hybridon  
10 Specialty Products (Milford, MA). ODN were tested for endotoxin using the LAL-assay (LAL-assay BioWhittaker, Walkersville, MD; lower detection limit 0.1 EU/ml). For *in vitro* assays, ODN were diluted in TE-buffer (10 mM Tris, pH 7.0, 1 mM EDTA), and stored at -20° C. For *in vivo* use, ODN were diluted in phosphate buffered saline (0.1 M PBS, pH 7.3) and stored at 4°C. All dilutions were carried out using pyrogen-free  
15 reagents.

**Isolation of human PBMC and cell culture:** Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers by Ficoll-Paque density gradient centrifugation (Histopaque-1077, Sigma Chemical Co., St. Louis, MO) as described (Hartmann et al., 1999 Proc. Natl. Acad. Sci USA 96:9305-10). Cells were  
20 suspended in RPMI 1640 culture medium supplemented with 10% (v/v) heat-inactivated (56°C, 1 h) FCS (HyClone, Logan, UT), 1.5 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all from Gibco BRL, Grand Island, NY) (complete medium). Cells (final concentration  $1 \times 10^6$  cells/ml) were cultured in complete medium in a 5% CO<sub>2</sub> humidified incubator at 37°C. ODN and LPS (from *Salmonella typhimurium*, Sigma  
25 Chemical Co., St. Louis, MO) or anti-IgM were used as stimuli. For measurement of human NK lytic activity, PBMC were incubated at  $5 \times 10^6$ /well in 24-well plates. Cultures were harvested after 24 hours, and cells were used as effectors in a standard 4 hours <sup>51</sup>Cr-release assay against K562 target cells as previously described (Ballas et al., 1996 J. Immunol. 157:1840-1845). For B cell proliferation, 1 µCi of <sup>3</sup>H thymidine was  
30 added 18 hours before harvest, and the amount of <sup>3</sup>H thymidine incorporation was determined by scintillation counting at day 5. Standard deviations of the triplicate wells were < 5%.



- 124 -

**Flow cytometry on human PBMC:** Surface antigens on primate PBMC were stained as previously described (Hartmann et al., 1998 J. Pharmacol. Exp. Ther. 285:920-928). Monoclonal antibodies to CD3 (UCHT1), CD14 (M5E2), CD19 (B43), CD56 (B159), CD69 (FN50) and CD86 (2331 [FUN-1]) were purchased from Pharmingen, San Diego, CA. IgG<sub>1</sub>, $\kappa$  (MOPC-21) and IgG<sub>2b</sub>, $\kappa$  (Hartmann et al., 1999 Proc. Natl. Acad. Sci USA 96:9305-10) were used to control for non-specific staining. NK cells were identified by CD56 expression on CD3, CD14 and CD19 negative cells, whereas B cells were identified by expression of CD19. Flow cytometric data of 10000 cells per sample were acquired on a FACScan (Beckton Dickinson Immunocytometry Systems, San Jose, CA). The viability of cells within the FSC/SSC gate used for analysis was examined by propidium iodide staining (2  $\mu$ g/ml) and found to be higher than 98%. Data were analyzed using the computer program FlowJo (version 2.5.1, Tree Star, Inc., Stanford, CA).

**Results:**

*Example 1: CpG-dependent stimulation of human B cells depends on methylation and ODN length.*

Human PBMC were obtained from normal donors and cultured for five days at  $2 \times 10^5$  cells/well with the indicated concentrations of the indicated ODN sequences. As shown in Table F, human PBMCs proliferate above the background when cultured with a variety of different CpG ODN, but also show some proliferation even with ODN that do not contain any CpG motifs. The importance of unmethylated CpG motifs in providing optimal immune stimulation with these ODN is demonstrated by the fact that ODN 1840 (SEQ ID NO. 83) induces 56,603 counts of <sup>3</sup>H-thymidine incorporation whereas the same T-rich ODN with the CpG motifs methylated (non-CpG), 1979 (SEQ ID NO. 222), induces lower, but still increased over background, activity (only 18,618 counts) at the same concentration of 0.6  $\mu$ g/ml. The reduced proliferation at higher ODN concentrations may be an artifact of the cells becoming exhausted under these experimental conditions or could reflect some toxicity of the higher ODN concentrations. Interestingly, shorter ODN containing CpG motifs, such as the 13-14 mers 2015 and 2016, are less stimulatory despite the fact that their molar concentration would actually be higher since the ODNs were added on the basis of mass rather than molarity. This demonstrates that ODN length may also be an important determinant in the immune



- 125 -

effects of the ODN. A non-CpG ODN but slight T-rich ODN (about 30% T), 1982 (SEQ ID NO. 225), caused only a small amount of background cell proliferation.

**Table F**

| <b>Oligo Concentration</b> |                   |                  |                |
|----------------------------|-------------------|------------------|----------------|
| <b>ODN#</b>                | <b>0.15 µg/ml</b> | <b>0.6 µg/ml</b> | <b>2 µg/ml</b> |
| Cues only                  | 648               | 837              | 799            |
| 1840<br>(SEQ ID NO. 83)    | 5744              | 56,603           | 31,787         |
| 2016<br>(SEQ ID NO. 256)   | 768               | 4607             | 20,497         |
| 1979<br>(SEQ ID NO. 222)   | 971               | 18,618           | 29,246         |
| 1892<br>(SEQ ID NO. 135)   | 787               | 10,078           | 22,850         |
| 2010<br>(SEQ ID NO. 250)   | 849               | 20,741           | 8,054          |
| 2012<br>(SEQ ID NO. 252)   | 2586              | 62,955           | 52,462         |
| 2013<br>(SEQ ID NO. 253)   | 1043              | 47,960           | 47,231         |
| 2014<br>(SEQ ID NO. 254)   | 2700              | 50,708           | 46,625         |
| 2015<br>(SEQ ID NO. 255)   | 1059              | 23,239           | 36,119         |

Numbers represent cpm of <sup>3</sup>H-thymidine incorporation for cultures of human  
5 PBMCs set up as described above.

*Example 2. Concentration-dependent activation of human NK cell activity with thymidine-rich ODN.*



- 126 -

Human PBMCs were cultured for 24 hours with a panel of different CpG or non-CpG ODN at two different concentrations, and then tested for their ability to kill NK target cells as described previously (Ballas et al., 1996 J. Immunol. 157:1840-1845). Killing is measured as lytic units, or L.U. The human donor used in this experiment had a background level of 3.69 L.U. which increased to 180.36 L.U. using the positive control, IL-2. A CpG oligo, 2006 (SEQ ID NO. 246), induced high levels of NK lytic function at a low concentration of 0.6, and a lower level at a concentration of 6.0. Surprisingly, a T-rich ODN in which the CpG motifs of 2006 were methylated (ODN at 2117 (SEQ ID NO. 358)) or inverted to GpCs (ODN 2137 (SEQ ID NO. 886)) retained strong immune stimulatory function at the higher ODN concentrations, as shown in Table G. These concentration-dependent immune stimulatory effects are not a general property of the phosphorothioate backbone since the experiments described below demonstrate that a poly-A ODN, is nonstimulatory above background levels. Some stimulation is seen with a 24-base long ODN in which all of the base positions are randomized so that A, C, G, and T will occur at a frequency of 25% in each of the base positions (ODN 2182 (SEQ ID NO. 432)). However, the stimulatory effect of such a 24-base ODN is greatly enhanced if it is pure poly-T, in which case stimulation is also seen at the lowest concentration of 0.6  $\mu$ g/ml (ODN 2183 (SEQ ID NO. 433)). In fact, the stimulatory activity of ODN SEQ ID NO. 433 at this low concentration is higher than that of any other ODN tested at this low concentration, aside from the optimal human immune stimulatory ODN of SEQ ID NO. 246. In fact, the higher concentration of ODN SEQ ID NO. 433 stimulated more NK activity than any other phosphorothioate ODN except for the strong CpG ODN 2142 (SEQ ID NO. 890), which was marginally higher. If the G content of ODN SEQ ID NO. 246 is increased relative to the T content by addition of more Gs, thus resulting in a decrease in the proportion of T nucleotides the immune stimulatory effect of the ODN is reduced (see ODN 2132 (SEQ ID NO. 373)). Thus, the T content of an ODN is an important determinant of its immune stimulatory effect. Although a poly-T ODN is the most stimulatory of the non-CpG ODN, other bases are also important in determining the immune stimulatory effect of a non-CpG ODN. ODN 2131 (SEQ ID NO. 372), in which slightly more than half of the bases are T and in which there are no Gs, is immune stimulatory at a concentration of 6  $\mu$ g/ml but has less activity than other T-rich ODN. If the 6 A's in ODN 2131 (SEQ ID NO. 372)



- 127 -

are replaced by 6 Gs, the immune stimulatory effect of the ODN can be increased (see ODN 2130 (SEQ ID NO. 371)).

**Table G*****HUMAN PBL CULTURED OVERNIGHT WITH OLIGOS***

|                     |       |       |       |        |       |       |               |
|---------------------|-------|-------|-------|--------|-------|-------|---------------|
| MR                  | 3605  |       |       |        |       |       |               |
| SR                  | 256   |       |       |        |       |       |               |
| %SR                 | 7.11  |       |       |        |       |       |               |
| EFFECTOR            | 0.63  | 1.25  | 2.50  | 5.00   | 10.00 | 20.00 |               |
| <b>CONTROL [RM]</b> |       |       |       |        |       |       | <b>L.U.</b>   |
| ALONE               | 2.65  | 5.45  | 10.15 | 17.65  | 29.92 | 39.98 | <b>3.69</b>   |
| + IL2 (100 U/ml)    | 35.95 | 57.66 | 86.26 | 100.39 | 99.71 | 93.64 | <b>180.36</b> |
| + 1585 (0.6 ug/ml)  | 3.75  | 6.10  | 12.14 | 23.70  | 36.06 | 43.98 | <b>5.48</b>   |
| + 1585 (6.0 ug/ml)  | 15.42 | 31.09 | 47.07 | 73.34  | 94.29 | 97.73 | <b>35.85</b>  |
| + 2006 (0.6 ug/ml)  | 6.71  | 15.99 | 26.92 | 44.75  | 64.12 | 68.83 | <b>16.96</b>  |
| + 2006 (6.0 ug/ml)  | 6.19  | 8.18  | 16.13 | 24.35  | 39.35 | 56.07 | <b>8.04</b>   |
| + 2117 (0.6 ug/ml)  | 4.54  | 4.73  | 9.56  | 18.04  | 28.57 | 39.85 | <b>3.49</b>   |
| + 2117 (6.0 ug/ml)  | 7.03  | 10.76 | 16.90 | 30.59  | 52.14 | 59.46 | <b>10.96</b>  |
| + 2137 (0.6 ug/ml)  | 4.61  | 5.35  | 10.04 | 15.16  | 23.79 | 37.86 | <b>2.57</b>   |
| + 2137 (6.0 ug/ml)  | 7.99  | 10.37 | 16.55 | 32.32  | 49.78 | 60.30 | <b>11.01</b>  |
| + 2178 (0.6 ug/ml)  | 2.88  | 4.52  | 11.47 | 16.05  | 24.85 | 34.27 | <b>2.37</b>   |
| + 2178 (6.0 ug/ml)  | 4.21  | 5.03  | 11.16 | 16.39  | 28.22 | 36.45 | <b>2.94</b>   |
| + 2182 (0.6 ug/ml)  | 2.42  | 6.57  | 10.49 | 19.73  | 26.55 | 35.30 | <b>2.89</b>   |
| + 2182 (6.0 ug/ml)  | 4.11  | 7.98  | 14.60 | 26.56  | 40.40 | 51.98 | <b>7.59</b>   |



WO 01/22972

PCT/US00/26383

- 128 -

|                    |      |       |       |       |       |       |              |
|--------------------|------|-------|-------|-------|-------|-------|--------------|
| + 2183 (0.6 ug/ml) | 3.73 | 8.46  | 15.52 | 24.48 | 37.78 | 56.77 | <b>7.80</b>  |
| + 2183 (0.6 ug/ml) | 8.86 | 12.89 | 23.08 | 41.49 | 66.26 | 75.85 | <b>16.57</b> |
| + 2140 (0.6 ug/ml) | 3.78 | 5.27  | 12.30 | 20.79 | 35.75 | 45.62 | <b>5.40</b>  |
| + 2140 (6.0 ug/ml) | 6.56 | 13.24 | 21.26 | 37.96 | 60.80 | 73.05 | <b>14.82</b> |
| + 2141 (0.6 ug/ml) | 2.63 | 6.34  | 10.21 | 17.73 | 30.93 | 43.57 | <b>4.29</b>  |
| + 2141 (6.0 ug/ml) | 4.98 | 15.30 | 25.22 | 37.88 | 58.47 | 69.12 | <b>14.83</b> |
| + 2142 (0.6 ug/ml) | 3.18 | 3.66  | 6.99  | 14.62 | 19.68 | 32.52 | <b>1.56</b>  |
| + 2142 (6.0 ug/ml) | 7.08 | 15.80 | 25.65 | 41.72 | 68.09 | 73.14 | <b>17.11</b> |
| + 2143 (0.6 ug/ml) | 4.12 | 6.90  | 10.77 | 22.96 | 35.78 | 42.94 | <b>5.19</b>  |
| + 2143 (6.0 ug/ml) | 3.16 | 8.40  | 12.38 | 21.69 | 34.80 | 54.21 | <b>6.64</b>  |
| + 2159 (6.0 ug/ml) | 5.05 | 11.76 | 21.67 | 41.12 | 51.68 | 65.47 | <b>13.19</b> |
| + 2132 (6.0 ug/ml) | 4.23 | 6.06  | 10.50 | 18.74 | 32.68 | 44.06 | <b>4.61</b>  |
| + 2179 (6.0 ug/ml) | 6.14 | 9.49  | 21.06 | 42.48 | 60.12 | 71.87 | <b>14.54</b> |
| + 2180 (6.0 ug/ml) | 2.37 | 8.57  | 15.44 | 29.66 | 44.35 | 61.31 | <b>9.47</b>  |
| + 2133 (6.0 ug/ml) | 6.53 | 12.58 | 23.10 | 38.03 | 61.16 | 68.36 | <b>14.62</b> |
| + 2134 (6.0 ug/ml) | 7.51 | 12.14 | 21.14 | 32.46 | 54.47 | 67.12 | <b>12.98</b> |
| + 2184 (6.0 ug/ml) | 5.22 | 9.19  | 17.54 | 30.76 | 45.35 | 63.55 | <b>10.42</b> |
| + 2185 (6.0 ug/ml) | 8.11 | 14.77 | 26.27 | 40.31 | 55.61 | 70.65 | <b>15.60</b> |
| + 2116 (6.0 ug/ml) | 5.58 | 10.54 | 16.77 | 37.82 | 59.80 | 66.33 | <b>13.07</b> |
| + 2181 (6.0 ug/ml) | 4.43 | 9.85  | 17.55 | 27.05 | 53.16 | 69.16 | <b>11.43</b> |
| + 2130 (6.0 ug/ml) | 3.81 | 8.07  | 17.11 | 27.17 | 42.04 | 53.73 | <b>8.27</b>  |



- 129 -

|                    |      |       |       |       |       |       |              |
|--------------------|------|-------|-------|-------|-------|-------|--------------|
| + 2131 (6.0 ug/ml) | 2.29 | 6.73  | 7.30  | 18.02 | 32.73 | 49.06 | <b>5.08</b>  |
| + 2156 (0.3 ug/ml) | 2.50 | 5.26  | 8.20  | 15.95 | 26.64 | 33.07 | <b>2.31</b>  |
| + 2156 (1.0 ug/ml) | 5.91 | 10.99 | 17.31 | 26.97 | 50.64 | 63.78 | <b>10.84</b> |
| + 2157 (0.3 ug/ml) | 2.36 | 4.00  | 6.65  | 12.94 | 24.13 | 38.86 | <b>2.58</b>  |
| + 2157 (1.0 ug/ml) | 3.72 | 9.55  | 17.15 | 34.55 | 52.27 | 65.33 | <b>11.58</b> |
| + 2158 (0.3 ug/ml) | 1.25 | 2.36  | 6.90  | 16.39 | 15.63 | 29.82 | <b>1.17</b>  |
| + 2158 (1.0 ug/ml) | 4.73 | 7.26  | 11.07 | 15.55 | 30.80 | 43.71 | <b>4.16</b>  |
| + 2118 (0.6 ug/ml) | 1.55 | 3.38  | 6.85  | 13.36 | 20.15 | 27.71 | <b>1.13</b>  |
| + 2118 (6.0 ug/ml) | 2.65 | 3.88  | 9.29  | 12.19 | 22.47 | 28.99 | <b>1.34</b>  |

*Example 3: Induction of B cell proliferation by T-rich non-CpG ODN.*

To assess the ability of T-rich ODN to activate B cell proliferation, human PBMCs were stained with the cytoplasmic dye CFSE, incubated with five days with the indicated ODN at either 0.15 or 0.3 ug/ml, and then analyzed by flow cytometry. B cells were identified by gating on cells positive for the lineage marker CD19). CpG ODN 2006 was a strong inducer of B cell proliferation, and this effect was reduced if the CpG motifs were methylated or inverted to GpC as shown in Figure 1 at an ODN concentration of 0.3 ug/ml. The base composition of the ODN appears to be important in determining the immune stimulatory effect. Reducing the T content of an ODN substantially reduces immune stimulatory effect, as exemplified by ODN 2177 (SEQ ID NO. 427) in which 6 of the Ts present in ODN 2137 (SEQ ID NO. 886) have been switched to A's, resulting in a greatly reduced immune stimulatory effect. The importance of T's in the immune stimulatory effect of an ODN is also shown by comparison of ODN 2116 (SEQ ID NO. 357) and 2181 (SEQ ID NO. 431), which differ in the 3' end of the ODN. ODN 2181, in which the 3' end is poly-T is more stimulatory



- 130 -

than ODN 2116, in which the 3' end is poly-C, despite the fact that both ODN have a TCGTCG at the 5' end.

*Example 4: B Cell Proliferation Induced by TG Oligonucleotides*

The stimulatory effects of TG motifs are shown in Figure 2. ODN 2137 has the  
5 identical base composition as ODN 2006, but the CG motifs have all been inverted to  
GC's resulting in a CG-free nucleic acid. ODN does however contain 6 TG  
dinucleotides. In ODN 2177, all the TG dinucleotides of ODN 2137 have been changed  
to AG. Although ODN 2177 contains only 6 adenines, it is virtually nonstimulatory at a  
concentration of 0.2 µg/ml. For comparison, an ODN 24 bases in length in which each  
10 position is randomized to be any of the four bases (ODN 2182) induces > 12% of B cells  
to proliferate at a concentration of 0.2 µg/ml. These results indicate that the stimulatory  
effects of ODN 2137 are not simply those of a phosphorothioate backbone, but relate to  
the presence of TG dinucleotides.

In order to determine the effect of varying the number of TG dinucleotide motifs,  
15 ODN 2200 and ODN 2202 were compared, as shown in Figure 2. Both ODN contain 18  
Ts and 6 Gs, but in ODN 2200 all of the Gs are consecutive, so that there is only one TG  
dinucleotide, whereas in ODN 2202, the Gs are split up as GG dinucleotides throughout  
the ODN so that there are three TGs. ODN 2202 is significantly more stimulatory than  
ODN 2200, consistent with the model that at least three TG motifs in an ODN are  
20 required for optimal stimulatory activity. It is likely that even higher levels of  
stimulation could be achieved if the TG motifs had been optimized as taught herein.

*Example 5: Effects of TTG versus TTG motifs.*

Figure 3 shows the results of experiments conducted to study TG content in terms  
of the relative levels of Ts versus Gs as it relates to the stimulatory effect of an ODN.  
25 The Figure shows that an ODN in which all of the bases are randomized to be either T or  
G (ODN 2188 (SEQ ID NO. 905)) is nonstimulatory at a concentration of 0.2 µg/ml,  
similar to an ODN in which all of the bases are randomized to be either A or G (ODN  
2189 (SEQ ID NO. 906)). However, at the higher concentration of 2 µg/ml, the  
randomized T/G ODN 2188 is significantly more stimulatory. This latter level of  
30 stimulation is still lower than that which occurs with a totally randomized ODN (ODN  
2182 (SEQ ID NO. 432)). The highest stimulation at low concentrations is seen with an



ODN in which half of the bases are fixed at T and the other half of the bases are randomized to be either T or G (ODN 2190 (SEQ ID NO. 907)). Since every other base is fixed to be a T, there cannot be any TG motifs. The data in Figure 3 show that increasing the TG content of an ODN improves its stimulatory activity.

5 In yet other experiments, the results of which are not diagrammed herein, ODN 2190 (SEQ ID NO. 907) exhibited a stimulation of NK activity compared to ODN 2188 (SEQ ID NO. 905) or ODN 2189 (SEQ ID NO. 906).

### Examples 6-8

**Introduction:**

10           Above, we demonstrated that Poly T sequences are able to enhance stimulation of B and NK cells. Here and below we investigate the effect of a variety of non-CpG T-rich ODN as well as Poly C ODN for their ability to stimulate human B cells, NK cells and monocytes.

### Materials and Methods:

[illegible]



- 132 -

**Cell preparation and cell culture:** Human PBMC were isolated from peripheral blood of healthy volunteers, obtained by the German Red Cross (Ratingen, Germany), as described above in Example 1, but all material were purchased from Life Technologies, Germany and were endotoxin-tested. For the B cell, NK cell and monocyte activation assays PBMC were cultured in complete medium at a concentration of  $2 \times 10^6$  cells/ml in 200  $\mu$ l in 96 round bottom plates in a humidified incubator at 37°C. Different ODNs, LPS (Sigma) or IL-2 (R&D Systems, USA) were used as stimuli. At the indicated time points, cells were harvested for flow cytometry.

**Flow cytometry:** MAbs used for staining of surface antigens were: CD3, CD14, CD19, CD56, CD69, CD80 and CD86 (all obtained from Pharmingen/Becton Dickinson, Germany). For monocytes Fc receptors were blocked using human IgG (Myltenyi, Germany) as previously described (Bauer, M et al 1999 *Immunology* 97:699). Flow cytometric data of at least 1000 cells of a specified subpopulation (B cells, monocytes, NK cells, NKT cells or T cells) were acquired on a FACSCalibur (Becton Dickinson). Data were analyzed using the program CellQuest (Becton Dickinson).

**NK-mediated cytotoxicity:** PBMC were cultured overnight with or without 6  $\mu$ g/ml ODN or 100U/ml IL-2 at 37°C, 5% CO<sub>2</sub>. The next morning, K-562 target cells were labeled with a fluorescent dye, CFSE, as described previously for human B cells (Hartmann, G., and A. M. Krieg. 2000 *J. Immunol.* 164:944). PBMC were added in different ratios (50:1, 25:1 and 12.5:1) to  $2 \times 10^5$  target cells and incubated for 4h at 37°C. Cells were harvested and incubated with the DNA-specific dye 7-AAD (Pharmingen) for detection of apoptotic cells. Results were measured by flow cytometry.

**ELISA:** PBMC ( $3 \times 10^6$  cells/ml) were cultured with the specified concentrations of ODN or LPS for 24h (IL-6, IFN $\gamma$  and TNF $\alpha$ ) or 8h (IL-1 $\beta$ ) in 48 well plates in a humidified atmosphere at 37°C. Supernatants were collected and cytokines were measured using OPTeia ELISA Kits (Pharmingen) for IL-6, IFN $\gamma$  and TNF $\alpha$  or an Eli-pair ELISA assay (Hoelzel, Germany) for IL-1 $\beta$  according to the manufacturer protocols.

***Example 6: B cell activation induced by ODNs lacking CpG motifs***

In the Experiments described above in Example 3, we demonstrate that T-rich ODN were capable of activating B cells. We expand those studies here using additional ODN and different cell and reagent sources. In a first set of experiments, we compared the activation potential of different non-CpG T-rich ODNs with the very potent known



- 133 -

CpG ODN 2006 (SEQ ID NO.: 246). PBMC ( $2 \times 10^6$  cells/ml) of a blood donor (n=2) were incubated with the indicated concentrations of ODNs 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 5126 (SEQ ID NO.: 1058), and 5162 (SEQ ID NO.: 1094). Cells were incubated for 48h at 37°C as described above and  
5 stained with mAb for CD19 (B cell marker) and CD86 (B cell activation marker, B7-2). Expression was measured by flow cytometry.

Using different concentrations of ODNs, we showed (Fig. 4) that T-rich ODNs without a CpG motif, can induce stimulation of human B cells. ODN 5126 (SEQ ID NO.: 1058) which contains only a single poly-T sequence but is greater than 50% T,  
10 caused high levels of human B cell activation. Although there are some similarities to SEQ ID NO.: 246 (e.g. more than 80% T/G content), this ODN clearly lacks any known immunostimulatory CpG motif. Surprisingly, for all tested T-rich ODNs, the highest stimulatory index was obtained at concentrations between 3 and 10 µg/ml. The highest stimulatory index of the tested ODNs was achieved by CpG/T-rich ODN SEQ ID NO.:  
15 246 at 0.4 µg/ml. Interestingly, the activity decreased at high concentrations.

Poly A, Poly C and Poly T sequences were synthesized and tested for biological activity. PBMC ( $2 \times 10^6$  cells/ml) of one representative donor (n=3) were stimulated as described above by 0.4 µg/ml, 1.0 µg/ml or 10.0 µg/ml of the following ODNs: 2006 (SEQ ID NO.: 246), 2196 (SEQ ID NO.: 913) (Poly T, 18 bases), 2194 (SEQ ID NO.: 911)  
20 (Poly T, 27 bases), 5162 (SEQ ID NO.: 1094) (Poly T, 30 bases), 5163 (SEQ ID NO.: 1095) (Poly A, 30 bases), 5168 (SEQ ID NO.: 1096) (Poly C, 30 bases) and 5169 (SEQ ID NO.: 1097) (Poly CG, 30 bases). Expression of the activation marker CD86 (B7-2) on CD19-positive B cells was measured by flow cytometry.

Fig. 5 demonstrates that the length of the sequence, at least for Poly T ODNs, has  
25 an important impact on its activity. A Poly T sequence containing only 18 bases (SEQ ID NO.: 913) was shown to be less stimulatory than one with 27 bases (SEQ ID NO.: 911) or one with 30 bases (SEQ ID NO.: 1094) with a clear rank of stimulation: SEQ ID NO.: 1094 > SEQ ID NO.: 911 > SEQ ID NO.: 913. Poly A (SEQ ID NO.: 1095) or Poly CG (SEQ ID NO.: 1097) sequences, in contrast, do not induce activation of human B  
30 cells. Surprisingly it was also discovered that Poly C sequences (SEQ ID NO.: 1096) can activate human B cells at least at high concentrations (10 µg/ml) (Fig. 5).



- 134 -

Two other T-rich ODNs, namely 1982 (SEQ ID NO.: 225) and 2041 (SEQ ID NO.: 282) lacking CpG motifs were tested for their effect on human B cells. PBMC (n=2) were incubated with the indicated concentrations of ODN 2006 (SEQ ID NO.: 246), 1982 (SEQ ID NO.: 225) and 2041 (SEQ ID NO.: 282) as described above. B cell activation (expression of the activation marker CD86) was measured by flow cytometry.

Fig. 6 demonstrates that T-rich non-CpG ODN are immunostimulatory at concentrations higher than 1 µg/ml. Incorporation of a CpG motif into 1982 enhanced the immunostimulatory activity. Elongation with a Poly T sequence did not enhance the immunostimulatory activity of this already T-rich ODN but rather, decreased the activation potential slightly.

***Example 7: Immunostimulation of non-CpG ODNs is reflected in the enhancement of NK activation, NK cytotoxicity and monocyte activation***

NK cells as well as monocytes were tested for their response to non-CpG ODNs. PBMC ( $2 \times 10^6$  cells/ml) were incubated with 6 µg/ml of the following ODNs (n=4): 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058). After 24h of cultivation at 37°C cells were harvested and stained with mAb for CD3 (T cell marker), CD56 (NK cell marker) and CD69 (early activation marker) as described above. Expression of CD69 on CD56-positive NK cells was measured by flow cytometry.

Fig. 7 shows that for Poly T ODNs similar effects can be observed as described in Fig. 5. The stimulation of NK cells, like B cells, may be influenced by the length of the ODN. ODN 2183 (SEQ ID NO.: 433) (21 bases) induced activation of NK cells but to a lesser extent than the longer ODN 2194 (SEQ ID NO.: 911) (27 bases), as measured by enhanced expression of the early activation marker CD69. ODN 5126 (SEQ ID NO.: 1058) was also demonstrated to activate human NK cells (Fig. 7).

It is believed that the anti-tumor activity of CpG ODNs can be assessed by the ability of the ODN to enhance NK-mediated cytotoxicity *in vitro*. ODNs containing at the 5' and 3' ends stretches of Poly G were shown to result in the highest induction of cytotoxicity (Ballas, Z. K., et al. 1996 *J. Immunol.* 157:1840). To investigate the influence of non-CpG T-rich ODN on NK cytotoxicity, we analyzed the effect of the



- 135 -

ODNs 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058) on NK-mediated lysis (Fig. 8). NK-mediated lysis of K-562 target cells was measured after over night incubation of PBMC with 6µg/ml of the ODN 2006 (SEQ ID NO.: 246), SEQ ID NO.: 911 (SEQ ID NO.: 911 ) (Poly T, 27 bases) and 5126 (SEQ ID NO.: 1058) as described  
5 above. SEQ ID NO.: 1058 demonstrated small increases in lysis by human NK cells as compared to no ODN. SEQ ID NO.: 911 and SEQ ID NO.: 246 enhanced human NK cell cytotoxicity to an even higher extent.

Previous reports demonstrated that not only NK cells but also NKT cells are mediators of cytotoxic responses to tumor cells (14). We, therefore, looked at the  
10 potential activation of human NKT cells by T-rich non-CpG ODN. PBMC of one representative donor (n=2) were incubated with 6µg/ml ODN 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 913) and 5126 (SEQ ID NO.: 1058) for 24h as described above. Activation of NKT cells was measured by flow cytometry after staining of cells with  
15 mAb for CD3 (T cell marker), CD56 (NK cell marker) and CD69 (early activation marker). Shown is the expression of CD69 on CD3 and CD56 double-positive cells (NKT cells).

In Fig. 9, SEQ ID NO.: 911 as well as SEQ ID NO.: 1058 were found to stimulate NKT cells. Similar to NK cells SEQ ID NO.: 911 (Poly T) was more active  
20 than SEQ ID NO. 1058. In addition, as described above for B cells and NK cells, the length of the ODN has some influence on the immunostimulatory potential, with the longer ODN having stronger effects on NKT cells. Similar results were observed for human T cells.

Another type of cell of the immune system involved in fighting infections is the  
25 monocytes. These cells release upon activation a variety of cytokines and can mature into dendritic cells (DC), professional antigen-presenting cells (Roitt, I., J. Brostoff, and D. Male. 1998. *Immunology*. Mosby, London). Fig. 10 shows activation of human monocytes after culturing of PBMC with different ODNs. PBMC ( $2 \times 10^6$  cells/ml) were incubated with 6µg/ml 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ  
30 ID NO.: 886), 2178 (SEQ ID NO.: 1096), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911), 5126 (SEQ ID NO.: 1058) and 5163 (SEQ ID NO.: 1095) overnight at 37°C as



- 136 -

described above (n=3). Cells were harvested and stained for CD14 (monocyte marker) and CD80 (B7-1, activation marker). Expression was measured by flow cytometry.

As demonstrated above for NK and B cells, T-rich sequences (e.g., SEQ ID NO.: 433, SEQ ID NO.: 911) of different length induce monocyte stimulation but have  
5 different levels of activity e.g., SEQ ID NO.: 433 > SEQ ID NO.: 911. Poly A (SEQ ID NO.: 1095) as well as Poly C (SEQ ID NO.: 1096 (2178) sequences, in contrast, did not lead to activation of monocytes (measured by the upregulation of CD80 at a concentration of 6µg/ml ODN).

***Example 8: Induction of cytokine release by non-CpG ODNs***

10 Next the ability of different T-rich ODNs to influence the cytokine milieu was examined. PBMC ( $3 \times 10^6$  cells/ml) were cultured for 24h with or without 6µg/ml of the indicated ODNs or 1µg/ml LPS as positive control (n=2). After incubation supernatants were collected and TNFα measured by ELISA as described above and the results are shown in Fig. 11. PBMC were cultured with the indicated ODNs (1.0µg/ml) as  
15 described in Fig. 11 and IL-6 was measured in the supernatants by ELISA and the results are shown in Fig. 12.

Fig. 11 and 12 demonstrate that T-rich non-CpG and T-rich/CpG ODNs can induce the secretion of the pro-inflammatory cytokines TNFα and IL-6. For both cytokines, ODN 5126 (SEQ ID NO.: 1058) was found in most assays to be as potent as  
20 ODN 2194 (SEQ ID NO.: 911). It is known that CpG ODNs influence the Th1/Th2 balance by preferentially inducing Th1 cytokines (Krieg, A. M. 1999 *Biochemica et Biophysica Acta* 93321:1). To test whether T-rich ODN caused a similar shift to Th1 cytokines, IFNγ production in PBMC was measured. In a first set of experiments, it was demonstrated that, as described for IL-6 and TNFα, ODNs SEQ ID NO.: 1058 and SEQ  
25 ID NO.: 911 induced the release of comparable amounts of this Th1 cytokine IFNγ. In addition, it was demonstrated that another pro-inflammatory cytokine, IL-1β, was released upon culture of PBMC with these two ODNs. Although the amount of these cytokines induced by the T-rich ODN lacking CpG motifs was less than when CpG ODN SEQ ID NO.: 246 was used the amounts induced by T-rich ODN were significantly  
30 higher than the control.



- 137 -

**Examples 9-11***Introduction:*

An optimal CpG motif for immune system activation in non-rodent vertebrates is described herein. A phosphodiester oligonucleotide containing this motif was found to strongly stimulate CD86, CD40, CD54 and MHC II expression, IL-6 synthesis and proliferation of primary human B-cells. These effects required internalisation of the oligonucleotide and endosomal maturation. This CpG motif was associated with the sustained induction of the NF $\kappa$ B p50/p65 heterodimer and of the transcription factor complex activating protein-1 (AP-1). Transcription factor activation by CpG DNA was preceded by increased phosphorylation of the stress kinases c-jun NH<sub>2</sub> terminal kinase (JNK) and p38, and of activating transcription factor-2 (ATF-2). In contrast to CpG, signaling through the B-cell receptor led to activation of extracellular receptor kinase (ERK) and to phosphorylation of a different isoform of JNK.

*Materials and Methods:*

**Oligodeoxynucleotides:** Unmodified (phosphodiester, PE) and modified nuclease-resistant (phosphorothioate, PS) ODN were purchased from Operon Technologies (Alameda, CA) and Hybridon Specialty Products (Milford, MA). The sequences used are provided in Table H. *E. coli* DNA and calf thymus DNA were purchased from Sigma Chemical Co., St. Louis, MO. Genomic DNA samples were purified by extraction with phenol-chloroform-isoamyl alcohol (25/24/1) and ethanol precipitation. DNA was purified from endotoxin by repeated extraction with triton x-114 (Sigma Chemical Co., St. Louis, MO) and tested for endotoxin using the LAL-assay (LAL-assay BioWhittaker, Walkersville, MD; lower detection limit 0.1 EU/ml) and the high sensitivity assay for endotoxin described earlier (lower detection limit 0.0014 EU/ml) (Hartmann G., and Krieg A. M. 1999. CpG DNA and LPS induce distinct patterns of activation in human monocytes. *Gene Therapy* 6:893). Endotoxin content of DNA samples was below 0.0014 U/ml. *E. coli* and calf thymus DNA were made single stranded before use by boiling for 10 minutes, followed by cooling on ice for 5 minutes. DNA samples were diluted in TE-buffer using pyrogen-free reagents.

Table H: Oligonucleotide panel used<sup>1</sup>



- 138 -

|                            | Name (SEQ<br>ID NO)  | Sequence 5' to 3'                                            |
|----------------------------|----------------------|--------------------------------------------------------------|
| Starting sequence          | PE 2079 (320)        | <u>TCG</u> <u>ACG</u> TTC CCC CCC CCC CC                     |
| Middle base                | PE 2100 (341)        | TCG <b>GCG</b> TTC CCC CCC CCC CC                            |
|                            | PE 2082 (323)        | TCG <b>CCG</b> TTC CCC CCC CCC CC                            |
| <b>Human CpG motif</b>     | <b>PE 2080 (321)</b> | <b>TCG TCG</b> TTC CCC CCC CCC CC                            |
| 5' flanking base           | PE 2105 (346)        | <b>GCG</b> TCG TTC CCC CCC CCC CC                            |
|                            | PE 2107 (348)        | <b>ACG</b> TCG TTC CCC CCC CCC CC                            |
|                            | PE 2104 (345)        | <b>CCG</b> TCG TTC CCC CCC CCC CC                            |
| 3' flanking base           | PE 2098 (339)        | TCG TCG <b>CTC</b> CCC CCC CCC CC                            |
|                            | PE 2099 (340)        | TCG TCG <b>GTC</b> CCC CCC CCC CC                            |
|                            | PE 2083 (324)        | TCG TCG <b>ATC</b> CCC CCC CCC CC                            |
| First CpG deleted          | PE 2108 (349)        | CTG <u>TCG</u> TTC CCC CCC CCC CC                            |
| Second CpG deleted         | PE 2106 (347)        | <u>TCG</u> TCA TTC CCC CCC CCC CC                            |
| Methylation                | PE 2095 (336)        | <b>TZG</b> <b>TZG</b> TTC CCC CCC CCC CC                     |
|                            | PE 2094 (335)        | TCG TCG TTC CCC CCC <b>ZCC</b> CC                            |
| Non-CpG control of<br>2080 | PE 2078 (319)        | <b>TGC</b> <b>TGC</b> TTC CCC CCC CCC CC                     |
|                            | PE 2101 (342)        | <b>GGC</b> <b>CTT</b> TTC CCC CCC CCC CC                     |
| PS form of 2080            | PS 2116 (357)        | <u>TCG</u> <u>TCG</u> TTC CCC CCC CCC CC                     |
| Additional CpG motifs      | PE 2059 (300)        | <u>TCG</u> <u>TCG</u> TTT TGT <u>CGT</u> TTT GTC <u>GTT</u>  |
| Best PS                    | PS 2006 (246)        | <u>TCG</u> <u>TCG</u> TTT TGT <u>CGT</u> TTT GTC <u>GTT</u>  |
| Methylated 2006            | PS 2117 (358)        | <b>TZG</b> <b>TZG</b> TTT TGT <b>ZGT</b> TTT GT <b>Z</b> GTT |

<sup>1</sup>PE, phosphodiester; PS, phosphorothioate; bold, base exchange; bold Z, methylated cytidine; underlined, CpG dinucleotides.



- 139 -

**Cell preparation and cell culture:** Human peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers by Ficoll-Paque density gradient centrifugation (Histopaque-1077, Sigma Chemical Co., St. Louis, MO) as described (Hartmann G., et al 1996 *Antisense Nucleic Acid Drug Dev* 6:291)). Cells  
5 were suspended in RPMI 1640 culture medium supplemented with 10 % (v/v) heat-inactivated (56°C, 1 h) FCS (HyClone, Logan, UT), 1.5 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all from Gibco BRL, Grand Island, NY) (complete medium). All compounds were purchased endotoxin-tested. Viability was determined before and after incubation with ODN by trypan blue exclusion  
10 (conventional microscopy) or by propidium iodide exclusion (flow cytometric analysis). In all experiments, 96 % to 99 % of PBMC were viable. Cells (final concentration  $1 \times 10^6$  cells/ml) were cultured in complete medium in a 5 % CO<sub>2</sub> humidified incubator at 37°C. Different oligonucleotides (see table I, concentration as indicated in the figure legends), LPS (from salmonella typhimurium, Sigma Chemical Co., St. Louis, MO) or  
15 anti-IgM were used as stimuli. Chloroquine (5 µg/ml; Sigma Chemical Co., St. Louis, MO) was used to block endosomal maturation/acidification. At the indicated time points, cells were harvested for flow cytometry as described below.

For signal transduction studies, human primary B-cells were isolated by immunomagnetic cell sorting using the VARIOMACS technique (Miltenyi Biotec Inc.,  
20 Auburn, CA) as described by the manufacturer. In brief, PBMC obtained from buffy coats of healthy blood donors (Elmer L. DeGowin Blood Center, University of Iowa) were incubated with a microbeads-conjugated antibody to CD19 and passed over a positive selection column. Purity of B-cells was higher than 95%. After stimulation, whole cellular extracts (Western blot) and nuclear extracts (EMSA) for signal  
25 transduction studies were prepared.

For CpG binding protein studies, Ramos cells (human Burkitt lymphoma B cell line, ATCC CRL-1923 or CRL-1596; Intervirology 5: 319-334, 1975) were grown in complete medium. Untreated cells were harvested and cytosolic protein extracts were prepared and analyzed for the presence of CpG oligonucleotide binding proteins by  
30 EMSA and UV-crosslink as described below.

**Flow cytometry:** Staining of surface antigens was performed as previously described (Hartmann G. et al. 1998 *J Pharmacol Exp Ther* 285:920). Monoclonal



- 140 -

antibodies to HLA-DR were purchased from Immunotech, Marseille, France. All other antibodies were purchased from Pharmingen, San Diego, CA: mABs to CD19 (B43), CD40 (5C3), CD54 (HA58), CD86 (2331 (FUN-1)). IgG<sub>1,κ</sub> (MOPC-21) and IgG<sub>2b,κ</sub> were used to control for specific staining. Intracellular cytokine staining for IL-6 was performed as described (Hartmann G., and Krieg A. M. 1999. CpG DNA and LPS induce distinct patterns of activation in human monocytes. *Gene Therapy* 6:893). In brief, PBMC (final concentration  $1 \times 10^6$  cells/ml) were incubated in the presence of brefeldin A (final concentration 1 µg/ml, Sigma Chemical Co., St. Louis, MO). After incubation, cells were harvested and stained using a FITC-labeled mAB to CD19 (B43), a PE-labeled rat anti-human IL-6 mAb (MQ2-6A3, Pharmingen) and the Fix and Perm Kit (Caltag Laboratories, Burlingame, CA). Flow cytometric data of 5000 cells per sample were acquired on a FACScan (Beckton Dickinson Immunocytometry Systems, San Jose, CA). Non-viable cells were excluded from analysis by propidium iodide staining (2 µg/ml). Data were analyzed using the computer program FlowJo (version 2.5.1, Tree Star, Inc., Stanford, CA).

**Proliferation assay:** CFSE (5-(and-6-) carboxyfluorescein diacetate succinimidyl ester, Molecular Probes, USA) is a fluorescein-derived intracellular fluorescent label which is divided equally between daughter cells upon cell division. Staining of cells with CFSE allows both quantification and immunophenotyping (phycoerythrin-labeled antibodies) of proliferating cells in a mixed cell suspension. Briefly, PBMC were washed twice in PBS, resuspended in PBS containing CFSE at a final concentration of 5 µM, and incubated at 37°C for 10 minutes. Cells were washed three times with PBS and incubated for five days as indicated in the figure legends. Proliferating CD19-positive B-cells were identified by decreased CFSE content using flow cytometry.

**Preparation of whole cell, nuclear and cytosolic protein extracts:** For Western blot analysis, whole cell extracts were prepared. Primary B-cells were treated with medium, the phosphodiester oligonucleotides 2080 (SEQ ID NO.: 321) or 2078 (SEQ ID NO.: 319) at 30 µg/ml, or anti-IgM (10 µg/ml). Cells were harvested, washed twice with ice-cold PBS containing 1 mM Na<sub>3</sub>VO<sub>4</sub>, resuspended in lysis buffer (150 mM NaCl, 10 mM TRIS pH 7.4, 1 % NP40, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 50 mM NaF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml antipain, 5 mg/ml pepstatin, 50 µg/ml



- 141 -

phenylmethylsulfonylfluoride (PMSF)), incubated for 15 min on ice and spun at 14000 rpm for 10 min. The supernatant was frozen at -80 C. For the preparation of nuclear extracts, primary B-cells were resuspended in hypotonic buffer (10 mM HEPES/KOH (pH 7.9), 10 mM KCl, 0.05 % NP40, 1.5 mM MgCl<sub>2</sub>, 0.5 mM dithiothreitol (DTT), 0.5 mM PMSF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml antipain, 5 mg/ml pepstatin). After 15 minutes incubation on ice, the suspension was centrifuged at 1000 x g for 5 minutes. The pelleted nuclei were resuspended in extraction buffer (20 mM HEPES (pH 7.9), 450 mM NaCl, 50 mM NaF, 20% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml antipain, 5 mg/ml pepstatin) and incubated on ice for one hour. The nuclear suspension was centrifuged for 10 minutes at 16,000 g at 4°C. Supernatant was collected and stored at -80°C. Cytosolic extracts for the CpG binding protein studies were prepared from unstimulated Ramos cells, which were lysed with hypotonic buffer as described for the preparation of the nuclear extract. After centrifugation, the supernatant was removed as cytoplasmic fraction and stored at -80°C. Protein concentrations were measured using a Bradford protein assay (Bio-Rad, Hercules, CA) according to the manufacturer.

**Western blot analysis:** Equal concentrations of whole cell protein extracts (25 µg/lane) were boiled in SDS sample buffer (50 mM Tris-Cl, pH 6.8; 1% β-mercaptoethanol; 2% SDS; 0.1% bromphenolblue; 10% glycerol) for 4 min before being subjected to electrophoresis on a 10 % polyacrylamide gel containing 0.1 % SDS (SDS-PAGE). After electrophoresis, proteins were transferred to Immobilon-P transfer membranes (Millipore Corp. Bedford, MA). Blots were blocked with 5 % nonfat dry milk. Specific antibodies against the phosphorylated form of extracellular receptor kinase (ERK), c-jun NH2-terminal kinase (JNK), p38 and activating transcription factor-2 (ATF-2) were used (New England BioLabs, Beverly, MA). Blots were developed in enhanced chemiluminescence reagent (ECL; Amersham International, Aylesbury, U.K.) according to the manufacturer's recommended procedure.

**Electrophoretic mobility shift assay (EMSA):** To detect the DNA-binding activity of the transcription factor activator protein-1 (AP-1) and NFκB, nuclear extracts (1 µg/lane) were analyzed by EMSA using the dsODNs 5' GAT CTA GTG ATG AGT CAG CCG GAT C 3' (SEQ ID NO.: 838) containing the AP-1 binding sequence, and the NFκB URE from the c-myc promotor region 5' TGC AGG AAG TCC GGG TTT TCC



- 142 -

CCA ACC CCC C 3' (SEQ ID NO.: 1142), as probes. ODNs were end labeled with T4-polynucleotide kinase (New England Biolabs) and ( $\gamma$ -<sup>32</sup>P) ATP (Amersham, Arlington Heights, IL). Binding reactions were performed with 1  $\mu$ g nuclear protein extract in DNA-binding buffer (10 mM Tris-HCl (pH 7.5), 40 mM MgCl<sub>2</sub>, 20 mM EDTA, 1 mM dithiothreitol, 8% glycerol and 100 - 400 ng of poly (dI-dC) with 20.000 - 40.000 cpm labeled ODN in 10  $\mu$ l total volume. Specificity of the NF $\kappa$ B bands was confirmed by competition studies with cold oligonucleotides from unrelated transcription factor binding sites (10 - 100 ng). For the supershift assay, 2  $\mu$ g of specific antibodies for c-Rel, p50 and p65 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were added into the reaction mixture for 30 min before the radiolabeled probe was added. Following incubation for 30 minutes at room temperature loading buffer was added and the probes were electrophoresed on a 6 % polyacrylamide gel in Tris-borate-EDTA running buffer (90 mM Tris, 90 mM boric acid, 2 mM EDTA, pH 8.0). Gels were dried and then autoradiographed.

**UV-crosslinking and denaturing protein electrophoresis:** Nuclear extracts were incubated with labeled phosphodiester oligonucleotide as described for the EMSA. DNA-protein complexes were crosslinked with UV-light in a Stratalinker (Stratagene) for 10 minutes. Probes were mixed with SDS-sample buffer, boiled for 10 minutes and loaded on a 7.5% SDS-PAGE. The gel was dried on Whatman paper and autoradiographed. Plotting the distance against the molecular weight of the marker proteins yielded a standard curve which was used to calculate the approximate molecular weight of the crosslinked protein-ODN complexes. The molecular weight of the oligonucleotide was subtracted from this value to give the size.

***Example 9: Identification of an Optimal CpG motif for use alone or in combination with a T-rich ODN***

Phosphorothioate oligonucleotides containing the murine CpG motif GACGTT (SEQ ID NO.: 1143) (for example 1826 (SEQ ID NO.: 69)) and used at concentrations which are active in murine B-cells (Yi A. K., Chang M., Peckham D. W., Krieg A. M., and Ashman R. F. 1998. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. *J Immunol* 160:5898), have showed little or no immunostimulatory activity on human immune cells. At higher



- 143 -

concentrations this ODN was found to demonstrate some stimulatory effect on human B cells.

In earlier studies on B-cell activation in mice, it was found that a CpG-dinucleotide flanked by two 5' purines and two 3' pyrimidines and preferably the 6mer motif 5' GACGTT 3' (SEQ ID NO:1143) was optimal for a phosphodiester oligonucleotide to be active (Krieg A. M., et al. 1995 *Nature* 374:546, Yi A. K., Chang M., et al.. 1998 *J Immunol* 160:5898).

In order to identify an optimal motif for stimulation of an immune response in humans and non-rodent vertebrates we designed a series of ODN and tested their activity. First we designed a 20 mer phosphodiester oligonucleotide with a TC dinucleotide at the 5' end preceding the optimal murine CpG motif 5' GACGTT 3' (SEQ ID NO.: 1143) and followed by a poly C tail (2079: 5' TCG ACG TTC CCC CCC CCC CC 3'(SEQ ID NO.: 320)). This oligonucleotide if added to human primary B-cells under the same conditions as found to be optimal for E. coli DNA (repeated addition at 0 hours, 4 hours and 18 hours; 30 µg/ml for each time point) stimulated high levels of CD86 expression on human primary B-cells after two days. To determine the structure-function relationship of the CpG motifs, we replaced the bases adjacent to the CpG dinucleotides while maintaining the two CpG dinucleotides within the sequence. Exchange of the adenine located between both CpG dinucleotides by thymidine (2080 (SEQ ID NO.: 321)) resulted in slightly higher activity. Replacement by guanosine (2100 (SEQ ID NO.: 341)) or cytidine (2082 (SEQ ID NO.: 323)) at this position showed no major changes compared to 2079 (SEQ ID NO.: 320). In contrast, replacement of the thymidine 3' to the second CpG dinucleotide by the purines guanosine (2099 (SEQ ID NO.: 340)) or adenine (2083 (SEQ ID NO.: 324)) resulted in a major drop in activity of the oligonucleotide, while the pyrimidine cytidine caused only a minor decrease. The thymidine immediately 5' to the first CpG dinucleotide was also important. Replacement of the thymidine by any other base (2105 (SEQ ID NO.: 346), guanosine; 2107 (SEQ ID NO.: 348), adenine; 2104 (SEQ ID NO.: 345), cytidine) led to a marked decrease in activity of the oligonucleotide. Elimination of the first (2108 (SEQ ID NO.: 349)) or the second (2106 (SEQ ID NO.: 347)) CpG dinucleotide also partially reduced the activity.



- 144 -

The addition of more 5' GTCGTT 3' (SEQ ID NO.: 1144) CpG motifs to the phosphodiester oligonucleotide containing the 8mer duplex CpG motif (5' TCGTCGTT 3' (SEQ ID NO.: 1145), 2080 (SEQ ID NO.: 321)) did not further enhance CD86 expression on B-cells (2059 (SEQ ID NO.: 300)). An oligonucleotide with the same sequence as 2080 (SEQ ID NO.: 321) but with a phosphorothioate backbone showed no activity above background (2116 (SEQ ID NO.: 357)). This was surprising since the phosphorothioate backbone has been reported to greatly stabilize oligonucleotides and enhance CpG-induced stimulation (Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., and Klinman D. M. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374:546). We therefore performed further structure-function analysis of phosphorothioate oligonucleotides containing the 5' GTCGTT 3' (SEQ ID NO.: 1144) and 5' TCGTCGTT 3' (SEQ ID NO.: 1145) motifs, which showed that additional CpG motifs (2006 (SEQ ID NO.: 246)) tended to increase the activity of phosphorothioate oligonucleotides.

Purified B-cells isolated from peripheral blood by immunomagnetic cell sorting were activated by CpG DNA to the same extent as unpurified B-cells within PBMC. Thus, activation of B-cells is a primary response and not a secondary effect caused by cytokines secreted by other cells.

In addition to the co-stimulatory molecule CD86, the functional stage of B-cells is characterized by other surface markers. For example, activated T helper cells stimulate B-cells by CD40 ligation, the intercellular adhesion molecule-1 (ICAM-1, CD54) mediates binding to other immune cells, and major histocompatibility complex II (MHC II) is responsible for antigen presentation. We found that B cell expression of CD40, CD54 and MHC II was upregulated by the CpG oligonucleotide 2080 (SEQ ID NO.: 321). The non-CpG control oligonucleotide 2078 (SEQ ID NO.: 319) showed no activity compared to medium alone.

When PBMC were incubated for 5 days in the presence of 2080 (SEQ ID NO.: 321) (added at 0 hours, 4 hours, 18 hours and every subsequent morning), it was intriguing that a subpopulation of lymphocytes increased in cell size (FSC) and became more granular (SSC). To examine if this subpopulation represented proliferating B-cells, we stained freshly isolated PBMC with CFSE (5-(and-6-) carboxyfluorescein diacetate succinimidyl ester) at day 0 and incubated them for 5 days with 2080 (SEQ ID NO.: 321)



- 145 -

as above. CFSE is a fluorescent molecule that binds irreversibly to cell proteins. Each cell division decreases CFSE stain by 50 %. Cells staining low with CFSE (proliferating cells) were found to be mainly CD19-positive B-cells. The oligonucleotide 2080 (SEQ ID NO.: 321) induced 60 to 70 % of CD19 positive B-cells to proliferate within 5 days.

5 The control oligonucleotide 2078 (SEQ ID NO.: 319) induced less than 5 % of B-cells to proliferate. Proliferating B-cells (CFSE low) showed a larger cell size (FSC) and higher granularity.

Proliferating B-cells expressed higher levels of CD86 than non-proliferating cells (not shown). In agreement with this finding, the oligonucleotide panel tested above for  
10 induction of CD86 expression resulted in an almost identical pattern of B-cell proliferation. Replacement of the 3' thymidine reduced activity more than changing the thymidine in the middle position.

***Example 10: B-cell activation requires endosomal maturation/acidification***

15 It has previously been shown that chloroquine, an inhibitor of endosomal acidification, blocks CpG-mediated stimulation of murine antigen presenting cells and B-cells, while not influencing LPS-mediated effects (Hacker H., et al 1998 *Embo J* 17:6230, Yi A. K. et al 1998 *J Immunol* 160:4755, Macfarlane D. E., and Manzel L. 1998 *J Immunol* 160:1122). We found that the addition of 5 µg/ml chloroquine  
20 completely blocked CpG DNA-mediated induction of CD86 expression on primary B-cells (MFI CD86: 2006 (SEQ ID NO.: 246), 4.7 vs 1.4; E. coli DNA, 3.4 vs. 1.4; medium only, 0.9; n=4). Furthermore, chloroquine completely inhibited the induction of B-cell proliferation by the phosphorothioate oligonucleotide 2006 (SEQ ID NO.: 246) measured with the CFSE proliferation assay as well as with the standard . These results  
25 suggest that as with murine cells, activation of human B-cells by CpG DNA requires the uptake of DNA in endosomes and subsequent endosomal acidification.

***Example 11: Analysis of sub-cellular events resulting upon human B cell stimulation with optimal human ODN.***

30 Since the CpG motif requirement for maximal B-cell activation is substantially different between mouse (GACGTT) (SEQ ID NO:1143) and humans (TCGTCGTT) (SEQ ID NO:1145), we were interested if the basic intracellular signaling events are



- 146 -

comparable. Rapid induction of NF $\kappa$ B binding activity has been found earlier in murine B-cells and macrophages (Stacey K. J., et al 1996 *J Immunol* 157:2116, Yi A. K et al 1998 *J Immunol* 160:4755). To investigate the NF $\kappa$ B response to CpG DNA in humans, human primary B-cells were isolated from peripheral blood by immunomagnetic cell sorting and incubated with the CpG oligonucleotide 2080 (SEQ ID NO.: 321), the non-CpG control oligonucleotide 2078 (SEQ ID NO.: 319), or medium. At the indicated time points, cells were harvested and nuclear extracts were prepared. In the presence of CpG oligonucleotide, NF $\kappa$ B binding activity was increased within one hour and maintained up to 18 hours (latest time point examined). The non-CpG control oligonucleotide 2078 (SEQ ID NO.: 319) did not show enhanced NF $\kappa$ B activity compared to cells incubated with medium only. The NF $\kappa$ B band was identified by cold competition, and shown to consist of p50 and p65 subunits by supershift assay.

The activating protein-1 (AP-1) transcription factor is involved in the regulation of immediate early genes and cytokine expression (Karin M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. *J Biol Chem* 270:16483). In murine B-cells, AP-1 binding activity is induced in response to CpG DNA (Yi A. K., and Krieg A. M. 1998. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. *J Immunol* 161:4493). To determine whether this transcription factor would also be induced by CpG DNA in humans, we examined AP-1 DNA binding activity in human primary B-cells. Cells were incubated with the CpG oligonucleotide 2080 (SEQ ID NO.: 321) or the control oligonucleotide 2078 (SEQ ID NO.: 319). Nuclear extracts were prepared and the AP-1 binding activity was analyzed by EMSA. AP-1 binding activity was enhanced within one hour, and increased up to 18 hours (latest time point examined), showing a sustained response.

Since AP-1 activity is induced by many stimuli (Angel P., and Karin M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim Biophys Acta* 1072:129), we were interested in signal transduction pathways upstream of AP-1. The AP-1 transcription factor complex integrates different mitogen activated protein kinase (MAPK) pathways (Karin M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. *J Biol Chem* 270:16483). Western blots were performed using whole cell extracts from primary B-cells incubated with the CpG oligonucleotide 2080 (SEQ ID NO.: 321), the control 2078 (SEQ ID NO.: 319), or



- 147 -

medium only. Specific antibodies to the phosphorylated form of JNK, p38, ATF-2 and ERK were used. Strong induction of JNK phosphorylation was found 30 min and 60 min after exposure to CpG-DNA, while the non-CpG oligonucleotide showed no activity above background. The protein kinase p38, another stress activated protein kinase (SAPK), was also phosphorylated in response to CpG DNA within 60 min. ATF-2, a substrate of both p38 and JNK (Gupta S., Campbell D., Derijard B., and Davis R. J. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. *Science* 267:389) and a component of the AP-1 complex, showed weak phosphorylation after 30 min which increased after 60 min. CpG DNA failed to induce substantial phosphorylation of ERK. In contrast, anti-IgM, stimulating the B-cell receptor, did trigger phosphorylation of ERK. Anti-IgM activated different isoforms of JNK than CpG DNA.

***Example 12: Assay for in vivo adjuvant activity.***

An *in vitro* screening assay to identify ODN useful as an adjuvant *in vivo* in humans and other non-rodent animals was developed. Since we saw not only quantitative but also qualitative differences in activities of different CpG ODN in mice, we first screened a panel of CpG and non-CpG control ODN on mouse cells to find *in vitro* assays with reliable and strong correlation to *in vivo* adjuvant activity with hepatitis B surface antigen (HBsAg). We then systematically tested a panel of more than 250 ODN in corresponding human assays to identify sequences with *in vitro* immunostimulatory activity. We next examined if the ODN with the highest activity in these human assays also activate B cell proliferation in chimpanzees and monkeys, and finally, if they are active as adjuvants with HBsAg in chimpanzees and cynomolgus monkeys *in vivo*. These studies revealed that the sequence, number and spacing of individual CpG motifs contribute to the immunostimulatory activity of a CpG phosphorothioate ODN. An ODN with a TC dinucleotide at the 5' end followed by three 6mer CpG motifs (5' GTCGTT 3') separated by TT dinucleotides consistently showed the highest activity for human, chimpanzee, and rhesus monkey leukocytes. Chimpanzees or monkeys vaccinated once against hepatitis B with this CpG ODN adjuvant developed 15 times higher anti-HBs antibody titers than those receiving vaccine alone.



### ***Materials and Methods***

**Oligodeoxynucleotides:** Phosphorothioate-modified ODN were purchased from Operon Technologies (Alameda, CA) and Hybridon Specialty Products (Milford, MA). ODN were tested for endotoxin using the LAL-assay (LAL-assay BioWhittaker, Walkersville, MD; lower detection limit 0.1 EU/ml). For *in vitro* assays, ODN were diluted in TE-buffer (10 mM Tris, pH 7.0, 1 mM EDTA), and stored at -20° C. For *in vivo* use, ODN were diluted in phosphate buffered saline (0.1 M PBS, pH 7.3) and stored at 4°C. All dilutions were carried out using pyrogen-free reagents.

**Mouse spleen cell cultures:** Spleens were removed from 6-12 week old female BALB/c (The Jackson Laboratory),  $2 \times 10^6$  splenocytes were cultured with 0.2  $\mu$ M ODN for 4 hours (TNF- $\alpha$ ) or 24 hours (IL-6, IFN- $\gamma$ , IL-12), and cytokines were detected by ELISA as previously described (Yi A. K., Klinman D. M., Martin T. L., Matson S., and Krieg A. M. 1996. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. *J Immunol* 157:5394). To evaluate CpG-induced B cell proliferation, spleen cells were depleted of T cells with anti-Thy-1.2 and complement and centrifugation over lympholyte M<sup>®</sup> (Cedarlane Laboratories, Hornby, ON, Canada), cultured for 44 hours with the indicated ODN, and then pulsed for 4 hours with 1  $\mu$ Ci of <sup>3</sup>H thymidine as described previously (Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., and Klinman D. M. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374:546). To examine NK cell lytic activity murine spleen cells were depleted of B cells using magnetic beads coated with goat anti-mouse Ig as previously detailed (Ballas Z. K., and Rasmussen W. 1993. Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1<sup>+</sup>CD8  $\alpha^+\beta^-$  TCR- $\alpha\beta$  B220<sup>+</sup> lymphokine-activated killer subset. *J Immunol* 150:17). Cells were cultured at  $5 \times 10^6$ /well in 24-well plates and harvested at 18 hours for use as effector cells in a standard 4 hour <sup>51</sup>Cr-release assay against YAC-1 target cells. One unit (LU) was defined as the number of cells needed to effect 30 % specific lysis.

**Immunization of mice against HBsAg and evaluation of the humoral response:** Groups of 6-8 week old female BALB/c mice (n = 5 or 10, Charles River, Montreal, QC) were immunized against HBsAg as previously described (Davis H. L., et



- 149 -

al 1998 *J Immunol* 160:870). In brief, each mouse received a single IM injection of 50  $\mu$ l PBS containing 1  $\mu$ g recombinant HBsAg (Medix Biotech, Foster City, CA) and 10  $\mu$ g of CpG ODN or non-CpG ODN as a sole adjuvant or combined with alum (Alhydrogel "85", Superfos Biosector, Vedbaek, Denmark; 25 mg  $\text{Al}^{3+}$ /mg HBsAg).

- 5 Control mice were immunized with HBsAg without adjuvant or with alum. Plasma was recovered from mice at various times after immunization and Abs specific to HBsAg (anti-HBs) were quantified by end-point dilution ELISA assay (in triplicate) as described previously (Davis H. L et al 1998 *J Immunol* 160:870). End-point titers were defined as the highest plasma dilution that resulted in an absorbance value (OD450) two times  
10 higher than that of non-immune plasma with a cut-off value of 0.05.

- Isolation of primate PBMC and cell culture:** Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers, chimpanzees or rhesus or cynomolgus monkeys by Ficoll-hypaque density gradient centrifugation (Histopaque-1077, Sigma Chemical Co., St. Louis, MO) as described (Hartmann G., et al  
15 1996 *Antisense Nucleic Acid Drug Dev* 6:291). Cells were suspended in RPMI 1640 culture medium supplemented with 10 % (v/v) heat-inactivated ( $56^{\circ}\text{C}$ , 1 h) FCS (HyClone, Logan, UT), 1.5 mM L-glutamine, 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin (all from Gibco BRL, Grand Island, NY) (complete medium). Cells (final concentration  $1 \times 10^6$  cells/ml) were cultured in complete medium in a 5 %  $\text{CO}_2$   
20 humidified incubator at  $37^{\circ}\text{C}$ . ODN and LPS (from *Salmonella typhimurium*, Sigma Chemical Co., St. Louis, MO) or anti-IgM were used as stimuli. For measurement of human NK lytic activity, PBMC were incubated at  $5 \times 10^6$ /well in 24-well plates. Cultures were harvested after 24 hours, and cells were used as effectors in a standard 4 hours  $^{51}\text{Cr}$ -release assay against K562 target cells as previously described (Ballas Z. K.,  
25 Rasmussen W. L., and Krieg A. M. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. *J Immunol* 157:1840; Ballas Z. K., and Rasmussen W. 1993. Lymphokine-activated killer cells. VII. IL-4 induces an  $\text{NK1.1}^+\text{CD8}^+\text{TCR-}\alpha\beta^-$  lymphokine-activated killer subset. *J Immunol* 150:17). For B cell proliferation, 1  $\mu\text{Ci}$  of  $^3\text{H}$  thymidine was added 18 hours  
30 before harvest, and the amount of  $^3\text{H}$  thymidine incorporation was determined by scintillation counting at day 5. Standard deviations of the triplicate wells were  $< 5\%$ .



- 150 -

**Flow cytometry on primate PBMC:** Surface antigens on primate PBMC were stained as previously described (Hartmann G et al 1998 *J Pharmacol Exp Ther* 285:920). Monoclonal antibodies to CD3 (UCHT1), CD14 (M5E2), CD19 (B43), CD56 (B159), CD69 (FN50) and CD86 (2331 (FUN-1)) were purchased from Pharmingen, San Diego, CA. IgG<sub>1</sub>, $\kappa$  (MOPC-21) and IgG<sub>2b</sub>, $\kappa$  (Hartmann G et al 1999 *PNAS* 96:9305) were used to control for non-specific staining. NK cells were identified by CD56 expression on CD3, CD14 and CD19 negative cells, whereas B cells were identified by expression of CD19. Flow cytometric data from 10000 cells per sample were acquired on a FACScan (Beckton Dickinson Immunocytometry Systems, San Jose, CA). The viability of cells within the FSC/SSC gate used for analysis was examined by propidium iodide staining (2  $\mu$ g/ml) and found to be higher than 98 %. Data were analyzed using the computer program FlowJo (version 2.5.1, Tree Star, Inc., Stanford, CA).

**Immunization of chimpanzees and cynomolgus monkeys against HBsAg and evaluation of the humoral response:** Fourteen cynomolgus monkeys (2.0–3.5 kg) were immunized with a pediatric dose of Engerix-B (SmithKline Beecham Biologicals, Rixensart, BE) containing 10  $\mu$ g HBsAg adsorbed to alum (25 mg Al<sup>3+</sup>/mg HBsAg). This was administered alone (n=5), or combined with CpG ODN 1968 (n=5, 500  $\mu$ g) or CpG ODN 2006 (SEQ ID NO.: 246) (n=4, 150  $\mu$ g). Four chimpanzees (10-20 kg) were immunized in the same fashion with two receiving control vaccine (Engerix-B only) and two receiving experimental vaccine (Engerix-B plus 1 mg CpG ODN 2006). All vaccines were administered IM in the right anterior thigh in a total volume of 1 ml. Monkeys were maintained in the animal facility of the Primate Research Center (Bogor, Indonesia) and chimpanzees were housed at Bioqual (Rockville, MD). Animals were monitored daily by animal care specialists. No symptoms of general ill health or local adverse reactions at the injection site were noted. Plasma was recovered by IV puncture prior to and at various times after immunization and was stored frozen (-20°C) until assayed for antibodies. Anti-HBs antibodies were detected using a commercial ELISA kit (Monolisa Anti-HBs; Sanofi-Pasteur, Montreal, QC) and titers were expressed in mIU/ml based on comparison with WHO defined standards (Monolisa Anti-HBs Standards; Sanofi-Pasteur).

## Results



- 151 -

Identification of CpG ODN with different profiles of *in vitro* immune activities: Our studies showed that the precise bases on the 5' and 3' sides of a CpG dinucleotide within a CpG motif may have an impact on the level of immune activation of a synthetic ODN, but it has been unclear whether different CpG motifs might display different immune effects. To evaluate this possibility, we tested a panel of CpG ODN for their ability to induce NK lytic activity, B cell proliferation, and to stimulate synthesis of TNF- $\alpha$ , IL-6, IFN- $\gamma$  and IL-12 in murine spleen cells. Immunostimulatory activity of ODN without CpG motifs (ODN 1982 (SEQ ID NO.: 225), ODN 1983 (SEQ ID NO.: 226)) was negative or weak compared to CpG ODN. ODN with non optimal CpG motifs (ODN 1628 (SEQ ID NO.: 767), ODN 1758 (SEQ ID NO.: 1)) were less active than ODN containing CpG motifs flanked by two 5' purines and two 3' pyrimidines (ODN 1760 (SEQ ID NO.: 3), ODN 1826 (SEQ ID NO.: 69), ODN 1841 (SEQ ID NO.: 84)). ODN 1826 containing two optimal murine CpG motifs (5' GACGTT 3') (SEQ ID NO.: 1143) had the highest activity for 5 of 6 measured endpoints. Except for ODN 1628, all ODN showed a generally similar pattern of activity (NK cell-mediated lysis, B cell proliferation, IL-12, IL-6, TNF  $\alpha$ , IFN- $\gamma$ ). Of note, ODN 1628, which was unique in this panel for containing two G-rich regions, showed preferential induction of IFN- $\gamma$  synthesis but relatively low stimulation of the other activities.

Identification of *in vitro* assays which correlate with *in vivo* adjuvant activity: Since adjuvant activity is an *in vivo* endpoint, we were interested in identifying *in vitro* assays that would predict the adjuvant activity of a CpG ODN *in vivo*. The same ODN used for *in vitro* endpoints therefore were tested for their adjuvant activity to immunize mice against HBsAg. This was carried out both with ODN alone and with ODN combined with alum, since earlier studies had shown strong synergy for CpG ODN and alum adjuvants (PCT Published Patent Application WO98/40100).

BALB/c mice immunized with HBsAg without adjuvant attained only low titers of anti-HBs by 4 weeks, and this was not affected by addition of control ODN. In contrast, addition of CpG ODN raised anti-HBs titers by 5 to 40 fold, depending on the sequence used. When alum was added, titers of anti HBs were approximately 6 times higher than with HBsAg alone. Specifically, control ODN had no effect and the various CpG ODN augmented these titers 2 to 36 fold. Results obtained with the different ODN



- 152 -

alone correlated very strongly ( $r = 0.96$ ) with those obtained using the same ODN plus alum. When linear regression was performed, a very high degree of correlation was found between certain *in vitro* assays and *in vivo* augmentation of anti-HBs titers. Of all the *in vitro* endpoints examined, the induction of NK lytic activity showed the best correlation to *in vivo* adjuvant activity (without alum,  $r = 0.98$ ; with alum,  $r = 0.95$ ;  $p < 0.0001$ ). A good correlation regarding adjuvant activity was also obtained for B-cell stimulation ( $r = 0.84$  and  $0.7$ ), as well as secretion of TNF- $\alpha$  ( $r = 0.9$  and  $0.88$ ), IL-12 ( $r = 0.88$  and  $0.86$ ) and IL-6 ( $r = 0.85$  and  $0.91$ ). The one *in vitro* assay that did not correlate well with the *in vivo* results was IFN- $\gamma$  secretion ( $r = 0.57$  and  $0.68$ ). These data demonstrate that *in vitro* assays for NK lytic activity, B cell activation and production of TNF- $\alpha$ , IL-6 and IL-12 provide valuable information *in vitro* to predict the adjuvant activity of a given ODN *in vivo*.

Screening of a phosphorothioate ODN panel to activate human NK cells: In previous studies we found that synthesis of inflammatory cytokines by human PBMC is induced by extremely low amounts of endotoxin (induced TNF- $\alpha$  secretion is detectable with just 6 pg/ml endotoxin, 2 logs more sensitive than murine immune cells). In contrast, activation of human B cells and induction of human NK cell lytic activity with endotoxin is low even at high endotoxin concentrations. Based on these results we selected activation of NK cells (lytic activity and CD69 expression) and B cells (proliferation and CD86 expression) as the most highly specific and reproducible assays with low inter-subject variability and used these assays for *in vitro* screening of a pool of ODN.

First we studied the effect of phosphorothioate ODN containing various combinations and permutations of CpG motifs on NK cell-mediated lysis of target cells. For clarity and ease of presentation, only data with selected representative CpG and control ODN are shown. Human PBMC were incubated with different phosphorothioate ODN (6  $\mu\text{g/ml}$ ) for 24 hours and tested for their ability to lyse  $^{51}\text{Cr}$ -labeled K562 cells. ODN with two 6-mer CpG motifs (either 5' GACGTT 3' (SEQ ID NO.: 1143) or 5' GTCGTT 3' (SEQ ID NO.: 1144)) in combination with a TpC at the 5' end of the ODN (ODN 1840 5' TCCATGTCGTTTCCTGTCGTT 3' (SEQ ID NO.: 83), ODN 1851 5' TCCTGACGTTTCCTGACGTT 3' (SEQ ID NO.: 94) or with at least three 6-mer motifs without a TpC at the 5' end (ODN 2013 (SEQ ID NO.: 253)) show intermediate activity.



- 153 -

High activity was found when the 5' TpC directly preceded a 6-mer human CpG motif (5' **TCGTCGTT** 3' (SEQ ID NO.: 1145)) and was followed by two 6-mer motifs (ODN 2005 (SEQ ID NO.: 245), ODN 2006 (SEQ ID NO.: 246) and ODN 2007 (SEQ ID NO.: 247)). The best results were obtained when the 6-mer CpG motifs were separated from each other and from the 5' 8-mer CpG motif by TpT (ODN 2006 (SEQ ID NO.: 246)).

Expression of the activation marker CD69 is rapidly upregulated on the surface of NK cells subsequent to stimulation. To confirm the results from the NK cell lysis assay, PBMC were incubated for 18 hours with ODN (2 µg/ml). CD69 expression was examined on CD56 positive NK cells (CD3, CD14 and CD19 negative). Although induction of CD69 expression was less sequence restricted than stimulation of NK cell functional activity, control ODN (ODN 1982, ODN 2116, ODN 2117, ODN 2010) showed only low activity similar to background levels. ODN with two human CpG motifs separated by 5' TTTT 3' (ODN 1965 (SEQ ID NO.: 208)) or four human CpG motifs without spacing (ODN 2013 (SEQ ID NO.: 253)) were relatively more active at inducing CD69 expression than at stimulating NK cell lytic activity. Optimal NK cell functional activity, as well as CD69 expression, was obtained with ODNs containing a TpC dinucleotide preceding the human CpG motif, and additional human motifs within the sequence (ODN 2006 (SEQ ID NO.: 246), ODN 2007 (SEQ ID NO.: 247)).

Activity of phosphorothioate ODN for stimulating human B cells: In preliminary experiments we found that the percentage of proliferating B cells (CFSE assay, see methods section) correlated with the surface expression of the co-stimulatory CD86 on B cells, as measured by flow cytometry. Thus we used CD86 expression on B cells to screen a panel of ODN for their immunostimulatory activity. PBMC were incubated with 0.6 µg/ml ODN. Expression of CD86 (mean fluorescence intensity, MFI) was examined on CD19 positive B cells. A poly C ODN (ODN 2017 (SEQ ID NO.: 257)) or ODN without CpG dinucleotides (ODN 1982 (SEQ ID NO.: 225)) failed to stimulate human B cells under these experimental conditions. A phosphorothioate ODN (ODN 2116 (SEQ ID NO.: 256)) with one optimal human CpG motif preceded by a TpC (5' **TCGTCGTT** 3' (SEQ ID NO.: 1145)) had low activity. The presence of one human 6-mer CpG motif (5' **GTCGTT** 3' (SEQ ID NO.: 1144)) had no activating effect. Two of these CpG motifs within the sequence showed no (ODN 1960 (SEQ ID NO.: 203), ODN 2016 (SEQ ID NO.: 256)) or intermediate (ODN 1965 (SEQ ID NO.: 208)) activity dependent on the



- 154 -

sequence context. If the ODN was composed of three or four copies of this motif (ODN 2012 (SEQ ID NO.: 252), ODN 2013 (SEQ ID NO.: 253), ODN 2014 (SEQ ID NO.: 254)), intermediate activity on B cells could be detected. The combination of the human 8-mer CpG motif on the 5' end of the ODN with two 6-mer CpG motifs (ODN 2005 (SEQ ID NO.: 245), ODN 2006 (SEQ ID NO.: 246), ODN 2007 (SEQ ID NO.: 247), ODN 2102 (SEQ ID NO.: 343), ODN 2103 (SEQ ID NO.: 344)) led to a considerable increase in the ability of the ODN to stimulate B cells. The spacing between the single motifs was critical. The separation of CpG motifs by TpT was preferable (ODN 2006 (SEQ ID NO.: 246)) compared to unseparated CpG motifs (ODN 2005 (SEQ ID NO.: )); also compare ODN 1965 (SEQ ID NO.: 208) to ODN 1960 (SEQ ID NO.: 203)). The human 6-mer CpG motif (5' GTCGTT 3') was better than the optimal mouse 6-mer CpG motif (5' GACGTT 3' (SEQ ID NO.: 246)) when combined with the human 8-mer CpG motif on the 5' end (ODN 2006 vs. ODN 2102 (SEQ ID NO.: 343) and ODN 2103 (SEQ ID NO.: 344)). A (TCG)<sub>poly</sub> ODN was inactive or only weakly active, as were ODN containing CpG dinucleotides flanked by guanines or other CpG dinucleotides (ODN 2010 (SEQ ID NO.: 250)). Taken together, the findings for NK cells and B cells showed consistently that of the ODN tested, ODN 2006 (SEQ ID NO.: 246) has the highest immunostimulatory activity on human immune cells.

Comparative analysis of potency of CpG phosphorothioate ODNs in different primates: Different CpG motifs are optimal to activate murine and human immune cells. Furthermore, the number and location of CpG motifs within an active phosphorothioate ODN is different in mice and humans. We were interested to know if CpG phosphorothioate ODN show a similar activity among different species of primates. We compared a panel of CpG ODN for their ability to induce B cell proliferation in humans, chimpanzees and rhesus or cynomolgus monkeys. The capability of ODN to stimulate human B cell proliferation (Table J) correlated well with their ability to induce CD86 expression on B cells. ODN 2006 (SEQ ID NO.: 246), which showed the highest activity in human B cells and NK cells, was also the most active in stimulating chimpanzee and rhesus monkey B cell proliferation (Table J). ODN 1968 (SEQ ID NO.: 211) and ODN 2006 (SEQ ID NO.: 246) gave the highest activation of cynomolgus monkey B-cells *in vitro* (SI of 25 and 29 respectively at 6 µg ODN/ml). Surprisingly, CpG ODN 2007 (SEQ ID NO.: 247), which displayed similarly high activity as the optimal ODN 2006



- 155 -

(SEQ ID NO.: 246) in human cells, did not stimulate Rhesus monkey or chimpanzee B cell proliferation, and the ODN 1968 (SEQ ID NO.: 211) showed low activity. CpG ODN originally identified with high activity in mice (ODN 1760 (SEQ ID NO.: 3), ODN 1826 (SEQ ID NO.: 69)) showed little activity in monkeys (Table J).

5 **Table J:** Proliferative response of PBMC to phosphorothioate CpG ODN in primates

|                                      | Humans       | Chimpanzee       | Rhesus<br>monkey |
|--------------------------------------|--------------|------------------|------------------|
| No addition                          | 0.5+-0.1     | 0.5+-0.1         | 0.5+-0.0         |
| ODN 1760<br>(SEQ ID NO.: 3)          | 23+-7        | 0.3+-0.1         | 0.5+-0.3         |
| ODN 1826<br>(SEQ ID NO.: 69)         | 0.8+-0.1     | 0.4+-0.1         | 0.6+-0.1         |
| ODN 1968<br>(SEQ ID NO.: 211)        | 35+-9        | 20.0+-3.8        | 1.9+-0.7         |
| ODN 1982<br>(SEQ ID NO.: 225)        | 9.7+-1.1     | 2.5+-1.1         | 0.7+-0.1         |
| <b>ODN 2006</b><br>(SEQ ID NO.: 246) | <b>58+-8</b> | <b>27.4+-8.9</b> | <b>6.3+-3.3</b>  |
| ODN 2007<br>(SEQ ID NO.: 247)        | 47+-11       | 0.5+-0.1         | 0.4+-0.2         |

PBMC were prepared from peripheral blood and incubated with ODN (0.6 µg/ml) as indicated for five days. Proliferation was measured by uptake of <sup>3</sup>H/thymidine (cpm/1000) during the last 18 hours. More than 95 % of proliferating cells were B-cells as determined using the CFSE assay. Four human probands, six chimpanzees and two rhesus monkeys were tested.

In vivo adjuvant activity of CpG ODN in chimpanzees and cynomolgus monkeys: In order to evaluate whether CpG ODN with strong *in vitro* stimulatory effects on primate cells had detectable adjuvant activity *in vivo*, Cynomolgus monkeys and chimpanzees were immunized with Engerix B, which comprises HBsAg adsorbed to



- 156 -

alum, alone or with added ODN 1968 (500  $\mu$ g) or ODN 2006 (SEQ ID NO.: 246) (1 mg) respectively. Compared to controls not receiving CpG ODN, anti-HBs titers at 4 weeks post-prime and 2 weeks post-boost were 66- and 16-fold higher respectively in the monkeys, and 15- and 3-fold higher in the chimpanzees (Table K). Thus a clear adjuvant effect of CpG ODN was seen, and this was particularly striking after a single immunization.

**Table K** Anti-HBs responses in primates immunized against HBsAg with CpG ODN<sup>3</sup>

| <u>Primate species</u> | <u>n</u> | <u>CpG ODN</u>                             | <u>Anti-HBs (mIU/ml)</u> |                         |
|------------------------|----------|--------------------------------------------|--------------------------|-------------------------|
|                        |          |                                            | <u>4 wks post-prime</u>  | <u>2 wks post-boost</u> |
| Cynomolgus monkey      | 5        | None                                       | 15 $\pm$ 44              | 4880 $\pm$ 13113        |
|                        | 5        | ODN 1968 (500 $\mu$ g)<br>(SEQ ID NO. 211) | 995 $\pm$ 1309           | 76449 $\pm$ 42094       |
| Chimpanzee             | 2        | None                                       | 6, 11                    | 3712, 4706              |
|                        | 2        | ODN 2006 (1 mg)<br>(SEQ ID NO. 246)        | 125, 135                 | 9640, 16800             |

<sup>3</sup>Animals were immunized by IM injection of Engerix B containing 10  $\mu$ g HBsAg adsorbed to alum, alone or with added CpG ODN. Cynomolgus monkeys were boosted at 10 wks and chimpanzees were boosted at 4 wks post-prime. Anti-HBs was determined by ELISA assay; values for monkeys are GMT  $\pm$  SEM (n=5) whereas individual values for the two chimpanzees in each group are provided.

I claim:



## SEQUENCE LISTING

<110> University of Iowa Research Foundation  
Coley Pharmaceutical Group GmbH

<120> Immunostimulatory Nucleic Acids

<130> C1039/7035WO (HCL/MAT)

<150> US 60/156,113

<151> 1999-09-25

<150> US 60/156,135

<151> 1999-09-27

<150> US 60/227,436

<151> 2000-08-23

<160> 1145

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1

tctcccagcg tgcgccat

18

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 2

ataatccagc ttgaaccaag

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 3

ataatcgacg ttcaagcaag

20

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<400> 4

taccgcgtgc gaccctct

18

<210> 5

<211> 9

<212> DNA



<213> Artificial Sequence  
 <400> 5  
 ggggaggggt 9  
 <210> 6  
 <211> 9  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 6  
 ggggagggg 9  
 <210> 7  
 <211> 9  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 7  
 ggtgaggtg 9  
 <210> 8  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> modified\_base  
 <222> (8)...(8)  
 <223> m5c  
 <400> 8  
 tccatgtngt tcctgatgct 20  
 <210> 9  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> modified\_base  
 <222> (11)...(11)  
 <223> m5c  
 <400> 9  
 gctaccttag ngtaga 15  
 <210> 10  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> modified\_base  
 <222> (8)...(8)  
 <223> m5c  
 <400> 10  
 tccatgangt tcctgatgct 20  
 <210> 11



<211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (13)...(13)  
 <223> m5c  
  
 <400> 11  
 tccatgacgt tcntgatgct 20  
  
 <210> 12  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (7)...(7)  
 <223> m5c  
  
 <400> 12  
 gctagangtt agtgt 15  
  
 <210> 13  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 13  
 agctccatgg tgctcactg 19  
  
 <210> 14  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 14  
 ccacgtcgac cctcaggcga 20  
  
 <210> 15  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 15  
 gcacatcgtc ccgcagccga 20  
  
 <210> 16  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 16  
 gtcactcgtg gtacctcga 19  
  
 <210> 17  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence



<400> 17  
gttggataca ggccagactt tgttg 25

<210> 18  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<400> 18  
gattcaactt gcgctcatct taggc 25

<210> 19  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 19  
accatggacg aactgtttcc cctc 24

<210> 20  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 20  
accatggacg agctgtttcc cctc 24

<210> 21  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 21  
accatggacg acctgtttcc cctc 24

<210> 22  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 22  
accatggacg tactgtttcc cctc 24

<210> 23  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 23  
accatggacg gtctgtttcc cctc 24

<210> 24  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 24  
accatggacg ttctgtttcc cctc 24

<210> 25



WO 01/22972

PCT/US00/26383

5

<211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 25  
 ccactcacat ctgctgctcc acaag 25  
  
 <210> 26  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 26  
 acttctcata gtccctttgg tccag 25  
  
 <210> 27  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 27  
 tccatgagct tcctgagtct 20  
  
 <210> 28  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (9)...(9)  
 <223> I  
  
 <221> modified\_base  
 <222> (11)...(11)  
 <223> I  
  
 <221> modified\_base  
 <222> (15)...(15)  
 <223> I  
  
 <400> 28  
 gaggaaggng nggangacgt 20  
  
 <210> 29  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (7)...(7)  
 <223> I  
  
 <221> modified\_base  
 <222> (13)...(13)  
 <223> I  
  
 <221> modified\_base  
 <222> (18)...(18)  
 <223> I



|                           |    |
|---------------------------|----|
| <400> 29                  |    |
| gtgaatncgt tcncgggnct     | 20 |
| <210> 30                  |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 30                  |    |
| aaaaaa                    | 6  |
| <210> 31                  |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 31                  |    |
| cccccc                    | 6  |
| <210> 32                  |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 32                  |    |
| ctgtca                    | 6  |
| <210> 33                  |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 33                  |    |
| tcgtag                    | 6  |
| <210> 34                  |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 34                  |    |
| tcgtgg                    | 6  |
| <210> 35                  |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 35                  |    |
| cgtcgt                    | 6  |
| <210> 36                  |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 36                  |    |
| tccatgtcgg tcctgagtct     | 20 |
| <210> 37                  |    |



<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 37  
tccatgccgg tcctgagtct 20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 38  
tccatgacgg tcctgagtct 20

<210> 39  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 39  
tccatgacgg tcctgagtct 20

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 40  
tccatgtcga tcctgagtct 20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 41  
tccatgtcgc tcctgagtct 20

<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 42  
tccatgtcgt tcctgagtct 20

<210> 43  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 43  
tccatgacgt tcctgagtct 20

<210> 44  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 44



WO 01/22972

PCT/US00/26383

8

tccataacgt tcctgagtct

20

&lt;210&gt; 45

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 45

tccatgacgt ccctgagtct

20

&lt;210&gt; 46

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 46

tccatcacgt gcctgagtct

20

&lt;210&gt; 47

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 47

tccatgctgg tcctgagtct

20

&lt;210&gt; 48

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (8)...(8)

&lt;223&gt; m5c

&lt;400&gt; 48

tccatgtngg tcctgagtct

20

&lt;210&gt; 49

&lt;211&gt; 39

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 49

ccgcttcctc cagatgagct catgggtttc tccaccaag

39

&lt;210&gt; 50

&lt;211&gt; 39

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 50

cttggtggag aaacccatga gctcatctgg aggaagcgg

39

&lt;210&gt; 51

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 51



WO 01/22972

PCT/US00/26383

9

ccccaagggtt atgagaagtt

20

&lt;210&gt; 52

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 52

agatagcaaa tcggctgacg

20

&lt;210&gt; 53

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 53

ggttcacgtg ctcatggctg

20

&lt;210&gt; 54

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 54

tctcccagcg tgcgccat

18

&lt;210&gt; 55

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 55

tctcccagcg tgcgccat

18

&lt;210&gt; 56

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 56

taccgcgtgc gaccctct

18

&lt;210&gt; 57

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 57

ataatccagc ttgaaccaag

20

&lt;210&gt; 58

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 58

ataatcgacg ttcaagcaag

20

&lt;210&gt; 59

&lt;211&gt; 20

&lt;212&gt; DNA



<213> Artificial Sequence  
 <400> 59  
 tccatgattt tcctgatttt 20  
 <210> 60  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 60  
 ttgttttttt gtttttttgt tttt 24  
 <210> 61  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 61  
 ttttttttgt ttttttgttt tt 22  
 <210> 62  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 62  
 tgctgctttt gtgcttttgt gctt 24  
 <210> 63  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 63  
 tgctgcttgt gcttttgtgc tt 22  
 <210> 64  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 64  
 gcattcatca ggcgggcaag aat 23  
 <210> 65  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 65  
 taccgagctt cgacgagatt tca 23  
 <210> 66  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 66  
 gcatgacgtt gagct 15



<210> 67  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 67  
 cacgttgagg ggcac 15  
  
 <210> 68  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 68  
 ctgctgagac tggag 15  
  
 <210> 69  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 69  
 tccatgacgt tcctgacgtt 20  
  
 <210> 70  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 70  
 gcatgagctt gagctga 17  
  
 <210> 71  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 71  
 tcagcgtgcg cc 12  
  
 <210> 72  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 72  
 atgacgttcc tgacgtt 17  
  
 <210> 73  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 73  
 ttttggggtt ttggggtttt 20  
  
 <210> 74  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



<400> 74  
 tctaggcttt ttaggcttcc 20  
  
 <210> 75  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 75  
 tgcatttttt aggccaccat 20  
  
 <210> 76  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 76  
 tctcccagcg tgcgtgcgcc at 22  
  
 <210> 77  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 77  
 tctcccagcg ggcgcat 17  
  
 <210> 78  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 78  
 tctcccagcg agcgccat 18  
  
 <210> 79  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 79  
 tctcccagcg cgcgccat 18  
  
 <210> 80  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 80  
 ggggtgacgt tcagggggg 19  
  
 <210> 81  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 81  
 ggggtccagc gtgcgccatg gggg 24  
  
 <210> 82  
 <211> 19



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 82  
 ggggtgtcgt tcagggggg 19  
  
 <210> 83  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 83  
 tccatgtcgt tcctgtcgtt 20  
  
 <210> 84  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 84  
 tccatagcgt tcctagcgtt 20  
  
 <210> 85  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 85  
 tcgtcgctgt ctccgcttct t 21  
  
 <210> 86  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 86  
 gcatgacgtt gagct 15  
  
 <210> 87  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 87  
 tctcccagcg tgcgccatat 20  
  
 <210> 88  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (8)...(8)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (17)...(17)  
 <223> m5c  
  
 <400> 88



|                           |    |    |
|---------------------------|----|----|
|                           | 14 |    |
| tccatgangt tcctgangtt     | 20 |    |
| <210> 89                  |    |    |
| <211> 15                  |    |    |
| <212> DNA                 |    |    |
| <213> Artificial Sequence |    |    |
| <220>                     |    |    |
| <221> modified_base       |    |    |
| <222> (7)...(7)           |    |    |
| <223> m5c                 |    |    |
| <400> 89                  |    |    |
| gcatgangtt gagct          |    | 15 |
| <210> 90                  |    |    |
| <211> 16                  |    |    |
| <212> DNA                 |    |    |
| <213> Artificial Sequence |    |    |
| <400> 90                  |    |    |
| tccagcgtgc gccata         |    | 16 |
| <210> 91                  |    |    |
| <211> 18                  |    |    |
| <212> DNA                 |    |    |
| <213> Artificial Sequence |    |    |
| <400> 91                  |    |    |
| tctcccagcg tgcgcat        |    | 18 |
| <210> 92                  |    |    |
| <211> 20                  |    |    |
| <212> DNA                 |    |    |
| <213> Artificial Sequence |    |    |
| <400> 92                  |    |    |
| tccatgagct tcctgagtct     |    | 20 |
| <210> 93                  |    |    |
| <211> 15                  |    |    |
| <212> DNA                 |    |    |
| <213> Artificial Sequence |    |    |
| <400> 93                  |    |    |
| gcatgtcgtt gagct          |    | 15 |
| <210> 94                  |    |    |
| <211> 19                  |    |    |
| <212> DNA                 |    |    |
| <213> Artificial Sequence |    |    |
| <400> 94                  |    |    |
| tcctgacgtt cctgacgtt      |    | 19 |
| <210> 95                  |    |    |
| <211> 15                  |    |    |
| <212> DNA                 |    |    |
| <213> Artificial Sequence |    |    |
| <400> 95                  |    |    |



WO 01/22972

PCT/US00/26383

15

gcatgatggt gagct

15

<210> 96  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 96  
 gcatttcgag gagct

15

<210> 97  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 97  
 gcatgtagct gagct

15

<210> 98  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 98  
 tccaggacgt tcctagttct

20

<210> 99  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 99  
 tccaggagct tcctagttct

20

<210> 100  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 100  
 tccaggatgt tcctagttct

20

<210> 101  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 101  
 tccagtctag gcctagttct

20

<210> 102  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 102  
 tccagttcga gcctagttct

20

<210> 103  
 <211> 15  
 <212> DNA



<213> Artificial Sequence  
 <400> 103  
 gcatggcggtt gagct 15  
 <210> 104  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 104  
 gcatagcggtt gagct 15  
 <210> 105  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 105  
 gcattgcggtt gagct 15  
 <210> 106  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 106  
 gcttgcgttg cgttt 15  
 <210> 107  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 107  
 tctcccagcg ttgcgccata t 21  
 <210> 108  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 108  
 tctcccagcg tgcggttatat 20  
 <210> 109  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 109  
 tctccctgcg tgcgcatat 20  
 <210> 110  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 110  
 tctgcgtgcg tgcgcatat 20



<210> 111  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 111  
 tctcctagcg tgcgccatat 20  
  
 <210> 112  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 112  
 tctcccagcg tgcgcctttt 20  
  
 <210> 113  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_difference  
 <222> (5)...(5)  
 <223> n is a or g or c or t/u  
  
 <221> misc\_difference  
 <222> (6)...(6)  
 <223> d is a or g or t/u; not c  
  
 <221> misc\_difference  
 <222> (9)...(10)  
 <223> h is a or c or t/u; not g  
  
 <400> 113  
 gctandcghh agc 13  
  
 <210> 114  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 114  
 tcctgacgtt ccc 13  
  
 <210> 115  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 115  
 ggaagacgtt aga 13  
  
 <210> 116  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 116  
 tcctgacgtt aga 13



<210> 117  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 117  
 tcagaccagc tggtcgggtg ttcctga 27  
  
 <210> 118  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 118  
 tcaggaacac ccgaccagct ggtctga 27  
  
 <210> 119  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 119  
 gctagtcgat agc 13  
  
 <210> 120  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 120  
 gctagtcgct agc 13  
  
 <210> 121  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 121  
 gcttgacgtc tagc 14  
  
 <210> 122  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 122  
 gcttgacggt tagc 14  
  
 <210> 123  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 123  
 gcttgacgtc aagc 14  
  
 <210> 124  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence



|                                                                 |    |
|-----------------------------------------------------------------|----|
| <400> 124<br>gctagacggt tagc                                    | 14 |
| <210> 125<br><211> 20<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 125<br>tccatgacat tcctgatgct                              | 20 |
| <210> 126<br><211> 14<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 126<br>gctagacgtc tagc                                    | 14 |
| <210> 127<br><211> 19<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 127<br>ggctatgtcg ttcctagcc                               | 19 |
| <210> 128<br><211> 19<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 128<br>ggctatgtcg atcctagcc                               | 19 |
| <210> 129<br><211> 21<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 129<br>ctcatgggtt tctccaccaa g                            | 21 |
| <210> 130<br><211> 21<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 130<br>cttggtggag aaacccatga g                            | 21 |
| <210> 131<br><211> 20<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 131<br>tccatgacgt tcctagttct                              | 20 |
| <210> 132<br><211> 24                                           |    |



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 132  
 ccgcttcctc cagatgagct catg 24  
  
 <210> 133  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 133  
 catgagctca tctggaggaa gcgg 24  
  
 <210> 134  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 134  
 ccagatgagc tcatgggttt ctcc 24  
  
 <210> 135  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 135  
 ggagaaaccc atgagctcat ctgg 24  
  
 <210> 136  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 136  
 agcatcagga acgacatgga 20  
  
 <210> 137  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 137  
 tccatgacgt tcctgacgtt 20  
  
 <210> 138  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 138  
 gcgcgcgcgc gcgcgcgcgc 19  
  
 <210> 139  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 139  
 ccggccggcc ggccggccgg 20



<210> 140  
 <211> 43  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 140  
 ttccaatcag cccacccgc tctggcccca ccctcaccct cca 43  
  
 <210> 141  
 <211> 43  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 141  
 tggaggggtga ggggtggggcc agagcgggtg gggctgattg gaa 43  
  
 <210> 142  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 142  
 tcaaattgtgg gattttccca tgagtct 27  
  
 <210> 143  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 143  
 agactcatgg gaaaatccca catttga 27  
  
 <210> 144  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 144  
 tgccaagtgc tgagtcacta ataaaga 27  
  
 <210> 145  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 145  
 tctttattag tgactcagca cttggca 27  
  
 <210> 146  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 146  
 tgcaggaagt ccgggttttc cccaaccccc c 31  
  
 <210> 147  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence



<400> 147  
 gggggggttg ggaaaacccg gacttcctgc a 31

<210> 148  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence

<400> 148  
 ggggactttc cgctggggac tttccagggg gactttcc 38

<210> 149  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence

<400> 149  
 tccatgacgt tcctctccat gacgttcctc tccatgacgt tcctc 45

<210> 150  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence

<400> 150  
 gaggaacgtc atggagagga acgtcatgga gaggaacgtc atgga 45

<210> 151  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 151  
 ataatagagc ttcaagcaag 20

<210> 152  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 152  
 tccatgacgt tcctgacgtt 20

<210> 153  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 153  
 tccatgacgt tcctgacgtt 20

<210> 154  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 154  
 tccaggactt tcctcaggtt 20

<210> 155



23

<211> 45  
 <212> DNA  
 <213> Artificial Sequence

<400> 155  
 tcttgcgatg ctaaaggacg tcacattgca caatcttaat aaggt 45

<210> 156  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence

<400> 156  
 accttattaa gattgtgcaa tgtgacgtcc tttagcatcg caaga 45

<210> 157  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<400> 157  
 tcctgacgtt cctggcggtc ctgtcgct 28

<210> 158  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<400> 158  
 tcctgtcgct cctgtcgct 19

<210> 159  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 159  
 tcctgacgtt gaagt 15

<210> 160  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 160  
 tcctgtcggt gaagt 15

<210> 161  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 161  
 tcctggcggt gaagt 15

<210> 162  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 162



24

tcctgccgtt gaagt

15

<210> 163  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 163  
 tccttacgtt gaagt

15

<210> 164  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 164  
 tcctaacgtt gaagt

15

<210> 165  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 165  
 tcctcacgtt gaagt

15

<210> 166  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 166  
 tcctgacgat gaagt

15

<210> 167  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 167  
 tcctgacgct gaagt

15

<210> 168  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 168  
 tcctgacggt gaagt

15

<210> 169  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 169  
 tcctgacgta gaagt

15

<210> 170  
 <211> 15  
 <212> DNA



<213> Artificial Sequence  
 <400> 170  
 tcctgacgtc gaagt 15  
 <210> 171  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 171  
 tcctgacgtg gaagt 15  
 <210> 172  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 172  
 tcctgagctt gaagt 15  
 <210> 173  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 173  
 gggggacgtt ggggg 15  
 <210> 174  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 174  
 tcctgacgtt ccttc 15  
 <210> 175  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 175  
 tctcccagcg agcgagcgcc at 22  
 <210> 176  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 176  
 tcctgacgtt cccctggcgg tcccctgtcg ct 32  
 <210> 177  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 177  
 tcctgtcgct cctgtcgctc ctgtcgct 28



26

<210> 178  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 178  
 tcctggcggg gaagt 15  
  
 <210> 179  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (7)...(7)  
 <223> m5c  
  
 <400> 179  
 tcctgangtt gaagt 15  
  
 <210> 180  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (3)...(3)  
 <223> m5c  
  
 <400> 180  
 tcntgacgtt gaagt 15  
  
 <210> 181  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 181  
 tcctagcgtt gaagt 15  
  
 <210> 182  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 182  
 tccagacgtt gaagt 15  
  
 <210> 183  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 183  
 tcctgacggg gaagt 15  
  
 <210> 184  
 <211> 15  
 <212> DNA



27

<213> Artificial Sequence  
 <400> 184  
 tcctggcggt gaagt 15  
 <210> 185  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 185  
 ggctccgggg agggaatttt tgtctat 27  
 <210> 186  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 186  
 atagacaaaa attccctccc cggagcc 27  
 <210> 187  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 187  
 tccatgagct tccttgagtc t 21  
 <210> 188  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 188  
 tcgtcgctgt ctccgcttct t 21  
 <210> 189  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 189  
 tcgtcgctgt ctccgcttct t 21  
 <210> 190  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 190  
 tcgagacatt gcacaatcat ctg 23  
 <210> 191  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 191  
 cagattgtgc aatgtctcga 20



<210> 192  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 192  
tccatgtcgt tcctgatgcg 20

<210> 193  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 193  
gcgatgtcgt tcctgatgct 20

<210> 194  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 194  
gcgatgtcgt tcctgatgcg 20

<210> 195  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 195  
tccatgtcgt tccgcgcgcg 20

<210> 196  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 196  
tccatgtcgt tcctgccgct 20

<210> 197  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 197  
tccatgtcgt tcctgtagct 20

<210> 198  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 198  
gcggcgggcg gcgcgcgccc 20

<210> 199  
<211> 21  
<212> DNA  
<213> Artificial Sequence



|                           |    |
|---------------------------|----|
| <400> 199                 |    |
| atcaggaacg tcatgggaag c   | 21 |
| <210> 200                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 200                 |    |
| tccatgagct tcctgagtct     | 20 |
| <210> 201                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 201                 |    |
| tcaacggt                  | 8  |
| <210> 202                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 202                 |    |
| tcaagctt                  | 8  |
| <210> 203                 |    |
| <211> 19                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 203                 |    |
| tcctgtcggt cctgtcggt      | 19 |
| <210> 204                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 204                 |    |
| tccatgtcgt tttgtcgtt      | 20 |
| <210> 205                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 205                 |    |
| tcctgtcggt cctgtcggt      | 20 |
| <210> 206                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 206                 |    |
| tcctgtcgt tcctgtcgtt      | 20 |
| <210> 207                 |    |
| <211> 29                  |    |



<212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.  
  
 <400> 207  
 tccattccat gacgttcctg atgcttcca 29  
  
 <210> 208  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 208  
 tcctgtcggtt ttttgtegtt 20  
  
 <210> 209  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 209  
 tcgtcgctgt ctccgcttct t 21  
  
 <210> 210  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 210  
 tcgtcgctgt ctgcccttct t 21  
  
 <210> 211  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 211  
 tcgtcgctgt tgtcgtttct t 21  
  
 <210> 212  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 212  
 tcctgtcggtt cctgtcggtg gaacgacagg 30  
  
 <210> 213  
 <211> 40  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 213  
 tcctgtcggtt cctgtcggtt caacgacagg aacgacagga 40  
  
 <210> 214  
 <211> 21



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 214  
 ggggtctgtc gttttggggg g 21  
  
 <210> 215  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 215  
 ggggtctgtg cttttggggg g 21  
  
 <210> 216  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 216  
 tccggccgtt gaagt 15  
  
 <210> 217  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 217  
 tccggacggt gaagt 15  
  
 <210> 218  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 218  
 tcccgcggtt gaagt 15  
  
 <210> 219  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 219  
 tccagacggt gaagt 15  
  
 <210> 220  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 220  
 tcccgcggtt gaagt 15  
  
 <210> 221  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 221  
 tccagagctt gaagt 15



<210> 222  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (8)...(8)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (17)...(17)  
 <223> m5c  
  
 <400> 222  
 tccatgtngt tcctgtngtt 20  
  
 <210> 223  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 223  
 tccatgacgt tcctgacgtt 20  
  
 <210> 224  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 224  
 ggggttgacg ttttgggggg 20  
  
 <210> 225  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 225  
 tccaggactt ctctcaggtt 20  
  
 <210> 226  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 226  
 tttttttttt tttttttttt 20  
  
 <210> 227  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 227  
 tccatgccgt tcctgccgtt 20  
  
 <210> 228  
 <211> 20  
 <212> DNA



<213> Artificial Sequence  
 <400> 228  
 tccatggcgg gcctggcggg 20  
 <210> 229  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 229  
 tccatgacgt tcctgccgtt 20  
 <210> 230  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 230  
 tccatgacgt tcctggcggg 20  
 <210> 231  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 231  
 tccatgacgt tcctgcgttt 20  
 <210> 232  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 232  
 tccatgacgg tcctgacggt 20  
 <210> 233  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 233  
 tccatgcgtg cgtgcgtttt 20  
 <210> 234  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 234  
 tccatgcgtt gcgttgcgtt 20  
 <210> 235  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_feature  
 <222> (1)...(3)



34

<223> Biotin moiety attached at 5' end of sequence.

<400> 235  
tccattccat tctaggcctg agtcttccat 30

<210> 236  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 236  
tccatagcgt tcctagcggt 20

<210> 237  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 237  
tccatgtcgt tcctgtcggt 20

<210> 238  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 238  
tccatagcga tcctagcgat 20

<210> 239  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 239  
tccattgcgt tccttgcgtt 20

<210> 240  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 240  
tccatagcgg tcctagcggg 20

<210> 241  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<400> 241  
tccatgattt tcctgcagtt cctgatttt 29

<210> 242  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<400> 242  
tccatgacgt tcctgcagtt cctgacgtt 29



<210> 243  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 243  
 ggcggcggcg gcggcggcgg 20  
  
 <210> 244  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 244  
 tccacgacgt ttctgacgtt 20  
  
 <210> 245  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 245  
 tcgtcgttgt cgttgctcgtt 20  
  
 <210> 246  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 246  
 tcgtcgtttt gtcgttttgt cgtt 24  
  
 <210> 247  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 247  
 tcgtcgttgt cgttttgtcg tt 22  
  
 <210> 248  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 248  
 gcgtgcgttg tcgttgctgt t 21  
  
 <210> 249  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (2)...(2)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (6)...(6)  
 <223> m5c



<221> modified\_base  
 <222> (10)...(10)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (15)...(15)  
 <223> m5c  
  
 <400> 249  
 cnggcnggc n gggcnccgg 19  
  
 <210> 250  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 250  
 gcggcgggc gcgcgcgccc 20  
  
 <210> 251  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (3)...(3)  
 <223> I  
  
 <221> modified\_base  
 <222> (8)...(8)  
 <223> I  
  
 <221> modified\_base  
 <222> (14)...(14)  
 <223> I  
  
 <400> 251  
 agncccgnga acgnattcac 20  
  
 <210> 252  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 252  
 tgtcgtttgt cgtttgtcgt t 21  
  
 <210> 253  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 253  
 tgtcgttgtc gttgtcgttg tcggtt 25  
  
 <210> 254  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence



<400> 254  
 tgtcggtgtc gttgctggtg tcggt 25  
  
 <210> 255  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 255  
 tcgctgctgct cggt 14  
  
 <210> 256  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 256  
 tgtcggtgtc gtt 13  
  
 <210> 257  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 257  
 ccccccccccc ccccccccccc 20  
  
 <210> 258  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 258  
 tctagcggttt ttagcggtcc 20  
  
 <210> 259  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 259  
 tgcaccccc aggccaccat 20  
  
 <210> 260  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 260  
 tcgctgctgct cgctgctgct gtt 23  
  
 <210> 261  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 261  
 tcgctggtgt cggtgctggt 20  
  
 <210> 262



38

<211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 262  
 tcgtcgtttt gtcgttttgt cgtt 24

<210> 263  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<400> 263  
 tcgtcgttgt cgttttgtcg tt 22

<210> 264  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

<400> 264  
 ggggagggag gaacttctta aaattccccc agaatgttt 39

<210> 265  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

<400> 265  
 aaacattctg ggggaatttt aagaagttcc tccctcccc 39

<210> 266  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<400> 266  
 atgtttactt cttaaaattc ccccagaatg ttt 33

<210> 267  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<400> 267  
 aaacattctg ggggaatttt aagaagtaaa cat 33

<210> 268  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<400> 268  
 atgtttacta gacaaaattc ccccagaatg ttt 33

<210> 269  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<400> 269



WO 01/22972

PCT/US00/26383

39

aaacattctg ggggaatttt gtctagtaaa cat  
33

<210> 270  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 270  
aaaattgacg ttttaaaaaa 20

<210> 271  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 271  
ccccttgacg ttttcccccc 20

<210> 272  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 272  
ttttcgttgt tttgtcgtt 20

<210> 273  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 273  
tcgtcgtttt gtcgttttgt cggt 24

<210> 274  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<400> 274  
ctgcagcctg ggac 14

<210> 275  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<400> 275  
acccgtcgta attatagtaa aaccc 25

<210> 276  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 276  
ggtacctgtg gggacattgt g 21

<210> 277  
<211> 18



40

<212> DNA  
 <213> Artificial Sequence  
  
 <400> 277  
 agcaccgaac gtgagagg 18  
  
 <210> 278  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 278  
 tccatgccgt tcctgccgtt 20  
  
 <210> 279  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 279  
 tccatgacgg tcctgacggt 20  
  
 <210> 280  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 280  
 tccatgccgg tcctgccggt 20  
  
 <210> 281  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 281  
 tccatgcgcg tcctgcgcgt 20  
  
 <210> 282  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 282  
 ctggtctttc tggttttttt ctgg 24  
  
 <210> 283  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 283  
 tcaggggtgg ggggaacctt 20  
  
 <210> 284  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base



<222> (8)...(8)  
 <223> m5c  
  
 <400> 284  
 tccatgangt tcctagttct 20  
  
 <210> 285  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 285  
 tccatgatgt tcctagttct 20  
  
 <210> 286  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 286  
 cccgaagtca tttcctctta acctgg 26  
  
 <210> 287  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 287  
 ccaggttaag aggaaatgac ttcggg 26  
  
 <210> 288  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (7)...(7)  
 <223> m5c  
  
 <400> 288  
 tcctggnggg gaagt 15  
  
 <210> 289  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (2)...(2)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (5)...(5)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (9)...(9)  
 <223> m5c



42

<221> modified\_base  
 <222> (12)...(12)  
 <223> m5c

<221> modified\_base  
 <222> (14)...(14)  
 <223> m5c

<221> modified\_base  
 <222> (16)...(16)  
 <223> m5c

<400> 289  
 gnggngggng gngngngccc 20

<210> 290  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 290  
 tccatgtgct tcctgatgct 20

<210> 291  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 291  
 tccatgtcct tcctgatgct 20

<210> 292  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 292  
 tccatgtcgt tcctagttct 20

<210> 293  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 293  
 tccaagtagt tcctagttct 20

<210> 294  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 294  
 tccatgtagt tcctagttct 20

<210> 295  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 295



WO 01/22972

PCT/US00/26383

43

tcccgcgcgt tccgcgcgtt

20

&lt;210&gt; 296

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 296

tcctggcggt cctggcggtt

20

&lt;210&gt; 297

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 297

tcctggaggg gaagt

15

&lt;210&gt; 298

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 298

tcctgggggg gaagt

15

&lt;210&gt; 299

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 299

tcctggtggg gaagt

15

&lt;210&gt; 300

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 300

tcgtcgtttt gtcgttttgt cggt

24

&lt;210&gt; 301

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 301

ctggtctttc tggttttttt ctgg

24

&lt;210&gt; 302

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 302

tccatgacgt tcctgacgtt

20

&lt;210&gt; 303

&lt;211&gt; 20

&lt;212&gt; DNA



<213> Artificial Sequence

<400> 303  
tccaggactt ctctcaggtt 20

<210> 304  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> modified\_base  
<222> (2)...(2)  
<223> m5c

<221> modified\_base  
<222> (5)...(5)  
<223> m5c

<221> modified\_base  
<222> (13)...(13)  
<223> m5c

<221> modified\_base  
<222> (21)...(21)  
<223> m5c

<400> 304  
tngtngtttt gtngttttgt ngtt 24

<210> 305  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(3)  
<223> Biotin moiety attached at 5' end of sequence.

<400> 305  
tcgtcgtttt gtcgtttttgt cgttttttt 29

<210> 306  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<400> 306  
gctatgacgt tccaaggg 18

<210> 307  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 307  
tcaacggtt 8

<210> 308  
<211> 20



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 308  
 tccaggactt tcctcaggtt 20  
  
 <210> 309  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 309  
 ctctctgtag gcccgcttgg 20  
  
 <210> 310  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 310  
 ctttccgttg gaccctggg 20  
  
 <210> 311  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 311  
 gtccgggcca ggccaaagtc 20  
  
 <210> 312  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 312  
 gtgcgcgcga gcccgaaatc 20  
  
 <210> 313  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (8)...(8)  
 <223> I  
  
 <221> modified\_base  
 <222> (17)...(17)  
 <223> I  
  
 <400> 313  
 tccatgangt tcctgangtt 20  
  
 <210> 314  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 314



WO 01/22972

PCT/US00/26383

46

aatagtcgcc ataacaaaac

20

<210> 315  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 315  
 aatagtcgcc atggcggggc

20

<210> 316  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_difference  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.

<400> 316  
 tttttccatg tcgttcctga tgcttttt

28

<210> 317  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 317  
 tcctgtcgtt gaagtttttt

20

<210> 318  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 318  
 gctagcttta gagctttaga gctt

24

<210> 319  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 319  
 tgctgcttcc cccccccccc

20

<210> 320  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 320  
 tcgacgttcc cccccccccc

20

<210> 321  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 321



WO 01/22972

PCT/US00/26383

47

tcgtcgttcc cccccccccc

20

&lt;210&gt; 322

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 322

tcgtcgttcc cccccccccc

20

&lt;210&gt; 323

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 323

tcgccgttcc cccccccccc

20

&lt;210&gt; 324

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 324

tcgtcgatcc cccccccccc

20

&lt;210&gt; 325

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 325

tcctgacgtt gaagt

15

&lt;210&gt; 326

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 326

tcctgccgtt gaagt

15

&lt;210&gt; 327

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 327

tcctgacggt gaagt

15

&lt;210&gt; 328

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 328

tcctgagctt gaagt

15

&lt;210&gt; 329

&lt;211&gt; 15

&lt;212&gt; DNA



<213> Artificial Sequence

<400> 329  
tcctggcggg gaagt 15

<210> 330  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 330  
aaaatctgtg cttttaaaaa a 21

<210> 331  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<400> 331  
gatccagtca cagtgacctg gcagaatctg gat 33

<210> 332  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<400> 332  
gatccagatt ctgccaggtc actgtgactg gat 33

<210> 333  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<400> 333  
gatccagtca cagtgactca gcagaatctg gat 33

<210> 334  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<400> 334  
gatccagatt ctgctgagtc actgtgactg gat 33

<210> 335  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> modified\_base  
<222> (16)...(16)  
<223> m5c

<400> 335  
tcgtcggtcc ccccccnc 20

<210> 336  
<211> 20  
<212> DNA



<213> Artificial Sequence  
 <220>  
 <221> modified\_base  
 <222> (2)...(2)  
 <223> m5c  
 <221> modified\_base  
 <222> (5)...(5)  
 <223> m5c  
 <400> 336  
 tngtngttcc cccccccccc 20  
 <210> 337  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> modified\_base  
 <222> (2)...(2)  
 <223> m5c  
 <400> 337  
 tngtcgttcc cccccccccc 20  
 <210> 338  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> modified\_base  
 <222> (5)...(5)  
 <223> m5c  
 <400> 338  
 tcgtngttcc cccccccccc 20  
 <210> 339  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 339  
 tcgtcgctcc cccccccccc 20  
 <210> 340  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 340  
 tcgtcggtcc cccccccccc 20  
 <210> 341  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



WO 01/22972

PCT/US00/26383

50

<400> 341  
 tcggcggttcc cccccccccc 20  
  
 <210> 342  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 342  
 ggccttttcc cccccccccc 20  
  
 <210> 343  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 343  
 tcgtcgtttt gacgttttgt cgtt 24  
  
 <210> 344  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 344  
 tcgtcgtttt gacgttttga cgtt 24  
  
 <210> 345  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 345  
 ccgtcggttcc cccccccccc 20  
  
 <210> 346  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 346  
 gcgtcggttcc cccccccccc 20  
  
 <210> 347  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 347  
 tcgtcattcc cccccccccc 20  
  
 <210> 348  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 348  
 acgtcggttcc cccccccccc 20  
  
 <210> 349  
 <211> 20



51

<212> DNA  
 <213> Artificial Sequence  
  
 <400> 349  
 ctgtcgttcc cccccccccc 20  
  
 <210> 350  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.  
  
 <400> 350  
 tttttcgtcg ttcccccccc cccc 24  
  
 <210> 351  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (18)...(20)  
 <223> Biotin moiety attached at 3' end of sequence.  
  
 <400> 351  
 tcgtcgttcc cccccccccc 20  
  
 <210> 352  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (22)...(24)  
 <223> Biotin moiety attached at 3' end of sequence.  
  
 <400> 352  
 tcgtcgtttt gtcgttttgt cgtt 24  
  
 <210> 353  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 353  
 tccagttcct tccctcagtct 20  
  
 <210> 354  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (2)...(2)



<223> m5c  
  
 <400> 354  
 tngtcgttttt gtcgtttttgt cgtt 24  
  
 <210> 355  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 355  
 tcctggaggg gaagt 15  
  
 <210> 356  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 356  
 tcctgaaaag gaagt 15  
  
 <210> 357  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 357  
 tcgtcgttcc cccccc 17  
  
 <210> 358  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (2)...(2)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (5)...(5)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (13)...(13)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (21)...(21)  
 <223> m5c  
  
 <400> 358  
 tngtngtttt gtngttttgt ngtt 24  
  
 <210> 359  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 359  
 ggggtcaagc ttgagggggg 20



|                           |    |
|---------------------------|----|
| <210> 360                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 360                 |    |
| tgctgcttcc cccccccccc     | 20 |
| <210> 361                 |    |
| <211> 14                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 361                 |    |
| tcgtcgtcgt cggt           | 14 |
| <210> 362                 |    |
| <211> 14                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 362                 |    |
| tcgtcgtcgt cggt           | 14 |
| <210> 363                 |    |
| <211> 14                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 363                 |    |
| tcgtcgtcgt cggt           | 14 |
| <210> 364                 |    |
| <211> 10                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 364                 |    |
| tcaacggtga                | 10 |
| <210> 365                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 365                 |    |
| tcaacggt                  | 8  |
| <210> 366                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 366                 |    |
| atagttttcc atttttttac     | 20 |
| <210> 367                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |



<400> 367  
 aatagtcgcc atcgcgcgac 20  
  
 <210> 368  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 368  
 aatagtcgcc atcccgggac 20  
  
 <210> 369  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 369  
 aatagtcgcc atcccccccc 20  
  
 <210> 370  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 370  
 tgctgctttt gtgcttttgt gctt 24  
  
 <210> 371  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 371  
 ctgtgctttc tgtgtttttc tgtg 24  
  
 <210> 372  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 372  
 ctaatctttc taattttttt ctaa 24  
  
 <210> 373  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 373  
 tcgtcgttgg tgcgttggt gtcggt 26  
  
 <210> 374  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 374  
 tcgtcgttgg ttgtcgtttt gggt 24  
  
 <210> 375



<211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 375  
 accatggacg agctgtttcc cctc 24  
  
 <210> 376  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 376  
 tcgtcgtttt gcgtgcgttt 20  
  
 <210> 377  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 377  
 ctgtaagtga gcttggagag 20  
  
 <210> 378  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 378  
 gagaacgctg gaccttcc 18  
  
 <210> 379  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 379  
 cgggcgactc agtctatcgg 20  
  
 <210> 380  
 <211> 37  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 380  
 gttctcagat aaagcggaac cagcaacaga cacagaa 37  
  
 <210> 381  
 <211> 37  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 381  
 ttctgtgtct gttgctgggtt ccgctttatc tgagaac 37  
  
 <210> 382  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 382



WO 01/22972

PCT/US00/26383

56

cagacacaga agcccgatag acg

23

<210> 383  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 383  
 agacagacac gaaacgaccg 20

<210> 384  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 384  
 gtctgtccca tgatctcgaa 20

<210> 385  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 385  
 gctggccagc ttacctcccg 20

<210> 386  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 386  
 ggggcctcta tacaacctgg g 21

<210> 387  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 387  
 ggggtccctg agactgcc 18

<210> 388  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 388  
 gagaacgctg gaccttccat 20

<210> 389  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 389  
 tccatgtcgg tcctgatgct 20

<210> 390  
 <211> 20  
 <212> DNA



<213> Artificial Sequence

<400> 390  
ctcttgacgac ctggaaggta 20

<210> 391  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 391  
aggtacagcc aggactacga 20

<210> 392  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 392  
accatggacg acctgtttcc cctc 24

<210> 393  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 393  
accatggatt acctttttcc cctt 24

<210> 394  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 394  
atggaaggtc cagcgttctc 20

<210> 395  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 395  
agcatcagga ccgacatgga 20

<210> 396  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 396  
ctctccaagc tcacttacag 20

<210> 397  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 397  
tccctgagac tgccccacct t 21



<210> 398  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 398  
 gccaccaaaa cttgtccatg 20  
  
 <210> 399  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 399  
 gtccatggcg tgcgggatga 20  
  
 <210> 400  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 400  
 cctctataca acctgggac 19  
  
 <210> 401  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 401  
 cgggcgactc agtctatcgg 20  
  
 <210> 402  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 402  
 gcgctaccgg tagcctgagt 20  
  
 <210> 403  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 403  
 cgactgccga acaggatatc ggtgatcagc actgg 35  
  
 <210> 404  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 404  
 ccagtgctga tcaccgatat cctgttcggc agtcg 35  
  
 <210> 405  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence



|                            |    |
|----------------------------|----|
| <400> 405                  |    |
| ccaggttgta tagaggc         | 17 |
| <210> 406                  |    |
| <211> 18                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 406                  |    |
| tctcccagcg tacgccat        | 18 |
| <210> 407                  |    |
| <211> 18                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 407                  |    |
| tctcccagcg tgcgtttt        | 18 |
| <210> 408                  |    |
| <211> 18                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 408                  |    |
| tctcccagcg tgcgccat        | 18 |
| <210> 409                  |    |
| <211> 18                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 409                  |    |
| tctcccgtcg tgcgccat        | 18 |
| <210> 410                  |    |
| <211> 20                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 410                  |    |
| ataatcgtcg ttcaagcaag      | 20 |
| <210> 411                  |    |
| <211> 23                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 411                  |    |
| tcgtcgtttt gtcgttttgt cgt  | 23 |
| <210> 412                  |    |
| <211> 24                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 412                  |    |
| tcgtcgtttt gtcgttttgt cggt | 24 |
| <210> 413                  |    |
| <211> 24                   |    |



60

<212> DNA  
 <213> Artificial Sequence

<400> 413  
 tcgtcgtttt gtcgttttgt cggt

24

<210> 414  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_difference  
 <222> (3)...(3)  
 <223> n is a or c or g or t/u

<221> misc\_difference  
 <222> (8)...(8)  
 <223> n is a or c or g or t/u

<221> misc\_difference  
 <222> (11)...(11)  
 <223> n is a or c or g or t/u

<221> misc\_difference  
 <222> (16)...(16)  
 <223> n is a or c or g or t/u

<221> misc\_difference  
 <222> (19)...(19)  
 <223> n is a or c or g or t/u

<221> misc\_difference  
 <222> (24)...(24)  
 <223> n is a or c or g or t/u

<400> 414  
 tcntcgtntt ntcgtnttnt cgtn

24

<210> 415  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 415  
 tctcccagcg tcgccat

17

<210> 416  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 416  
 tctcccatcg tcgccat

17

<210> 417  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 417



WO 01/22972

PCT/US00/26383

61

ataatcgtgc gttcaagaaa g

21

&lt;210&gt; 418

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 418

ataatcgacg ttcccccccc

20

&lt;210&gt; 419

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 419

tctatcgacg ttcaagcaag

20

&lt;210&gt; 420

&lt;211&gt; 14

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 420

tcctgacggg gagt

14

&lt;210&gt; 421

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 421

tccatgacgt tcctgatcc

19

&lt;210&gt; 422

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 422

tccatgacgt tcctgatcc

19

&lt;210&gt; 423

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 423

tccatgacgt tcctgatcc

19

&lt;210&gt; 424

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 424

tcctggcgtg gaagt

15

&lt;210&gt; 425

&lt;211&gt; 19

&lt;212&gt; DNA



<213> Artificial Sequence

<400> 425  
tccatgacgt tcctgatcc 19

<210> 426  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 426  
tcgtcgctgt tgctgtttct t 21

<210> 427  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 427  
agcagcttta gagctttaga gctt 24

<210> 428  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 428  
cccccccccc ccccccccccc cccc 24

<210> 429  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<400> 429  
tcgtcgtttt gtcgttttgt cgttttgtcg tt 32

<210> 430  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<400> 430  
tcgtcgtttt ttgtcgtttt ttgtcgtt 28

<210> 431  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 431  
tcgtcgtttt tttttttttt 20

<210> 432  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 432  
tttttcaacg ttgatttttt 20



<210> 433  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 433  
 ttttttttttt ttttttttttt tttt 24  
  
 <210> 434  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 434  
 ggggtcgtcg ttttgggggg 20  
  
 <210> 435  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 435  
 tcgtcgtttt gtcgttttgg gggg 24  
  
 <210> 436  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 436  
 tcgtcgtgt ctccgcttct tcttgcc 27  
  
 <210> 437  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 437  
 tcgtcgtgt ctccg 15  
  
 <210> 438  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 438  
 ctgtaagtga gcttggagag 20  
  
 <210> 439  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 439  
 gagaacgctg gaccttccat 20  
  
 <210> 440  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence



|                           |    |
|---------------------------|----|
| <400> 440                 |    |
| ccaggttgta tagaggc        | 17 |
| <210> 441                 |    |
| <211> 17                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 441                 |    |
| gctagacggt agcgtga        | 17 |
| <210> 442                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 442                 |    |
| ggagctcttc gaacgccata     | 20 |
| <210> 443                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 443                 |    |
| tctccatgat ggttttatcg     | 20 |
| <210> 444                 |    |
| <211> 21                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 444                 |    |
| aaggtggggc agtctcaggg a   | 21 |
| <210> 445                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 445                 |    |
| atcggaggac tggcgcgccg     | 20 |
| <210> 446                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 446                 |    |
| ttaggacaag gtctaggggtg    | 20 |
| <210> 447                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 447                 |    |
| accacaacga gaggaacgca     | 20 |
| <210> 448                 |    |
| <211> 20                  |    |



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 448  
 ggacgtgcag gctcaccggg 20  
  
 <210> 449  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 449  
 gaaccttcca tgctgtt 17  
  
 <210> 450  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 450  
 gctagacgtt agcgtga 17  
  
 <210> 451  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 451  
 gcttggaggg cctgtaagtg 20  
  
 <210> 452  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 452  
 gtagccttcc ta 12  
  
 <210> 453  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 453  
 cggtagcctt ccta 14  
  
 <210> 454  
 <211> 16  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 454  
 cacgtagcc ttccta 16  
  
 <210> 455  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 455  
 agcacggtag ccttccta 18



<210> 456  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 456  
 gaacgctgga ccttccat 18  
  
 <210> 457  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 457  
 gaccttccat 10  
  
 <210> 458  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 458  
 tggaccttcc at 12  
  
 <210> 459  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 459  
 gctggacctt ccat 14  
  
 <210> 460  
 <211> 16  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 460  
 acgctggacc ttccat 16  
  
 <210> 461  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 461  
 taagctctgt caacgccagg 20  
  
 <210> 462  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 462  
 gagaacgctg gaccttccat gt 22  
  
 <210> 463  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



<400> 463  
 tccatgtcgg tcctgatgct 20  
  
 <210> 464  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 464  
 ttcatgcctt gcaaaatggc g 21  
  
 <210> 465  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 465  
 tgctagctgt gcctgtacct 20  
  
 <210> 466  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 466  
 agcatcagga ccgacatgga 20  
  
 <210> 467  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 467  
 gaccttccat gtcggtcctg at 22  
  
 <210> 468  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 468  
 acaaccacga gaacgggaac 20  
  
 <210> 469  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 469  
 gaaccttcca tgctgttccg 20  
  
 <210> 470  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 470  
 caatcaatct gaggagaccc 20  
  
 <210> 471



68

<211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 471  
 tcagctctgg tactttttca 20  
  
 <210> 472  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 472  
 tggttacggt ctgtcccatg 20  
  
 <210> 473  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 473  
 gtctatcgga ggactggcgc 20  
  
 <210> 474  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 474  
 cattttacgg gcgggcgggc 20  
  
 <210> 475  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 475  
 gaggggacca ttttacgggc 20  
  
 <210> 476  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 476  
 tgtccagccg aggggaccat 20  
  
 <210> 477  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 477  
 cgggcttacg gcggatgctg 20  
  
 <210> 478  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 478



69

tggaccttct atgtcggtcc

20

&lt;210&gt; 479

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 479

tgtcccatgt ttttagaagc

20

&lt;210&gt; 480

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 480

gtggttacgg tcgtgcccat

20

&lt;210&gt; 481

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 481

cctccaaatg aaagaccccc

20

&lt;210&gt; 482

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 482

ttgtactctc catgatgggtt

20

&lt;210&gt; 483

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 483

ttccatgctg ttccggctgg

20

&lt;210&gt; 484

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 484

gaccttctat gtcggtcctg

20

&lt;210&gt; 485

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 485

gagaccgctc gaccttcgat

20

&lt;210&gt; 486

&lt;211&gt; 20

&lt;212&gt; DNA



<213> Artificial Sequence

<400> 486  
 ttgccccata ttttagaaac 20

<210> 487  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 487  
 ttgaaactga ggtgggac 18

<210> 488  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 488  
 ctatcggagg actggcgcg c 21

<210> 489  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 489  
 cttggagggc ctcccggcgg 20

<210> 490  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 490  
 gctgaacctt ccatgctgtt 20

<210> 491  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

<400> 491  
 tagaaacagc attcttcttt tagggcagca ca 32

<210> 492  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 492  
 agatggttct cagataaagc ggaa 24

<210> 493  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 493  
 ttccgcttta tctgagaacc atct 24



<210> 494  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<400> 494  
gtcccagggtt gtatagaggc tgc 23

<210> 495  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 495  
gcgccagtcc tccgatagac 20

<210> 496  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 496  
atcggaggac tggcgcgccg 20

<210> 497  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 497  
ggtctgtccc atatttttag 20

<210> 498  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 498  
tttttcaacg ttgagggggg 20

<210> 499  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 499  
tttttcaagc gttgattttt t 21

<210> 500  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 500  
ggggtcaacg ttgatttttt 20

<210> 501  
<211> 25  
<212> DNA  
<213> Artificial Sequence



<400> 501  
 ggggttttca acgttttgag ggggg 25  
  
 <210> 502  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 502  
 ggttacggtc tgtcccatat 20  
  
 <210> 503  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 503  
 ctgtcccata tttttagaca 20  
  
 <210> 504  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 504  
 accatcctga ggccattcgg 20  
  
 <210> 505  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 505  
 cgtctatcgg gcttctgtgt ctg 23  
  
 <210> 506  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 506  
 ggccatccca cattgaaagt t 21  
  
 <210> 507  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 507  
 ccaaatatcg gtggtcaagc ac 22  
  
 <210> 508  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 508  
 gtgcttgacc accgatattt gg 22  
  
 <210> 509  
 <211> 26



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 509  
 gtgctgatca ccgatatacct gttcgg 26  
  
 <210> 510  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 510  
 ggccaacttt caatgtggga tggcctc 27  
  
 <210> 511  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 511  
 ttccgccgaa tggcctcagg atggtac 27  
  
 <210> 512  
 <211> 36  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 512  
 tatagtcctt gagactgccc caccttctca acaacc 36  
  
 <210> 513  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 513  
 gcagcctcta tacaacctgg gacggga 27  
  
 <210> 514  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 514  
 ctatcggagg actggcgcgcc cg 22  
  
 <210> 515  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 515  
 tatcggagga ctggcgcgcc g 21  
  
 <210> 516  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 516  
 gatcggagga ctggcgcgcc g 21



<210> 517  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<400> 517  
ccgaacagga tatcggtgat cagcac 26

<210> 518  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 518  
ttttggggtc aacggtgagg gggg 24

<210> 519  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 519  
ggggtcaacg ttgagggggg 20

<210> 520  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 520  
cgcgcgcgcg cgcgcgcgcg 20

<210> 521  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 521  
ggggcatgac gttcgggggg 20

<210> 522  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 522  
ggggcatgac gttcaaaaaa 20

<210> 523  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 523  
ggggcatgag cttcgggggg 20

<210> 524  
<211> 20  
<212> DNA  
<213> Artificial Sequence



|                            |    |
|----------------------------|----|
| <400> 524                  |    |
| ggggcatgac gttcgggggg      | 20 |
| <210> 525                  |    |
| <211> 20                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 525                  |    |
| aaaacatgac gttcaaaaaa      | 20 |
| <210> 526                  |    |
| <211> 20                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 526                  |    |
| aaaacatgac gttcgggggg      | 20 |
| <210> 527                  |    |
| <211> 20                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 527                  |    |
| ggggcatgac gttcaaaaaa      | 20 |
| <210> 528                  |    |
| <211> 24                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 528                  |    |
| accatggacg atctgtttcc cctc | 24 |
| <210> 529                  |    |
| <211> 24                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 529                  |    |
| gccatggacg aactgttccc cctc | 24 |
| <210> 530                  |    |
| <211> 20                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 530                  |    |
| cccccccccc ccccccccc       | 20 |
| <210> 531                  |    |
| <211> 20                   |    |
| <212> DNA                  |    |
| <213> Artificial Sequence  |    |
| <400> 531                  |    |
| gggggggggg gggggggggg      | 20 |
| <210> 532                  |    |



<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 532  
gctgtaaaat gaatcggccg 20

<210> 533  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 533  
ttcgggcgga ctctccatt 20

<210> 534  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 534  
tatgccgcgc ccggacttat 20

<210> 535  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 535  
ggggtaatcg atcagggggg 20

<210> 536  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 536  
tttgagaacg ctggaccttc 20

<210> 537  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 537  
gatcgctgat ctaatgctcg 20

<210> 538  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 538  
gtcggtcctg atgctgttcc 20

<210> 539  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 539



WO 01/22972

PCT/US00/26383

77

|                                                                 |    |
|-----------------------------------------------------------------|----|
| tcgtcgtcag ttcgctgtcg                                           | 20 |
| <210> 540<br><211> 18<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 540<br>ctggaccttc catgtcgg                                | 18 |
| <210> 541<br><211> 17<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 541<br>gctcgttcag cgcgtct                                 | 17 |
| <210> 542<br><211> 16<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 542<br>ctggaccttc catgtc                                  | 16 |
| <210> 543<br><211> 16<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 543<br>cactgtcctt cgtcga                                  | 16 |
| <210> 544<br><211> 20<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 544<br>cgctggacct tccatgtcgg                              | 20 |
| <210> 545<br><211> 20<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 545<br>gctgagctca tgccgtctgc                              | 20 |
| <210> 546<br><211> 20<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 546<br>aacgctggac cttccatgtc                              | 20 |
| <210> 547<br><211> 20<br><212> DNA                              |    |



<213> Artificial Sequence  
 <400> 547  
 tgcatgccgt acacagctct 20  
 <210> 548  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 548  
 ccttccatgt cggtcctgat 20  
 <210> 549  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 549  
 tactcttcgg atcccttgcg 20  
 <210> 550  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 550  
 ttccatgtcg gtcctgat 18  
 <210> 551  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 551  
 ctgattgctc tctcgtga 18  
 <210> 552  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 552  
 ggcgttatcc ctgactcgcc 20  
 <210> 553  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 553  
 cctacgttgt atgcgccag ct 22  
 <210> 554  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 554  
 ggggtaatcg atgagggggg 20



<210> 555  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 555  
 ttcgggcgga ctccctccatt 20  
  
 <210> 556  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 556  
 tttttttttt tttttttttt 20  
  
 <210> 557  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 557  
 ggggggtttt tttttggggg 20  
  
 <210> 558  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 558  
 tttttggggg ggggggtttt 20  
  
 <210> 559  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 559  
 gggggggggg ggggggggt 19  
  
 <210> 560  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 560  
 aaaaaaaaaa aaaaaaaaaa 20  
  
 <210> 561  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 561  
 cccccaaaaa aaaaaccccc 20  
  
 <210> 562  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



<400> 562  
 aaaaaccccc ccccaaaaaa 20  
  
 <210> 563  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 563  
 tttgaattca ggactggtga ggttgag 27  
  
 <210> 564  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 564  
 tttgaatcct cagcgggtctc cagtggc 27  
  
 <210> 565  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 565  
 aattctctat cggggcttct gtgtctgttg ctggttccgc tttat 45  
  
 <210> 566  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 566  
 ctagataaag cggaaccagc aacagacaca gaagccccga tagag 45  
  
 <210> 567  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 567  
 ttttctagag aggtgcacaa tgctctgg 28  
  
 <210> 568  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 568  
 tttgaattcc gtgtacagaa gcgagaagc 29  
  
 <210> 569  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 569  
 tttgcggccg ctagacttaa cctgagagat a 31  
  
 <210> 570  
 <211> 29



WO 01/22972

PCT/US00/26383

81

<212> DNA  
 <213> Artificial Sequence  
  
 <400> 570  
 tttgggcccga cgagagacag agacacttc 29  
  
 <210> 571  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 571  
 tttgggcccga cttctcgctt ctgtacacg 29  
  
 <210> 572  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 572  
 gagaacgctg gaccttccat 20  
  
 <210> 573  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 573  
 tccatgtcgg tcctgatgct 20  
  
 <210> 574  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 574  
 ctgtcgcg 6  
  
 <210> 575  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 575  
 tcgtga 6  
  
 <210> 576  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 576  
 cgtcga 6  
  
 <210> 577  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 577  
 agtgct 6



|                           |    |
|---------------------------|----|
| <210> 578                 |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 578                 |    |
| ctgtcg                    | 6  |
| <210> 579                 |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 579                 |    |
| agtgct                    | 6  |
| <210> 580                 |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 580                 |    |
| cgtcga                    | 6  |
| <210> 581                 |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 581                 |    |
| tcgtga                    | 6  |
| <210> 582                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 582                 |    |
| gagaacgctc cagcttcgat     | 20 |
| <210> 583                 |    |
| <211> 17                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 583                 |    |
| gctagacgta agcgtga        | 17 |
| <210> 584                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 584                 |    |
| gagaacgctc`gaccttccat     | 20 |
| <210> 585                 |    |
| <211> 21                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |



<400> 585  
 gagaacgctg gacctatcca t 21  
 <210> 586  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 586  
 gctagaggtt agcgtga 17  
 <210> 587  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<400> 587  
 gagaacgctg gacttccat 19  
 <210> 588  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 588  
 tcacgctaac gtctagc 17  
 <210> 589  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.

<400> 589  
 gctagacgtt agcgtga 17  
 <210> 590  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 590  
 atggaaggctc gagcgttctc 20  
 <210> 591  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 591  
 gagaacgctg gaccttcgat 20  
 <210> 592  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



|                                                     |    |
|-----------------------------------------------------|----|
| <400> 592                                           |    |
| gagaacgatg gaccttccat                               | 20 |
| <210> 593                                           |    |
| <211> 17                                            |    |
| <212> DNA                                           |    |
| <213> Artificial Sequence                           |    |
| <400> 593                                           |    |
| gagaacgctg gatccat                                  | 17 |
| <210> 594                                           |    |
| <211> 20                                            |    |
| <212> DNA                                           |    |
| <213> Artificial Sequence                           |    |
| <400> 594                                           |    |
| gagaacgctc cagcactgat                               | 20 |
| <210> 595                                           |    |
| <211> 20                                            |    |
| <212> DNA                                           |    |
| <213> Artificial Sequence                           |    |
| <400> 595                                           |    |
| tccatgtcgg tcctgctgat                               | 20 |
| <210> 596                                           |    |
| <211> 20                                            |    |
| <212> DNA                                           |    |
| <213> Artificial Sequence                           |    |
| <400> 596                                           |    |
| atgtcctcgg tcctgatgct                               | 20 |
| <210> 597                                           |    |
| <211> 20                                            |    |
| <212> DNA                                           |    |
| <213> Artificial Sequence                           |    |
| <400> 597                                           |    |
| gagaacgctc caccttccat                               | 20 |
| <210> 598                                           |    |
| <211> 20                                            |    |
| <212> DNA                                           |    |
| <213> Artificial Sequence                           |    |
| <400> 598                                           |    |
| gagaacgctg gaccttcgta                               | 20 |
| <210> 599                                           |    |
| <211> 20                                            |    |
| <212> DNA                                           |    |
| <213> Artificial Sequence                           |    |
| <220>                                               |    |
| <221> misc_feature                                  |    |
| <222> (1)...(3)                                     |    |
| <223> Biotin moiety attached at 5' end of sequence. |    |



|                           |    |
|---------------------------|----|
| <400> 599                 |    |
| atggaaggtc cagcgttctc     | 20 |
| <210> 600                 |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 600                 |    |
| tcctga                    | 6  |
| <210> 601                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 601                 |    |
| tcaacggtt                 | 8  |
| <210> 602                 |    |
| <211> 6                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 602                 |    |
| aacggtt                   | 6  |
| <210> 603                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 603                 |    |
| aacggttga                 | 8  |
| <210> 604                 |    |
| <211> 17                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 604                 |    |
| tcacgctaac ctctagc        | 17 |
| <210> 605                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 605                 |    |
| gagaacgctg gaccttgcac     | 20 |
| <210> 606                 |    |
| <211> 14                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 606                 |    |
| gctggacctt ccat           | 14 |
| <210> 607                 |    |



<211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 607  
 gagaacgctg gacctcatcc at 22  
  
 <210> 608  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 608  
 gagaacgctg gacgctcatc cat 23  
  
 <210> 609  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 609  
 aacgttgagg ggcac 15  
  
 <210> 610  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 610  
 atgcccctca acgtt 15  
  
 <210> 611  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 611  
 tcaacgttga 10  
  
 <210> 612  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 612  
 gctggacctt ccat 14  
  
 <210> 613  
 <211> 7  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 613  
 caacgtt 7  
  
 <210> 614  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 614



WO 01/22972

PCT/US00/26383

87

acaacgttga

10

<210> 615  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence

<400> 615  
 tcacgt

6

<210> 616  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<400> 616  
 tcaagctt

8

<210> 617  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence

<400> 617  
 tcgtca

6

<210> 618  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<400> 618  
 aggatatc

8

<210> 619  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<400> 619  
 tagacgtc

8

<210> 620  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<400> 620  
 gacgtcat

8

<210> 621  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<400> 621  
 ccatcgat

8

<210> 622  
 <211> 8  
 <212> DNA



88

|                           |    |
|---------------------------|----|
| <213> Artificial Sequence |    |
| <400> 622                 |    |
| atcgatgt                  | 8  |
| <210> 623                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 623                 |    |
| atgcatgt                  | 8  |
| <210> 624                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 624                 |    |
| ccatgcat                  | 8  |
| <210> 625                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 625                 |    |
| agcgctga                  | 8  |
| <210> 626                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 626                 |    |
| tcagcgct                  | 8  |
| <210> 627                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 627                 |    |
| ccttcgat                  | 8  |
| <210> 628                 |    |
| <211> 18                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 628                 |    |
| gtgccgggggt ctccgggc      | 18 |
| <210> 629                 |    |
| <211> 18                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 629                 |    |
| gctgtggggc ggctcctg       | 18 |



89

<210> 630  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.

<400> 630  
 tcaacggtt

8

<210> 631  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> FITC moiety attached at 5' end of sequence.

<400> 631  
 tcaacggtt

8

<210> 632  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> FITC moiety attached at 5' end of sequence.

<400> 632  
 aacggttga

8

<210> 633  
 <211> 7  
 <212> DNA  
 <213> Artificial Sequence

<400> 633  
 tcaacgt

7

<210> 634  
 <211> 7  
 <212> DNA  
 <213> Artificial Sequence

<400> 634  
 aacggttg

7

<210> 635  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence

<400> 635



WO 01/22972

PCT/US00/26383

90

cgacga

6

<210> 636  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 636  
tcaacggtt

8

<210> 637  
<211> 5  
<212> DNA  
<213> Artificial Sequence

<400> 637  
tcgga

5

<210> 638  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 638  
agaacggtt

8

<210> 639  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 639  
tcatcgat

8

<210> 640  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 640  
taaacggtt

8

<210> 641  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 641  
ccaacggtt

8

<210> 642  
<211> 6  
<212> DNA  
<213> Artificial Sequence

<400> 642  
gctcga

6

<210> 643  
<211> 6  
<212> DNA



|                       |                           |    |
|-----------------------|---------------------------|----|
|                       | <213> Artificial Sequence |    |
|                       | <400> 643                 |    |
| cgacgt                |                           | 6  |
|                       | <210> 644                 |    |
|                       | <211> 6                   |    |
|                       | <212> DNA                 |    |
|                       | <213> Artificial Sequence |    |
|                       | <400> 644                 |    |
| cgtcgt                |                           | 6  |
|                       | <210> 645                 |    |
|                       | <211> 6                   |    |
|                       | <212> DNA                 |    |
|                       | <213> Artificial Sequence |    |
|                       | <400> 645                 |    |
| acgtgt                |                           | 6  |
|                       | <210> 646                 |    |
|                       | <211> 6                   |    |
|                       | <212> DNA                 |    |
|                       | <213> Artificial Sequence |    |
|                       | <400> 646                 |    |
| cgttcg                |                           | 6  |
|                       | <210> 647                 |    |
|                       | <211> 20                  |    |
|                       | <212> DNA                 |    |
|                       | <213> Artificial Sequence |    |
|                       | <400> 647                 |    |
| gagcaagctg gaccttccat |                           | 20 |
|                       | <210> 648                 |    |
|                       | <211> 6                   |    |
|                       | <212> DNA                 |    |
|                       | <213> Artificial Sequence |    |
|                       | <400> 648                 |    |
| cgcgta                |                           | 6  |
|                       | <210> 649                 |    |
|                       | <211> 6                   |    |
|                       | <212> DNA                 |    |
|                       | <213> Artificial Sequence |    |
|                       | <400> 649                 |    |
| cgtacg                |                           | 6  |
|                       | <210> 650                 |    |
|                       | <211> 8                   |    |
|                       | <212> DNA                 |    |
|                       | <213> Artificial Sequence |    |
|                       | <400> 650                 |    |
| tcaccggt              |                           | 8  |



<210> 651  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 651  
 caagagatgc taacaatgca 20  
  
 <210> 652  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 652  
 acccatcaat agctctgtgc 20  
  
 <210> 653  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 653  
 ccatcgat 8  
  
 <210> 654  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 654  
 tcgacgtc 8  
  
 <210> 655  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 655  
 ctagcgct 8  
  
 <210> 656  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 656  
 taagcgct 8  
  
 <210> 657  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 657  
 tcgcgaattc gcg 13  
  
 <210> 658  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence



<400> 658  
 atggaagggtc cagcgttct 19  
  
 <210> 659  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 659  
 actggacgtt agcgtga 17  
  
 <210> 660  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 660  
 cgcctggggc tgggtctgg 18  
  
 <210> 661  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 661  
 gtgtcgggggt ctccgggc 18  
  
 <210> 662  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 662  
 gtgccgggggt ctccgggc 18  
  
 <210> 663  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 663  
 cgccgtcgcg gcggttgg 18  
  
 <210> 664  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 664  
 gaagttcacg ttgaggggca t 21  
  
 <210> 665  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 665  
 atctgggtgag ggcaagctat g 21  
  
 <210> 666  
 <211> 21



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 666  
 gttgaaaccc gagaacatca t 21  
  
 <210> 667  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 667  
 gcaacggtt 8  
  
 <210> 668  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 668  
 gtaacggtt 8  
  
 <210> 669  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 669  
 cgaacggtt 8  
  
 <210> 670  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 670  
 gaaacggtt 8  
  
 <210> 671  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 671  
 caaacggtt 8  
  
 <210> 672  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 672  
 ctaacggtt 8  
  
 <210> 673  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 673  
 ggaacggtt 8



<210> 674  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 674  
tgaacggt 8

<210> 675  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 675  
acaacggt 8

<210> 676  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 676  
ttaacggt 8

<210> 677  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 677  
aaaacggt 8

<210> 678  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 678  
ataacggt 8

<210> 679  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 679  
aacgttct 8

<210> 680  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<400> 680  
tccgatcg 8

<210> 681  
<211> 8  
<212> DNA  
<213> Artificial Sequence



|                                                                 |    |
|-----------------------------------------------------------------|----|
| <400> 681<br>tccgtacg                                           | 8  |
| <210> 682<br><211> 17<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 682<br>gctagacgct agcgtga                                 | 17 |
| <210> 683<br><211> 25<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 683<br>gagaacgctg gacctcatca tccat                        | 25 |
| <210> 684<br><211> 20<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 684<br>gagaacgcta gaccttctat                              | 20 |
| <210> 685<br><211> 17<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 685<br>actagacgtt agtgtga                                 | 17 |
| <210> 686<br><211> 22<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 686<br>cacaccttgg tcaatgtcac gt                           | 22 |
| <210> 687<br><211> 22<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 687<br>tctccatcct atggttttat cg                           | 22 |
| <210> 688<br><211> 15<br><212> DNA<br><213> Artificial Sequence |    |
| <400> 688<br>cgctggacct tccat                                   | 15 |
| <210> 689                                                       |    |



<211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 689  
 caccaccttg gtcaatgtca cgt 23  
  
 <210> 690  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 690  
 gctagacgtt agctgga 17  
  
 <210> 691  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 691  
 agtgcgattg cagatcg 17  
  
 <210> 692  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 692  
 ttttcgtttt gtggttttgt ggtt 24  
  
 <210> 693  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 693  
 ttttcgtttg tcgttttgtc gtt 23  
  
 <210> 694  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 694  
 tttttgtttt gtggttttgt ggtt 24  
  
 <210> 695  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 695  
 accgcatgga ttctaggcca 20  
  
 <210> 696  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 696



98

gctagacggt agcgt

15

<210> 697  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 697  
 aacgctggac cttccat

17

<210> 698  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (5)...(5)  
 <223> m5c

<400> 698  
 tcaangtt

8

<210> 699  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence

<400> 699  
 ccttcgat

8

<210> 700  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 700  
 actagacggt agtgtga

17

<210> 701  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 701  
 gctagagggt agcgtga

17

<210> 702  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 702  
 atggactctc cagcgttctc

20

<210> 703  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 703



WO 01/22972

PCT/US00/26383

99

atcgactctc gagcggttctc

20

&lt;210&gt; 704

&lt;211&gt; 13

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 704

gctagacggtt agc

13

&lt;210&gt; 705

&lt;211&gt; 9

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 705

gctagacgt

9

&lt;210&gt; 706

&lt;211&gt; 17

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 706

agtgcgattc gagatcg

17

&lt;210&gt; 707

&lt;211&gt; 8

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (5)...(5)

&lt;223&gt; m5c

&lt;400&gt; 707

tcagngct

8

&lt;210&gt; 708

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 708

ctgattgctc tctcgtga

18

&lt;210&gt; 709

&lt;211&gt; 8

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (2)...(2)

&lt;223&gt; m5c

&lt;400&gt; 709

tnaacggtt

8

&lt;210&gt; 710



100

<211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (6)...(6)  
 <223> m5c

<400> 710  
 gagaangctg gaccttccat 20

<210> 711  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 711  
 gctagacgtt aggctga 17

<210> 712  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence

<400> 712  
 gctacttagc gtga . 14

<210> 713  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 713  
 gctaccttag cgtga 15

<210> 714  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<400> 714  
 atcgacttcg agcgttctc 19

<210> 715  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 715  
 atgcactctg cagcgttctc 20

<210> 716  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 716  
 agtgactctc cagcgttctc 20

<210> 717



## 101

<211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 717  
 gccagatggt agctgga 17  
  
 <210> 718  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 718  
 atcgactcga gcgttctc 18  
  
 <210> 719  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 719  
 atcgatcgag cggttctc 17  
  
 <210> 720  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.  
  
 <400> 720  
 gagaacgctc gaccttcgat 20  
  
 <210> 721  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 721  
 gctagacggt agctgga 17  
  
 <210> 722  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 722  
 atcgactctc gagcgttctc 20  
  
 <210> 723  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 723  
 tagacgttag cgtga 15  
  
 <210> 724



102

<211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 724  
 cgactctcga gcgttctc 18

<210> 725  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 725  
 ggggtcgacc ttggaggggg g 21

<210> 726  
 <211> 16  
 <212> DNA  
 <213> Artificial Sequence

<400> 726  
 gctaacgtta gcgtga 16

<210> 727  
 <211> 9  
 <212> DNA  
 <213> Artificial Sequence

<400> 727  
 cgtcgtcgt 9

<210> 728  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (14)...(14)  
 <223> m5c

<400> 728  
 gagaacgctg gacnttccat 20

<210> 729  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (18)...(18)  
 <223> m5c

<400> 729  
 atcgacctac gtgcgttntc 20

<210> 730  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



<220>  
 <221> modified\_base  
 <222> (3)...(3)  
 <223> m5c  
  
 <400> 730  
 atngacctac gtgcgttctc 20  
  
 <210> 731  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (7)...(7)  
 <223> m5c  
  
 <400> 731  
 gctagangtt agcgt 15  
  
 <210> 732  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (14)...(14)  
 <223> m5c  
  
 <400> 732  
 atcgactctc gagngttctc 20  
  
 <210> 733  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 733  
 ggggtaatgc atcagggggg 20  
  
 <210> 734  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 734  
 ggctgtattc ctgactgcc 20  
  
 <210> 735  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 735  
 ccatgctaac ctctagc 17  
  
 <210> 736  
 <211> 17



<212> DNA  
 <213> Artificial Sequence

<400> 736  
 gctagatggt agcgtga 17

<210> 737  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 737  
 cgtaccttac ggtga 15

<210> 738  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 738  
 tccatgctgg tcttgatgct 20

<210> 739  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<400> 739  
 atcgactctc tcgagcgttc tc 22

<210> 740  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 740  
 gctagagctt agcgtga 17

<210> 741  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 741  
 atcgactctc gagtggttctc 20

<210> 742  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 742  
 aacgctcgac cttcgat 17

<210> 743  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 743  
 ctcaacgctg gaccttccat 20



<210> 744  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 744  
 atcgacctac gtgcgttctc 20  
  
 <210> 745  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 745  
 gagaatgctg gaccttccat 20  
  
 <210> 746  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 746  
 tcacgctaac ctctgac 17  
  
 <210> 747  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.  
  
 <400> 747  
 gagaacgctc cagcactgat 20  
  
 <210> 748  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.  
  
 <400> 748  
 gagcaagctg gaccttccat 20  
  
 <210> 749  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 749  
 cgctagaggt tagcgtga 18  
  
 <210> 750  
 <211> 15



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 750  
 gctagatggtt aacgt 15  
  
 <210> 751  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 751  
 atggaagggtc cacgttctc 19  
  
 <210> 752  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 752  
 gctagatggtt agcgt 15  
  
 <210> 753  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 753  
 gctagacgtt agtgt 15  
  
 <210> 754  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 754  
 tccatgacgg tcctgatgct 20  
  
 <210> 755  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 755  
 tccatggcgg tcctgatgct 20  
  
 <210> 756  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 756  
 gctagacgat agcgt 15  
  
 <210> 757  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 757  
 gctagtcgat agcgt 15



<210> 758  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 758  
 tccatgacgt tcctgatgct 20  
  
 <210> 759  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 759  
 tccatgtcgt tcctgatgct 20  
  
 <210> 760  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (13)...(13)  
 <223> m5c  
  
 <400> 760  
 gctagacgtt agngt 15  
  
 <210> 761  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 761  
 gctaggcgtt agcgt 15  
  
 <210> 762  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (8)...(8)  
 <223> m5c  
  
 <400> 762  
 tccatgtngg tcctgatgct 20  
  
 <210> 763  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (12)...(12)  
 <223> m5c



<400> 763  
 tccatgtcgg tnctgatgct 20  
  
 <210> 764  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (3)...(3)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (10)...(10)  
 <223> m5c  
  
 <221> modified\_base  
 <222> (14)...(14)  
 <223> m5c  
  
 <400> 764  
 atngactctn gagngttctc 20  
  
 <210> 765  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 765  
 atggaaggtc cagtgttctc 20  
  
 <210> 766  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 766  
 gcatgacgtt gagct 15  
  
 <210> 767  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 767  
 ggggtcaacg ttgagggggg 20  
  
 <210> 768  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 768  
 ggggtcaagt ctgagggggg 20  
  
 <210> 769  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



<400> 769  
 cgcgcgcgcg cgcgcgcgcg 20

<210> 770  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<400> 770  
 cccccccccc cccccccccc cccccccc 28

<210> 771  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<400> 771  
 cccccccccc cccccccccc cccccccccc ccccc 35

<210> 772  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 772  
 tccatgtcgc tcctgacct 20

<210> 773  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 773  
 gctaaacgtt agcgt 15

<210> 774  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 774  
 tccatgtcga tcctgatgct 20

<210> 775  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 775  
 tccatgccgg tcctgatgct 20

<210> 776  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 776  
 aaaatcaacg ttgaaaaaaa 20

<210> 777  
 <211> 20



110

<212> DNA  
<213> Artificial Sequence

<400> 777  
tccataacgt tcctgatgct 20

<210> 778  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<400> 778  
tggaggtccc accgagatcg gag 23

<210> 779  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 779  
cgtcgtcgtc gtcgtcgctg t 21

<210> 780  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 780  
ctgctgctgc tgctgctgct g 21

<210> 781  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<400> 781  
gagaacgctc cgaccttcga t 21

<210> 782  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 782  
gctagatggt agcgt 15

<210> 783  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 783  
gcatgacgtt gagct 15

<210> 784  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature



111

<222> (8)...(10)  
 <223> FITC moiety attached at 3' end of sequence.

<400> 784  
 tcaatgctga 10

<210> 785  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (8)...(10)  
 <223> FITC moiety attached at 3' end of sequence.

<400> 785  
 tcaacgttga 10

<210> 786  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (8)...(10)  
 <223> Biotin moiety attached at 3' end of sequence.

<400> 786  
 tcaacgttga 10

<210> 787  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (8)...(10)  
 <223> Biotin moiety attached at 3' end of sequence.

<400> 787  
 gcaatattgc 10

<210> 788  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (8)...(10)  
 <223> FITC moiety attached at 3' end of sequence.

<400> 788  
 gcaatattgc 10

<210> 789  
 <211> 10  
 <212> DNA



112

<213> Artificial Sequence  
 <400> 789  
 agttgcaact 10  
 <210> 790  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 790  
 tcttcgaa 8  
 <210> 791  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 791  
 tcaacgtc 8  
 <210> 792  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 792  
 ccatgtcggc cctgatgct 19  
 <210> 793  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 793  
 gtttttatat aatttggg 18  
 <210> 794  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 794  
 tttttgttg tcgttttgtc gtt 23  
 <210> 795  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 795  
 ttgggggggg tt 12  
 <210> 796  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 796  
 ggggttgggg gtt 13



113

<210> 797  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 797  
 ggtggtgtag gttttgg 17

<210> 798  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.

<221> modified\_base  
 <222> (6)...(6)  
 <223> m5c

<400> 798  
 gagaangctc gaccttcgat 20

<210> 799  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 799  
 tcaacgttaa cgttaacgtt 20

<210> 800  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.

<221> modified\_base  
 <222> (8)...(8)  
 <223> m5c

<400> 800  
 gagcaagntg gaccttccat 20

<210> 801  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.

<221> modified\_base



<222> (6)...(6)  
 <223> m5c

<400> 801  
 gagaangctc cagcactgat 20

<210> 802  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (5)...(5)  
 <223> m5c

<221> misc\_feature  
 <222> (8)...(10)  
 <223> Biotin moiety attached at 3' end of sequence.

<400> 802  
 tcaangttga 10

<210> 803  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (2)...(2)  
 <223> m5c

<221> misc\_feature  
 <222> (8)...(10)  
 <223> Biotin moiety attached at 3' end of sequence.

<400> 803  
 gnaatattgc 10

<210> 804  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 804  
 tgctgctttt gtcgttttgt gctt 24

<210> 805  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<400> 805  
 ctgcgttagc aatttaactg tg 22

<210> 806  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



WO 01/22972

PCT/US00/26383

115

|                                |    |
|--------------------------------|----|
| <400> 806                      |    |
| tccatgacgt tcctgatgct          | 20 |
| <210> 807                      |    |
| <211> 28                       |    |
| <212> DNA                      |    |
| <213> Artificial Sequence      |    |
| <400> 807                      |    |
| tgcatgccgt gcatccgtac acagctct | 28 |
| <210> 808                      |    |
| <211> 20                       |    |
| <212> DNA                      |    |
| <213> Artificial Sequence      |    |
| <400> 808                      |    |
| tgcatgccgt acacagctct          | 20 |
| <210> 809                      |    |
| <211> 12                       |    |
| <212> DNA                      |    |
| <213> Artificial Sequence      |    |
| <400> 809                      |    |
| tgcatcagct ct                  | 12 |
| <210> 810                      |    |
| <211> 8                        |    |
| <212> DNA                      |    |
| <213> Artificial Sequence      |    |
| <400> 810                      |    |
| tgcgctct                       | 8  |
| <210> 811                      |    |
| <211> 20                       |    |
| <212> DNA                      |    |
| <213> Artificial Sequence      |    |
| <400> 811                      |    |
| cccccccccc ccccccccc           | 20 |
| <210> 812                      |    |
| <211> 12                       |    |
| <212> DNA                      |    |
| <213> Artificial Sequence      |    |
| <400> 812                      |    |
| cccccccccc cc                  | 12 |
| <210> 813                      |    |
| <211> 8                        |    |
| <212> DNA                      |    |
| <213> Artificial Sequence      |    |
| <400> 813                      |    |
| cccccccc                       | 8  |
| <210> 814                      |    |
| <211> 12                       |    |



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 814  
 tgcattcagct ct 12  
  
 <210> 815  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 815  
 tgcattgccgt acacagctct 20  
  
 <210> 816  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 816  
 gagcaagctg gaccttccat 20  
  
 <210> 817  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 817  
 tcaacgttaa cgttaacggt aacgttaacg tt 32  
  
 <210> 818  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 818  
 gagaacgctc gaccttcgat 20  
  
 <210> 819  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 819  
 gtcccccattt cccagaggag gaaat 25  
  
 <210> 820  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 820  
 ctagcggctg acgtcatcaa gctag 25  
  
 <210> 821  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 821  
 ctagcttgat gacgtcagcc gctag 25



|                              |    |
|------------------------------|----|
| <210> 822                    |    |
| <211> 16                     |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |
| <400> 822                    |    |
| cggctgacgt catcaa            | 16 |
| <210> 823                    |    |
| <211> 8                      |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |
| <400> 823                    |    |
| ctgacgtg                     | 8  |
| <210> 824                    |    |
| <211> 10                     |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |
| <400> 824                    |    |
| ctgacgtcat                   | 10 |
| <210> 825                    |    |
| <211> 21                     |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |
| <400> 825                    |    |
| attcgatcgg ggcggggcga g      | 21 |
| <210> 826                    |    |
| <211> 21                     |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |
| <400> 826                    |    |
| ctcgccccgc cccgatcgaa t      | 21 |
| <210> 827                    |    |
| <211> 15                     |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |
| <400> 827                    |    |
| gactgacgtc agcgt             | 15 |
| <210> 828                    |    |
| <211> 26                     |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |
| <400> 828                    |    |
| ctagcggctg acgtcataaa gctagc | 26 |
| <210> 829                    |    |
| <211> 26                     |    |
| <212> DNA                    |    |
| <213> Artificial Sequence    |    |



<400> 829  
 ctagctttat gacgtcagcc gctagc 26  
  
 <210> 830  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 830  
 ctagcggctg agctcataaa gctagc 26  
  
 <210> 831  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 831  
 ctagtggctg acgtcatcaa gctag 25  
  
 <210> 832  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 832  
 tccaccacgt ggtctatgct 20  
  
 <210> 833  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 833  
 gggaatgaaa gattttatta taag 24  
  
 <210> 834  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 834  
 tctaaaaacc atctattctt aaccct 26  
  
 <210> 835  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 835  
 agctcaacgt catgc 15  
  
 <210> 836  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 836  
 ttaacggtgg tagcggtatt ggtc 24  
  
 <210> 837



<211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 837  
 ttaagaccaa taccgctacc accg 24

<210> 838  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<400> 838  
 gatctagtga tgagtcagcc ggatc 25

<210> 839  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<400> 839  
 gatccggctg actcatcact agatc 25

<210> 840  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 840  
 tccaagacgt tcctgatgct 20

<210> 841  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 841  
 tccatgacgt ccctgatgct 20

<210> 842  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 842  
 tccaccacgt ggctgatgct 20

<210> 843  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<400> 843  
 ccacgtggac ctctagc 17

<210> 844  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<400> 844



WO 01/22972

PCT/US00/26383

120

tcagaccacg tggtcgggtg ttcctga 27

<210> 845  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<400> 845  
 tcaggaacac ccgaccacgt ggtctga 27

<210> 846  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 846  
 catttccacg atttccca 18

<210> 847  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<400> 847  
 ttcctctctg caagagact 19

<210> 848  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<400> 848  
 tgtatctctc tgaaggact 19

<210> 849  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<400> 849  
 ataaagcgaa actagcagca gtttc 25

<210> 850  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<400> 850  
 gaaactgctg ctagtttcgc tttat 25

<210> 851  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<400> 851  
 tgcccaaaga ggaaaatttg tttcatacag 30

<210> 852  
 <211> 30  
 <212> DNA



121

<213> Artificial Sequence  
 <400> 852  
 ctgtatgaaa caaatTTTcc tctttgggca 30  
 <210> 853  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 853  
 ttagggtag ggtagggtt 20  
 <210> 854  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 854  
 tccatgagct tcctgatgct 20  
 <210> 855  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 855  
 aaaacatgac gttcaaaaaa 20  
 <210> 856  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 856  
 aaaacatgac gttcgggggg 20  
 <210> 857  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 857  
 ggggcatgag cttcgggggg 20  
 <210> 858  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 858  
 ctaggctgac gtcacaaagc tagt 24  
 <210> 859  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 859  
 tctgacgtca tctgacgttg gctgacgtct 30



122

<210> 860  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<400> 860  
 ggaattagta atagatatag aagtt 25

<210> 861  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<400> 861  
 tttaacctttt ataaacataa ctaaaacaaa 30

<210> 862  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 862  
 gcgttttttt ttgcg 15

<210> 863  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 863  
 atatctaatac aaaacattaa caaa 24

<210> 864  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 864  
 tctatcccag gtggttcctg ttag 24

<210> 865  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)  
 <223> Biotin moiety attached at 5' end of sequence.

<400> 865  
 tccatgacgt tcctgatgct 20

<210> 866  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(3)



123

<223> Biotin moiety attached at 5' end of sequence.

<400> 866

tccatgagct tcctgatgct

20

<210> 867

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (11)...(13)

<223> FITC moiety attached at 3' end of sequence.

<221> misc\_feature

<222> (0)...(0)

<223> Has phosphodiester backbone.

<400> 867

ttttttttttt ttt

13

<210> 868

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (11)...(13)

<223> Biotin moiety attached at 3' end of sequence.

<221> misc\_feature

<222> (0)...(0)

<223> Has phosphorothioate and phosphodiester chimeric backbone with phosphodiester on 3' end.

<400> 868

ttttttttttt ttt

13

<210> 869

<211> 25

<212> DNA

<213> Artificial Sequence

<400> 869

ctagcttgat gagctcagcc gctag

25

<210> 870

<211> 25

<212> DNA

<213> Artificial Sequence

<400> 870

ttcagttgtc ttgctgctta gctaa

25

<210> 871

<211> 20

<212> DNA

<213> Artificial Sequence



124

<400> 871  
 tccatgagct tcctgagtct 20

<210> 872  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<400> 872  
 ctagcggctg acgtcatcaa tctag 25

<210> 873  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 873  
 tgctagctgt gcctgtacct 20

<210> 874  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<400> 874  
 atgctaaagg acgtcacatt gca 23

<210> 875  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<400> 875  
 tgcaatgtga cgtcctttag cat 23

<210> 876  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<400> 876  
 gtaggggact ttccgagctc gagatcctat g 31

<210> 877  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<400> 877  
 cataggatct cgagctcgga aagtccccta c 31

<210> 878  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<400> 878  
 ctgtcaggaa ctgcaggtaa gg 22

<210> 879  
 <211> 27



125

<212> DNA  
 <213> Artificial Sequence  
  
 <400> 879  
 cataacatag gaatatttac tcctcgc 27  
  
 <210> 880  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 880  
 ctccagctcc aagaaaggac g 21  
  
 <210> 881  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 881  
 gaagtttctg gtaagtcttc g 21  
  
 <210> 882  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 882  
 tgctgctttt gtgcttttgt gctt 24  
  
 <210> 883  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 883  
 tcgtcgtttt gtggttttgt ggtt 24  
  
 <210> 884  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 884  
 tcgtcgtttg tcgttttgtc gtt 23  
  
 <210> 885  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 885  
 tcctgacgtt cggcgcgogc cc 22  
  
 <210> 886  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 886  
 tgctgctttt gtgcttttgt gctt 24



<210> 887  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 887  
 tccatgagct tcctgagctt 20  
  
 <210> 888  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 888  
 tcgtcgtttc gtcgttttga cggt 24  
  
 <210> 889  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 889  
 tcgtcgtttg cgtgcgtttc gtcgtt 26  
  
 <210> 890  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 890  
 tcgcgtgcgt tttgtcgttt tgacgtt 27  
  
 <210> 891  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 891  
 ttcgtcgttt tgtcgttttg tcgtt 25  
  
 <210> 892  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 892  
 tcctgacggg gaagt 15  
  
 <210> 893  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 893  
 tcctggcgtg gaagt 15  
  
 <210> 894  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence



<400> 894  
tcctggcggt gaagt 15

<210> 895  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 895  
tcctggcggt gaagt 15

<210> 896  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 896  
tcctgacgtg gaagt 15

<210> 897  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 897  
gcgacgttcg gcgcgcgccc 20

<210> 898  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 898  
gcgacgggcg gcgcgcgccc 20

<210> 899  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 899  
gcggcgtgcg gcgcgcgccc 20

<210> 900  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 900  
gcggcggtcg gcgcgcgccc 20

<210> 901  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 901  
gcgacggtcg gcgcgcgccc 20

<210> 902



128

<211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 902  
 gcggcggttcg gcgcgcgccc 20

<210> 903  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 903  
 gcgacgtgcg gcgcgcgccc 20

<210> 904  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 904  
 tcgtcgctgt ctccg 15

<210> 905  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 905  
 tgtggggggtt ttggtttttg 20

<210> 906  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 906  
 aggggagggg aggggagggg 20

<210> 907  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 907  
 tgtgtgtgtg tgtgtgtgtg t 21

<210> 908  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<400> 908  
 ctctctctct ctctctctct ct 22

<210> 909  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 909



WO 01/22972

PCT/US00/26383

129

gggggtcgacg tcgagggggg

20

<210> 910  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<400> 910  
 atatatatat atatatatat at 22

<210> 911  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<400> 911  
 tttttttttt tttttttttt ttttttt 27

<210> 912  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 912  
 tttttttttt tttttttttt t 21

<210> 913  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 913  
 tttttttttt tttttttt 18

<210> 914  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 914  
 gctagagggg aggggt 15

<210> 915  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 915  
 gctagatgtt agggg 15

<210> 916  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 916  
 gcatgagggg gagct 15

<210> 917  
 <211> 20  
 <212> DNA



130

<213> Artificial Sequence  
 <400> 917  
 atggaaggctc cagggggctc 20  
 <210> 918  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 918  
 atggactctg gagggggctc 20  
 <210> 919  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 919  
 atggaaggctc caaggggctc 20  
 <210> 920  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 920  
 gagaaggggg gaccttgat 20  
 <210> 921  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 921  
 gagaaggggg gaccttccat 20  
 <210> 922  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 922  
 gagaaggggc cagcactgat 20  
 <210> 923  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 923  
 tccatgtggg gcctgatgct 20  
 <210> 924  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 924  
 tccatgaggg gcctgatgct 20



<210> 925  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 925  
tccatgtggg gcctgctgat 20

<210> 926  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 926  
atggactctc cggggttctc 20

<210> 927  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 927  
atggaaggctc cggggttctc 20

<210> 928  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 928  
atggactctg gaggggtctc 20

<210> 929  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 929  
atggaggctc catggggctc 20

<210> 930  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 930  
atggactctg gggggttctc 20

<210> 931  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 931  
tccatgtggg tggggatgct 20

<210> 932  
<211> 20  
<212> DNA  
<213> Artificial Sequence



WO 01/22972

PCT/US00/26383

132

<400> 932  
 tccatgcggg tggggatgct 20

<210> 933  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 933  
 tccatggggg tcctgatgct 20

<210> 934  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 934  
 tccatggggg ccctgatgct 20

<210> 935  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 935  
 tccatggggg gcctgatgct 20

<210> 936  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 936  
 tccatggggg tcctgatgct 20

<210> 937  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 937  
 tccatcgggg gcctgatgct 20

<210> 938  
 <211> 14  
 <212> DNA  
 <213> Artificial Sequence

<400> 938  
 gctagaggga gtgt 14

<210> 939  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<400> 939  
 tttttttttt tttttttt 18

<210> 940  
 <211> 21



133

<212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_difference  
 <222> (2)...(2)  
 <223> m i s a o r c  
  
 <221> misc\_difference  
 <222> (18)...(18)  
 <223> m i s a o r c  
  
 <400> 940  
 gmgggtcaacg ttgaggggmgg g 21  
  
 <210> 941  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 941  
 ggggagttcg ttgagggggg g 21  
  
 <210> 942  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 942  
 tcgtcgtttc cccccccccc 20  
  
 <210> 943  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 943  
 ttgggggggtt tttttttttt ttttt 25  
  
 <210> 944  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 944  
 tttaaatttt aaaatttaaa ata 23  
  
 <210> 945  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 945  
 ttggtttttt tgggtttttt ttgg 24  
  
 <210> 946  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 946



134

tttccctttt ccccttttcc cctc

24

<210> 947  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_difference  
 <222> (21)...(21)  
 <223> s is g or c

<400> 947  
 ggggtcatcg atgagggggg s 21

<210> 948  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 948  
 tccatgacgt tcctgacgtt 20

<210> 949  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 949  
 tccatgacgt tcctgacgtt 20

<210> 950  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 950  
 tccatgacgt tcctgacgtt 20

<210> 951  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 951  
 tccatgacgt tcctgacgtt 20

<210> 952  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 952  
 tccatgacgt tcctgacgtt 20

<210> 953  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 953



WO 01/22972

PCT/US00/26383

135

tccatgacgt tcctgacgtt

20

<210> 954  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 954  
 tccatgacgt tcctgacgtt

20

<210> 955  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 955  
 tccatgacgt tcctgacgtt

20

<210> 956  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 956  
 tccatgacgt tcctgacgtt

20

<210> 957  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 957  
 tccatgacgt tcctgacgtt

20

<210> 958  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 958  
 tccatgacgt tcctgacgtt

20

<210> 959  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<400> 959  
 gggggacgat cgtcggggg

19

<210> 960  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 960  
 gggggtcgta cgacggggg

20

<210> 961  
 <211> 24  
 <212> DNA



136

<213> Artificial Sequence  
 <400> 961  
 tttttttttt tttttttttt tttt 24  
 <210> 962  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 962  
 aaaaaaaaaa aaaaaaaaaa aaaa 24  
 <210> 963  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 963  
 cccccccccc cccccccccc cccc 24  
 <210> 964  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 964  
 tcgtcgtttt gtcgttttgt cgtt 24  
 <210> 965  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 965  
 tcgtcgtttt gtcgttttgt cgtt 24  
 <210> 966  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 966  
 tcgtcgtttt gtcgttttgt cgtt 24  
 <210> 967  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 967  
 tcgtcgtttt gtcgttttgt cgtt 24  
 <210> 968  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 968  
 ggggtcaacg ttgagggggg 20



<210> 969  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 969  
 ggggtcaacg ttgagggggg 20

<210> 970  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 970  
 ggggtcaagc ttgagggggg 20

<210> 971  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 971  
 tgctgcttcc cccccccccc 20

<210> 972  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 972  
 ggggacgtcg acgtgggggg 20

<210> 973  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 973  
 ggggtcgtcg acgagggggg 20

<210> 974  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 974  
 ggggtcgacg tacgtcgagg gggg 24

<210> 975  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<400> 975  
 ggggaccggt accggtgggg gg 22

<210> 976  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence



<400> 976  
 ggggtcgacgt cgagggggg 19  
  
 <210> 977  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 977  
 ggggtcgacg tcgaggggg 19  
  
 <210> 978  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 978  
 ggggaacgtt aacgttgggg gg 22  
  
 <210> 979  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 979  
 ggggtcaccg gtgagggggg 20  
  
 <210> 980  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 980  
 ggggtcgttc gaacgagggg gg 22  
  
 <210> 981  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 981  
 ggggacgttc gaacgtgggg gg 22  
  
 <210> 982  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 982  
 tcaactttga 10  
  
 <210> 983  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 983  
 tcaagcttga 10  
  
 <210> 984  
 <211> 12



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 984  
 tcacgatcgt ga 12  
  
 <210> 985  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 985  
 tcagcatgct ga 12  
  
 <210> 986  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 986  
 gggggagcat gctggggggg 20  
  
 <210> 987  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 987  
 gggggggggg gggggggggg 20  
  
 <210> 988  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 988  
 gggggacgat atcgtcgggg gg 22  
  
 <210> 989  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 989  
 gggggacgac gtcgtcgggg gg 22  
  
 <210> 990  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 990  
 gggggacgag ctcgtcgggg gg 22  
  
 <210> 991  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 991  
 gggggacgta cgtcgggggg 20



|                           |    |
|---------------------------|----|
| <210> 992                 |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 992                 |    |
| tcaacggt                  | 8  |
| <210> 993                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 993                 |    |
| tccataccgg tcctgatgct     | 20 |
| <210> 994                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 994                 |    |
| tccataccgg tcctaccggt     | 20 |
| <210> 995                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 995                 |    |
| gggggacgat cggtgggggg     | 20 |
| <210> 996                 |    |
| <211> 20                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 996                 |    |
| ggggaacgat cgtcgggggg     | 20 |
| <210> 997                 |    |
| <211> 21                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 997                 |    |
| ggggggacga tcgtcggggg g   | 21 |
| <210> 998                 |    |
| <211> 21                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 998                 |    |
| gggggacgat cgtcgggggg g   | 21 |
| <210> 999                 |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |



<400> 999  
 aaagacgtta aa 12  
 <210> 1000  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence

<400> 1000  
 aaagagctta aa 12  
 <210> 1001  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (6)...(6)  
 <223> m5c

<400> 1001  
 aaagangtta aa 12  
 <210> 1002  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence

<400> 1002  
 aaattcggaa aa 12  
 <210> 1003  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 1003  
 ggggggtcatc gatgaggggg g 21  
 <210> 1004  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<400> 1004  
 ggggggtcaac gttgaggggg g 21  
 <210> 1005  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 1005  
 atgtagctta ataacaaagc 20  
 <210> 1006  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence



<400> 1006  
ggatcccttg agttacttct 20

<210> 1007  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1007  
ccattccact tctgattacc 20

<210> 1008  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1008  
tatgtattat catgtagata 20

<210> 1009  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1009  
agcctacgta ttcaccctcc 20

<210> 1010  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1010  
ttcctgcaac tactattgta 20

<210> 1011  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1011  
atagaaggcc ctacaccagt 20

<210> 1012  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1012  
ttacaccggt ctatggaggt 20

<210> 1013  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1013  
ctaaccagat caagtctagg 20

<210> 1014



143

<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1014  
cctagacttg atctggtag 20

<210> 1015  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1015  
tataagcctc gtccgacatg 20

<210> 1016  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1016  
catgtcggac gaggcttata 20

<210> 1017  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1017  
tggtggtggg gagtaagctc 20

<210> 1018  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1018  
gagctactcc cccaccacca 20

<210> 1019  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1019  
gccttcgatc ttcgttggga 20

<210> 1020  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1020  
tggacttctc tttgccgtct 20

<210> 1021  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1021



WO 01/22972

PCT/US00/26383

144

atgctgtagc ccagcgataa

20

&lt;210&gt; 1022

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 1022

accgaatcag cggaaagtga

20

&lt;210&gt; 1023

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 1023

tccatgacgt tcctgacgtt

20

&lt;210&gt; 1024

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 1024

ggagaaaccc atgagctcat ctgg

24

&lt;210&gt; 1025

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 1025

accacagacc agcaggcaga

20

&lt;210&gt; 1026

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 1026

gagcgtgaac tgcgcgaaga

20

&lt;210&gt; 1027

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 1027

tcggtaccct tgcagcgggtt

20

&lt;210&gt; 1028

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;400&gt; 1028

ctggagccct agccaaggat

20

&lt;210&gt; 1029

&lt;211&gt; 20

&lt;212&gt; DNA



145

<213> Artificial Sequence  
 <400> 1029  
 gcgactccat caccagcgat 20  
 <210> 1030  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1030  
 cctgaagtaa gaaccagatg t 21  
 <210> 1031  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1031  
 ctgtgttatc tgacatacac c 21  
 <210> 1032  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1032  
 aattagcctt aggtgattgg g 21  
 <210> 1033  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1033  
 acatctgggt cttacttcag g 21  
 <210> 1034  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1034  
 ataagtcata ttttggaac tac 23  
 <210> 1035  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1035  
 cccaatcacc taaggctaat t 21  
 <210> 1036  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1036  
 ggggtcgtcg acgagggggg 20



146

<210> 1037  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1037  
 ggggtcgttc gaacgagggg gg 22

<210> 1038  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1038  
 ggggacgttc gaacgtgggg gg 22

<210> 1039  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> modified\_base  
 <222> (9)...(9)  
 <223> n is 5-methylcytosine.  
  
 <400> 1039  
 tcctggcgng gaagt 15

<210> 1040  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1040  
 ggggaacgac gtcgttgggg gg 22

<210> 1041  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1041  
 ggggaacgta cgtcgggggg 20

<210> 1042  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1042  
 ggggaacgta cgtacgttgg gggg 24

<210> 1043  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1043  
 ggggtcaccg gtgagggggg 20



147

<210> 1044  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1044  
 ggggtcgacg tacgtcgagg gggg 24  
  
 <210> 1045  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1045  
 ggggaccggt accggtgggg gg 22  
  
 <210> 1046  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1046  
 gggtcgacgt cgagggggg 19  
  
 <210> 1047  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1047  
 ggggtcgacg tcgagggg 18  
  
 <210> 1048  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1048  
 ggggaacgtt aacgttgggg gg 22  
  
 <210> 1049  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1049  
 ggggacgtcg acgtggggg 19  
  
 <210> 1050  
 <211> 34  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1050  
 gcactcttcg aagctacagc cggcagcctc tgat 34  
  
 <210> 1051  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence



<400> 1051  
 cggctcttcc atgaggtctt tgctaattctt gg 32

<210> 1052  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<400> 1052  
 cggctcttcc atgaaagtct ttggacgatg tgagc 35

<210> 1053  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence

<400> 1053  
 tcctgcaggt taagt 15

<210> 1054  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 1054  
 gggggtcggt cgttgggggg 20

<210> 1055  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 1055  
 gggggatgat tgttgggggg 20

<210> 1056  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> modified\_base  
 <222> (7)...(7)  
 <223> m5c

<221> modified\_base  
 <222> (11)...(11)  
 <223> m5c

<400> 1056  
 gggggangat ngttgggggg 20

<210> 1057  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 1057  
 gggggagcta gcttgggggg 20

<210> 1058



149

<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1058  
ggttccttttg gtccttgtct 20

<210> 1059  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1059  
ggttccttttg gtcctcgtct 20

<210> 1060  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1060  
ggttccttttg gtccttatct 20

<210> 1061  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1061  
ggttccttggg ttccttgtct 20

<210> 1062  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1062  
tggtccttttg gtccttgtct 20

<210> 1063  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1063  
ggttcaaag gtccttgtct 20

<210> 1064  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<400> 1064  
gggtccttttg ggccttgtct 20

<210> 1065  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<400> 1065



WO 01/22972

PCT/US00/26383

150

tccaggactt ctctcagggtt tttt

24

<210> 1066  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 1066  
 tccaaaactt ctctcaaatt

20

<210> 1067  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 1067  
 tactactttt atacttttat actt

24

<210> 1068  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<400> 1068  
 tgttgtgtgtg tgttgtgtgtg tgtg

24

<210> 1069  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<400> 1069  
 ttgtttgtttgt tgtttgtttgt tgttg

25

<210> 1070  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<400> 1070  
 ggctccgggg agggaatttt tgtctat

27

<210> 1071  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<400> 1071  
 gggacgatcg tcggggggg

19

<210> 1072  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<400> 1072  
 gggtcgtcga cgaggggggg

20

<210> 1073  
 <211> 19  
 <212> DNA



151

<213> Artificial Sequence  
 <400> 1073  
 ggtcgctcgac gagggggggg 19  
 <210> 1074  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1074  
 gggtcgctcgt cgtggggggg 20  
 <210> 1075  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1075  
 ggggacgatc gtcggggggg 20  
 <210> 1076  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1076  
 ggggacgtcg tcgtggggggg 20  
 <210> 1077  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1077  
 ggggtcgcgc tcgacgtcga gggggggg 27  
 <210> 1078  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1078  
 ggggaaccgc ggttgggggg g 21  
 <210> 1079  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1079  
 ggggacgcgc tcgtggggggg g 21  
 <210> 1080  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <400> 1080  
 tcgtcgtcgt cgtcgtgggg ggg 23



152

<210> 1081  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 1081  
tcctgccggg gaagt 15

<210> 1082  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 1082  
tcctgcaggg gaagt 15

<210> 1083  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 1083  
tcctgaaggg gaagt 15

<210> 1084  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 1084  
tcctggcggg caagt 15

<210> 1085  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 1085  
tcctggcggg taagt 15

<210> 1086  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 1086  
tcctggcggg aaagt 15

<210> 1087  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<400> 1087  
tccgggcggg gaagt 15

<210> 1088  
<211> 15  
<212> DNA  
<213> Artificial Sequence



|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| <p>&lt;400&gt; 1088<br/>tcgggggcggg gaagt</p> <p>&lt;210&gt; 1089<br/>&lt;211&gt; 15<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> <p>&lt;400&gt; 1089<br/>tcccggcggg gaagt</p> <p>&lt;210&gt; 1090<br/>&lt;211&gt; 15<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> <p>&lt;400&gt; 1090<br/>gggggacgtt ggggg</p> <p>&lt;210&gt; 1091<br/>&lt;211&gt; 20<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> <p>&lt;400&gt; 1091<br/>gggggtttttt ttttgggggg</p> <p>&lt;210&gt; 1092<br/>&lt;211&gt; 20<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> <p>&lt;400&gt; 1092<br/>ggggcccccc ccccgggggg</p> <p>&lt;210&gt; 1093<br/>&lt;211&gt; 21<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> <p>&lt;400&gt; 1093<br/>ggggttgttg ttgttggggg g</p> <p>&lt;210&gt; 1094<br/>&lt;211&gt; 30<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> <p>&lt;220&gt;<br/>&lt;223&gt; Synthetic Sequence</p> <p>&lt;400&gt; 1094<br/>tttttttttt tttttttttt tttttttttt</p> <p>&lt;210&gt; 1095<br/>&lt;211&gt; 30<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> <p>&lt;220&gt;<br/>&lt;223&gt; Synthetic Sequence</p> | <p>15</p> <p>15</p> <p>15</p> <p>20</p> <p>20</p> <p>21</p> <p>30</p> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|



<400> 1095  
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 30

<210> 1096  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic Sequence

<400> 1096  
cccccccccc ccccccccccc ccccccccccc 30

<210> 1097  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic Sequence

<400> 1097  
cgcgcgcgcg cgcgcgcgcg cgcgcgcgcg 30

<210> 1098  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic Sequence

<400> 1098  
gattttatcg tc 12

<210> 1099  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<400> 1099  
tcgatttttc ga 12

<210> 1100  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<400> 1100  
tcatttttat ga 12

<210> 1101  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<400> 1101  
gttttttacg ac 12



155

<210> 1102  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<400> 1102  
tcaatttttt ga 12

<210> 1103  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<400> 1103  
acgttttttac gt 12

<210> 1104  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<400> 1104  
tcgttttttac ga 12

<210> 1105  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<400> 1105  
tcgattttta cgtcga 16

<210> 1106  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<400> 1106  
aatttttttaa cggt 14

<210> 1107  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<400> 1107  
tcgtttttta acga 14

<210> 1108  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<400> 1108  
acgtttttta acgt 14

<210> 1109  
<211> 13  
<212> DNA  
<213> Artificial Sequence



|                                                                                                    |    |
|----------------------------------------------------------------------------------------------------|----|
| <p>&lt;400&gt; 1109<br/>gattttttatc gtc</p>                                                        | 13 |
| <p>&lt;210&gt; 1110<br/>&lt;211&gt; 14<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> |    |
| <p>&lt;400&gt; 1110<br/>gacgattttt cgtc</p>                                                        | 14 |
| <p>&lt;210&gt; 1111<br/>&lt;211&gt; 14<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> |    |
| <p>&lt;400&gt; 1111<br/>gatttttagct cgtc</p>                                                       | 14 |
| <p>&lt;210&gt; 1112<br/>&lt;211&gt; 12<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> |    |
| <p>&lt;400&gt; 1112<br/>gattttttacg tc</p>                                                         | 12 |
| <p>&lt;210&gt; 1113<br/>&lt;211&gt; 10<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> |    |
| <p>&lt;400&gt; 1113<br/>atttttatcgt</p>                                                            | 10 |
| <p>&lt;210&gt; 1114<br/>&lt;211&gt; 14<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> |    |
| <p>&lt;400&gt; 1114<br/>aacgattttt cgtt</p>                                                        | 14 |
| <p>&lt;210&gt; 1115<br/>&lt;211&gt; 12<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> |    |
| <p>&lt;400&gt; 1115<br/>tcacttttgt ga</p>                                                          | 12 |
| <p>&lt;210&gt; 1116<br/>&lt;211&gt; 10<br/>&lt;212&gt; DNA<br/>&lt;213&gt; Artificial Sequence</p> |    |
| <p>&lt;400&gt; 1116<br/>tcgtatttta</p>                                                             | 10 |
| <p>&lt;210&gt; 1117<br/>&lt;211&gt; 14</p>                                                         |    |



<212> DNA  
 <213> Artificial Sequence  
  
 <400> 1117  
 actttttgtac cggt 14  
  
 <210> 1118  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1118  
 tcgatttttc gacgtcga 18  
  
 <210> 1119  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1119  
 acgatttttc gt 12  
  
 <210> 1120  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1120  
 gatgatcgtc 10  
  
 <210> 1121  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1121  
 tcgatgtcga 10  
  
 <210> 1122  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1122  
 tcatgtatga 10  
  
 <210> 1123  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1123  
 gtgttacgac 10  
  
 <210> 1124  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1124  
 tcaatgttga 10



|                           |    |
|---------------------------|----|
| <210> 1125                |    |
| <211> 10                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1125                |    |
| acgtgtacgt                | 10 |
| <210> 1126                |    |
| <211> 10                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1126                |    |
| tcgtgtacga                | 10 |
| <210> 1127                |    |
| <211> 14                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1127                |    |
| tcgatgtacg tcga           | 14 |
| <210> 1128                |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1128                |    |
| aatgttaacg tt             | 12 |
| <210> 1129                |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1129                |    |
| tcgtgttaac ga             | 12 |
| <210> 1130                |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1130                |    |
| acgtgttaac gt             | 12 |
| <210> 1131                |    |
| <211> 11                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1131                |    |
| gatgtatcgt c              | 11 |
| <210> 1132                |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |



|                           |    |
|---------------------------|----|
| <400> 1132                |    |
| gacgatgtcg tc             | 12 |
| <210> 1133                |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1133                |    |
| gatgagctcg tc             | 12 |
| <210> 1134                |    |
| <211> 10                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1134                |    |
| gatgtacgtc                | 10 |
| <210> 1135                |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1135                |    |
| atgatcgt                  | 8  |
| <210> 1136                |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1136                |    |
| aacgatgtcg tt             | 12 |
| <210> 1137                |    |
| <211> 10                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1137                |    |
| tcactggtga                | 10 |
| <210> 1138                |    |
| <211> 8                   |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1138                |    |
| tcgtatga                  | 8  |
| <210> 1139                |    |
| <211> 12                  |    |
| <212> DNA                 |    |
| <213> Artificial Sequence |    |
| <400> 1139                |    |
| actggtaccg gt             | 12 |
| <210> 1140                |    |



160

<211> 16  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1140  
 tcgatgtcga cgtcga 16  
  
 <210> 1141  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1141  
 acgatgtcgt 10  
  
 <210> 1142  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1142  
 tgcaggaagt ccgggttttc cccaaccccc c 31  
  
 <210> 1143  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic Sequence  
  
 <400> 1143  
 gacgtt 6  
  
 <210> 1144  
 <211> 6  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1144  
 gtcgtt 6  
  
 <210> 1145  
 <211> 8  
 <212> DNA  
 <213> Artificial Sequence  
  
 <400> 1145  
 tcgtcgtt 8



- 157 -

**CLAIMS**

1. A method of stimulating an immune response, comprising  
administering a Py-rich immunostimulatory nucleic acid to a non-rodent  
subject in an amount effective to induce an immune response in the non-rodent subject,  
wherein the nucleic acid is a T-rich nucleic acid that is greater than 60% T and contains a  
CpG dinucleotide.

2. (Cancelled)

3. The method of claim 1, wherein the T-rich immunostimulatory nucleic acid is a  
poly T nucleic acid comprising

5' TTTT 3'.

4. The method of claim 3, wherein the poly T nucleic acid comprises

5' X<sub>1</sub> X<sub>2</sub>TTTTX<sub>3</sub> X<sub>4</sub> 3'

wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> are nucleotides.

5. The method of claim 3, wherein the T-rich immunostimulatory nucleic acid  
comprises a plurality of poly T nucleic acid motifs.

6. The method of claim 4, wherein X<sub>1</sub>X<sub>2</sub> is TT.

7. The method of claim 4, wherein X<sub>3</sub>X<sub>4</sub> is TT.

8. The method of claim 4, wherein X<sub>1</sub>X<sub>2</sub> is selected from the group consisting of TA,  
TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC.

9. The method of claim 4, wherein X<sub>3</sub>X<sub>4</sub> is selected from the group consisting of TA,  
TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)



- 158 -

15. The method of claim 1, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 80% T.

16. The method of claim 1, wherein the immunostimulatory nucleic acid comprises at least 20 nucleotides.

17. The method of claim 1, wherein the immunostimulatory nucleic acid comprises at least 24 nucleotides.

18. The method of claim 1, wherein the immunostimulatory nucleic acid has a nucleotide backbone which includes at least one backbone modification.

19. The method of claim 18, wherein the backbone modification is a phosphorothioate modification.

20. The method of claim 18, wherein the nucleotide backbone is chimeric.

21. The method of claim 18, wherein the nucleotide backbone is entirely modified.

22. (Cancelled)

23. (Cancelled)

24. The method of claim 1, wherein the immunostimulatory nucleic acid is free of methylated CpG dinucleotides.

25. The method of claim 1, wherein the immunostimulatory nucleic acid is free of poly-C sequences.

26. The method of claim 1, wherein the immunostimulatory nucleic acid includes a poly-A sequence.

27. The method of claim 20, wherein the immunostimulatory nucleic acid includes a poly-G sequence.

28. The method of claim 1, wherein the immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25% C.

29. The method of claim 1, wherein the immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25% A.



- 159 -

30. The method of claim 1, wherein the immunostimulatory nucleic acid is administered orally.

31. The method of claim 1, wherein the immunostimulatory nucleic acid is administered locally.

32. The method of claim 1, wherein the immunostimulatory nucleic acid is administered in a sustained release device.

33. The method of claim 1, wherein the immunostimulatory nucleic acid is administered mucosally to a mucosal surface.

34. The method of claim 33, wherein the immune response is a mucosal immune response.

35. The method of claim 33, wherein the immune response is a systemic immune response.

36. The method of claim 33, wherein the mucosal surface is selected from the group consisting of an oral, nasal, rectal, vaginal, and ocular surface.

37. The method of claim 1, further comprising exposing the subject to an antigen and wherein the immune response is an antigen-specific immune response.

38. The method of claim 37, wherein a nucleic acid vector which encodes the antigen is administered to the subject, and wherein the nucleic acid vector is separate from the immunostimulatory nucleic acid.

39. The method of claim 37, wherein the antigen is a peptide antigen.

40. The method of claim 1, further comprising isolating an immune cell from the subject, contacting the immune cell with an effective amount to activate the immune cell of the immunostimulatory nucleic acid and re-administering the activated immune cell to the subject.

41. The method of claim 40, wherein the immune cell is a leukocyte.

42. The method of claim 41, further comprising contacting the immune cell with an antigen.



- 160 -

43. The method of claim 40, wherein the antigen is selected from the group consisting of a tumor antigen, a viral antigen, a bacterial antigen, and a parasitic antigen.

44. The method of claim 40, wherein the immune cell is a dendritic cell.

45. The method of claim 1, wherein the subject has or is at risk of developing asthma and the method is a method of treating or preventing asthma in the subject.

46. The method of claim 1, wherein the subject has or is at risk of developing allergy and the method is a method of treating or preventing allergy.

47. The method of claim 1, wherein the subject has cancer and the method is a method of treating the cancer.

48. The method of claim 47, wherein the cancer is selected from the group consisting of biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; CNS cancer; colon cancer; connective tissue cancer; endometrial cancer; eye cancer; gastric cancer; intraepithelial neoplasms; larynx cancer; lymphomas; Hodgkin's lymphoma; liver cancer; lung cancer (e.g. small cell and non-small cell); melanoma; neuroblastomas; oral cancer; oral cavity cancer; ovarian cancer; pancreas cancer; prostate cancer; rectal cancer; sarcomas; thyroid cancer; and renal cancer, as well as other carcinomas and sarcomas.

49. The method of claim 1, wherein the cancer is selected from the group consisting of bone cancer, brain and CNS cancer, connective tissue cancer, esophageal cancer, eye cancer, Hodgkin's lymphoma, larynx cancer, oral cavity cancer, skin cancer, and testicular cancer.

50. The method of claim 47, further comprising administering an anti-cancer therapy.

51. The method of claim 50, wherein the anti-cancer therapy is an antibody.

52. The method of claim 47, wherein the subject is a human.

53. The method of claim 47, wherein the subject is selected from the group consisting of a dog, a cat, and a horse.



- 161 -

54. The method of claim 1, further comprising administering an antibody specific for a cell surface antigen, and wherein the immune response results in antigen dependent cellular cytotoxicity (ADCC).

55. The method of claim 1, wherein the subject has or is at risk of developing an infectious disease and wherein the method is a method for treating or preventing the infectious disease.

56. The method of claim 54, wherein the subject is a human.

57. The method of claim 54, further comprising administering an antigen to the subject.

58. The method of claim 57, wherein the antigen is selected from the group consisting of a bacterial antigen, a viral antigen, a parasitic antigen, and a fungal antigen.

59. The method of claim 56, wherein the subject is selected from the group consisting of a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, and fish.

60. The method of claim 59, further comprising administering an antigen to the subject.

61. The method of claim 59, wherein the antigen is derived from a microorganism selected from the group consisting of herpesviridae, retroviridae, orthomyxoviridae, toxoplasma, haemophilus, campylobacter, clostridium, E.coli, and staphylococcus.

62. The method of claim 1, wherein the immunostimulatory nucleic acid further comprises a TG motif.

63. The method of claim 62, wherein the TG nucleic acid comprises  
5'N<sub>1</sub>X<sub>1</sub>TGX<sub>2</sub>N<sub>2</sub>3'.

64. The method of claim 62, wherein the TG nucleic acid comprises  
5'N<sub>1</sub>X<sub>1</sub>X<sub>2</sub>TGX<sub>3</sub>X<sub>4</sub>N<sub>2</sub>3'.

65. The method of claim 63, wherein N<sub>1</sub> is a nucleic acid sequence composed of a number of nucleotides ranging from (11-N<sub>2</sub>) to (21-N<sub>2</sub>).



- 162 -

66. The method of claim 63, wherein  $N_2$  is a nucleic acid sequence composed of a number of nucleotides ranging from  $(11-N_1)$  to  $(21-N_1)$ .

67. The method of claim 64, wherein  $N_1$  is a nucleic acid sequence composed of a number of nucleotides ranging from  $(9-N_2)$  to  $(19-N_2)$ .

68. The method of claim 64, wherein  $N_2$  is a nucleic acid sequence composed of a number of nucleotides ranging from  $(9-N_1)$  to  $(19-N_1)$ .

69. The method of claim 63, wherein  $X_2$  is thymidine.

70. The method of claim 64, wherein  $X_3$  is thymidine.

71. The method of claim 64, wherein  $X_1X_2$  are nucleotides selected from the group consisting of GT, GG, GA, AA, AT, AG, CT, CA, CG, TA and TT.

72. The method of claim 64, wherein  $X_3X_4$  are nucleotides selected from the group consisting of TT, CT, AT, AG, CG, TC, AC, CC, TA, AA, and CA.

73. The method of claim 63, wherein  $X_3X_4$  are nucleotides selected from the group consisting of TT, TC, TA and TG.

74. The method of claim 1, wherein the subject is at risk of developing cancer and the method is a method of preventing the cancer.

75. The method of claim 50, wherein the anti-cancer therapy is selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent and a cancer vaccine.

76. A method for preventing disease in a subject, comprising:

administering to the subject an immunostimulatory nucleic acid on a regular basis to prevent disease in the subject, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid that is greater than 60% T and contains a CpG dinucleotide, a TG nucleic acid that is free of CpG dinucleotides, and a T rich nucleic acid that is between 25% T and 60% T and is free of a CpG dinucleotide.

77. A method for inducing an innate immune response, comprising

administering to the subject an immunostimulatory nucleic acid in an amount effective



- 163 -

for activating an innate immune response, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid that is greater than 60% T and contains a CpG dinucleotide, a TG nucleic acid that is free of CpG dinucleotides, and a T rich nucleic acid that is between 25% T and 60% T and is free of a CpG dinucleotide.

78. A composition comprising

a sustained release device including an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

79. The composition of claim 78, wherein the immunostimulatory nucleic acid has a phosphodiester backbone.

80. A composition of a nutritional supplement comprising

an immunostimulatory nucleic acid in a delivery device selected from the group consisting of a capsule, a pill, and a sublingual tablet, wherein the immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

81. The composition of claim 80, wherein the immunostimulatory nucleic acid has a phosphorothioate backbone.

82. A composition comprising

an immunostimulatory nucleic acid and an antigen, wherein the immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a TG immunostimulatory nucleic acid comprising the sequence



wherein  $X_1 X_2$  is selected from the group consisting of TA, TG, TC, AA, AG, AC, CC, CA, GG, GA, and GC, and  $X_3 X_4$  is selected from the group consisting of AT, AA, AG, AC, CT, CC, CA, GT, GG, GA and GC, and

a Py-rich immunostimulatory nucleic acid comprising the sequence



wherein  $X_1 X_2$  is selected from the group consisting of TA, TG, TC, AA, AG, AC, CC, CA, GG, GA, and GC, and  $X_3 X_4$  is selected from the group consisting of AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC.



- 164 -

83. A composition comprising  
an immunostimulatory nucleic acid and an anti-microbial agent, wherein the immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

84. The composition of claim 83, wherein the anti-microbial agent is selected from the group consisting of an anti-viral agent, an anti-fungal agent, an anti-parasitic agent, and an anti-bacterial agent.

85. The method of claim 5, wherein the immunostimulatory nucleic acid comprises at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 poly T motifs.

86. The method of claim 5, wherein at least two of the plurality of poly T nucleic acid motifs each comprises at least three contiguous T nucleotide residues.

87. The method of claim 5, wherein at least two of the poly T nucleic acid motifs each comprises at least four contiguous T nucleotide residues.

88. The method of claim 5, wherein the plurality of poly T nucleic acid motifs is at least 3 poly T nucleic acid motifs and wherein the at least 3 poly T nucleic acid motifs each comprises at least 3 contiguous T nucleotide residues.

89. The method of claim 5, wherein the plurality of poly T nucleic acid motifs is at least 4 poly T nucleic acid motifs and wherein the at least 4 poly T nucleic acid motifs each comprises at least 3 contiguous T nucleotide residues.

90. The method of claim 5, wherein at least one of the plurality of poly T nucleic acid motifs comprises at least 5, at least 6, at least 7, or at least 8 contiguous T nucleotide residues.

91. (Cancelled)

92. (Cancelled)

93. The method of claim 1, wherein the immunostimulatory nucleic acid includes at least two poly C sequences of at least 3 contiguous C nucleotide residues.

94. The method of claim 1, wherein the immunostimulatory nucleic acid is free of two poly A sequences of at least 3 contiguous A nucleotide residues.



- 165 -

95. A pharmaceutical composition comprising an effective amount for stimulating an immune response of an isolated immunostimulatory nucleic acid of claim 1, 3, 4, 5, 6, 7, 8, 9, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 29, 32, 40, 41, 64, 65, 66, 67, 68, 69, 70, 71, 72, 85, 86, 87, 88, 89, 90, 93, or 94 and a pharmaceutically acceptable carrier.

96. A composition of matter, comprising an isolated immunostimulatory nucleic acid of claim 1, 3, 4, 5, 6, 7, 8, 9, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 29, 32, 40, 41, 64, 65, 66, 67, 68, 69, 70, 71, 72, 85, 86, 87, 88, 89, 90, 93, or 94 and a pharmaceutically acceptable carrier.

97. The method of claim 90, wherein the nucleic acid further comprises a plurality of CpG motifs, and wherein the plurality is at least 3 motifs, at least 4 motifs and wherein the at least 4 motifs each comprises at least 3 contiguous T nucleotide residues.

98. The method of claim 97, wherein the plurality of CpG motifs and poly T motifs are interspersed.

99. A composition, comprising:

an immunostimulatory nucleic acid and an anti-cancer therapy, formulated in a pharmaceutically-acceptable carrier and in an effective amount to treat a cancer or to reduce the risk of developing a cancer, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid that is greater than 60% T and contains a CpG dinucleotide, a TG nucleic acid that is free of CpG dinucleotides, and a T rich nucleic acid that is between 25% T and 60% T and is free of a CpG dinucleotide.

100. A composition, comprising:

an immunostimulatory nucleic acid and an asthma/allergy medicament, formulated in a pharmaceutically-acceptable carrier and in an effective amount for preventing or treating an immune response associated with exposure to a mediator of asthma or allergy, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid that is greater than 60% T and contains a CpG dinucleotide, A TG nucleic acid that is free of CpG dinucleotides, and a T rich nucleic acid that is between 25% T and 60% T and is free of a CpG dinucleotide.



- 166 -

101. A composition comprising

an immunostimulatory nucleic acid selected from the group consisting of SEQ ID NO:95-119, SEQ ID NO:121-136, SEQ ID NO:138-152, SEQ ID NO:154-210, SEQ ID NO:212-222, SEQ ID NO:224-244, SEQ ID NO:247-260, SEQ ID NO:263-272, SEQ ID NO:274-299, SEQ ID NO:301, SEQ ID NO:303-409, SEQ ID NO:414-420, SEQ ID NO:424, SEQ ID NO:427-758, SEQ ID NO:760-947, SEQ ID NO:959-963, SEQ ID NO:968-1022, and SEQ ID NO:1024-1093, and a pharmaceutically acceptable carrier.

102. A composition comprising

an immunostimulatory nucleic acid consisting essentially of:

5' M<sub>1</sub>TCGTCGTTM<sub>2</sub> 3'

wherein at least one of the Cs is unmethylated, wherein M<sub>1</sub> is a nucleic acid having at least one nucleotide, wherein M<sub>2</sub> is a nucleic acid having between 0 and 50 nucleotides, and wherein the immunostimulatory nucleic acid has less than 100 nucleotides.

103. A pharmaceutical composition comprising

an immunostimulatory nucleic acid comprising:

5' TCGTCGTT 3'

wherein at least one of the Cs is unmethylated, wherein the immunostimulatory nucleic acid has less than 100 nucleotides and a phosphodiester backbone, and a sustained release device.

104. The pharmaceutical composition of claim 103, wherein the sustained release device is a microparticle.

105. The pharmaceutical composition of claim 103, further comprising an antigen.

106. A method of stimulating an immune response, comprising

administering a TG immunostimulatory nucleic acid, to a non-rodent subject in an amount effective to induce an immune response in the non-rodent subject, wherein the TG immunostimulatory nucleic acid is free of CpG dinucleotides.

107. A composition comprising an oligonucleotide having a nucleic acid sequence of TCG TCG TTT TGA CGT TTT GTC GTT (SEQ ID NO: 343).



- 166/1 -

108. A method for treating or preventing allergy or asthma comprising administering the composition of claim 107 to a non-rodent subject in need thereof in an amount effective to treat or prevent allergy or asthma.

109. A method of stimulating an immune response, comprising administering a TG immunostimulatory nucleic acid to a non-rodent subject in an amount effective to induce an immune response in the non-rodent subject, wherein the nucleic acid comprises the sequence



wherein  $X_1 X_2$  is selected from the group consisting of TA, TG, TC, AA, AG, AC, CC, CA, GG, GA, and GC, and  $X_3 X_4$  is selected from the group consisting of AT, AA, AG, AC, CT, CC, CA, GT, GG, GA and GC, and wherein the nucleic acid is free of a CpG dinucleotide.

110. A method of stimulating an immune response, comprising administering a Py-rich immunostimulatory nucleic acid to a non-rodent subject in an amount effective to induce an immune response in the non-rodent subject, wherein the nucleic acid comprises the sequence



wherein  $X_1 X_2$  is selected from the group consisting of TA, TG, TC, AA, AG, AC, CC, CA, GG, GA, and GC, and  $X_3 X_4$  is selected from the group consisting of AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC, and wherein the nucleic acid is free of a CpG dinucleotide.

111. The method of claim 106, wherein the immunostimulatory nucleic acid is a T-rich nucleic acid.

112. The method of claim 111, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25% T.

113. The method of claim 111, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 35% T.



- 166/2 -

114. The method of claim 111, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 40% T.

115. The method of claim 111, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 50% T.

116. The method of claim 111, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 60% T.



1/10




Fig. 1A



2/10

## STATISTICAL ANALYSIS

|             | MEAN  | STD.DEV. | STD.ERROR | NUMBER | MINIMUM | MAXIMUM | # MISSING |
|-------------|-------|----------|-----------|--------|---------|---------|-----------|
| o1758       | 57.60 | .71      | .50       | 2      | 57.10   | 58.10   | 2         |
| o1812       | 20.70 | .57      | .40       | 2      | 20.30   | 21.10   | 2         |
| o2006       | 56.35 | .35      | .25       | 2      | 56.10   | 56.60   | 2         |
| o2117       | 40.00 | 1.13     | .80       | 2      | 39.20   | 40.80   | 2         |
| o2137       | 47.60 | 3.39     | 2.40      | 2      | 45.20   | 50.00   | 2         |
| o2178       | 21.00 | .99      | .70       | 2      | 20.30   | 21.70   | 2         |
| o2182       | 37.75 | .35      | .25       | 2      | 37.50   | 38.00   | 2         |
| o2183       | 35.30 | 1.84     | 1.30      | 2      | 34.00   | 36.60   | 2         |
| o2177       | 25.00 | .71      | .50       | 2      | 24.50   | 25.50   | 2         |
| o2143       | 34.70 | .71      | .50       | 2      | 34.20   | 35.20   | 2         |
| o2116       | 24.35 | .64      | .45       | 2      | 23.90   | 24.80   | 2         |
| o2181       | 44.25 | 3.18     | 2.25      | 2      | 42.00   | 46.50   | 2         |
| o2180       | 45.90 | 5.94     | 4.20      | 2      | 41.70   | 50.10   | 2         |
| o2179       | 50.70 | 6.93     | 4.90      | 2      | 45.80   | 55.60   | 2         |
| o2133       | 53.75 | 4.31     | 3.05      | 2      | 50.70   | 56.80   | 2         |
| o1965       | 56.20 | 3.82     | 2.70      | 2      | 53.50   | 58.90   | 2         |
| o1968       | 49.35 | 1.91     | 1.35      | 2      | 48.00   | 50.70   | 2         |
| o2159       | 46.80 | 7.92     | 5.60      | 2      | 41.20   | 52.40   | 2         |
| o2140       | 53.25 | 4.74     | 3.35      | 2      | 49.90   | 56.60   | 2         |
| o2141       | 47.40 | 4.10     | 2.90      | 2      | 44.50   | 50.30   | 2         |
| o2142       | 23.20 | .42      | .30       | 2      | 22.90   | 23.50   | 2         |
| o1840       | 33.50 | 1.13     | .80       | 2      | 32.70   | 34.30   | 2         |
| o1979       | 59.50 | 1.70     | 1.20      | 2      | 58.30   | 60.70   | 2         |
| o2186       | 36.90 | .14      | .10       | 2      | 36.80   | 37.00   | 2         |
| o2187       | 27.15 | .78      | .55       | 2      | 26.60   | 27.70   | 2         |
| o2188       | 22.25 | .21      | .15       | 2      | 22.10   | 22.40   | 2         |
| o2189       | 21.45 | 1.20     | .85       | 2      | 20.60   | 22.30   | 2         |
| o2190       | 22.95 | 1.20     | .85       | 2      | 22.10   | 23.80   | 2         |
| o2191       | 28.35 | .49      | .35       | 2      | 28.00   | 28.70   | 2         |
| o2192       | 20.40 | 1.70     | 1.20      | 2      | 19.20   | 21.60   | 2         |
| o2193       | 19.70 | .57      | .40       | 2      | 19.30   | 20.10   | 2         |
| o2194       | 34.00 | 1.70     | 1.20      | 2      | 32.80   | 35.20   | 2         |
| o2195       | 27.30 | 1.27     | .90       | 2      | 26.40   | 28.20   | 2         |
| o2196       | 22.45 | 2.76     | 1.95      | 2      | 20.50   | 24.40   | 2         |
| NO ADDITION | 20.90 | 2.77     | 1.38      | 4      | 18.60   | 24.90   | 0         |

Fig. 1B



3/10




Fig. 2



4/10




Fig. 3



5/10




Fig. 4



6/10




Fig. 5



7/10




Fig. 6






Fig. 7




Fig. 8






Fig. 9




Fig. 10



10/10




Fig. 11




Fig. 12